<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1401256605
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CITALOGEN 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>How does Citalogen work?<br />Citalogen is a Selective Serotonin Reuptake<br />Inhibitors (SSRIs) and belongs to a group<br />of medicines called antidepressants. These<br />medicines help to correct certain chemical<br />imbalances in the brain that are causing the<br />symptoms of your illness.<br />What is Citalogen used for?<br />Citalogen Tablets are used for the treatment of<br />depression, and when you feel better, to help<br />prevent these symptoms recurring. Citalogen<br />tablets is also used for long-term treatment<br />to prevent the occurrence of new episodes of<br />depression or if you have recurrent depression.<br />Citalogen Tablets are also used to relieve<br />symptoms if you are suffering from panic attacks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Citalogen:<br />&bull; If you are allergic (hypersensitive) to Citalogen<br />or to any of the other ingredients of Citalogen<br />Tablets (see What Citalogen Tablet contains,<br />section 6).<br />&bull; at the same time as taking medication<br />known as monoamine oxidase inhibitors<br />(MAOIs). MAOIs include medicines such<br />as phenelzine, iproniazid, isocarboxazid,<br />nialamide, tranylcypromine and moclobemide<br />(used for the treatment of depression),<br />selegiline (used in the treatment of Parkinson&rsquo;s<br />disease) and linezolid (an antibiotic). Even if<br />you have finished taking one of the following<br />MAOIs: phenelzine, iproniazid, isocarboxazid,<br />nialamide or tranylcypromine you will need<br />to wait 2 weeks before you start taking your<br />Citalogen tablets. One day must elapse after<br />you have finished taking moclobemide. After<br />stopping Citalogen you must allow 1 week<br />before taking any MAOI.<br />&bull; If you are born with or have had an episode<br />of abnormal heart rhythm (seen at ECG; an<br />examination to evaluate how the heart is<br />functioning)<br />&bull; If you take medicines for heart rhythm problems<br />or that may affect the heart&rsquo;s rhythm. Also refer<br />to the section &ldquo;Taking other medicines&rdquo; below.<br />Warnings and Precautions<br />Please tell your doctor if you have any medical<br />problems, especially if you have<br />&bull; History of bleeding disorders or have ever<br />suffered from bleeding in the stomach<br />or intestine, or if you are pregnant (see<br />&lsquo;Pregnancy, breast-feeding and fertility&rsquo;).<br />&bull; Liver disease.<br />&bull; kidney disease.<br />&bull; Diabetes (you may need an adjustment of your<br />antidiabetic therapy).<br />&bull; Epilepsy or a history of seizures or fits.<br />&bull; A bleeding disorder or have ever suffered from<br />bleeding in the stomach or intestine.<br />&bull; Mania or panic disorder.<br />&bull; Low blood levels of sodium.<br />&bull; ECT (electroconvulsive therapy).<br />&bull; Suffered or suffer from heart problems or have<br />recently had a heart attack.<br />&bull; A low resting heart-rate and/or you know<br />that you may have salt depletion as a result<br />of prolonged severe diarrhoea and vomiting<br />(being sick) or usage of diuretics (water<br />tablets).<br />&bull; Experienced a fast or irregular heartbeat,<br />fainting, collapse or dizziness on standing up<br />which may indicate abnormal functioning of<br />the heart rate<br />&bull; If you have or have previously had eye<br />problems, such as certain kinds of glaucoma<br />(increased pressure in the eye).<br />Please consult your doctor, even if these<br />statements were applicable to you at any time<br />in the past.<br />Please note:<br />Some patients with manic-depressive illness may<br />enter into a manic phase. This is characterized<br />by unusual and rapidly changing ideas,<br />inappropriate happiness and excessive physical<br />activity. If you experience this, contact your<br />doctor.<br />Symptoms such as restlessness or difficulty<br />in sitting or standing still can also occur during<br />the first weeks of the treatment. Tell your doctor<br />immediately if you experience these symptoms.<br />Medicines like Citalogen (so called SSRIs/SNRIs)<br />may cause symptoms of sexual dysfunction (see<br />section 4). In some cases, these symptoms have<br />continued after stopping treatment.<br />Special information relating to your disease<br />As with other medicines used to treat depression<br />or related diseases, the improvement is not<br />achieved immediately. After the start of Citalogen<br />treatment it may take several weeks before you<br />experience any improvement. In the beginning<br />of the treatment certain patients may experience<br />increased anxiety, which will disappear during<br />continued treatment. Therefore, it is very<br />important that you follow exactly your doctor&rsquo;s<br />orders and do not stop the treatment or change<br />the dose without consulting your doctor.<br />Thoughts of suicide and worsening of your<br />depression or anxiety disorder<br />If you are depressed and/or have anxiety<br />disorders you can sometimes have thoughts<br />of harming or killing yourself. These may be<br />increased when first starting antidepressants,<br />since these medicines all take time to work,<br />usually about two weeks but sometimes longer.<br />You may be more likely to think like this:<br />&bull; If you have previously had thoughts about<br />killing or harming yourself.<br />&bull; If you are a young adult. Information from<br />clinical trials has shown an increased risk of<br />suicidal behaviour in adults aged less than 25<br />years with psychiatric conditions who were<br />treated with an antidepressant.<br />If you have thoughts of harming or killing yourself<br />at any time, contact your doctor or go to a<br />hospital straight away.<br />You may find it helpful to tell a relative or<br />close friend that you are depressed or have an<br />anxiety disorder, and ask them to read this leaflet.<br />You might ask them to tell you if they think your<br />depression or anxiety is getting worse, or if they<br />are worried about changes in your behaviour.<br />Use in children and adolescents under 18<br />years of age<br />Citalogen tablets should normally not be used<br />for children and adolescents under 18 years.<br />Also, you should know that patients under 18<br />years have an increased risk of side-effects<br />such as suicide attempt, suicidal thoughts and<br />hostility (predominantly aggression, oppositional<br />behaviour and anger) when they take this class<br />of medicines. Despite this, your doctor may<br />prescribe Citalogen for patients under 18 years<br />because he/she decides that this is in their<br />best interests. If your doctor has prescribed<br />Citalogen tablets for a patient under 18 years<br />and if you want to discuss this, please go back<br />to your doctor. You should inform your doctor<br />if any of the symptoms listed above develop<br />or worsen when patients under 18 years are<br />taking Citalogen tablets. Also, the long-term<br />safety effects concerning growth, maturation<br />and cognitive and behavioural development of<br />Citalogen in this age group have not yet been<br />demonstrated.<br />Other medicines and Citalogen<br />Medicines may affect the action of other<br />medicines and this can sometimes cause serious<br />adverse reactions. Please tell your doctor or<br />your pharmacist if you are taking, have taken<br />or might take any other medicines This includes<br />other medicines for depression (see Do not take<br />Citalogen).<br />&bull; The herbal remedy St John&rsquo;s Wort (Hypericum<br />perforatum). This should not be taken at the<br />same time as Citalogen.<br />&bull; Monoamine oxidase inhibitors (MAOIs). These<br />should not be taken at the same time as<br />Citalogen (see Do not take Citalogen).<br />Tell your doctor if you are taking any of the<br />following medicines:<br />&bull; Linezolid (an antibiotic).<br />&bull; Sumatriptan (used to treat migraine) or<br />tramadol (a pain killer). If you feel unwell when<br />using these medicines with Citalogen tablets<br />then you should see your doctor.<br />&bull; Lithium (used to prevent and treat mania) and<br />tryptophan (an antidepressant)<br />&bull; Pimozide (a neuroleptic). This should not be<br />taken at the same time as Citalogen.<br />&bull; Imipramine and desipramine (used to treat<br />depression).<br />&bull; Medicines containing selegiline (used to treat<br />Parkinson&rsquo;s disease).<br />&bull; Cimetidine, lansoprazole and omeprazole<br />(used to treat stomach ulcers), fluconazole<br />(used to treat fungal infections), fluvoxamine<br />(antidepressant) and ticlopidine (used to<br />reduce the risk of stroke). These may cause<br />increased blood levels of citalopram.<br />&bull; Mefloquine (used to treat malaria).<br />&bull; Bupropion (used to treat depression).<br />&bull; Medicines known to affect the blood platelets<br />(e.g. anticoagulant drugs used to treat or<br />prevent blood clots; aspirin and non-steroidal<br />anti-inflammatory drugs (NSAIDs) such as<br />ibuprofen and diclofenac used as painkillers<br />and some antipsychotic drugs and tricyclic<br />antidepressants).<br />&bull; Metoprolol, a beta blocker used to treat<br />migraine, some heart conditions and high<br />blood pressure. The effects of either drug could<br />be increased, decreased or altered.<br />&bull; Neuroleptics (used in the treatment of<br />schizophrenia).<br />DO NOT TAKE CITALOGEN if you take<br />medicines for heart rhythm problems or<br />medicines that may affect the heart&rsquo;s rhythm,<br />e.g. such as Class IA and III antiarrhythmics,<br />antipsychotics (e.g. fentiazine derivatives,<br />pimozide, haloperidol), tricyclic antidepressants,<br />certain antimicrobial agents (e.g. sparfloxacin,<br />moxifloxacin, erythromycin IV, pentamidine,<br />anti-malarian treatment particularly halofantrine),<br />certain antihistamines (astemizole, mizolastine).<br />If you have any further questions about this, you<br />should speak to your doctor.<br />Taking Citalogen with food , drink &amp; Alcohol<br />Citalogen can be taken with or without food. (see<br />section 3 &ldquo;How to take Citalogen&rdquo;).<br />As with all antidepressants, it is sensible to<br />avoid drinking alcohol whilst receiving treatment<br />although Citalogen tablets have not been shown<br />to increase the effects of alcohol.<br />Pregnancy<br />If you take Citalogen near the end of your<br />pregnancy there may be an increased risk<br />of heavy vaginal bleeding shortly after birth,<br />especially if you have a history of bleeding<br />disorders. Your doctor or midwife should be<br />aware that you are taking Citalogen so they can<br />advise you.<br />Ask your doctor or pharmacist for advice before<br />taking any medicine. If you are pregnant, think<br />you might be pregnant, or are trying to become<br />pregnant, tell your doctor. Do not take Citalogen<br />if you are pregnant unless you and your doctor<br />have discussed the risks and benefits involved.<br />Make sure your midwife and/or doctor know you<br />are on Citalogen Tablets. When taken during<br />pregnancy, particularly in the last 3 months of<br />pregnancy, medicines like Citalogen Tablets may<br />increase the risk of a serious condition in babies,<br />called persistent pulmonary hypertension of<br />the new born (PPHN), making the baby breathe<br />faster and appear bluish. These symptoms<br />usually begin during the first 24 hours after<br />the baby is born. If this happens to your baby<br />you should contact your midwife and/or doctor<br />immediately. Also, if you take Citalogen during<br />the last 3 months of your pregnancy and until<br />the date of birth you should be aware that the<br />following effects may be seen in your newborn:<br />fits, being too hot or cold, feeding difficulties,<br />vomiting, low blood sugar, stiff or floppy muscles,<br />overactive reflexes, tremor, jitteriness, irritability,<br />lethargy, constant crying, sleepiness or sleeping<br />difficulties. If your newborn baby gets any of<br />these symptoms, please contact your midwife<br />and/or doctor immediately.<br />Breast-feeding<br />If you are breast-feeding, ask your doctor for<br />advice. You should not breastfeed your baby<br />while taking Citalogen tablets because small<br />amounts of the medicine can pass into the breast<br />milk.<br />Fertility<br />Citalogen has been shown to reduce the quality<br />of sperm in animal studies. Theoretically, this<br />could affect fertility, but impact on human fertility<br />has not been observed as yet.<br />Driving and using machines<br />Citalogen tablets do not usually affect the ability<br />to carry out normal daily activities. However,<br />if you feel dizzy or sleepy when you start to<br />take this medicine, you should be careful when<br />driving, operating machinery or performing jobs<br />that need you to be alert until these effects wear<br />off.<br />Important information about some of the<br />ingredients of Citalogen<br />This product contains lactose.<br />If you have been told by your doctor that you<br />have an intolerance to some sugars, contact your<br />doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Citalogen exactly as your doctor<br />has told you. You should check with your<br />doctor or pharmacist if you are not sure.<br />Adults<br />Depression<br />The usual dose is 20 mg per day. This may be<br />increased by your doctor to a maximum of 40<br />mg per day.<br />Panic disorder<br />The starting dose is 10 mg per day for the first<br />week before increasing the dose to 20-30 mg per<br />day. The dose may be increased by your doctor<br />to a maximum of 40 mg per day.<br />Elderly patients (above 65 years of age)<br />The starting dose should be decreased to half of<br />the recommended dose, e.g. 10-20 mg per day.<br />Elderly patients should not usually receive more<br />than 20 mg per day.<br />Children and adolescents (&lt; 18 years)<br />Citalogen tablets is not recommended for<br />children or adolescents. For further information,<br />please see section 2, Before you take<br />Citalogen.<br />Patients with special risks<br />Patients with liver complaints should not receive<br />more than 20 mg of Citalogen tablets per day.<br />How and when to take Citalogen tablets<br />Citalogen tablets is taken every day as a single<br />daily dose. Citalogen tablets can be taken any<br />time of the day with or without food. Swallow the<br />tablets with a drink of water. Do not chew them<br />(they have a bitter taste).<br />Duration of treatment<br />Like other medicines for depression and panic<br />disorder these tablets may take a few weeks<br />before you feel any improvement. Continue<br />to take Citalogen tablets even if it takes some<br />time before you feel any improvement in your<br />condition. The duration of treatment is individual,<br />usually at least 6 months. Continue to take<br />Citalogen tablets for as long as your doctor<br />recommends. Do not stop taking them even<br />if you begin to feel better, unless you are told<br />to do so by your doctor. The underlying illness<br />may persist for a long time and if you stop your<br />treatment too soon your symptoms may return.<br />Patients who have recurrent depression benefit<br />from continued treatment, sometimes for<br />several years, to prevent the occurrence of new<br />depressive episodes.<br />Never change the dose of the medicine without<br />talking to your doctor first.<br />If you take more Citalogen than you should,<br />If you think that you or anyone else may have<br />taken too many Citalogen tablets, contact<br />your doctor or nearest hospital emergency<br />department immediately. Do this even if there<br />are no signs of discomfort or poisoning. Take<br />the Citalogen box/container with you if you go<br />to a doctor or hospital. Some of the signs of an<br />overdosage could be life-threatening.<br />Symptoms of overdosage may include:<br />&bull; Irregular heart beat<br />&bull; Seizures<br />&bull; Changes in heart rhythm<br />&bull; Feeling sick (nausea)<br />&bull; Vomiting<br />&bull; Sweating<br />&bull; Drowsiness<br />&bull; Unconsciousness<br />&bull; Fast heart beats<br />&bull; Tremor<br />&bull; Changes in blood pressure<br />&bull; Serotonin syndrome (see Section 4)<br />&bull; Agitation<br />&bull; Dizziness<br />&bull; Enlarged eye pupils<br />&bull; Bluish skin<br />&bull; Breathing too quickly<br />If you forget to take Citalogen Tablets<br />If you forget to take a dose, take the next dose at<br />the usual time. Do not take a double dose.<br />Effects when treatment with Citalogen is<br />stopped<br />Stopping this medicine quickly may cause<br />symptoms such as dizziness, nausea and<br />numbness or tingling in hands or feet, sleep<br />disturbances (vivid dreams, nightmares, inability<br />to sleep), feeling anxious, headaches, feeling or<br />being sick, sweating, feeling restless or agitated,<br />tremor, feeling confused or disorientated, feeling<br />emotional or irritable, diarrhoea (loose stools),<br />visual disturbances, fluttering or pounding<br />heartbeat (palpitations). These symptoms are<br />generally non-serious and disappear within a few<br />days. When you have completed your course<br />of treatment, the dose of Citalogen is usually<br />reduced gradually over a couple of weeks.<br />If you have any further questions on the use of<br />this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Citalogen tablets can have<br />side effects and some people may experience<br />unwanted effects (side effects) whilst taking<br />Citalogen tablets. Several of the effects listed<br />below can also be symptoms of your illness and<br />may disappear as you start to get better.<br />Serious side effects<br />Stop taking Citalogen tablets and seek medical<br />advice immediately if you suffer from any of the<br />following symptoms:<br />&bull; Difficulty in breathing<br />&bull; Swelling of the face, lips, tongue or throat that<br />causes difficulty in swallowing or breathing.<br />&bull; Severe itching of the skin (with raised lumps)<br />&bull; Fast, irregular heart beat, fainting which could<br />be symptoms of a lifethreatening condition<br />known as torsades de pointes.<br />If you notice any of the following symptoms you<br />should contact your doctor immediately as your<br />dose may need to be reduced or stopped:<br />&bull; you start having fits for the first time or fits that<br />you have suffered from in the past become<br />more frequent.<br />&bull; your behaviour changes because you feel<br />elated or over excited.<br />&bull; you experience high fever, agitation, confusion,<br />trembling or abrupt contractions of muscles.<br />These may be signs of a rare condition called<br />serotonin syndrome.<br />&bull; Tiredness, confusion and twitching of your<br />muscles. These may be signs of a low blood<br />level of sodium (hyponatraemia).<br />If you have thoughts of harming or killing yourself<br />at any time, contact your doctor or go to a<br />hospital straight away.<br />The following side effects are often mild and<br />usually disappear after a few days&rsquo; treatment.<br />Very common side effects (may affect more than<br />1 in 10 people)<br />&bull; Sleepiness<br />&bull; Difficulty in sleeping<br />&bull; Headache<br />&bull; Changes in your sleeping pattern<br />&bull; Loss of body strength, weakness<br />&bull; Increased sweating<br />&bull; Dry mouth (a dry mouth increases the risk of<br />tooth decay, so be sure to clean your teeth<br />more often than usual)<br />&bull; Feeling sick (nausea)<br />Common side effects (may affect up to 1 in 10<br />people)<br />&bull; Lack of appetite<br />&bull; Agitation<br />&bull; Decreased sex drive<br />&bull; Anxiety<br />&bull; Nervousness<br />&bull; Confusion<br />&bull; Abnormal dreams<br />&bull; Reduced emotions, indifference (apathy)<br />&bull; Tremor<br />&bull; Tingling or numbness in the hands or feet<br />&bull; Dizziness<br />&bull; Problems concentrating<br />&bull; Migraine<br />&bull; Loss of memory (amnesia)<br />&bull; Ringing in the ears (tinnitus)<br />&bull; Palpitations<br />&bull; Yawning<br />&bull; Blocked or runny nose (rhinitis)<br />&bull; Diarrhoea<br />&bull; Vomiting<br />&bull; Constipation<br />&bull; Stomach pain<br />&bull; Flatulence (wind)<br />&bull; Increase in saliva (drooling)<br />&bull; Itching<br />&bull; Pain in muscles and joints<br />&bull; For men, problems with ejaculation and<br />erection<br />&bull; For females, failing to reach an orgasm<br />&bull; Tiredness<br />&bull; Prickling of the skin<br />&bull; Loss of weight<br />Uncommon (may affect up to 1 in every 100<br />people)<br />&bull; Bruising easily<br />&bull; Increased appetite<br />&bull; Aggression<br />&bull; Hallucinations<br />&bull; Mania<br />&bull; Fainting<br />&bull; Large pupils (the dark centre of the eye)<br />&bull; Fast heart beat<br />&bull; Slow heart beat<br />&bull; Nettle rash<br />&bull; Loss of hair<br />&bull; Rash<br />&bull; Sensitivity to sunlight<br />&bull; Difficulties urinating<br />&bull; Excessive menstrual bleeding<br />&bull; Swelling of the arms or legs<br />&bull; Increased weight<br />Rare (may affect up to 1 in every 1000 people)<br />&bull; Increased sex drive<br />&bull; Convulsions<br />&bull; Involuntary movements<br />&bull; Taste disturbances<br />&bull; Bleeding<br />&bull; Coughing<br />&bull; Hepatitis<br />&bull; Feeling unwell (malaise)<br />Some patient have reported (frequency not<br />known)<br />&bull; Heavy vaginal bleeding shortly after birth<br />(postpartum haemorrhage), see &lsquo;Pregnancy,<br />breast-feeding and fertility&rsquo; in section 2 for<br />more information.<br />&bull; Thoughts of harming or killing themselves, see<br />also section 2 &ldquo;before you take Citalogen&rdquo;<br />&bull; An increase in bleeding or bruising caused by a<br />decrease in blood platelets (thrombocytopenia)<br />&bull; Rash (hypersensitivity)<br />&bull; Low potassium levels in the blood<br />(hypokalaemia), which can cause muscle<br />weakness, twitching or abnormal heart rhythms<br />&bull; Panic attack<br />&bull; Grinding teeth<br />&bull; Restlessness<br />&bull; Unusual muscle movements or stiffness<br />&bull; Involuntary movements of the muscles<br />(akathisia)<br />&bull; Low blood pressure<br />&bull; Nosebleed<br />&bull; Sudden swelling of skin or<br />mucosa<br />&bull; Bleeding disorders<br />including skin and mucosal<br />bleeding (ecchymosis)<br />&bull; In men, painful erections<br />&bull; Flow of breast milk in<br />men or in women who<br />are not breast-feeding<br />(galactorrhoea)<br />&bull; Abnormal liver function<br />tests<br />&bull; An increased risk of<br />bone fractures has been<br />observed in patients taking<br />this type of medicines.<br />&bull; Abnormal heart rhythm<br />SSRIs can, very rarely,<br />increase the risk of bleeding,<br />including stomach or intestinal bleeding. Let your<br />doctor know if you vomit blood or develop black<br />or blood stained stools.<br />Also let your doctor know if you continue to<br />have other symptoms associated with your<br />depression. This might include hallucinations,<br />anxiety, mania or confusion.<br />Any side effects that do occur will usually<br />disappear after a few days. If they are<br />troublesome or persistent, or if you develop any<br />other unusual side effects while taking Citalogen<br />tablets, please tell your doctor.<br />If any of the side effects gets serious, or if you<br />notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the sight and reach of children.<br />&bull; Store below 30 &deg;C.<br />&bull; Do not use your tablets after the expiry date<br />stated on the carton.<br />&bull; Medicines should not be disposed of via<br />waste water or household waste. Ask your<br />pharmacist how to dispose of medicines no<br />longer required. These measures will help to<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Citalogen Tablet contains?<br />Film Coated Tablets<br />&bull; The active substance is Citalopram<br />Hydrobromide (USP) equivalent to Citalopram<br />10 mg, 20 mg or 40 mg.<br />&bull; Excipients are Lactose (200 mesh), Maize<br />Starch, Microcrystalline Cellulose PH101,<br />Povidone (K30), Crospovidone, Magnesium<br />Stearate and Coating material (Opadry II White<br />OY-L-28900).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
What Citalogen looks like and contents of
the packs
Citalogen 10 mg: white to off white, circular
biconvex film coated tablet, with RP on one side
and 83 on the other side.
Citalogen 20 mg: white to off white, oblong
shaped, biconvex film coated tablet, with RP 84
on one side and break line on the other side.
Citalogen 40 mg: white to off white, capsule
shaped, biconvex film coated tablet, with RP 85
on one side and break line on the other side.
Pack size:
Packs contain (30) film coated tablets of
CITALOGEN 10 mg, 20 mg and 40 mg.
Each Transparent PVC/PVDC – Aluminum foil
blister Pack of 15 tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd.<br />(Riyadh Pharma)<br />P.O.Box 442, Riyadh 11411<br />Fax: +966 11 265 0505<br />Email: contact@riyadhpharma.com<br />For any information about this medicinal product,<br />please contact the local representative of<br />marketing authorisation holder:<br />Saudi Arabia<br />Marketing department<br />Riyadh<br />Tel: +966 11 265 0111<br />Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in (10/2022);
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>كيف يعمل سيتالوجن ؟<br />سيتالوجن هو من مثبطات اعادة امتصاص السيروتونين الانتقائية<br />وينتمي إلى مجموعة من الأدوية تسمى مضادات الاكتئاب. )SSRIs(<br />هذه الأدوية تساعد على تصحيح اختلالات كيميائية معينة في الدماغ<br />التي تسبب أعراض مرضك.<br />ما هي استخدامات سيتالوجن ؟<br />تستخدم أقراص سيتالوجن لعلاج الاكتئاب، وعندما تشعر بتحسن،<br />للمساعدة في منع تكرار هذه الأعراض. تستخدم أقراص سيتالوجن<br />أيضا للعلاج على المدى الطويل لمنع وقوع نوبة جديدة من الاكتئاب<br />أو إذا كان لديك الاكتئاب المتكرر. وتستخدم أقراص سيتالوجن أيضا<br />لتخفيف الأعراض إذا كنت تعاني من نوبات الهلع.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سيتالوجن:<br />&bull;إذا كان لديك حساسية )شديد التحسس( لسيتالوجن أو إلى أي من<br />المكونات الأخرى من سيتالوجن أقراص )راجع على ماذا تحتوي<br />.) أقراص سيتالوجن ، القسم 6<br />&bull;بالتزامن مع تناول دواء يعرف باسم مثبطات مونوأمين<br />تشمل مثبطات أوكسيديز أحادي الأمين MAOIs أوكسيديز<br />أدوية مثل فينيلزين وإبرونيازيد وإيزوكاربوكسازيد ونيالاميد<br />وترانيلسيبرومين وموكلوبيميد )المستخدم لعلاج الاكتئاب(<br />والسيليجيلين )المستخدم في علاج مرض باركنسون( ولينزوليد<br />)مضاد حيوي(.<br />حتى إذا كنت قد توقفت عن تناول أحد مثبطات أوكسيديز أحادي<br />الأمين التالية: فينيلزين ، إبرونيازيد ، إيزوكاربوكسازيد ، نيالاميد<br />أو ترانيلسيبرومين ، سوف تحتاج إلى الانتظار أسبوعين قبل أن<br />تبدأ في تناول أقراص سيتالوجن. يجب أن ينقضي يوم واحد بعد<br />الانتهاء من تناول موكلوبميد. بعد التوقف عن تناول سيتالوجن،<br />MAOI يجب أن تنتظر أسبوعًا واحدًا قبل تناول أي<br />&bull;إذا ولدت مع أو كان لديك اي نوبة من ضربات القلب الغير طبيعية<br />هوفحص لتقييم كيفية عمل القلب( ؛ ECG )تظهر في<br />&bull;إذا تناولت أدوية لمشاكل ضربات القلب أو التي قد تؤثر على<br />ضربات القلب. راجع أيضا قسم &quot;تناول أدوية أخرى&quot; أدناه.<br />التحذيرات و الاحتياطات<br />من فضلك أخبر طبيبك إذا كان لديك أي مشاكل طبية ، خاصة إذا<br />كان لديك<br />&bull;تاريخ من اضطرابات النزف أو عانيت في أي وقت من نزيف في<br />المعدة أو الأمعاء ، أو إذا كنتِ حاملاً )أنظري &quot;الحمل ، الإرضاع<br />والخصوبة&quot;(.<br />&bull;مرض الكبد.<br />&bull;مرض الكلى.<br />&bull;مرض السكري )قد تحتاج إلى تعديل العلاج الخاص بك المضاد<br />لمرض السكر(.<br />&bull;الصرع أو تاريخ من نوبات أو تشنجات.<br />&bull;اضطراب النزيف أو عانيت في أي وقت مضى من نزيف في<br />المعدة أو الأمعاء.<br />&bull;هوس أو اضطراب الهلع.<br />&bull;مستويات منخفضة من الصوديوم في الدم.<br />العلاج بالصدمة الكهربائية(. ( ECT&bull;<br />&bull;عانيت أو تعاني من مشاكل في القلب أو تعرضت مؤخرا لنوبة<br />قلبية.<br />&bull;معدل ضربات قلب منخفض أثناء الراحة و / أو أنك تعلم أنك قد<br />تكون مصابًا بنضوب الملح نتيجة الإسهال الشديد والقيء لفترات<br />طويلة )المرض( أو استخدام مدرات البول )أقراص الماء(.<br />&bull;عانيت من ضربات قلب سريعة أو غير منتظمة ، إغماء ،<br />انهيار أو دوار عند الوقوف مما قد يشير إلى معدل غير طبيعي<br />لضربات القلب<br />&bull;إذا كنت تعاني أو عانيت من قبل من مشاكل في العين ، مثل أنواع<br />معينة من الجلوكوما )زيادة الضغط في العين(.<br />يرجى استشارة طبيبك ، حتى لو كانت هذه العبارات تنطبق عليك في<br />أي وقت في الماضي.<br />يرجى الملاحظة :<br />بعض المرضى الذين يعانون من مرض الهوس الاكتئابي قد يصلون<br />إلى مرحلة الهوس. تتميز بالأفكار غير العادية وسريعة التغير،<br />والسعادة غير الملائمة والنشاط البدني المفرط. إذا واجهت هذا،<br />اتصل بطبيبك.<br />الأعراض مثل الأرق أو صعوبة في الجلوس أو الوقوف لا تزال يمكنها<br />أيضا أن تحدث خلال الأسابيع الأولى من العلاج. أخبر طبيبك فورا<br />إذا واجهت هذه الأعراض.<br />قد تسبب أدوية مثل سيتالوجن )تسمى مثبطات اعادة امتصاص<br />السيروتونين الانتقائية / مثبطات اعادة امتصاص السيروتونين و<br />.) النورابينيفرين الانتقائية( أعراض الضعف الجنسي )انظر القسم 4<br />في بعض الحالات ، تستمر هذه الأعراض بعد التوقف عن العلاج.<br />معلومات خاصة تتعلق بمرضك<br />كما هو الحال مع الأدوية الأخرى المستخدمة لعلاج الاكتئاب أو<br />الأمراض ذات الصلة ، فإن التحسن لا يتحقق على الفور. بعد بدء<br />العلاج بتناول سيتالوجن ، قد يستغرق الأمر عدة أسابيع قبل أن تشعر<br />بأي تحسن. في بداية العلاج ، قد يعاني بعض المرضى من القلق<br />المتزايد ، والذي سيختفي أثناء العلاج المستمر. لذلك ، من المهم جدًا<br />أن تتبع أوامر طبيبك تمامًا ولا تتوقف عن العلاج أو تغير الجرعة<br />دون استشارة الطبيب.<br />خواطر انتحار وتفاقم الاكتئاب أو اضطراب القلق<br />إذا كنت تعاني من الاكتئاب و / أو لديك اضطرابات القلق ، فيمكنك<br />أحيانًا التفكير في إيذاء نفسك أو قتلها. يمكن زيادة هذه الأفكار عند البدء<br />بمضادات الاكتئاب لأول مرة ، لأن هذه الأدوية تستغرق وقتًا حتى<br />تعمل ، عادةً حوالي أسبوعين ولكن أحيانًا أطول.<br />قد تكون أكثر عرضة للتفكير من هذا القبيل:<br />&bull;إذا كان لديك مسبقا الأفكار حول قتل أو إيذاء نفسك.<br />&bull;إذا كنت من الشباب البالغين. أظهرت المعلومات المستقاة من<br />التجارب السريرية أن هناك زيادة لخطر السلوك الانتحاري لدى<br />البالغين الذين تقل أعمارهم عن 25 عاما الذين يعانون من حالات<br />نفسية والذين عولجوا بمضاد للاكتئاب.<br />إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو<br />اذهب إلى المستشفى على الفور.<br />قد تجد أنه من المفيد لإخبار صديق وثيق أو قريب اذا كنت مكتئبا أو<br />لديك اضطرابات القلق، واطلب منهم قراءة هذه النشرة. قد تطلب منهم<br />أن يخبروك إذا كانوا يعتقدون ان الاكتئاب أو القلق يزداد سوءا، أو إذا<br />أنهم يشعرون بالقلق إزاء التغيرات في السلوك الخاص بك.<br />الاستخدام في الأطفال والمراهقين تحت سن 18 سنة من العمر<br />عادة لا ينبغي استخدام أقراص سيتالوجن للأطفال والمراهقين دون سن<br />18 عاما. أيضا، يجب أن نعرف أن المرضى الذين تقل أعمارهم عن<br />18 سنوات تزيد لديهم مخاطر الآثار الجانبية مثل محاولة الانتحار،<br />والأفكار الانتحارية والعداء )في الغالب العدوانية، وسلوك المعارضة<br />والغضب( عندما يتناولون هذا النوع من الأدوية. على الرغم من<br />هذا، فإن الطبيب قد يصف سيتالوجن للمرضى تحت 18 عاما لأنه<br />/ لأنها قررت أن هذا في مصلحتهم. إذا كان طبيبك وصف أقراص<br />سيتالوجن للمريض تحت سن 18 عاما، وإذا كنت ترغب في مناقشة<br />هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب إذا كان<br />أي من الأعراض المذكورة أعلاه تطور أو ازداد سوءا عند المرضى<br />الذين تقل أعمارهم عن 18 عاما وتناول أقراص سيتالوجن. أيضا،<br />لم يتم حتى الآن اثبات آثار السلامة على المدى الطويل بشأن النمو<br />والنضج والتطور المعرفي والسلوكي للسيتالوجن في هذه الفئة العمرية.<br />سيتالوجن و الأدوية الأخرى<br />قد تؤثر الأدوية على عمل الأدوية الأخرى ويمكن أن يسبب ذلك أحيانًا<br />ردود فعل سلبية خطيرة. يرجى إخبار طبيبك أو الصيدلي الخاص بك<br />إذا كنت تتناول أو تناولت أو قد تتناول أي أدوية أخرى. وهذا يشمل<br />أدوية أخرى للاكتئاب )انظر لا تتناول سيتالوجن(<br />&bull;العلاج بالاعشاب نبتة سانت جون )بيرفوراتوم(. لا ينبغي ان يتم<br />تناولها في نفس الوقت مع سيتالوجن.<br />لا ينبغي أن يتم .)MAOIs( &bull;مثبطات أوكسيديز أحادي الأمين<br />تناولها في نفس الوقت مع سيتالوجن )انظر لا تتناول سيتالوجن(.<br />أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:<br />&bull;لينيزوليد )مضاد حيوي(.<br />&bull;سوماتريبتان )لعلاج الشقيقة( أو ترامادول )مسكن للألم(. إذا<br />شعرت بتوعك عند استخدام هذه الأدوية مع أقراص سيتالوجن<br />فعليك مراجعة طبيبك.<br />&bull;الليثيوم )يستخدم لمنع وعاج الهوس( والتربتوفان )مضاد<br />للاكتئاب(.<br />&bull;بيموزيد )مضاد للذهان(. لا ينبغي أن يتم تناوله في نفس الوقت<br />مع سيتالوجن.<br />&bull;إيميبرامين و ديسيبرامين )يستعملان لعلاج الإكتئاب(.<br />&bull;الأدوية التي تحتوي على السيليجيلين )المستخدمة لعلاج مرض<br />باركنسون(.<br />&bull;سيميتيدين ، لانسوبرازول وأوميبرازول )يستعمل لعلاج قرحة<br />المعدة( ، فلوكونازول )يستعمل لمعالجة الإنتانات الفطرية( ،<br />فلوفوكسامين )مضاد للإكتئاب( وتيكلوبيدين )يستعمل لتقليل<br />خطورة السكتة الدماغية(. قد تسبب هذه زيادة مستويات الدم من<br />سيتالوبرام.<br />&bull;ميفلوكين )لعلاج الملاريا(.<br />&bull;بوبروبيون )لعلاج الإكتئاب(.<br />&bull;الأدوية المعروفة بتأثيرها على الصفائح الدموية )مثل الأدوية<br />المضادة للتخثر المستخدمة لعلاج أو منع تجلط الدم ، الأسبرين<br />مثل ) )NSAIDs والأدوية غير الستيرويدية المضادة للالتهابات<br />الإيبوبروفين والديكلوفيناك التي تستخدم كمسكنات للألم وبعض<br />الأدوية المضادة للذهان ومضادات الاكتئاب ثلاثية الحلقات(.<br />&bull;ميتوبرولول ، حاصرات بيتا تستعمل لعلاج الشقيقة وبعض<br />أمراض القلب وضغط الدم المرتفع. يمكن زيادة تأثيرات أي من<br />العقارين أو تقليلها أو تغييرها.<br />&bull;مضادات الذهان )المستخدمة في علاج الفصام(.<br />لا تتناول سيتالوجن إذا كنت تتناول أدوية لمشاكل ضربات القلب أو<br />أدوية قد تؤثر على نظم القلب ، على سبيل المثال. مثل مضادات<br />اضطراب النظم من الصنف الأول والثالث ، ومضادات الذهان )على<br />سبيل المثال مشتقات الفنتيازين ، بيموزيد ، هالوبيريدول( ، مضادات<br />الاكتئاب ثلاثية الحلقات ، بعض العوامل المضادة للميكروبات )مثل<br />بنتاميدين ، IV سبارفلوكساسين ، موكسيفلوكساسين ، إريثروميسين<br />، علاج مضاد للملاريا ، وخاصةهالوفنترين ( ، بعض مضادات<br />الهيستامين )أستيميزول ، ميزولاستين(.إذا كان لديك أي أسئلة أخرى<br />حول هذا الأمر ، يجب عليك التحدث إلى طبيبك.<br />تناول سيتالوجن مع الطعام والشراب والكحول<br />يمكن تناول سيتالوجن مع أو بدون طعام. )انظر القسم 3 &quot;كيفية تناول<br />سيتالوجن&quot;(.<br />كما هو الحال مع جميع مضادات الاكتئاب ، من المنطقي تجنب شرب<br />الكحول أثناء تلقي العلاج على الرغم من أن أقراص سيتالوجن لم تثبت<br />أنها تزيد من تأثير الكحول.<br />الحمل<br />إذا كنتِ تتناولين سيتالوجين بالقرب من نهاية الحمل ، فقد يكون هناك<br />خطر متزايد من حدوث نزيف مهبلي حاد بعد الولادة بفترة وجيزة ،<br />خاصة إذا كان لديك تاريخ من اضطرابات النزيف. يجب أن يكون<br />طبيبك أو ممرضة التوليد على دراية بأنكِ تتناولين سيتالوجين حتى<br />يتمكنوا من تقديم النصح لكِ.<br />اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.<br />إذا كنتِ حاملاً ، أو تعتقدين أنك حامل ، أو تحاولين الحمل ، أخبري<br />طبيبك. لا تتناولي سيتالوجين إذا كنتِ حاملاً إلا إذا ناقشت أنت وطبيبك<br />المخاطر والفوائد المتضمنة.<br />تأكدي من أن قابلتك و / أو الطبيب يعرفان أنك تتناولين أقراص<br />سيتالوجن. عند تناوله خلال فترة الحمل، وخصوصا في آخر 3 أشهر<br />من الحمل، الأدوية مثل سيتالوجن قد تزيد من خطر حدوث حالة<br />خطيرة في الأطفال تسمى ارتفاع ضغط الدم الرئوي المستمر للمولود<br />مما يجعل الطفل يتنفس بشكل أسرع ويبدو لونه ،)PPHN( الجديد<br />مزرق. عادة ما تبدأ هذه الأعراض خلال ال 24 ساعة الأولى بعد<br />ولادة الطفل. فإذا حدث ذلك لطفلك يجب عليك الاتصال بالقابلة و / أو<br />الطبيب على الفور. أيضا، إذا كنت تتناولين سيتالوجن خلال 3 أشهر<br />الأخيرة من الحمل وحتى تاريخ الميلاد يجب عليك أن تدركي أن الآثار<br />التالية قد يمكن مشاهدتها في المولود الجديد: نوبات، أن يكون ساخناً<br />جدا أو بارداً، صعوبات بالتغذية ، التقيؤ، مستوى السكر منخفض في<br />الدم، تصلب العضلات أو مرونتها، ردود فعل فرط النشاط، رعاش،<br />العصبيه، التهيج، الخمول، البكاء المستمر، النعاس أو صعوبات بالنوم.<br />إذا حدث لمولودك الجديد أي من هذه الأعراض يرجى الاتصال بقابلتك<br />و / أو الطبيب على الفور.<br />الرضاعة الطبيعية<br />إذا كنت تقومين بالرضاعة الطبيعية استفسري من طبيبك للحصول<br />على المشورة. يجب أن لا ترضعي طفلك أثناء تناول أقراص سيتالوجن<br />لأن كميات صغيرة من الدواء يمكن أن تنتقل إلى حليب الثدي.<br />الخصوبة<br />لقد تبين أن سيتالوجن يحد من نوعية الحيوانات المنوية في الدراسات<br />على الحيوانات. من الناحية النظرية يمكن أن يؤثر هذا على الخصوبة،<br />ولكن لم يلاحظ الأثر على الخصوبة البشرية حتى الآن.<br />القيادة واستخدام الآلات<br />أقراص سيتالوجن لا تؤثر عادة على القدرة على القيام بالأنشطة اليومية<br />العادية. ولكن إذا كنت تشعر بالدوار أو النعاس عند البدء في تناول هذا<br />الدواء، يجب أن تكون حذرا عند القيادة، تشغيل الآلات أو أداء الوظائف<br />التي تحتاج منك أن تكون في حالة تأهب حتى تختفى هذه الآثار .<br />معلومات مهمة عن بعض مكونات سيتالوجن<br />يحتوي هذا المنتج على اللاكتوز.<br />إذا أخبرك طبيبك أنك لا تتحمل بعض السكريات ، فاتصل بطبيبك قبل<br />تناول هذا المنتج الطبي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تناول دائما سيتالوجن تماما كما طبيبك قد أخبرك. يجب عليك التحقق<br />مع طبيبك أو الصيدلي إذا لم تكن متأكدا.<br />الكبار<br />الاكتئاب<br />الجرعة المعتادة هي 20 ملجم يوميا. ويمكن زيادة الجرعة من قبل<br />الطبيب إلى حد أقصى قدره 40 ملجم يوميا.<br />اضطرابات الهلع<br />جرعة البداية هي 10 ملجم يوميا لمدة الأسبوع الأول قبل زيادة<br />30 ملجم يوميا. ويمكن زيادة الجرعة من قبل الطبيب - الجرعة إلى 20<br />إلى حد أقصى قدره 40 ملجم يوميا.<br />المرضى المسنين )فوق 65 سنة من العمر(<br />يجب إنقاص جرعة البداية لنصف الجرعة الموصى بها، على سبيل<br />20 ملجم يوميا. وينبغي على المرضى كبار السن عادة عدم - المثال 10<br />تناول أكثر من 20 ملجم يوميا.<br />الأطفال والمراهقين )&gt; 18 عاما(<br />لا ينصح بإعطاء أقراص سيتالوجن للأطفال أو المراهقين. لمزيد من<br />المعلومات، الرجاء مراجعة قسم 2، قبل أن تتناول سيتالوجن.<br />المرضى الذين يعانون من مخاطر خاصة<br />المرضى الذين يعانون من شكاوى الكبد يجب أن لا يتناولوا أكثر من<br />20 ملجم من أقراص سيتالوجن يوميا.<br />كيف ومتى تتناول أقراص سيتالوجن<br />يتم تناول أقراص سيتالوجن كل يوم كجرعة واحدة يوميا. يمكن أن<br />تتناول أقراص سيتالوجن أي وقت من اليوم مع أو بدون الطعام. ابتلع<br />الأقراص مع شربة ماء. لا تمضغهم )لديهم مذاقا مرا(.<br />مدة العلاج<br />مثل الأدوية الأخرى لعلاج الاكتئاب و اضطرابات الهلع هذه الاقراص<br />قد تستغرق بضعة أسابيع قبل أن تشعر بأي تحسن. استمر في تناول<br />أقراص سيتالوجن حتى لو استغرق ذلك بعض الوقت قبل أن تشعر بأي<br />تحسن في حالتك. مدة العلاج حسب الشخص عادة ما لا يقل عن 6<br />أشهر. استمر في تناول أقراص سيتالوجن طالما يوصي بذلك الطبيب.<br />لا تتوقف عن تناولهم حتى لو كنت تبدأ في الشعور بالتحسن، إلا إذا<br />قيل لك أن تفعل ذلك من قبل الطبيب. قد يستمر المرض الأساسي لفترة<br />طويلة فإذا توقفت عن العلاج في وقت قصير قد ترجع الأعراض<br />مرة اخرى.<br />المرضى الذين لديهم الاكتئاب المتكرر يستفيدون من استمرار العلاج،<br />وأحيانا لعدة سنوات، لمنع وقوع نوبات اكتئاب جديدة.<br />لا تغير جرعة الدواء أبداً دون التحدث مع طبيبك أولا.<br />إذا كنت قد تناولت سيتالوجن أكثر مما يجب،<br />إذا كنت تعتقد أنك أو أي شخص آخر قد تناولت الكثير من أقراص<br />سيتالوجن ، فاتصل بطبيبك أو أقرب قسم طوارئ في المستشفى على<br />الفور. افعل ذلك حتى لو لم تكن هناك علامات عدم الراحة أو التسمم.<br />خذ علبة سيتالوجن معك إذا ذهبت إلى الطبيب أو المستشفى. قد تكون<br />بعض علامات فرط الجرعة مهددة للحياة.<br />أعراض الجرعة الزائدة قد تشمل:<br />&bull;عدم انتظام ضربات القلب<br />&bull;النوبات<br />&bull;تغيرات في نظم القلب<br />&bull;الشعور بالغثيان )الغثيان(.<br />&bull;قيء<br />&bull;التعرق<br />&bull;نعاس<br />&bull;فقدان الوعي<br />&bull;ضربات قلب سريعة<br />&bull;رعاش<br />&bull;تغيرات في ضغط الدم<br />.) &bull;متلازمة السيروتونين )انظر القسم 4<br />&bull;الهياج<br />&bull;دوار<br />&bull;تضخم بؤبؤ العين<br />&bull;جلد مزرق<br />&bull;التنفس بسرعة كبيرة<br />إذا نسيت أن تتناول أقراص سيتالوجن<br />إذا نسيت تناول جرعة ، فتناول الجرعة التالية في الوقت المعتاد. لا<br />تتناول جرعة مضاعفة.<br />الآثار المترتبة على إيقاف العلاج بسيتالوجن<br />إيقاف هذا الدواء بسرعة قد يسبب أعراض مثل الدوخة، والغثيان<br />التنميل أو وخز في اليدين أو القدمين، واضطرابات النوم )أحلام<br />اليقظة، والكوابيس، وعدم القدرة على النوم(، والشعور بالقلق،<br />والصداع، والشعور بالاعياء، والتعرق، والشعور بضيق الصدر أو<br />مهتاج ، رعاش، الشعور بالتشويش أو عدم الادراك، الشعور العاطفي<br />أو الانفعال، الإسهال )براز رخو(، اضطرابات بصرية، رفرفة أو قوة<br />ضربات القلب )خفقان(. هذه الأعراض عادة ما تكون غير خطيرة<br />وتختفي في غضون أيام قليلة. عند إكمال دورتك من العلاج عادة ما<br />تخفض جرعة سيتالوجن تدريجيا على مدى بضعة أسابيع.<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، إسأل طبيبك<br />أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>مثل جميع الأدوية يمكن لأقراص سيتالوجن أن يكون لها آثار جانبية<br />وبعض الناس قد تواجه الآثار غير المرغوب فيها )الآثار الجانبية(<br />في حين تناول اقراص سيتالوجن. العديد من الآثار الواردة أدناه يمكن<br />أيضا أن تكون أعراض مرضك وربما تختفي وأنت تبدأ في التحسن.<br />آثار جانبية خطيرة<br />توقف عن تناول أقراص سيتالوجن وطلب المشورة الطبية على الفور<br />إذا كنت تعاني من الأعراض التالية:<br />&bull;صعوبة في التنفس<br />&bull;تورم في الوجه والشفتين واللسان أو الحلق الذي يسبب صعوبة<br />في البلع أو التنفس.<br />&bull;حكة شديدة في الجلد )مع بقع مرتفعة المستوى(<br />&bull;سرعة وعدم انتظام ضربات القلب، والاغماء التي يمكن أن تكون<br />أعراض لحالة تهدد الحياة تعرف باسم &quot;تروساد دي بوينت&quot;.<br />&bull;إذا لاحظت أيًا من الأعراض التالية ، يجب عليك الاتصال بطبيبك<br />على الفور لأن جرعتك قد تحتاج إلى تقليلها أو إيقافها:<br />&bull;بدأت أن يحدث لك تشنجات لأول مرة أو أن النوبات التي كانت<br />تحدث لك زاد معدل تكرارها.<br />&bull;تغير سلوكك كأن تشعر بالغبطة أو بالحماسة.<br />&bull;واجهت ارتفاع في درجة الحرارة، والإثارة، والارتباك، ارتجاف<br />أو تقلصات مفاجئة للعضلات. هذه قد تكون دلائل على وجود حالة<br />نادرة تسمى متلازمة السيروتونين.<br />&bull;التعب، والارتباك وارتعاش العضلات الخاصة بك. قد تكون هذه<br />دلائل على وجود مستوى منخفض من الصوديوم في الدم.<br />إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو<br />اذهب إلى المستشفى على الفور.<br />الآثار الجانبية التالية غالبا ما تكون خفيفة وعادة ما تختفي بالعلاج<br />لبضعة أيام.<br />الآثار الجانبية الشائعة جدا )قد تؤثر على أكثر من 1 من كل 10<br />أشخاص(<br />&bull;النعاس<br />&bull;صعوبة في النوم<br />&bull;الصداع<br />&bull;تغييرات في نمط نومك<br />&bull;فقدان قوة الجسم ، ضعف<br />&bull;زيادة التعرق<br />&bull;جفاف الفم )يزيد الفم الجاف من خطر تسوس الأسنان ، لذا احرص<br />على تنظيف أسنانك أكثر من المعتاد(<br />&bull;الشعور بالغثيان )التوعك(.<br />الآثار الجانبية الشائعة )قد تؤثر على ما يصل إلى 1 من كل 10<br />أشخاص(<br />&bull;عدم وجود شهية<br />&bull;الانفعال<br />&bull;انخفاض الدافع الجنسي<br />&bull;القلق<br />&bull;العصبية<br />&bull;الارتباك<br />&bull;أحلام غير طبيعية<br />&bull;انخفاض الانفعالات واللامبالاة )اللامبالاة(<br />&bull;رعاش<br />&bull;وخز أو تنميل في اليدين أو القدمين<br />&bull;دوار<br />&bull;مشاكل التركيز<br />&bull;الصداع النصفي<br />&bull;فقدان الذاكرة .<br />&bull;رنين في الأذنين )الطنين(<br />&bull;خفقان القلب<br />&bull;التثاؤب<br />&bull;انسداد أو سيلان الأنف )التهاب مخاطية الأنف(.<br />&bull;الإسهال<br />&bull;القيء<br />&bull;الإمساك<br />&bull;آلام في المعدة<br />&bull;انتفاخ البطن )الريح(<br />&bull;زيادة إفراز اللعاب )سيلان اللعاب(<br />&bull;حكة<br />&bull;ألم في العضلات والمفاصل<br />&bull;الحكة<br />&bull;بالنسبة للرجال، ومشاكل في القذف والانتصاب<br />&bull;بالنسبة للإناث، فشل في الوصول إلى النشوة الجنسية<br />&bull;التعب<br />&bull;الثقب من الجلد<br />&bull;فقدان الوزن<br />غير شائعة )قد تؤثر على ما يصل إلى 1 من كل 100 شخص(<br />&bull;كدمات بسهولة<br />&bull;زيادة الشهية<br />&bull;العدوان<br />&bull;الهلوسة<br />&bull;هوس<br />&bull;الإغماء<br />&bull;كبر حدقة العين )المنتصف المظلم من العين(<br />&bull;ضربات القلب السريعة<br />&bull;ضربات القلب البطيئة<br />&bull;الطفح<br />&bull;فقدان الشعر<br />&bull;طفح<br />&bull;حساسية لأشعة الشمس<br />&bull;صعوبات التبول<br />&bull;نزيف حاد في الدورة الشهرية<br />&bull;تورم في الذراعين أو الساقين<br />&bull;زيادة الوزن<br />نادرة )قد تؤثر على ما يصل إلى 1 من كل 1000 شخص(<br />&bull;زيادة الدافع الجنسي<br />&bull;التشنجات<br />&bull;الحركات لا إرادية<br />&bull;اضطرابات التذوق<br />&bull;النزيف<br />&bull;السعال<br />&bull;التهاب الكبد الوبائي<br />&bull;الشعور بالتوعك<br />تم الابلاغ من بعض المرضى )تكرارها غير معروف(<br />&bull;نزيف مهبلي غزير بعد الولادة بفترة قصيرة )نزيف ما بعد<br />الولادة(، انظر &quot;الحمل والرضاعة والخصوبة&quot; في القسم 2 لمزيد<br />من المعلومات.<br />&bull;خواطر إيذاء أو قتل أنفسهم , انظر أيضًا القسم 2 &quot;قبل تناول<br />سيتالوجن&quot;<br />&bull;زيادة في النزف أو الكدمات الناجمة عن انخفاض في الصفائح<br />الدموية )سيولة الدم(<br />&bull;طفح جلدي )فرط الحساسية(<br />&bull;مستويات البوتاسيوم في الدم انخفاض )نقص بوتاسيوم الدم(،<br />الذي يمكن أن يسبب ضعف العضلات، والوخز أو عدم انتظام<br />ضربات القلب<br />&bull;نوبات الذعر<br />&bull;طحن بالأسنان<br />&bull;الأرق<br />&bull;حركات بالعضلات غير عادية أو تصلبها<br />&bull;حركات لا إرادية في العضلات )الاكاسزيا(<br />&bull;انخفاض ضغط الدم<br />&bull;النزيف الأنفي<br />&bull;تورم مفاجئ في الجلد أو الغشاء المخاطي<br />&bull;اضطرابات النزيف بما في ذلك الجلد والغشاء المخاطي )كدمة(<br />&bull;انتصاب مؤلم في الرجال<br />&bull;تدفق حليب الثدي عند الرجال أو في النساء اللواتي لا يقمن<br />بالرضاعة الطبيعية )ثر اللبن(<br />&bull;اختبارات وظائف الكبد غير طبيعية<br />&bull;وقد لوحظ زيادة خطر كسور العظام من كل المرضى الذين<br />يتناولون هذا النوع من الأدوية.<br />&bull;عدم انتظام ضربات القلب<br />نادرا جدا، تزيد من خطر النزيف، بما ،SSRIs مضادات الاكتئاب<br />في ذلك نزيف المعدة أو الامعاء. أخبر طبيبك إذا حدث تقيؤ الدم أو<br />براز أسود أو ملطخة بالدم.<br />دع أيضا طبيبك يعرف ما إذا كنت لا تزال تواجه الأعراض الأخرى<br />المرتبطة بالاكتئاب لديك. قد تشمل هذه الهلوسة، والقلق، الهوس أو<br />الارتباك.<br />أي آثار جانبية تحدث بالفعل سوف تختفي عادة بعد بضعة أيام. إذا<br />كانت مزعجة أو ثابتة، أو إذا ظهرت أي آثار جانبية غير عادية أخرى<br />أثناء تناول اقراص سيتالوجن، يرجى إخبار الطبيب بذلك.<br />إذا اصبح أي من الآثار الجانبية خطير، أو إذا لاحظت أي آثار جانبية<br />غير المذكورة من كل هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;يحفظ بعيداً عن متناول يد و نظر الأطفال<br />&bull;يحفظ في درجة حرارة أقل من 30 درجة مئوية<br />&bull;لا تستخدم الأقراص بعد تاريخ انتهاء الصلاحية المدون على العبوه<br />&bull;لا يجب التخلص من الأدوية عن طريق الصرف الصحي أو<br />النفايات المنزلية، اسأل الصيدلي عن كيفية التخلص من الأدوية<br />التي لا حاجة لها. هذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ماذا تحتوي أقراص سيتالوجن ؟<br />أقراص مغلفة<br />&bull;المادة الفعالة هي سيتالوبرام هيدروبرومايد )دستور الأدوية<br />الأمريكي( ما يعادل سيتالوبرام 10 ملجم، 20 ملجم أو 40 ملجم<br />&bull;السواغ هي اللاكتوز ) 200 شبكة( ، نشا الذرة ، السليلوز<br />كروسبوفيدون ،)K البوفيدون ) 30 ، PH ميكروكريستالين 101<br />Opadry II White( ، ستيرات المغنيسيوم و مادة التغليف<br />)OY-L-28900</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سيتالوجن 10 ملجم: قرص مغلف أبيض إلى أبيض داكن ، دائري<br />على جانب و 83 على الجانب RP محدب من الجانبين ، محفور<br />الآخر.<br />سيتالوجن 20 ملجم: قرص مغلف أبيض إلى أبيض داكن ، مستطيل<br />على جانب وخط فاصل على RP محدب من الجانبين ، محفور 84<br />الجانب الآخر.<br />سيتالوجن 40 ملجم: قرص مغلف أبيض إلى أبيض داكن ، على شكل<br />على جانب واحد وخط RP كبسولة محدب من الجانبين ، محفور 85<br />فاصل على الجانب الآخر.<br />العبوة:<br />عبوات تحتوي على ) 30 ( قرص مغلف من سيتالوجن 10 ملجم، 20<br />ملجم أو 40 ملجم.<br />يحتوي على 15 PVC/PVDC كل شريط شفاف من الألومنيوم<br />قرص مغلف .</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p>ص.ب. 442 الرياض 11411</p><p>فاكس: 966112650505</p><p>contact@riyadhpharma.com:البريد الإلكتروني</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111</p><p>marketing@riyadhpharma.comالبريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CITALOGEN 10mg FILM COATED TABLET
CITALOGEN 20mg FILM COATED TABLET
CITALOGEN 40mg FILM COATED TABLET
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet contains citalopram hydrobromide equivalent to 10 mg citalopram.
Coated tablet contains citalopram hydrobromide equivalent to 20 mg citalopram.
Coated tablet contains citalopram hydrobromide equivalent to 40 mg citalopram.
For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets
Citalogen 10 mg: white to off white,circular biconvex film coated tablet, with RP on one side and 83 on the other side.
Citalogen 20 mg: white to off white,boblong shaped, biconvex film coated tablet, with RP 84 on one side and break line on the other side.
Citalogen 40 mg: white to off white,capsule shaped, biconvex film coated tablet, with RP 85 on one side and break line on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence.</p><p>Citalogen/Citalopram is also indicated in the treatment of panic disorder with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology<br />MAJOR DEPRESSIVE EPISODES</strong></p><p>Adults:</p><p>Citalopram should be administered as a single oral dose of 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily. In general, improvement in patients starts after one week, but may only become evident from the second week of therapy.</p><p>As with all antidepressant medicinal products, dosage should be reviewed and adjusted, if necessary, within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen, some patients may benefit from having their dose increased up to a maximum of 40 mg a day (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose.</p><p>Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.</p><p><strong>PANIC DISORDER</strong></p><p>Adults:</p><p>A single oral dose of 10 mg is recommended for the first week before increasing the dose to 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily.</p><p>Patients should be started on 10 mg/day and the dose gradually increased in 10 mg steps according to the patient&#39;s response up to the recommended dose. A low initial starting dose is recommended to minimise the potential worsening of panic symptoms, which is generally recognised to occur early in the treatment of this disorder. Although there may be an increased potential for undesirable effects at higher doses, if after some weeks on the recommended dose insufficient response is seen some patients may benefit from having their dose increased gradually up to a maximum of 40 mg/day (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose.</p><p>Patients with panic disorder should be treated for a sufficient period to ensure that they are free from symptoms. This period may be several months or even longer.</p><p><u>Elderly patients (&gt; 65 years of age)</u></p><p>For elderly patients the dose should be decreased to half of the recommended dose, e,g, 10-20 mg daily. The recommended maximum dose for the elderly is 20 mg daily.</p><p><u>Children and adolescents (&lt; 18 years of age)</u></p><p>Citalopram should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4).</p><p><u>Reduced hepatic function</u></p><p>An initial dose of 10 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2).</p><p><u>Reduced renal function</u></p><p>Dosage adjustment is not necessary in cases of mild or moderate renal impairment. No information is available in cases of severe renal impairment (creatinine clearance &lt;20 mL / min).</p><p><u>Poor metabolisers of CYP2C19</u></p><p>An initial dose of 10 mg daily during the first two weeks of treatment is recommended for patients who are known to be poor metabolisers with respect to CYP2C19. The dose may be increased to a maximum of 20 mg daily depending on individual patient response (see section 5.2).</p><p><strong>Withdrawal symptoms seen on discontinuation of citalopram</strong>Abrupt discontinuation should be avoided. When stopping treatment with citalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see section 4.4 Special Warnings and Precautions for Use and section 4.8 Undesirable Effects). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><strong>Method of administration</strong></p><p>Citalopram tablets are administered as a single daily dose. Citalopram tablets can be taken at any time of the day without regard to food intake</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Monoamine Oxidase Inhibitors (MAOIs)
Some cases presented with features resembling serotonin syndrome.
Citalopram should not be given to patients receiving MAOIs, including selegiline, in daily doses exceeding 10 mg/day.
Citalopram should not be given for fourteen days after discontinuation of an irreversible MAOI or for the time specified after discontinuation of a reversible MAOI (RIMA) as stated in the prescribing text of the RIMA.
MAOIs should not be introduced for seven days after discontinuation of citalopram (see section 4.5).
Citalopram is contraindicated in combination with linezolid unless there are facilities for close observation and monitoring of blood pressure (see section 4.5).
Citalopram is contraindicated in patients with known QT-interval prolongation or congenital long QT syndrome.
Citalopram is contraindicated together with medicinal products that are known to prolong the QT-interval (see section 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Suicide/suicidal thoughts or clinical worsening<br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related<br />events). This risk persists until significant remission occurs. As improvement may not occur during the first few<br />weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general<br />clinical experience that the risk of suicide may increase in the early stages of recovery.<br />Other psychiatric conditions for which Citalogen is prescribed can also be associated with an increased risk of<br />suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The<br />same precautions observed when treating patients with major depressive disorder should therefore be observed<br />when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation<br />prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and<br />should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of<br />antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour<br />with antidepressants compared to placebo in patients less than 25 years old.<br />Close supervision of patients and in particular those at high risk should accompany drug therapy especially in<br />early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the<br />need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour<br />and to seek medical advice immediately if these symptoms present.<br />Use in children and adolescents under 18 years of age<br />Citalogen should not be used in the treatment of children and adolescents under the age of 18 years. Suiciderelated<br />behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional<br />behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated<br />with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is<br />nevertheless taken; the patient should be carefully monitored for the appearance of suicidal symptoms.<br />In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and<br />behavioural development are lacking.<br />Elderly patients<br />Caution should be used in the treatment of elderly patients (see section 4.2).<br />Reduced kidney and liver function<br />Caution should be used in the treatment of patients with reduced kidney and liver function (see section 4.2).<br />Paradoxical anxiety<br />Some patients with panic disorder may experience intensified anxiety symptoms at the start of treatment with<br />antidepressants. This paradoxical reaction usually subsides within the first two weeks of starting treatment. A<br />low starting dose is advised to reduce the likelihood of a paradoxical anxiogenic effect (see section 4.2).<br />Hyponatraemia<br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported as a<br />rare adverse reaction with the use of SSRIs and generally reverses on discontinuation of therapy. Elderly female<br />patients seem to be at particularly high risk.<br />Akathisia/psychomotor restlessness<br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively<br />unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still.<br />This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms,<br />increasing the dose may be detrimental.<br />Mania<br />In patients with manic-depressive illness a change towards the manic phase may occur. Should the patient enter<br />a manic phase citalopram should be discontinued.<br />Seizures<br />Seizures are a potential risk with antidepressant drugs. Citalopram should be discontinued in any patient who<br />develops seizures. Citalopram should be avoided in patients with unstable epilepsy and patients with controlled<br />epilepsy should be carefully monitored. Citalopram should be discontinued if there is an increase in seizure<br />frequency.<br />Diabetes<br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral<br />hypoglycaemic dosage may need to be adjusted.<br />Angle-closure Glaucoma<br />SSRIs including citalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has<br />the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma,<br />especially in patients pre-disposed. Citalopram should therefore be used with caution in patients with angleclosure<br />glaucoma or history of glaucoma.<br />Serotonin syndrome<br />In rare cases, serotonin syndrome has been reported in patients using SSRIs. A combination of symptoms such<br />as agitation, tremor, myoclonus, and hyperthermia may indicate the development of this condition (see section<br />4.5). Treatment with citalopram should be discontinued immediately and symptomatic treatment initiated.<br />Concomitant administration of serotonergic agents, such as MAO inhibitors, selective serotonin re-uptake<br />inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants, and<br />buprenorphine-containing medicinal products may result in serotonin syndrome, a potentially life-threatening<br />condition (see section 4.5).<br />If concomitant treatment with buprenorphine-containing medicinal products is clinically warranted, careful<br />observation of the patient is advised, particularly during treatment initiation and dose increases.<br />Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular<br />abnormalities, and/or gastrointestinal symptoms.<br />If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered<br />depending on the severity of the symptoms.<br />Serotonergic medicines<br />Citalopram should not be used concomitantly with medicinal products with serotonergic effects such as<br />sumatriptan or other triptans, tramadol, oxitriptan and tryptophan.<br />Haemorrhage<br />There have been reports of prolonged bleeding time and /or bleeding abnormalities such as ecchymoses,<br />gynaecological haemorrhages, gastrointestinal bleeding and other cutaneous or mucous bleedings with SSRIs<br />(see section 4.8). SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections 4.6, 4.8).<br />Caution is advised in patients taking SSRIs, particularly with concomitant use of active substances known to<br />affect platelet function or other active substances that can increase the risk of haemorrhage, as well as in<br />patients with a history of bleeding disorders (see section 4.5).<br />ECT (electroconvulsive therapy)<br />There is limited clinical experience of concurrent administration of SSRIs and ECT; therefore caution is<br />advisable.<br />Reversible, selective MAO-A inhibitors<br />For information on concomitant treatment with non-selective, irreversible MAO-inhibitors see section 4.5.<br />St. John&#39;s wort<br />Undesirable effects may be more common during concomitant use of citalopram and herbal preparations<br />containing St John&#39;s wort (Hypericum perforatum). Therefore citalopram and St John&#39;s wort preparations should<br />not be taken concomitantly (see section 4.5).<br />Withdrawal symptoms seen on discontinuation of SSRI treatment<br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see<br />section 4.8 Undesirable effects). In a recurrence prevention clinical trial with citalopram, adverse events after<br />discontinuation of active treatment were seen in 40% patients versus 20% in patients continuing citalopram.<br />The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of<br />therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep<br />disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor,<br />confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances<br />are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some<br />patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment,<br />but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.<br />Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they<br />may be prolonged (2-3 months or more). It is therefore advised that citalopram should be gradually tapered<br />when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see<br />&ldquo;Withdrawal symptoms seen on discontinuation of citalopram&rdquo;, Section 4.2)<br />Sexual dysfunction<br />Selective serotonin reuptake inhibitors (SSRIs/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause<br />symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction<br />where the symptoms have continued despite discontinuation of SSRIs/SNRI.<br />Psychosis<br />Treatment of psychotic patients with depressive episodes may increase psychotic symptoms.<br />QT-interval prolongation<br />Citalopram has been found to cause a dose-dependent prolongation of the QT-interval. Cases of QT interval<br />prolongation and ventricular arrhythmia including torsade de pointes have been reported during the postmarketing<br />period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT<br />prolongation or other cardiac diseases (see sections 4.3, 4.5, 4.8, 4.9 and 5.1).<br />Caution is advised in patients with significant bradycardia; or in patients with recent acute myocardial infarction<br />or uncompensated heart failure.<br />Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for malignant<br />arrhythmias and should be corrected before treatment with citalopram is started.<br />If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is<br />started.<br />ECG monitoring may be advisable in case of overdose or conditions of altered metabolism with increased peak<br />levels, e.g. liver impairment.<br />If signs of cardiac arrhythmia occur during treatment with citalopram, the treatment should be withdrawn and<br />an ECG should be performed.<br />Sexual dysfunction<br />Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause<br />symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction<br />where the symptoms have continued despite discontinuation of SSRIs/SNRI.<br />Excipients<br />The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not receive this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>At the pharmacodynamic level cases of serotonin syndrome with citalopram and moclobemide and buspirone have been reported.</p><p><em><u>Contraindicated combinations</u></em></p><p><em>MAO-inhibitors</em></p><p>The simultaneous use of citalopram and MAO-inhibitors can result in severe undesirable effects, including serotonin syndrome (see section 4.3).</p><p>Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), including the irreversible MAOI selegiline and the reversible MAOIs linezolid and moclobemide and in patients who have recently discontinued an SSRI and have been started on a MAOI.</p><p>Some cases presented with features resembling serotonin syndrome. Symptoms of an active substance interaction with a MAOI include: agitation, tremor, myoclonus, and hyperthermia.</p><p><em>QT interval prolongation</em></p><p>Pharmacokinetic and pharmacodynamic studies between citalopram and other medicinal products that prolong the QT interval have not been performed. An additive effect of citalopram and these medicinal products cannot be excluded. Therefore, co-administration of citalopram with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (astemizole, mizolastine) etc., is contraindicated.</p><p><em>Pimozide</em></p><p>Co-administration of a single dose of pimozide 2 mg to subjects treated with racemic citalopram 40 mg/day for 11 days caused an increase in AUC and Cmax of pimozide, although not consistently throughout the study. The co-administration of pimozide and citalopram resulted in a mean increase in the QTc interval of approximately 10 msec. Due to the interaction noted at a low dose of pimozide, concomitant administration of citalopram and pimozide is contraindicated.</p><p><em><u>Combinations requiring precaution for use</u></em></p><p><em>Selegiline (selective MAO-B inhibitor)</em></p><p>A pharmacokinetic / pharmacodynamic interaction study with concomitantly administered citalopram (20 mg daily) and selegiline (10 mg daily) (a selective MAO B inhibitor) demonstrated no clinically relevant interactions. The concomitant use of citalopram and selegiline (in doses above 10 mg daily) is contraindicated.</p><p><em>Serotonergic medicinal products</em></p><p>Lithium and tryptophan</p><p>No pharmacodynamic interactions have been found in clinical studies in which citalopram has been given concomitantly with lithium. However there have been reports of enhanced effects when SSRIs have been given with lithium or tryptophan and therefore the concomitant use of citalopram with these medicinal products should be undertaken with caution. Routine monitoring of lithium levels should be continued as usual.</p><p>Co-administration with serotonergic medicinal products (e.g. tramadol, sumatriptan) may lead to enhancement of 5-HT associated effects.</p><p>Until further information is available, the simultaneous use of citalopram and 5-HT agonists, such as sumatriptan and other triptans, is not recommended (see section 4.4).</p><p><em>Buprenorphine-containing medicinal products</em></p><p>Citalopram should be used cautiously when co-administered with Buprenorphine-containing medical products as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).</p><p><em><u>Desipramine, imipramine</u></em></p><p>In a pharmacokinetic study no effect was demonstrated on either citalopram or imipramine levels, although the level of desipramine, the primary metabolite of imipramine, was increased. When desipramine is combined with citalopram, an increase of the desipramine plasma concentration has been observed. A reduction of the desipramine dose may be needed.</p><p><em>St. John&#39;s wort</em></p><p>Dynamic interactions between SSRIs and the herbal remedy St John&#39;s wort (<em>Hypericum perforatum</em>) can occur, resulting in an increase in undesirable effects (see section 4.4). Pharmacokinetic interactions have not been investigated.</p><p><em>Haemorrhage</em></p><p>Caution is warranted for patients who are being treated simultaneously with anticoagulants, medicinal products that affect the platelet function, such as non steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, dipyridamole, and ticlopidine or other medicines (e.g. atypical antipsychotics) that can increase the risk of haemorrhage (see section 4.4).</p><p><em>ECT (electroconvusive therapy)</em></p><p>There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and citalopram (see section 4.4).</p><p><em>Alcohol</em></p><p>No pharmacodynamic or pharmacokinetic interactions have been demonstrated between citalopram and alcohol. However, the combination of citalopram and alcohol is not advisable.</p><p><em>Medicinal products inducing hypokalaemia/hypomagnesaemia</em></p><p>Caution is warranted for concomitant use of hypokalaemia- / hypomagnesaemia-inducing medicinal products as these conditions increase the risk of malignant arrhythmias.</p><p><em>Medicinal products lowering the seizure threshold</em></p><p>SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g. antidepressants [SSRIs], neuroleptics [thioxanthenes and butyrophenones]), mefloquine, bupropion and tramadol).</p><p><u>Pharmacokinetic interactions</u></p><p>Biotransformation of citalopram to demethylcitalopram is mediated by CYP2C19 (approx. 38%), CYP3A4 (approx. 31%) and CYP2D6 (approx. 31%) isozymes of the cytochrome P450 system. The fact that citalopram is metabolised by more than one CYP means that inhibition of its biotransformation is less likely as inhibition of one enzyme may be compensated by another. Therefore co-administration of citalopram with other medicinal products in clinical practice has very low likelihood of producing pharmacokinetic medicinal product interactions.</p><p><em>Food</em></p><p>The absorption and other pharmacokinetic properties of citalopram have not been reported to be affected by food.</p><p><em><u>Effect of other medicinal products on the pharmacokinetics of citalopram</u></em></p><p>Co-administration with ketoconazole (potent CYP3A4 inhibitor) did not change the pharmacokinetics of citalopram.</p><p>A pharmacokinetic interaction study of lithium and citalopram did not reveal any pharmacokinetic interactions (see also above).</p><p><u>Cimetidine</u></p><p>Cimetidine (potent CYP2D6, 3A4 and 1A2 inhibitor) caused a moderate increase in the average steady state levels of citalopram. Caution is advised when administering citalopram in combination with cimetidine. Dose adjustment may be warranted.</p><p>Co-administration of escitalopram (the active enantiomer of citalopram) with omeprazole 30 mg once daily (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram.</p><p>Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluconazole, fluvoxamine, lansoprazole, ticlopidine). A reduction in the dose of citalopram may be necessary based on monitoring of undesirable effects during concomitant treatment.</p><p><u>Metoprolol</u></p><p>Escitalopram (the active enantiomer of citalopram) is an inhibitor of the enzyme CYP2D6. Caution is recommended when citalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted. Co-administration with metoprolol resulted in a twofold increase in the plasma levels of metoprolol, but did not statistically significant increase the effect of metoprolol on the blood pressure and cardiac rhythm.</p><p><em><u>Effects of citalopram on other medicinal products</u></em></p><p>A pharmacokinetic / pharmacodynamic interaction study with concomitant administration of citalopram and metoprolol (a CYP2D6 substrate) showed a twofold increase in metoprolol concentrations, but no statistically significant increase in the effect of metoprolol on blood pressure and heart rate in healthy volunteers.</p><p>Citalopram and demethylcitalopram are negligible inhibitors of CYP2C9, CYP2E1 and CYP3A4, and only weak inhibitors of CYP1A2, CYP2C19 and CYP2D6 as compared to other SSRIs established as significant inhibitors.</p><p><em>Levomepromazine, digoxin, carbamazepine</em></p><p>No change or only very small changes of clinical importance were observed when citalopram was given with CYP1A2 substrates (clozapine and theophylline), CYP2C9 (warfarin), CYP2C19 (imipramine and mephenytoin), CYP2D6 (sparteine, imipramine, amitriptyline, risperidone) and CYP3A4 (warfarin, carbamazepine (and its metabolite carbamazepine epoxid) and triazolam).</p><p>No pharmacokinetic interaction was observed between citalopram and levomepromazine, or digoxin, (indicating that citalopram neither induces nor inhibits P-glycoprotein).</p><p><em>Desipramine, imipramine</em></p><p>In a pharmacokinetic study no effect was demonstrated on either citalopram or imipramine levels, although the level of desipramine, the primary metabolite of imipramine was increased. When desipramine is combined with citalopram, an increase of the desipramine plasma concentration has been observed. A reduction of the desipramine dose may be needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Published data on pregnant women (more than 2500 exposed outcomes) indicate no malformative foeto / neonatal toxicity, however, citalopram should not be used during pregnancy unless clearly necessary and only after careful consideration of risk/benefit.</p><p>Neonates should be observed if maternal use of citalopram continues into the later stages of pregnancy, particular in the third trimester. Abrupt discontinuation should be avoided during pregnancy.</p><p>The following symptoms may occur in the neonates after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours) after delivery.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p><u>Breast-feeding</u></p><p>Citalopram is excreted into breast milk. It is estimated that the suckling infant will receive about 5% of the weight related maternal daily dose (in mg/kg). No or only minor events have been observed in the infants. However, the existing information is insufficient for assessment of the risk to the child.</p><p>Caution is recommended. If treatment with citalopram is considered necessary, discontinuation of breast feeding should be considered.</p><p><u>Fertility</u></p><p>Animal data have shown that citalopram may affect sperm quality (see section 5.3).</p><p>Human case reports with some SSRIs have shown that an effect on sperm quality is reversible.</p><p>Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citalopram has minor or moderate influence on the ability to drive and use machines.</p><p>Patients who are prescribed psychotropic medication may be expected to have some impairment of general attention and concentration due to the illness itself and psychoactive medicinal products can reduce the ability to make judgements and to react to emergencies. Patients should be informed of these effects and be warned that their ability to drive a car or operate machinery could be affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects observed with citalopram are in general mild and transient. They are most frequent during the<br />first one or two weeks of treatment and usually attenuate subsequently. The adverse reactions are presented at<br />the MedDRA Preferred Term Level.<br />For the following reactions a dose-response was discovered: Sweating increased, dry mouth, insomnia,<br />somnolence, diarrhoea, nausea and fatigue.<br />The table shows the percentage of adverse drug reactions associated with SSRIs and/or citalopram seen in either<br />&ge; 1% of patients in double-blind placebo-controlled trials or in the post-marketing period. Frequencies are<br />defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1000 to &lt;1/100); rare (&ge;1/10000<br />to &lt;1/1000); very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RD+RXhpZgAATU0AKgAAAAgABAE7AAIAAAARAAAISodpAAQAAAABAAAIXJydAAEAAAAiAAAQ1OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE1vaGFtbWVkIE1haG1vdWQAAAAFkAMAAgAAABQAABCqkAQAAgAAABQAABC+kpEAAgAAAAMyNwAAkpIAAgAAAAMyNwAA6hwABwAACAwAAAieAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMzowNjoxOSAxNjo1MzozOAAyMDIzOjA2OjE5IDE2OjUzOjM4AAAATQBvAGgAYQBtAG0AZQBkACAATQBhAGgAbQBvAHUAZAAAAP/hCyNodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIzLTA2LTE5VDE2OjUzOjM4LjI3MDwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5Nb2hhbW1lZCBNYWhtb3VkPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAXICLwMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APad+k2K3txr2qG1iF4I45Lm/aFQWRGCD5gOrHA61rJpFhKm6KS4dckZW9lI44/vVxXiiLF99vtdfj0C/sZ5JYru8hD2ZQxQq6TEkBc5XByD1x3FVrS/8TrpvhrUIVm06zvmlsbzTtPhiMcUrlxHdRmSMsELYbBOAGXggEEWq/r+vL+rg9D0D+xLP1uv/Ayb/wCKo/sSz9br/wADJv8A4quLl1PW7PxHqOmS6/c3kg06V7SOGGDKlEA3yJ5YcOXDYYZjbkAKRiuR8N+LfFZtvCOm2Or27reaal211qU6ILqbfiW2G2BizKM/KCr5OSxwRTSu9P63/wAgeiv/AF0/zPYv7Es/W6/8DJv/AIqj+xLP1uv/AAMm/wDiq8V1T4ja3H4jvLGPxitvFH4rTTMiO1JitXjJJ+aM/dYEBj6EHNdd4R8aa1qvwa1TW7aZNc1iye8jhZVTMxjdvLysYAzt2nAAz+NL7PN/Wyf6odrS5f66r9DvP7Es/W6/8DJv/iqP7Es/W6/8DJv/AIqvJdS8f63beENVu7TxIj29rdWCWutOtuyzNKw8+EgIEIQE9AGGOTkE1d8eeIvEWh6tbaVZeMrS2kuLcy280stjbsWabgyiYEGMR/KDEC5IyQadtbedvwuLpc9N/sSz9br/AMDJv/iqP7Es/W6/8DJv/iq85fxpqkHxM0/TYtckubB799NuopraJFQi280OGC7ixP8AESFbkBOMnO+H3xD1fVPE2gWep+IodQi1JdRjdGSBSWhmxEQUUHcUz7EDOO9CV7W/rqJ6K7PVm0ayRSzvcqqjJJvZQAP++qr6db6Jq9kl5pN+19auSEnttRkkRsHBwyuQcHiubvPEGpSfFSXRptaTRbW1hgntbeSGN11RDu84ZYbsrhR8jDb1IIrzfSvGVzpXwvT/AIRvXPIu1l1a7RLeGOUTGOYuAzsGAGGB2qu5gwO5QMlaWuVbW39ao91/sSz9br/wMm/+Ko/sSz9br/wMm/8Aiq4ZfEusz64m3W41+3ab51lbQwJJFE3kBi8qbfNI3nh1coeFIDcno/Aepz6p4fke8v5tQnhuHhe4k8llZgBnY8SqjqCSAdoPUEZBquVp2/rsTzJpPv8A5XNb+xLP1uv/AAMm/wDiqP7Es/W6/wDAyb/4qtCipGZ/9iWfrdf+Bk3/AMVR/Yln63X/AIGTf/FVoUUAZ/8AYln63X/gZN/8VR/Yln63X/gZN/8AFVoUUAchfy6bpPiKYatqTWOmRWQleS51B40RzIFBLswx1x1qxpep+D9cuza6J4itNRuApcw2msmVwo6nCyE45HPvWV43vLawfXpr65htov7AlTzJpAi7mOFGT3JIAHcmuG8Ma3f6T+zO+s2niDT0m0/T1Wxltoo99rIDzFJvLhmbKg8DIIwAeSLr5W/G47fCl1v+h7L/AGJZ+t1/4GTf/FUf2JZ+t1/4GTf/ABVee+KvEfifSrfQIdM1m0eLWnZxqt00cEMTeWhji3CKRdrtuI4yfuhgeao6/wDELX9N1e5ilvIbO7t7+xsk07YpWeKcJvuBuXecMWVTkKMfMCejs27fL+v689ib6X8r/wBf1+J6h/Yln63X/gZN/wDFUf2JZ+t1/wCBk3/xVeU2fjjxBa+OrHStS14t/wAVHeWEtrNHboXt/J3wZwgIJONpBG7PeqFx8QvGI+Het6/c6vY6dPDLGi26yRyTWU3nhGieNoVCqUOcMzseobHRLVJ97fjb/Mp6O39btfoey/2JZ+t1/wCBk3/xVH9iWfrdf+Bk3/xVeV/8LE1ZbPWIDrUbwWfiNLCbVUSEvY2joG8wgKUwGyoZlIHfOCa6OdvFFrrmjwjxJdahYataPa/arO0t1WC4UBlnAKN8rIr8Elc9ByMNK/8AXlf+vMX9fjb+vI7H+xLP1uv/AAMm/wDiqP7Es/W6/wDAyb/4qr6KVjVWYuQMFmxk+/HFLSAz/wCxLP1uv/Ayb/4qj+xLP1uv/Ayb/wCKrQooAz/7Es/W6/8AAyb/AOKo/sSz9br/AMDJv/iq0KKAM/8AsSz9br/wMm/+Ko/sSz9br/wMm/8Aiq0KKAOd1CHTdMvlkv72S0sUtZJZpZ7+RETDIASxfgfMe/eoU1TwfLb2s8fiK0eG8lMNtIuskrPIDjYh8zDNyOBzzV/VoXuL9oYhl5NOuEUepJjArkPhtqNlP4E8NaNHdx/2npcSpfWgYebaMqOD5iHlOeORz2zQuvlb9b/d+oP/AD/4H3ncf2JZ+t1/4GTf/FVTRNBk1eTSo9SD6jFH5klmupuZkTj5im/IHI5x3ryzwf8AErXbvU9Kiudci1c3tvqgFuUgUySQSfuduxV+Zl/AjnHesrTvFepN4x/t+2u11nW28GSzi3KIuy4Eu5oAiAH5CCNpy3HJJp+b21/J/wCQ7brre34pfqe6f2JZ+t1/4GTf/FVFFp+lzzTRQXMskkDBJkS/lJjYgEBgH4OCDz2NebReKPEx8EW2r3XiWzNs0xl+0adLDNPLGUAEYZ7dImkEhx5YVWIIAbcDux7rx5fWN54mNn4mtraSDxPZWySNBahnhkCq6yfIC20Bhk/MPLxu4NPlfNy/1ul+pN/dv/XX/I9m/sSz9br/AMDJv/iqqWMWhamJzpuo/bBbSmGf7PqUknlSDqjYfhh6HmuB8ceLdb8L6lDbWniKSeezFtNPFJZRIk0UtyUJdsEnCnHybMYySdwAo6VqWqaR4/1WLS7k+dqHij59NdExcWhiQSXAyu8BCp+YHbnIOTSiub+vNL9fwG9F/XZv9D03ToNE1e1+1aTfm+t9xTzrbUpJE3DqMq5GRVr+xLP1uv8AwMm/+Krw7RfF2q2WjpZ+F76wt4r/AMRaksmoz3SJFHJ5m6JGYxyAB88fKCw4DAnNek/ELxFrfh/wfp1zZeRBPc3MMF7eeZ5cVmrA7pNzxvtXdgbmQgA8il0T72/EPtNev4G7exaFp01vFqGofZJLqTyrdJ9SkQzP/dUF/mPsKLCLQtV8/wDszUftn2eQxTfZ9Skk8px1VsOcH2PNeU6tcR3fxE05PFnieyiu08NTySiGS3eFJFdWV0MsXcKJASBymR8oIOd4S17V9O8N+DbDwte6dCNRsDLLf3kkcS3NzGQv2ZmWByxVcgL8rkD7/HNRV/682v0Ym7a/1sv8z3L+xLP1uv8AwMm/+Ko/sSz9br/wMm/+Krzs+JPEOpJ4vZdbax1HS0u4odEjto3cKqZgnQld/wA2DydynIAAIrr/AIdyNN8OdCmfUZNSaSyjdriRkJJKjK5QAcHj145JOTSWqv6fjf8AyG9Hb1/C3+Zq/wBiWfrdf+Bk3/xVH9iWfrdf+Bk3/wAVWhRSAz/7Es/W6/8AAyb/AOKo/sSz9br/AMDJv/iq0KKAM/8AsSz9br/wMm/+Ko/sSz9br/wMm/8Aiq0KKAM/+xLP1uv/AAMm/wDiqP7Es/W6/wDAyb/4qtCigDP/ALEs/W6/8DJv/iqP7Es/W6/8DJv/AIqtCigDP/sSz9br/wADJv8A4qj+xLP1uv8AwMm/+KrQooAz/wCxLP1uv/Ayb/4qj+xLP1uv/Ayb/wCKrQooAz/7Es/W6/8AAyb/AOKo/sSz9br/AMDJv/iq0KKAM/8AsSz9br/wMm/+Ko/sSz9br/wMm/8Aiq0KKAM/+xLP1uv/AAMm/wDiqP7Es/W6/wDAyb/4qtCigDB02+nW41HydNuZl+1Y3BkXkRoOjMD2yD6EVO8k0l2ly+j3xkQYUfaU2Drzs8zbnk84z+Qri/F2p6hpWrac1nreqada3mrG2uU02xjupGX7JvDKhhkbdlAOBjBPHcN0zxdrV5p2nSw6mJIR4iXTpJLmzEdzPBj/AJaR8eU+c/wgkYIC5prX+vNL9Ql7qu/63f6He/2hef8AQHuv+/kP/wAXR/aF5/0B7r/v5D/8XWN/wn+mJKTdWt9bWbxSS2t9JGphuwn3vL2sWz6BlUt1GRTh45tVS4iudK1K11GF40TTZUiM0xk3eXsKuUIO1uS4xtO7GKQGv/aF5/0B7r/v5D/8XR/aF5/0B7r/AL+Q/wDxdYXgvxBqF/4X1LUNcE009pfXUZijtgsgSNyAgjUtlsDHBbJ7mq1p8U9JuzHEmm6oLyS9NgLURxyMJhGJNpdJGjXKnu/Y5xg4P6+8dn+f4HTf2hef9Ae6/wC/kP8A8XWPrGgaV4huPO17weupSCPylN4IJRGvP3AzkKTnkrgnAyeBjC8V/EaU+Ary/wDCsF5HqC6e14We2jf7CoLD96pcDJKOvy78EZwQK3vEuqanYp4cksblIkutSggulaEM0qODkAk4XkdcH8Kdvzt+gm+VX8m/u1NSC5uLa3jgg0W6SKJAiKJYuABgD79P/tC8/wCgPdf9/If/AIuubv8A4l2umaPPqF5oGtKlrdSW9zCiQSSwBFDNKyrKfkwQcjJxg4wQS9viTp8c0sc+k6tEIZreOV3hjwi3BAikOHyVJOMAFweqgc0av+u4Wt/XY6H+0Lz/AKA91/38h/8Ai6P7QvP+gPdf9/If/i65n/hYltqlkV0q2vrJ7sXMFlfXtqBEbiEPuQx7w+RsY4YKCARnPFReGPiCb3wrBNqOm6nNqEOl2t7Lst0/0vzRjdGA2ANwbO7YAOTheaLOzf8AWt/8g62/r+tTq/7QvP8AoD3X/fyH/wCLo/tC8/6A91/38h/+LrlLX4n2+pX2lrp2k30tpeQ3ck0q+U7Q/Z2CuMJId/J/g3ZyMZycXtK8b2t5b6athaavqiXEEEst0LePMCy/6tpVUryep2Kdo5OBzRZ/1/XkGxu/2hef9Ae6/wC/kP8A8XR/aF5/0B7r/v5D/wDF1oUUgM/+0Lz/AKA91/38h/8Ai6P7QvP+gPdf9/If/i60KKAM/wDtC8/6A91/38h/+Lo/tC8/6A91/wB/If8A4utCigDmPtU6+NfNFhM0jafgwh03KPM6k7sdux71r/2hef8AQHuv+/kP/wAXVJf+SgP/ANg3/wBqCt2gDP8A7QvP+gPdf9/If/i6z9ZsofEFpFbav4furiGGeO4RftCJiRDuVsrIOh7dK6CigDP/ALQvP+gPdf8AfyH/AOLo/tC8/wCgPdf9/If/AIutCigDP/tC8/6A91/38h/+LqDfN9sN0dHvjLgAbrlCq8EZCmTaDyeQMmteigDP/tC8/wCgPdf9/If/AIuj+0Lz/oD3X/fyH/4utCigDP8A7QvP+gPdf9/If/i6P7QvP+gPdf8AfyH/AOLrQooAz/7QvP8AoD3X/fyH/wCLo/tC8/6A91/38h/+LrQooAz/AO0Lz/oD3X/fyH/4uj+0Lz/oD3X/AH8h/wDi60KKAMSS8uf7btpP7NuN/wBnmXyt8e7G6P5s7sY7dc1b/tC8/wCgPdf9/If/AIuiT/kZLb/r0m/9DjrQoAz/AO0Lz/oD3X/fyH/4uj+0Lz/oD3X/AH8h/wDi60KKAM/+0Lz/AKA91/38h/8Ai6P7QvP+gPdf9/If/i60KKAM/wDtC8/6A91/38h/+Lo/tC8/6A91/wB/If8A4utCigDP/tC8/wCgPdf9/If/AIuj+0Lz/oD3X/fyH/4utCigDP8A7QvP+gPdf9/If/i6P7QvP+gPdf8AfyH/AOLrQooAz/7QvP8AoD3X/fyH/wCLo/tC8/6A91/38h/+LrQooAz/AO0Lz/oD3X/fyH/4uj+0Lz/oD3X/AH8h/wDi60KKAM/+0Lz/AKA91/38h/8Ai6P7QvP+gPdf9/If/i60KKAM/wDtC8/6A91/38h/+Lo/tC8/6A91/wB/If8A4utCigDP/tC8/wCgPdf9/If/AIuj+0Lz/oD3X/fyH/4utCigDP8A7QvP+gPdf9/If/i6P7QvP+gPdf8AfyH/AOLrQooAz/7QvP8AoD3X/fyH/wCLo/tC8/6A91/38h/+LrQooAz/AO0Lz/oD3X/fyH/4uj+0Lz/oD3X/AH8h/wDi60KKAM/+0Lz/AKA91/38h/8Ai6P7QvP+gPdf9/If/i60KKAM/wDtC8/6A91/38h/+Lo/tC8/6A91/wB/If8A4utCigDP/tC8/wCgPdf9/If/AIuj+0Lz/oD3X/fyH/4utCigDjrzwp/wkOqi7Gt6lpsmm3xmgFkICN5t1TcfNifJ2swx056Z5pV+HFkqxuNX1U3X9opqVxds8LSXUyrtXfmPaFCjG1FWodU1u6tZ7/R9Ii36leCaZX+0CHyY44YQzhijgsC67QVwT1IHNZfhTxdeL4X06SfT7/UL6Lw7bXhne5dxdFyAfkXccgjJbaWx0B6U1tf+ur/9t/qw5LTX+un6m+nw70o28tpc3V9dWGyRLayllXy7MPnd5RVQ468bmbb0XFOk8BWlxan7Xq2p3GoCSKSPVHeIXERi3eXt2xhMDe/VDncc5qs3ji7uLcf2PpVrqFzDbtdXUS6iFVYldk+Rth3OSjYVgmMfMVPFVrf4lNdw6hcw6K8draXEFtG89yqtcSTiMw7VAIAPmrksQQD0JyAa9P61/wAxGvYeB9O0/wAOaro0d1qEsOrPNJcyzXJaTdLncVPRevQDH1rLT4X2kV7BdW/iDWIZYbpLv5Ba4aVYRCGI8jA+QEYGByTjpjmrHx/q/h/VNdsdRs7nVtUl1WTyLOOWa4SCJbeF2VGhgZtoMgC/ux1+Yg5NdLbfEDUb4ak1r4Vu4l0+GGWRLuUpM3mpuAESI7Aj+IEZAyQCRgmyv5L/ADG3Z29f+CR/8Kl0xtNlspNb1p47i3a1um82FWuYizOEfbEPus7EFcH5iCSOK39U8Kw6nZ6TbDUb+1TSp454jFIjtI0YwodpFct79CfWruh6oNZ0mO8CwqWZlIhmEqgqxBw2B6dCAR0IB4rQo1WhOjOMuPB8fiS4165v4L3R/wC1rUWDBZYml2AkO4A3opddgzydqLnBHENz8MIblLrzvE2us1yLXew+yg/6Od0eP3GOvJ9fpXc0Uttir3PNvCHga9n0m4bxG+rWE63t7La28ktq4gMzvidNgcb9khGGJAO7C85N5PhVZJarbt4h1qSJLOCyjVjbYRIX3xniHkg/3sggnINd3RTuxdb/ANdzkbf4d2No8UtpqmpwzxPdOkyvFuH2hgzjmPGNyhhx2wcjIo0T4fW+gNaHTtd1hRBbpayqzw4uo0zsD/uuCoYgMm1iOpNddRRdoHruFFFFIAooooAKKKKAOH8Xvew3+r3OmahNp91baI88c8KRuco24AiRWGDjnjPoRVKz8SarealpOn6rqsulapYXJj1W2gji8q7i8l5FmXejMEby+qkY+deoBGxrWkjXfEl9pb3dxZpdaSYnmttnmBTIAQN6sORkdO/GDzWhP4Q0y8v9M1DUA93f6bC8CXcgQPMjoVYPtUAg5zgAAHpjpQtLjdml/XYwtY+JiWGj3NzbaHqJn+zrcWaTrEq3cRdU8xT5nABdcq21vmHFaHi7Xb3SLbQb2O4TTbefUYYr2O4RGYRsDld24qpBHJGfY96j/wCFc6c+lS2FzqWp3Mf2f7LavNJGXs4tysFjOznBROX3n5QCSKveJPB9r4o06xstQvbxILOdJyqeW3nlRjEm9GyDk5Ax1pvpbuvuv/lv5+ROrvfs/vt/nsZd58S7bT5JIb7w5r0FxHZSX5gaCInyEIDPuEm3jdnbncMcgEgHQu/G9jaXflrZX1xbJLHDPewohit5JApRXywbnenIUgbhkisu5+GSXbE3HivX5P8AiXyacNzWpKwPt3LkwZJO0fMST71fh8B2cM6s2qalJC5ie6t2eIR3kkQUJJIAgIb5FzsKg7RkGhW/r1/y/HyG/wCvw/W/yKqfEuxZoFk0fU4ZJ4buQRyNbBla2JEkZHnfeyOMZHI5HOJrX4iWN1qYsTpOrQSLeJYzvNAirbzOm9Vb5+Qc43JuGSOcEEyXXw90i71Ga9llvBLLfpfYWUAIyrtKKMcI4Lbh1O489KguPh5FPq11fr4i1mJrnUItQeKP7NsEkahVAzCTt2hRjPbrnORW0v8A1qv0v9wS2dvl+n6fedhRRRSAKKKKACiiigAooooAxdXt7q61OOCwvGsZ3tJQtwiKzRjzIskBgVzjOMgjPauFlu/Fln4V8T6xb+Lrq4l0aa7jjivbK2aN0iTKnEcSNvz3zj/ZNeiS/wDIyW3/AF6Tf+hx1hp4AiGga5pM2vatPDrbu87v9nDxl+H2bYQBuHHIOO2DzS1u/T8br/glK11fuvu1/wCAQL8R7G1s1/tHT9VjuFuLa1KfZQxkacAo42khVOT97aQeMZwKuL45thdRR3GlanBDJL9nN0Y43jS4xzCdjs27I25AKFuAxNZ03wxS4uvOm8Va8x8y2lZMWgVmt8GM/wDHv2Iycda1f+ELtF1SW6jv75IJJzd/YQ0ZgS4/57AFC27PzY3bc87c1Tt/Xy/4P4dLmaulb+uv/A/Ey4/inps9uk9vo+syJLZy3sH7iNDNHE+2TAZwVK5Bw23IPGTxVfTvH00Wuat/aUdxdaUt1apbXVvbqqWsc8SMnmAvvOWcAkA47hRUkHwrtreGCNPE2ulbezuLKMMbU4jnO6T/AJYcnIBB7YHvm7afDnTrby1fUdSuIMQfaIJnj2XbQhRE0mEByoRRhSoOPmBoVr/13/yt8yv6/L/gks/xB0q0mdr23vbawxN5WovGpgnaIMZFXaxfICNjcoDbTtJp8njQwWsU914d1m3WS7jtW85IFEfmEBJC3m7ShJA+UlgeCAeKjPw80mVZ7e7uL2606QzNFp8si+TbNKGEhQhQ/Id8AsQu44Ao1DQLqDwrPovnanr5vYzbCa6mhQ2y7TtZmUIcA4+ZQz5x1xkLoPqVB8RMeJrixudEvrXT7W1muJL6UwsG8uTy8qqyFipKsB8u4kjgDmppfiNZW15HYXuj6xbalLOkMdi8CM7FwxRt6uYwrbGwS45U5xg1ZufAek3flLM90Ik046c8SS7VkjyCCTjduB5BBHJyc8YwPEng3UEfRm06bWNVvBqUL3WpmW1WaCGNJApwwRDtMpOAjE85z3Oy/rf/ACFq7v8Arb/Ms6n8YPDWkWVvPqP2i3llaVZbWV4Y5bfyn2Sbg0gDEN/DGXY/wg1fsviNpWoaqtna2OptG181h9ra22RiYReaBgkOQy5wQpB/EZki8BWdrNa3OnapqVnfQ+YJr2J4mkuxI+9xKHjZTluflVcfw4HFVf8AhW8S6g13F4l1uN21H+0toNsQJfL8vvCSRs4wSfXOeaat1/rX/L8Q9P60/wA/wIj8StMsNGsL+eDV7i0vZnX7VPDFF5GZ/LCuGZOQTgKoZ9oywzk13FcGPhNpxtfIm13WZwY3jLyNb7sNL5x6QjHz5PGM5wcgADu1GFAJLEDqe9HQWtxaKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjrnTfDWs3VyNdkgMlvdExH7WYXAMUauuVYEqcEMpyDjBBxTbPwt4E06VHsGt7YR262yRw6nIsaxht4AQSbQd3zbsZzk5yac3iKLw5q0enrpF/eHVdSMUT2pi2pIYVkbd5kikcB24B6Y64B7GjoD8zkH8PeCZIrdGnizb79sg1SQSSBzl1kcSbpVY8kOWB7inDQfBQj1WMy27x6syvdxvqLsrMuApVS+IyABgptxtXHQY62igDiU8IeAImeSH7PDcySCV72LU5EumcLtyZxIJDx1+bnJznJq5b6R4Qtrm+nhu4xJqHl/aC2qSMG8vGwgGTCkYHK4NdVRQBjaXN4f0exW0sL+2SIMWJkvPNdmJyWZ3YsxJ6kkmrn9taV/0E7P/wACF/xq7RQBS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xqcXlub9rISqblYxK0Q6hCSAT9SD+RqagCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2szVtftdGvdMtbqO4Z9Tufs0JiiLKr7S3zN0UYB+vagCb+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8asW8rzRF5LeS3bcy7JCpOASA3ykjBAyOc4PIB4qWgCl/bWlf9BOz/8AAhf8aP7a0r/oJ2f/AIEL/jSa1q1voOiXeq3qTPb2cTSyLBGZHKjk4Udas2twl5Zw3MQYJNGsihuoBGRn86AK/wDbWlf9BOz/APAhf8aP7a0r/oJ2f/gQv+NXaKAKX9taV/0E7P8A8CF/xo/trSv+gnZ/+BC/41dooA5hdTsP+E4ef7bbeT9g2eZ5q7d28HGc4z7Vtf21pX/QTs//AAIX/Gud13WP7A8SXmqNY3V9Ha6UZJIrXy94QPlm+d1BwBnGc+gNXIvGlpeQ6JcaVY3uoWusuUing8pVgIBJEgd1YEBWyACRtI64BFqGxrf21pX/AEE7P/wIX/Gj+2tK/wCgnZ/+BC/41NeXlvp9nLd3sqwwRLud26AVT1jX7XRJ9Oiu47h21G6W1hMURZVds4LHoo47/hmgCb+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAFL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAGJJq+mnxBbyDULXYLWVS3nLgEtHgZz7H8qvf21pX/QTs/wDwIX/GqGt6gdJvft4tJ7wW9hNIYLbZ5jAPHnG9lXgc8kdKoJ48jdPDzDQNWx4gOLbm3/dfKXzJ++4+QFvl3ccdeKFrsD03N7+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtR3Erww744JLhtwHlxlQcEgE/MQMDOTz0HGTxQBW/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xpyajFPIyWatdeXcfZ5zEVxCwXcS2SMgZA+XJyenXFmRikbMqNIVBIRcZb2GSB+dHS4FT+2tK/6Cdn/wCBC/40f21pX/QTs/8AwIX/ABqS31CC4uWtQ2y7jiSaW3YgvEr527sEjqrDgnpVmgCl/bWlf9BOz/8AAhf8aP7a0r/oJ2f/AIEL/jV2igCl/bWlf9BOz/8AAhf8aP7a0r/oJ2f/AIEL/jV2sxNetZPFEmgrHcC7jtRdM7RERlC20YY9Tn0zjvR1sGyuTf21pX/QTs//AAIX/Gj+2tK/6Cdn/wCBC/41cY7VJOcAZ4GazfDuv2vibRY9UsI7iOCSSSMLcR+W4KOyHKnkcqeDz6gdKAJv7a0r/oJ2f/gQv+NH9taV/wBBOz/8CF/xq3JIkMTySsERFLMzHAAHUmoLa9W78mS2jeS2mhEyXIwEIOMDBO7JBz0x754oAj/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GrtFAFL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8au1DcXlvaNCtzKsbTyCKIHq7kE4H4An8KAIP7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrMErzKxkgkgKuygSFSWAOAw2k8HqM8+oHSpKAKX9taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NXaKAKX9taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NXaKAKX9taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NXaKAKX9taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NXaKAPPtdt9Un8SaTNpui3eow2OsNcXL280KeWhs/L/5aSKScyA8dgec4B5LTPBWqQrYrfeB76YLDqUd2Zru1lMySyF4EctOTJj0bIDHPqa9R0xNRafUTHcWsY+1dGgZ+PLTHO8dsZ465rQ8rVf+fyz/APARv/jlG6sO+qZ4pH4O8Ty6fO174P1Wa/8AsmlpDLLqNs7JPbsfOdCbj5MrwCuCcngZNbEHg/UU8SC7HgtlsoNankihaS15tJ7UxOABIQF8wbmXqQ2QCcivU/K1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xyqcm22+v/A/yJtpb+trHi8ngbxGNDFrc+ELi4uIvDy2Vv5OowyRRXKyZRlDyLsYAKSyrwRwT1PT+GfCOrReP31zWYNWjuHmkmScSWXkGFx8sEhUGdimcbdzJlcg16D5Wq/8AP5Z/+Ajf/HKPK1X/AJ/LP/wEb/45RzO9/X8dRtX/AK8rHMah4fuLn4gLeHSFurS4HlXM1z5TxiERFSo5EgyWxsIdDgn5Sa52HwNFNY31mNHtbq30W4NrpgtYoN5iLec6kSjYeWWMqSM7WJYE5Ho0lrqM0TxTXNjJG6lWRrNiGB6gjzORUdpp13p9nFaWEmnWttCu2OGGwKIg9AokwBUrT+v6/pjep5pfeBNfu5Lq7t9JtbPULvRoLc3MLRB43SZ2kjyxfDOhVf4k6gkgDLI/A13Z/wBgCLw3rd/YQ3lzNdWN3dWKrFG8Bj8vyYnSHaWIIAB43ZxnB9V8rVf+fyz/APARv/jlHlar/wA/ln/4CN/8cp3F/X4WPOPAPh7W9F17QpLvw1d2Kpo8tnf3LXFu+ZBIpi3bZWZgFVgODt3gDAzhdT8L69L4vgvk8OxXlzBrf2s6s12kZez2OFiHJcFN2NuAucEHkkejeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OUN3afb/O4d/P8Ayseaad4Z1xND0gP4du1vLGeZI4r24t51RJJy+9m80uDs43o5bkgqwpNR8H6zcw3pXQZl1Rftfn6pbXccbapHIsgijDCRXGC0Zw+0LswpIr0zytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKT1Vn5/iEfddzy/V/BOpTeGre1g8KJeebobW628s8KtZ32zaZ3YuQzEALvUswwB0JwyHwJrr+IjqGuWmpyzLDGbdtKu7RY40WAI9uZXVZwCwbhCEJYE7Tk16n5Wq/wDP5Z/+Ajf/AByjytV/5/LP/wABG/8AjlNu9/P+v1EtEl/XT/I8ysvBmp23gnQAPDUjaza27R3Ec81vIGlOF3yNvzjaDiRH3qpICnO2vWhnAz171S8rVf8An8s//ARv/jlHlar/AM/ln/4CN/8AHKbdxl2iqXlar/z+Wf8A4CN/8co8rVf+fyz/APARv/jlSBy3i2K7uL/WLfTrKW+urjQ3higidFZmdtvV2VQBnJyeg4yeKrHwnqsXiex1TRc2FjeeZcX1jPtLWt0YHRZV2sV53AMFJBIBHc1sLHf/APCcOPtNt532DO/7O23bvHG3fnPvn8K2vK1X/n8s/wDwEb/45R0HfRI8rvPAGoal4euYh4XjtLgWIivIXlhddVuVkjYTA7iCcLJ88m1jvweOa6rx3pWs3vh/RLTwzprRTwX0Mn7gw7bJEUjO12UMBkDC+nFdV5Wq/wDP5Z/+Ajf/AByjytV/5/LP/wABG/8AjlD1++/43Jtv936HkGq+C7u7ll+xfDm5s4m0Oe1a3iu7TyTduUKSKvngZBUnzCA2Qp5wMb8vhrV9T1JZtQ0BzeyS2s9pqkk8JfTY1WMSwNhy3O1+E3K+/wCYivQPK1X/AJ/LP/wEb/45R5Wq/wDP5Z/+Ajf/ABymn/XzuN6/16f5Hl8/w51CDUlTTdDsVsbW5uLOAbIR5lldBmkbpkCNnwF7jdwcihfCWoab4quLjT/B960MOu29xYzrdW+IbZYgkgQNNlFOG+QAcEDHGB6h5Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlCdreX+af5r8WEtU13/X+vwRdoql5Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlIC7RVLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8coAu0VS8rVf+fyz/wDARv8A45R5Wq/8/ln/AOAjf/HKALtFUvK1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xygDK8TfaD562NnLfXEmm3CR28LIrOWaMdXZVHXPJHSuJ0vwjqOmT+B7iLQNdkkssrqSXWsC4jtwYGiOI5Lll6sG/dj7uR1+Wu9kj1L/hILcG7td/2WXDfZWwBujyMeZ9O9XTDqhGDeWf/gI3/wAcoWjb/rr/AJiav+P42/yPIfGPgywt/DniW2TTrFdN0Tddab9m/dPFPMUdlJXG3bj15WRQeAKvat4H1fULW4k0/SJ9N0me/inm0OBrRpJlEbq8gWTfASzsjbW67MnDV30nha3l0f8AsiWy0N9N3bvsTaUDDnOc7N+3OeenWtCK11GCFIobmxjjjUKiJZMAoHAAHmcCjpb+v60D7V/6/rU840nwNdw61fx3WkavPaHRY7e0ur+/gd1mBfONrERuEdVDKm0bW5OctS1LwJreo29jDcaVdw6TbyTRix04WKTjIjEc+yUvApGxwPLKsAQRglhXq/lar/z+Wf8A4CN/8co8rVf+fyz/APARv/jlO4/6/Cx5Xb+FdasfEMt3/wAIvql5LFrVtcW99Nf20jiFYQkpDNMCNxDEqFGQw4GMCa88Ma7bWM0Vh4cvJQuoWd0hjubeOWUpMZJSzCVVlXaSoLqHLEZBwGHp3lar/wA/ln/4CN/8co8rVf8An8s//ARv/jlCdmn/AF0/yDr/AF5/5nmcPg6+07xbBPbeE3MDa/Pd3FxbTW6RyW0sLJ86GQF8M/QgkYfHUbrz+BntdA1jT4PD0RSxhuodFNm0UUsguDuO1ty+Xt4U5IyAevfvvK1X/n8s/wDwEb/45R5Wq/8AP5Z/+Ajf/HKX2eXyt+Fv69R31v8A1u3+p51D8PIdY1HUpvEHhu1gS/0W1hFzcpBI9tPGHDZwWyc+WcjKkKMnjFdB4Pb7JDaXl7pUEeqeIB51zPZLHsUJGBGGJIcrtAwQpALHOMjO7e6VcanbfZ9SOmXcG5W8qfTzIuQcg4MmMggEVOIdUAwLyzA/69G/+OVTk22/6/r/ACJSskjgPG/hnWdU8cWmqWGiNOLKWzkiu4ZIRIyLKfOjzI4KfKc4QLu/iY4C1h6L4V8QaZFA1v4NvUuzZ6nBNNcahCTIJZN8CPIs5kIAGMg5BYkHkmvXPK1X/n8s/wDwEb/45R5Wq/8AP5Z/+Ajf/HKlaK3r+OhV/ev6fgeJ/wDCLXWhalpUV/4cuHs7rWy8GlJJbxxzRtYN5kflLJ5WQ6H7x5/vHcSbd/4I8Qf2fc2reF7i/wBukyw2Gy6t9tpK1y0kSDfKpHlKVAYDjb8vv6ne6B/ad1a3OpQ6Pd3Fm++2ln0zzGgbg5QmTKngcj0FXvK1X/n8s/8AwEb/AOOVXM9H2/ysJ66f1vc4lvC9vL40Rf7Fsks9Vhj1LU7aaKJpVuIT8ucZBLM4OdxGY2xncTXJan4M8T6r4Ths28LyxXcJv5rd5J7Z3hme482LGZSi5U43qC4IIBQHJ9attJuLKa4lszplvJdP5k7xaeVaV8Y3MRJ8xwOpqz5Wq/8AP5Z/+Ajf/HKE7Wt/X9bfIVjgm8JXF/ca3Hq3hj7Rf3iXP2fWJJoirRSIQkDjfv8AlyBtKlPl3A5rOh8K69Bbta6X4cn05W0K3tiBdwrC0kcu+SIBJCULrlSyrjJ5J616d5Wq/wDP5Z/+Ajf/AByjytV/5/LP/wABG/8AjlT/AF+a/Uf9fin+hg2WkxQeBdSs9N8M3WjrPHKU0uK4jjfcy4whjk2R5PTa4Hfgk1wU3w31G50Tw1DdaVqMMUOnrDfQWElkbmK7AVftBebcpO1cB0bzFAGPQet+Vqv/AD+Wf/gI3/xyjytV/wCfyz/8BG/+OU7639Pwv/n+QdLf10/yPLbzwX4nn8UXl/Yac1hdTQ3lqb9J4iZVeFRFI0m7zT8y9MKFP3U71fm8Gpdw6HcWngWPTzZaolzc2U0tuwb9y6GRQrsgG4oxPDHGSuQM+h+Vqv8Az+Wf/gI3/wAco8rVf+fyz/8AARv/AI5Qna3kHf5/irHmen+GtWOlW0Gt+ErrUdNiu77fpV3dW80jCWYSQz5aUqxVcqdzbgSSM98yXwV4gtbu6kl8Oahq11Gmlm2u/t8LhZIHLSshlmDL8h25wu75uPmJPr/lar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOU1Jp3Q27tt9S4pLICVKkjJU4yPbilql5Wq/8AP5Z/+Ajf/HKPK1X/AJ/LP/wEb/45UiLtFUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcoAu0VS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxygC7RVLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKAPPPGiSjWtHMA1mfz9ZaCW00rUntHuE+xb8ZEsa8MinJYHggHnB1IvEF94eg0zTLDQNSmm1BbqWNNX1Te1uYgT5bykyOc4yCNwGeCRip7zR/Det6jLLrl48c9ldl7Yw6rNamNjCilh5ci8/eXPUcj1pX8L+CZXheS/maWDzNkx1+58z94oV8v525iQAMknAAxijW1kN2bX9f12MLxJ441DW/C8V14filsoY20+a7nW7CSRmdo2EQXYd42v8x3IeRjPIreuviAbLdf3GmZ0ITT2wvY7jdKJYd+7MO0AKTGwBDk5xlQDmq58E/Dt7OK1lS1mt44ki8qbU5JFdEbcgcNIQ+09N2cDgYHFaUWkeDIdRkvY3sw8pZmiN6TCGZdrMIS3lqxUkFgoJBPPNOVtbef8AX9fiJbK5VuPGet2MFi974WH/ABMbyG3tmg1FHj2yAkM5KqykY5AVh6E1WPji7tL25i/4R64N42sRaZKp1ANErtCjCQE/dQg8BVyepAJIqyvhnwSkFrCt4fLs7hbi3X+25yIXX7oX97wo7IPlHpTZ/Cvgi41Ca9lvH8+a7W9dl124UGZRhXCiXAwOAAMYAHQCjS/9baf8H8Ba2+X46/8AAMyT4szKLeGHw1d3d8Fd7y1sxNcGIJM8J2NHCwYlo2I3+WCO+eK6rxDrVxata6bpduJtR1FJDEHn8gRoigu+4o/I3DA2nJIzgZNZFr4U8DWPlfZLoxNFI8iyDW5953tuZWbzcshbkoSVJJOMk1q6vB4X12O3XU7q1k+zPvheO98pozjBwyMDgjgjOCODmlLWNkPaVzj/AAt4vvovDukNdWGoanfjQmvPtD3TMJz5qqylE3FiMglthIGQoOSK3m8cXdxbj+x9KtdQuYbdrq6iXUQqrErsnyNsO5yUbCsExj5ip4qO08I+ALCS3ewNvai2hMEUcGpyJGqFt5+QSbSSwDbiM5AOeBU7+HvBMkVujTxZt9+2QapIJJA5y6yOJN0qseSHLA9xTbv+P6/8AF/X4f8ABKy/EdpW1GaPRZFsbFLd/PluVVp/PXMQRAD1YqDuK4yT2xXPxeO9Y8Pa7rttqdlNqGoz38cdrYRTy3EUC/Z1kYK0UDPt5/55ZyeT3rrv7G8GmXVHea2kGrIsd5HJqDNHIqjCgIX2pgdNoGKpL4P+H6NJIgtkupHSRr1dTkF0WVdoPniTzBxx97nJz1pdRK9tRbXx/f315Nb23hW+je302LUZI7qQRylXDfu1jALb9yFcELnB9s9D4d1ptc0w3MkUEUiv5bpBOZVDAAkZKqwIJIwyqeOnNZUekeEI9Tub8XcbXF1ai0mL6pIyvEOgKGQrnJJzjOWY5yTm/pTeHdGhlisL+3AmlMsrzXxmeRyAMs7sWPAAGTwAAOBT0/r1/wAhvy/rT/M26Kpf21pX/QTs/wDwIX/Gj+2tK/6Cdn/4EL/jSAu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aAOQ8awefca0VuLq2kh0KSaOW1uZIHR1OVO5GB6jpnB75rKj1WeHxBouieKr+9TVNMlebz4LuWFNTtBC7iVkRgrkMihlIOCPR+d3VV0XXPEd1a6leRtp9zp3lSNFeNDu/eAld6MDyOoB5Gc8VrbPDJNg0l3aTSacpW2lnvPMkQFdjZdmLNkddxOep5oWl7f1/X9dBuzSX9dDl9d+IWtWegyzW2jW1vcXVmt5p0j3pdXiLxoS4EfyOPNQ7RuXn7xxWl491afRdN0HU7u+l0+OLU4ftsdtJujdCDuVjtDMoI9BnuO1Sw+HfBEGn3Niklt9muY/KaNtRdvLTOdkeXzEuQCFTaAQMdKt6rZeFdat7GDUbyF4rCVZrdY9RaLa6jAJ2ON2P8AazTdtLd1+f8AkTbe/Z/kYupfEDXdJmkt7vwrbmdNMm1QGLVQ0TRRlQy7vLB34bpt25wAxySNC68bzxzyy2WlLc6daTw215O11slieVUK7Y9hDKPNTJ3A9cBsVSbwV4BcENdSFfszWgX+37nasLYzGB52ApwOBxxV+LQ/BkN5BcpcQmSBY1G/U3ZZPL+40ilyJGXAwzhiMDBoVuv9a/5WG/6/D/gmV/wsq/int7e70SzhuJEvFeMahI2ye3LYjz5GMOFyDwcZwpxzatvHuoyaw1jd+HRbLb6lFp11J9uD7HkjDqyAJ868gclTgg4zkC9PpHgu5u5rqc2DzTXkd9I5u+s0Y2o33uMDsODk5Byaqz+F/BNzqM99LeN9onu0vZCmuTqpmUYV9olCjAwAAMYAHYUK2l/61X/BX3BLZ2+X9fd+J2dFUv7a0r/oJ2f/AIEL/jR/bWlf9BOz/wDAhf8AGkBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBleKIvOS5TzJoj/ZdyweCZ4nUgxkEOhDDkdjXI6d42vPDfheyto9JutT+zaFFq1xeXuplmlVseZgtvcsMsQDgdAMDp1mqz6Nqt8LW71CE2k1nLFK0N4Yjy0fG9GBGQD0I71jt4I8ANbmBrqRojaiyKHxBckGAHPl/677ue3px0ojo3fy/X9Wgetv67fon94urfEmXSvE8ml/2L9qi2yiN4LsNK7pB521l27EyMgbpA3GduOaqzfFG8tIdPa78Mtu1OK1ntBDfKwEczpHmQlV2lWkUYXfnIORzizqPhnwoLO4m0qe2fUgrPbm51mYIJjCYtzHc3VThjtJbqcnmsC48H2yfD6w0uxn0VtWD2YvXn1qUx7IHVysTlWZVJXhVVQCxPUc1G11fy/W/6C1/P9P8AgnQD4h6j/atvo58OqdTkvpbGXbfD7PFIsHnKfMKB2VkI5EfHPBIAK3PxGurTTv7Tm0Ey6dcW01xYyW14rSTeUpch1ZVEeVDMMM3A5weKuRaD4Min0+dLpBNp8zXEEn9rSljKwwzuTJmUkcZfdxx0qnq+geHRoesx+Hp9PS/v7aaGJbnUnEETSghiq5ZYsk5OxRk9amT93Te34/1/TKjZyV9v+D/kQ3fxKvrCe3t7vwy5mums2gEF6rL5Vw+wM5ZVwytwVAbqOcZItTeMLyy/td5NHSPULSe3tmin1Q+RIzoG3IdpIHOMLHvYj7tVtO8JeEToVnb6tNb/AGuMwSytBrc7YliHyBZN6tsUklUwFB5CitCfw/4MudQub6a7DXNzPHcSSDWJhiRBhWUCTCYBI+XHBweOKqVtl3/DT/g/1tKu1r2/H+v674MfxSvWaHVZdMji0caK1/NEJnM4k83ywoXyxn5hjscNnGRiut8IeJLrxJYXEt/o91pU0E3l7ZopkSUYBDIZYo3I5wcoOQeowTQj8O+BooY4R9iaKO3ktljkvi6+VI25lIZyCMk4z0ycYzV+wi8Oabpclha6oPJkUozS6rJLKARjAleQuMZ4wRjtil0/ru/00DW/9dl+upysfiu4X4uW2brUDpd8ZdNWGSzmS1SRAGSRZWURszMsqnaxONo7GorPRftF741n/t/W7OXTb5haTnV7h47Zfs0cnMbuY2UM7HDKeOOwrobnQfB134fs9Fnvd1jZSrLbqNZmV0ZSSp8wSbzgnjLHHGOgqmngzwEjzGS6e4W4k8y4iuteuJ47hsAZkjeYq/AA+YHoPSl0t5Wv807/AJlX1v8A1/WxzOh6zqmo+ILLUbjTtf1KTU/DdvdXFnp+pmKKGWQsrOI5biNUyAMbeQeeDzXVeALqe0+FcOpSDUdQujHNO0VxcvczuwZsIGZmOcKBgEj0zmrv9leE/wC3J9XXUNl7cW/2Z3j1eVFEeMBVQSbVxkkbQMEkjB5qXS7Hwro2gvo1heQiwfdmKbUWm+994BncsAfQHHJ9abe9v61bsT1Tf9aJGBqHxSks4bSK20RtQ1CdZHa2sXnnCrGE3/6uBnDbnAAdEHHJXIzqReM9SvPtV1p3hua40+0DJKzXSxXKyrEJCvkuAAOQuS4O4/dxzQ3h/wAFuqf6UqzRzNOt0mryrcbmADZmEnmEEKo2lsYUDGAKfLofg2W6urgXUcL3cflzrb6rJCkgC7QxRJAu8AAB8bhgc8Untp/X9f12H1X9f1/XqYc/xVvYtP0ueHwvcXU+o2a6glravNcSLAQvXyoGAcsxADFVIGS6k4Ek3jXUzf6ymoaSX0+21SxsoTbXjRSx+d5bBpBtUgAyLkAnP3SMZJ1hoPgxLPTbaK6SJdLTyrSSLVpUljj4+QyCQOycD5WJHA44FN1Lw74J1V53u5oVa4kilk+z6pJBueMAI37uRcEbV+u1SfujF3jzeV/wv/kC21GSePLmNkuRohm066aeKxlhu1Ms0sSuxVo2VVQN5b7TvPQZC5qx4R8ZXHiadUutJFgs2nW+owMLrzS0cu4YYbRtIKnpnII6dKauheDElupEuIUN0JN6rqcgVC4Ido1EmI2bJyyBWOTk80aJofg7w9fJd6VeCOWO1W0TzNXlmVYV+6m15CuB244yfWpVuv8AW/8AwAfl/W36XOtoql/bWlf9BOz/APAhf8aP7a0r/oJ2f/gQv+NIC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aALtFUv7a0r/oJ2f/gQv+NH9taV/wBBOz/8CF/xoAu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aALtFUv7a0r/oJ2f/gQv+NH9taV/wBBOz/8CF/xoAu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgCHRkVJNRCKFH2vOAMcmKMk/nWnWbpH+u1H/r6H/oqOtKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDk9Z1m08P8AiS91XUWZba10re+0ZY/vBgAdyTgAepq/p+ra5LcW41XQY7OC4Y7ZIb3zmhUKWBlGxQpOAMKWGT97pnI8UaBH4o1jUNHlmaAXOlgLKoyY3EoZWx3wwBx3q3caZ4m13Qr3Stak0/T1mtpIBcWEzytMWUqGKui+WOc7QW9N3qdx9Ua1v4l0K7tpLi11rT54I5hA8sd0jKshONhIOA3t1otvE2hXrRLZ61p1w00bSxCK7RjIinDMuDyAeCRwK4TW/Aeva3Na6hcad4eF/b3FkfLFxJ5ZS3kZy4YwkhmB2BcYUE/M3Sqlx4B8UzRqG0vw5KDql9eyxSX8uyRLiJ0CH/RjkjzDnI/hHrwdPv8A0t9/4WF/X5/lt87nof8Awlnh0hiNf0vCtGjH7ZHw0gygPPVh09e1WZNa0uHVU0ubUrOPUJE8xLRp1ErL/eCZyRx1xXlh+HHiv+wZdPWz8Pq7eHItGSUX0vDq2TJ/x78A5Jx6geuR0U3g/W7ySe3vodKktLq9h1J5DO7SxSoEzCAY8Mh2bd5IIViNhqmlfT+tf8tfw3Fr/Xp/np+J2Fnrelahdva2Gp2d1cRpveGG4R3VckZIByBkEZ9RV6vOfBfg3xD4e1PRDd2OiQ2mn2NzaSmzu5GYmWVZAVUwqMDYBgkfeJ7c+jUmlZf11BXCiiikMKKKKACiiigAooooAz5P+Rktv+vSb/0OOs3RfF0WseJ9X0c2j2x08K8MzuCLqMlkZ1HYK6Mv4A9CKm1s6j9u/wCJIlu9+bGYQC6laOPdvj5ZlVjx16HPT3rlG8DXeiarpOsaalu6RWctvrSaprVxNGYXClhGJEZcBgW6Rg9MDPCvbV/1/X6j6f1/XodrF4j0OdrhYNZ0+RraPzZwl0hMSf3mwflHuab/AMJRoAsLi+Ouab9ktZPKuLj7XH5cL/3WbOFPI4NeIf2ZDqHwL/ti+Oippem6HdW9o0Mu8zSSMMBwVCoVdFwAWJbB4PFdbceA9U8Sta+I457FJcWzQWlhqU8MFxFHHIoc3ESh0YibI2ggBQPmBzVuOn9f1sGit8/wsdxN4z0QalPpltqlg9/FZfbBHJdKiFD0JbnA7kgHAOe4ysfjPQG1HULGXVrGK40yFJr0NcoFhVu5JI4HGSQB8w9a4zUvhrqJ0fUrHSLTShBfaKmnrbXV3NIsEiySOCJGRmcDzchiAcoOBnK2dX8B69q326RpbKBrk2NyIoryZMzQDDR+aiqyoezr82cfLxyv6/H/ACE/L+tF+t0egWt9aXtjHe2V1DcWsib0nikDoy+oYcEe9c3pvxC0a/vtZEl3ZW2m6X5P/Eze+iME3mbuQwOFwVxyc57DuxPBzj4c33h61SLTZrxJTgXUt4iSOcsWklw8gLEk5A6niuW1D4deKNW1yTWrybSoHMtvKNOsry5tw5jieMg3UYV14kJBCdgDx1Ha4j0iTXtIhuLOCbVbGOa+GbSNrlA1wPVBnLfhmoZ/FXh61hlmudd0yGKHHmvJeRqseWKjcSeMsrDnupHauW0vwVfaJeCOy0zR7jTLi3hSW2u7qaVrR42Zl2M6MZhls/NsIIyOuBk23w01eHwppVn5GnQXGnahc3P2Oy1O4tYZo5ixx50UauhUPgYUggY78Gg15noja/o6anb6c+rWK31ynmQWpuUEsq/3lTOWHB5A7UjeItEW1urptYsBb2bFbmU3SbICDghznCnPHNcKPh7q9vq2mNYJp1vp2nXFpLBAl3KCqRqysjEoTKQG+V3Y8cbV60l/8PdbvINiT20EVrPDPbWsWoToJSm/cpnVRLCv7w7VDOF28cEil/X5ah/l/nodN4s8c6Z4X8KSa0Jra+3QmW1gS7jQ3YAyfLLHDYHPy5OBwD0roVnT7ILiUrGmzexZsBRjJya8xv8A4aawNGvtP0SPS7aDVNLNlNFdXk9x9jcySSFo5HUtLuMhzu2cgHtivQNGl1HbLa6nBCDarHGtxCWCznYNxCMPl57BnGMfNnIFNKzsHb+u3/BIV8Y+GXUMniLSWU25uQRfREGEEgyfe+4CCN3Tg1YTxBo8109pb6tYS3aQicwLdIXEZGQ5AOQp/vYxXG/8IBrC6tDNHfWwtILuaJIS7/8AHhMxkkjxjG/ftA7BUHPJFVpfhrdf2tqs8tpaaqlxJc3FrJe6tdKqtMpUxtbBWiAwxG8AnGPlJ5qXtp2/4b+vJoOv9f1/w6OyufFuh6XZ2cuv63pGmyXUQkQS6ggR+Bkozbd689cDPoKpaR470zUL7UrS/lt9Lns7uS3jiubuPfcIkayGVQD93a4PGcDrjoPPNQsbix1bS9L1KbSY7u10y0gubEaqYDfmF2dBHutnaXGAQI/LIJIJbjG+nhDxO2vSah9h0VY5te/tQs19J5qxfZ/J248jG7GW+9jtnvVO13bzt96/S4lsr/1pf89DudD8QaZ4j0WLVtHu4riylBIlRwQMdc4PB9j0rG034haNf32siS7srbTdL8n/AImb30Rgm8zdyGBwuCuOTnPYd4LPwjqK/CY+FLm6to7pbI2iTRBnjwBgFgQCQe49Djnqea1D4deKNW1yTWrybSoHMtvKNOsry5tw5jieMg3UYV14kJBCdgDx1Tsm7DPSJNe0iG4s4JtVsY5r4ZtI2uUDXA9UGct+Gahn8VeHrWGWa513TIYocea8l5Gqx5YqNxJ4yysOe6kdq5bS/BV9ol4I7LTNHuNMuLeFJba7uppWtHjZmXYzoxmGWz82wgjI64GTbfDTV4fCmlWfkadBcadqFzc/Y7LU7i1hmjmLHHnRRq6FQ+BhSCBjvwaAvM9EbX9HTUoNOfVrFb65TzILU3KCWVeu5UzlhweQO1J/wkWifYJ77+2LD7JbEie4+1J5cRBIIZs4XkEc9xXCN8PNXh1PTjp6abBp+nT2ssEC3cwKpGrK0bHYTKQG+V3Y8cbV60t18PtcutN8gT20KWdzbzWdrFqE6B1jV1Km4VRLGvz/ACqC+3b1IJFLuH+X+eh0vizxzpnhfwpJrQmtr7dCZbWBLuNDdgDJ8sscNgc/Lk4HAPSujhk82FJMY3qGx6ZFeX3/AMNNYGjX2n6JHpdtBqmlmymiurye4+xuZJJC0cjqWl3GQ53bOQD2xXpljFPDp9vFdvHJOkSrI8SFVZgOSASSBntk/Wq0sHb+u3/BJ6KKKkAooooAKKKKACiiigDJ0FZVbUhOwZvtpII/u7E2j8BgVrV5x4r1TW9Auo9X0i9YWVvqBbUrExIyz26wIzsCVLhlAJGCAcYq5qniW8n+IWkWtjqn2XQkt557p4Ujb7Q0axvtLMrYQK4yVwTnqMUAd3RXmx+M+lX9kz+HLGfUrhbu1hMMc9uxMc0mxXBWXAJ5G1irAkbgo5qXxf8AEd7Sw13T9JhudN1ixsJ7y3mvYI2SVYiN5VBJvHXAZlCnqNwHLs/6+8aV3b+tT0SiuTh8e2297KfTNSXVUMYisGWIS3QdWZXjPmbNpEbn5mXG05AqnN4ynuNc0O4tHmg02ZL1b2xktM3CywrkqcE8ggjC5zxgkUnpuTudxRXJ6N44sL6Oxgtk1G9aexivDM8cXmbHBKl40IbJAP3U2jGM5wKqR/FPTZ7dJ7fR9ZkSWzlvYP3EaGaOJ9smAzgqVyDhtuQeMnim1Z2Y+tjt6KxNW8UW2l+HYdYS0u72CdVdFt1QEKy7tzNIyogA6lmA7dSBWJL8VNGWzjuoLHVbmJtOTU2aK2AEduxA3FmYAkZyQpJ4PWizvYV9LnbUVw+t+Mbs+J9Fs9FSdbGTVRZXl00CNFKfLZjGrFtwIK8nZg9A2QRWhr/j3T/D2o3NncWGpXMlpaC9na3txsSHdtLbmZQ2OpC5OAeM8Ulr/Xlf8hvT+vO35nUUVyp8fWovprT+yNT8yHUl01ziHAd0Do/+s+4wYYPUE8gVQ0H4lpqsenw3OhapDf6gk80ECRIymKOTaW8wPt4BGQSDntyuT+vwv+QdbHc0VwFr8R0e8tI4LDVrqwuLG8vpLySGMTRLFLt2+UCG4+7jYW5TIPzEaX/CdWNlpVrObfU7+3Wzhuru8EUWbaORcrJMAV5IBJEatjBOAMU7P+vmv0Yrq9v6/rU62iuVtfiDpt5rg02Gw1LH9oPpzXUluEiWdY/Mx8zBsFc4YKRx6EE9VS6XGFFFFAHMX1vd3HjgpYXv2OQWAJk8oSZG/pg/hz7Vc/svXf8AoYv/ACRT/GuX+IthFqVn4kt57ZLoHw9M6Rugb51OVIB7ggEHsRU99pWhTWHhE2el6Vcz2qmbT0eJdqBbd2BUhTtXf5ZJA4O09cUaWbfT/g/5Dtt53/C3+Z0P9l67/wBDF/5Ip/jR/Zeu/wDQxf8Akin+NcTZ/EnXP7Js73UIdLUalp9tcwBFcLbNLOsRMjFvmQbw3AXoRnvW7d674jt7uHRvtmhpqot5rp7h4ZDDKkZXCiPzAUYhwSdzbRg4bPA9N/P8N/u/4YXW39a7fmbP9l67/wBDF/5Ip/jR/Zeu/wDQxf8Akin+NcTN8SPEUiXV1bWGmW9vbW2m3QhnaR5JEumKspI2hCD0OG4HQ54sjxt4mbxBHoiJo/nNq1xpz3bRygDbbCdGEW7nrg/OM44xninFptdv+B/mK63/AK2udb/Zeu/9DF/5Ip/jR/Zeu/8AQxf+SKf41xVn8S9YSwsrzU4NO8u+0k3iLCrqIJFmjiJdixyn7zceAVCnlutX7vxd4n0++i0uRNHu7k6lb2rXsaSRxlJlLAiLcx3jacjf0KnvgK23n/nb8wva9+n+Vzpv7L13/oYv/JFP8aP7L13/AKGL/wAkU/xpPCGr3et+HEu9SFv9qSee3lNspWNmilePcoJJAO3OCTjPU1uUNWYzE/svXf8AoYv/ACRT/Gj+y9d/6GL/AMkU/wAa26KQGJ/Zeu/9DF/5Ip/jR/Zeu/8AQxf+SKf41t0UAYn9l67/ANDF/wCSKf40f2Xrv/Qxf+SKf41t0UAc1Jp2r/2xbx/24TOYJW837ImAu6P5dv15zntVr+y9d/6GL/yRT/Gq3iu1t72C7t7yCK4hfSrrdHKgZWwUIyDx1FcLYeJNU8K+EbOy8PWOj21jY+GotW+dHJlbjeu1SoUt8x3Zbk5IPSiOrt6fq/0E3a39dl+p6H/Zeu/9DF/5Ip/jR/Zeu/8AQxf+SKf41jN4m127u9Xn0s6P9k0uR7d7S6aRJmcRB1cyAkAEsoC7OnO7tWA3j7xlPZ6Iul6TZ32oappq6n5EMaqgTCZi3S3Cc5YkuA20EDY3UtK/4fjd/krj0/r7vzZ3H9l67/0MX/kin+NH9l67/wBDF/5Ip/jXJN8QNa/4SaS2gh0+eykhuhAFBTy5oY1bY87SBW5JB2oFH981DffEDxKLi00nRtNh1DWH84zILYRBTGsZMZSW4QKT5mcrJJhcEBucIDs/7L13/oYv/JFP8aP7L13/AKGL/wAkU/xrz3xL4nl1e70q61C4sNNtNP8AENlbvayTnzfNKq5YuHCMuGIClWBxuDdq6Xx34y1Pw3fQLpQs5kjjjmuoJIXeQxtKsed29FjHLYJ3kkYC9TTtt5u34J/qTzb+l/xa/NG7/Zeu/wDQxf8Akin+NH9l67/0MX/kin+NclF468SNIJTbaO6tqt1pYskeTeHjV2WQy/3fk+YeXkA5z2qivxQ1y18P2mqXlnY3g1LSEv4IrJGU2zmSOMrIzSYZcy5z8mNjAn+KktVdf1pf8i2rOz/rW35nd/2Xrv8A0MX/AJIp/jR/Zeu/9DF/5Ip/jXFf8JJ42l1bRYdQisdLkMt1vgnRQt4qxBkJ8ueQRAliMFnwQG54FUY/HOrabZ2OrxLYQ6cnhhb4aTbwFF81mAwrbwAB15HChumcg/r8G/0/zF0v/W6X6nof9l67/wBDF/5Ip/jR/Zeu/wDQxf8Akin+NV/Buqa/qdjcf8JRpyWVxHIPJZDGvnxEAh9iTS7Ocj75zjPGcDK8a+Jtf0C+lh0w2Mn2ixaTTopbR5HluEdQYiRKoO5X46YwScgYI9HYFrsbv9l67/0MX/kin+NH9l67/wBDF/5Ip/jXG3nj/wARSx2H/CO21rqn9rs7WDxWwA2RohYN5lyisxdmAwwKhT8rc1O/i/WIE1u7fRdOtNRgttPICE3EmJWYMH2YMpRi+2NDlugOW4dmJO9vM6v+y9d/6GL/AMkU/wAaP7L13/oYv/JFP8a8/a88U32vaBqV+9nBqJOoLa+ZZXFvEYVj+R3t3lLbj15KkA4+u54T8Tavr3jC3kuru1isLjQLS9FmkTZEspcna+/nGw/wnj0wSRJv+vX/ACH3f9bpfqdJ/Zeu/wDQxf8Akin+NH9l67/0MX/kin+NczqXinWLHxRd2lhp2kRvJq1rYG4dnLtHJEWDsABuYcjbkADuc0mneMfEOsCy0+zfR4NUZLt5XuI5PJuPs85hKxqH3JnhixL7QejUlqrr+tL/AJA9N/61sdP/AGXrv/Qxf+SKf40f2Xrv/Qxf+SKf41x174/8R29rq9wtnpzi11ZdLto7cGUuZFjZJGd5IlwA5+UlQSQNwxlotT+IHirS7C1a90+xtr6DD6hZNH5shjM6xq+UmKQgqc4LyNngA4zTSvbz/wAr/k0JtJX/AK7fmdt/Zeu/9DF/5Ip/jR/Zeu/9DF/5Ip/jXK638QdW0SO/821tpZvOMdjAkf3lM6Qh/MMmxwC2WBaMgkKcctVHV/FPiC/0G60XXLey0S9bT7u4uZLh8eZDGFHyCGdvKYhwSfMbbjo2alv3eZf1bf7ira2O4/svXf8AoYv/ACRT/Gj+y9d/6GL/AMkU/wAaZ4FuIrn4faBLbypNGdOgAdGDAkIAeR7git6rlHlk49iIS5oqXcxP7L13/oYv/JFP8aP7L13/AKGL/wAkU/xrboqSjE/svXf+hi/8kU/xo/svXf8AoYv/ACRT/GtuigDE/svXf+hi/wDJFP8AGj+y9d/6GL/yRT/GtuigDE/svXf+hi/8kU/xo/svXf8AoYv/ACRT/GtuigDlbfR01rWJL4aneRRWd46taxLF5U5MKIwfchb1HysKiT4b6bBNpQtdQ1CC00u3kt47JTC0UqSf6wOWjLncMA4YYxxiq+paxcWU1/o2iwA6jemadWE4g8mNIod8gYo4L5kGAVwT1IHNZnhTxdeL4X06SfT7/UL6Lw7bXhne5dxdFyAfkXccgjJbaWx0B6UJXTf9df8AJjd1r/XT/M6FfAdv/YkelT61q09tbzQy2nmSRbrXynVkVSIxuAKgZfccd6qH4X6NJc3ElxeahPFcLdo8EkibSlzgyLuCBzyoIJYkdM44pzeOLu4tx/Y+lWuoXMNu11dRLqIVViV2T5G2Hc5KNhWCYx8xU8VWt/iU13DqFzDorx2tpcQW0bz3Kq1xJOIzDtUAgA+auSxBAPQnID1b/rrp+O3mJabf1/VzQPw/smUTy6nqUmqI8bRaqWiFxFsDBFXEfl7QJHGChzuOcnmll8B273FhcW+tapazWQuCJIzAxmkmH7yR98TfN6Ywo6AY4rjLHx/q/h/VNdsdRs7nVtUl1WTyLOOWa4SCJbeF2VGhgZtoMgC/ux1+Yg5NdLbfEDUb4ak1r4Vu4l0+GGWRLuUpM3mpuAESI7Aj+IEZAyQCRgjV1d9vzQPR2LVh8PLWwtNKtv7a1W4i0nH2YTmAkFV2ociIEbR/dxu/i3VSg+FdtbwwRp4m10rb2dxZRhjanEc53Sf8sOTkAg9sD3z1eh6oNZ0mO8CwqWZlIhmEqgqxBw2B6dCAR0IB4rQod7u4J9Uc5ceDLa50PSNNl1K/I0mRHhuMxeY+1SgDjy9h+ViOFB6EEHmsZ/hRYnT/ALFF4h1uG3/swaXsRrY/uN2cZMJOT0zXeUUXd7gtFZHHL8NdO+2208uq6vIlveLfrALhY0a4CkNIdiKfmySyghc5wBk5m8R+AoPEmoXl1Preq2YvLH7BLDamDZ5Rbccb4mIJPfNdXRS/r9Py0D+v1/PU5KT4d2M169zcarq0hknt7qVFnSMSTQoEWQlEVgSFGQCF9AKXTvh9a6Xqthe2msaoP7PjniggZoWjCzNuYcx54IXHP8IznJz1lFH9fp+QHG2nw2tbOGMR67rDTRw3MC3DNBv2TuHccRBeHG4cdyDkcU+H4c2MFrDbLq2qNALRLK6jLxYvoUyEWXEfGASuU2Ejgk119FO7/r+vNisv6/ryOOX4dQpqxv08Q6wpOp/2n5I+zbPN2eXt/wBTnbs+XGc45znmuxoopdLDCiiigDnJriO38du0qyMp07biOJpD/rPRQTRaaZ4WsDdmx8PQW321St15OjMn2gHOQ+I/mByeuetUPEmq3Wh61qWqWNpFeS2ejtOYJZzCHVXy3zBWwcA445Pp1qXw740uNT1mbSta0630+5jsI9QD216biLynJA3MY0KMMdCMY5BNG9x6pX/rp/mh9v4e8F2jFrXwpZQkxNCTHoRX922dycR/dOTkdDmp20vwq+n29g3h2BrO1fzLe3OjN5cL/wB5V8vCn3FXrfxR4furD7da65ps1oWKfaI7uNo9wGSNwOMgckVPba3pV7fyWNnqdncXcSB5LeK4RpEU8hioOQDnrR1EYt7oXg/Urqa51HwvaXc8+DLLPoZdpMDA3Ex5OB0zUR8L+BmuWuG8H6eZ2JZpToHzEnqSfKzzXW0UAcvbaD4Os5o5bPwtZwSRI0cbxaGVZEbO5QRHwDubI75PrTjo3hE2EFifDNqbS2kMsFv/AGIfLic9WVfLwD7iumooAxNLTQtDtWttE0n+zoGcu0VppckSljwSQqAZ4HPtV7+1rf8A553n/gFN/wDE1dooApf2tb/887z/AMApv/iaP7Wt/wDnnef+AU3/AMTV2igCl/a1v/zzvP8AwCm/+Jo/ta3/AOed5/4BTf8AxNXaKAKX9rW//PO8/wDAKb/4mj+1rf8A553n/gFN/wDE1dooA53UZdN1PU0t9RspLu0ktJUlguLCR1cF4zgoU5HHpjpVP/hFvAmzZ/wh2nbduzH9gcbc5x/qumecetaGv3l1p1y15YW0V1Pb6fPIsM0xiV8NGSN4VscZ7H+tZK+NdXaHwpI2iWKr4g5fOpv/AKKPLMuf9R8/yKf7vzcdPmoWu39b/wDBBu39di++keE5JBJJ4bt3cW/2UM2isSIcY8vPl/cxxt6Yp0mmeFpbC1sZfDsD2lm2+2t20ZjHA3qi+XhT7irI8Z+FzawXI8SaQYLh2jhl+3RbZWX7yqd2CRkZA6ZqwviPRG02fUV1nTzY2zlJ7oXSeVEw4IZ84BHoaPMCibHw0bx7s6DEbmRy7zHR33sxXaSW8vJOOM+nFRyaV4Vl05LCXw5bvZxymZLZtGYxrIeS4Xy8BuevWtCbxNoNtaxXNxrenRW80Ylilku41SRCQAyknBGSBkdyKfP4i0W11E6fc6xYQ3vlGb7NJcosnlgZL7Cc7cAnOMcUbAU3t/D0mpDUJNFVr1VVRctpLmQBfujdszgdvSjULfw/q0yzapoy3sqIY1e50l5GVTyVBZDwcDj2pdM8aeHNX022vrPWbEw3X+p3XCAt8wTGM9dxUY65IHU1PF4q8PzWN1ew67pklrZtsuZ0vIzHA3o7Zwp+tGwHL6D4bttFj1adhbzarfTTyQ36+HpkaBZTu8s8lnUMc4DL+HWrXg/QNI8LeFodJks0uZvIWC6uYtEkh+1hRtBkXDbjtwDknPt0roZvEmh28MU1xrOnxRTKrxO90irIrHCkEnkEkAY65pG16xmjY6bf6dctHdLayg3igI5YAoSA3z4PCHBJwOM5pq9uX5fd/wAP/mDd9fn95nLpXhRdOj09fDluLKFmaO2Git5aFgQxC+XgEgkH1BNSWtj4asY4o7HQY7ZII3iiWHSHQRo5y6qBHwGPJA6960rTW9Kv9QubCx1Ozuby14uLeG4R5If99Qcr+NXqQeRzVvpXhqzaz/s/RvsSWUrTQx2uktGquwwSMR8Eg84xnvmtGa6025mgmuLKaWW3YtC8mnSs0RIKkqSnBIJHHY1qUUAYFzZ+G7zSo9Mu9Cjn0+Igx2kukO0SEdMIY8D8qytc8N6DqVpc/wBn6XbWV5clBNPJoDSrcKhBEcq7VLp8q8bh0HNdpRQBw2meD/CdtahdS8O6ddTc/wCq8ONFDHkYYRxlW2A9/mOc8mtywt/D+lmI6Zoq2ZgjMUX2fSXj8tC24quEGATzgcZ5rdop3A5W58PeC7zUHv7vwpZT3kj+Y9xLoRaRm/vFjHkn3py6F4OSzjtE8LWi20U3nxwjQyESTGN4Xy8BsAc9eK6iiltsBz0en+GIYb2GLQIki1AlrxF0dgtyeeZB5fz9T1z1pjaT4UeGGF/Ddu0VvGYoUOisVjQnJVR5fAJGcDiukooAwBaeHFe6YaGga8j8q5I0h8zp/df938w5PBqP+zPCxsbazPh2D7LaOXt4P7GbZCx7ovl4U89RXR0UAZ8Wo2cEKRQ291HGgCqiWEoCj0A2cU/+1rf/AJ53n/gFN/8AE1dooApf2tb/APPO8/8AAKb/AOJo/ta3/wCed5/4BTf/ABNXaKAKX9rW/wDzzvP/AACm/wDiaP7Wt/8Annef+AU3/wATV2igCl/a1v8A887z/wAApv8A4mj+1rf/AJ53n/gFN/8AE1dooApf2tb/APPO8/8AAKb/AOJo/ta3/wCed5/4BTf/ABNXaKAOYk8NaT4hnuTq1qZWt7o+W6TPEwDQxhlJQglWHBU8HuDS2fw88MadKj2GnyWwjt1tkjhu5ljWMNvACB9oO75t2M5yc5NaOiK6PqQkk8w/bCQduMAxoQPwGB+FatAHPP4E8PSRW6NaT5t9+2QXs4kkDnLrI4fdKrHkhywPcUo8D+HxHqsZspHj1Zle7je6lZWZcBSqlsRkADBTbjauOgx0FFAHLJ8NvCsTPJDprw3Mkgle9ivJkumcLtyZw4kPHX5ucnOcmrtv4O0W2ub6eGC4EmoeX9oLXszBvLxsIBfCkYHK4NblFAFTS9LtNHsVtLBHSIMWJkleV2YnJZnclmJPUkk1boooAKKKKACiiigAooooAKKKKACiiigAooooA4rxVY3+qalq2naQls93eaK9un2qZo413vtLFlVjwDnGOcY461n2XgrXdC0OfT/DtjoNtBqVmUu7WSRjDb3GzZ5kY8nEisMFkZVGQTzk56OaF5vHjLHcSW5Gn53RhST+86fMCK1fsFx/0Frz/viH/wCN0u/mO+3l/X6Hmtp8OPEEPiOx1Ge10e4WLV49Rkea+lkkiAtlhZEJg5+Ybh90fIowO234a8BT6J4qlv7tEukS5uZ7a9bVLlnAmYsyfZj+6XrjcDztHGeR1/2C4/6C15/3xD/8bo+wXH/QWvP++If/AI3VXf8AX9eQnqrP+t/82XaKpfYLj/oLXn/fEP8A8bo+wXH/AEFrz/viH/43SAu0VS+wXH/QWvP++If/AI3R9guP+gtef98Q/wDxugC7RVL7Bcf9Ba8/74h/+N0fYLj/AKC15/3xD/8AG6ALtFUvsFx/0Frz/viH/wCN0fYLj/oLXn/fEP8A8boAu0VS+wXH/QWvP++If/jdH2C4/wCgtef98Q//ABugC7RVL7Bcf9Ba8/74h/8AjdH2C4/6C15/3xD/APG6AMzxFBe3MklvpccEt3Np1xHGtzK0ceWaMZLKrEYBz0P9a5DS/hzdaLc+ELzTPDvhmyu9JJ/tK5tpTG84MTRHawtwXyG3/NjkY/2q7SSyn/4SC3X+07ok2sp37Ysj5o+PuY/TtV77Bcf9Ba8/74h/+N0LR3X9b/5g1dWf9X/4Y8o8a22mTeDfFmpHULC70JQG04yBWhS5kZWlKuThvnUY29CzjrXSJ4W1q6vB4jtm0sXrXUN1FZR3DtazIkTxgmXy87iJNwYIQNqjnGa7P7Bcf9Ba8/74h/8AjdH2C4/6C15/3xD/APG6a0VhWu7nmd78NNb+3XdzYWGgM97pd7ayl7h4/LkuZd+BiFtyJzg8ElmOFzitAeCfEtz4k07Urz+y4ktLqKcpb3MgyBbGFwQIh5jAnIdjkr8uFxz3n2C4/wCgtef98Q//ABuj7Bcf9Ba8/wC+If8A43R0t/W9/wBSrvXzv+Nl+hwPhzwDrej61pFzcW+iMun6JJpZukkdpWJYFGKmMAgbem4Y3sOcZbMj+FviJg01zcWiyqtk4ht9TnhSSSBZUKh440MKESAr5YAUrjaeSfUfsFx/0Frz/viH/wCN0fYLj/oLXn/fEP8A8bo5m/682/zYt7/10seX33wv1dYNRh0TSNCto7/RZNPJm1O4lkSSSQuzGR4WZwNx5JBPotXLvwV4qn1r7Wml+Hdn2uwuoy2oS7oTbqFYL/o38QyAcjj64r0T7Bcf9Ba8/wC+If8A43R9guP+gtef98Q//G6E2reX+d/zE4pp/wBbq35I4/w34P1zTPG41nUHsTAILuBlt53AIknWVGWLy1RTgENgkk8lm7d7VL7Bcf8AQWvP++If/jdH2C4/6C15/wB8Q/8Axui+iXb/AIcfVvuXaKpfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdIC7RVL7Bcf9Ba8/74h/+N0fYLj/AKC15/3xD/8AG6ALtFUvsFx/0Frz/viH/wCN0fYLj/oLXn/fEP8A8boAu0VS+wXH/QWvP++If/jdH2C4/wCgtef98Q//ABugC7RVL7Bcf9Ba8/74h/8AjdH2C4/6C15/3xD/APG6ALtFUvsFx/0Frz/viH/43R9guP8AoLXn/fEP/wAboAu0VS+wXH/QWvP++If/AI3R9guP+gtef98Q/wDxugC7RVL7Bcf9Ba8/74h/+N0fYLj/AKC15/3xD/8AG6ALtFUvsFx/0Frz/viH/wCN0fYLj/oLXn/fEP8A8boAu0VS+wXH/QWvP++If/jdH2C4/wCgtef98Q//ABugC7RVL7Bcf9Ba8/74h/8AjdH2C4/6C15/3xD/APG6AItI/wBdqP8A19D/ANFR1pVhaZqduk+ojE7/AOlYzHbSOMiNFIyqnuDWh/a1v/zzvP8AwCm/+JoAu0VS/ta3/wCed5/4BTf/ABNH9rW//PO8/wDAKb/4mgC7RVL+1rf/AJ53n/gFN/8AE0f2tb/887z/AMApv/iaALtFUv7Wt/8Annef+AU3/wATR/a1v/zzvP8AwCm/+JoAu0VS/ta3/wCed5/4BTf/ABNH9rW//PO8/wDAKb/4mgC7RVL+1rf/AJ53n/gFN/8AE0f2tb/887z/AMApv/iaALtFUv7Wt/8Annef+AU3/wATR/a1v/zzvP8AwCm/+JoAu0VS/ta3/wCed5/4BTf/ABNH9rW//PO8/wDAKb/4mgC7RVL+1rf/AJ53n/gFN/8AE0f2tb/887z/AMApv/iaALtFUv7Wt/8Annef+AU3/wATR/a1v/zzvP8AwCm/+JoA43x5YWeo/wBvQ6jaw3MS6BLIqzRhwrqSVYZ6EHkHtWK0CaV4o8P6F4lsBqj6bJLdaPqM0AleW3WBz5ZcjiVGCf72EbqDjqr+PTNU8UyRatYfbrKfTwGt7iyaUNiUEboypPUZ5Hp7VswzaTbwW0Nvp8kUVoMW8aabIqwjG3CAJ8vBI47cULS9v6/4Ybs0l/XQ4DXfGniVvDLTWl5pi/2lpy31pcWsDsbZTLGjRv8AvPmOJeHG3lW+Wtn4iXIsdJ8N6nceZeS2uq27kWW4CY7WztjDHdnGQCWx25rcisfDUEF5DDoMccV+SbuNNIcLcE9TIPL+fPvmpL6HQdTjt01LRxeJauHt1uNKeQQsOhXKfKR6im+lu6f43/4HnuTbe/VNfh/XocfqnjLxbpzNHFceHrxDok+rx3UUEwRxGU/d7fMPBDff3c5ztGMHSuvGeqtc3FxYDT1tLC5tra4tJkczzeesZDxuGAABkwAVO7aeRVw+F/ArOzt4P08s42sx0Dlh6H91zV6Kx8NQXVrcwaDHHPZR+VayppDhoE/uoRHlR7DihNf16/5afjuN/wBfh+t3+Bx0nxA8Q2d9FZXk2lm4V7qzuNli4VLpdxthzPkCRQDt5PBGRkYv2/jDxKmvS2eoJpHk2esQabOYUk3TCWJX3qS2EILD5Tu7jPGT1DjRJJXkfSi0kky3DudLkJaVQArk7OWAAAPUYFUJtB8G3F5Jd3HhazluZJRM8z6GWd5B/GWMeS3J5680Lpf+tV/wV9wS1Tt/X9aHU0VS/ta2/wCed5/4BTf/ABNH9rW//PO8/wDAKb/4mkBdoql/a1v/AM87z/wCm/8AiaP7Wt/+ed5/4BTf/E0AXaKpf2tb/wDPO8/8Apv/AImj+1rf/nnef+AU3/xNAF2iqX9rW/8AzzvP/AKb/wCJo/ta3/553n/gFN/8TQBjeLrO1v7a7t9Qt4bm3bSrktHMgZTgxkZB44IB/CvO9J0eSWX4ZLqfhrQbW2jybWa3mMzlvsryAshgQLlgHOGPzDPXmvSNTOmapfxQ6nYteWUttKklvcWLyB/niPMZU5HHXGM1ENF8IgWYXwzaj7Ac2f8AxJD/AKMd27Mf7v5fm54xzzTi+Vt+n4X/AMxSV0vn+Nv8jlNb8c+LNK0rUBDJoc+p6K8kmpRy2s0UfkZXymUiVipZWLc5B2sOMZOq/jDWYdWm0OaTTTeyXsVvb6gsD/Z4xJE8gDp5mS42bcB13b1PGcU/WtGm1rwzqtjPqLJqOqKkc12NDnMaxqeFWLdnpnkueWJ6cDXgsPD0ehHSZdEhazk5mtk0Z1gkc8s3l7COTzzn6mjoGtzgn8SXv/CwdOu5jbwanNYXmnPc/vJLJHjuo0EpTeCqk5GAc7iFLcZG/deLtZg8a2Wh3Mmn3llPcDT7uS1t5YnSU27Slt5k+UnHCKHwCCXB4rcm0fwlcSI9x4atpXjg+zIz6KzFYv8AnmMx8Lyfl6c0f2R4TEgk/wCEbt94CgN/YrZwoIUZ8vsCQPQE0dEn/Wrf6/1YfVv+lp/X9M4HTfGGo+GPA2hxaP8AZbiKGLzbqKaOSWVo2ujGG3l1CDk/MS7Ej7p5NX7j4keKxa63qln4ft20qw+1pHJcypFteAt94iVncsEY7fKTHHJHzV1iaF4Ojgjhj8L2ixRKyRxjQyFRWOWAHl8AkAn1qS40nwpdz3E114bt55bpBHcSSaKzNMoxhWJj+YDA4PoKX/BCNk/LT8P6/Q5q58ceJLK4uxcLpLxWk+ns4SGQF4rpghQEvwynJ38gjjaOtR6l411fTdDvZtMtdIttRW/vt8CQPN5ywDJbhoxuPy7nZgBkcMcCugPhjwMY3Q+D9PKPtDqdA4baMLn91zgdPSpINB8G20Kw23hWzhiWQyqkehlVD427sCPrjjPpQ9b2/rb/ACBaWv8A1v8A5m/pV4dR0ezvSuw3MCSlR23KDj9atVm299YWdtHb2lrcQQRKFjii0+VVQDoAAmAKl/ta3/553n/gFN/8TTlZvQUbpJMu0VS/ta3/AOed5/4BTf8AxNH9rW//ADzvP/AKb/4mkMu0VS/ta3/553n/AIBTf/E0f2tb/wDPO8/8Apv/AImgC7RVL+1rf/nnef8AgFN/8TR/a1v/AM87z/wCm/8AiaALtFUv7Wt/+ed5/wCAU3/xNH9rW/8AzzvP/AKb/wCJoAu0VS/ta3/553n/AIBTf/E0f2tb/wDPO8/8Apv/AImgC7RVL+1rf/nnef8AgFN/8TR/a1v/AM87z/wCm/8AiaALtFUv7Wt/+ed5/wCAU3/xNH9rW/8AzzvP/AKb/wCJoAu0VS/ta3/553n/AIBTf/E0f2tb/wDPO8/8Apv/AImgC7RVL+1rf/nnef8AgFN/8TR/a1v/AM87z/wCm/8AiaALtFUv7Wt/+ed5/wCAU3/xNH9rW/8AzzvP/AKb/wCJoAu0VS/ta3/553n/AIBTf/E0f2tb/wDPO8/8Apv/AImgCLSP9dqP/X0P/RUdaVZukf67Uf8Ar6H/AKKjrSoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5HXW1ZPEV8/h02v9pJpRaBbuJpI3YSA7SFZTz0znjOeelFjr2r6npfhq7s73Tf8ATYvtGol7SQARBQXKDzf3ZDEL827k+2Dor/yUB/8AsG/+1BVXSPBUOlvrcbXkk9nqbyeTbBAgs0ky0iKR13OzNntkDtS1V7f1/wAP+g9NP6/qwH4j+FEUGbVlg3SxwotxBJE0rSEhCisoLq2Dh1ypweeKmt/HOiXMdw8Z1Ffs00cEqSaTdRuryfcGxowxzkcgYAIJxmuXtvhRJp+k21lpl5olk9vd28/2m30FY5J0hcOqylZRvbKjLDA6/Lk5HQf2ampfEJdTgF5FFZQGK6WSBoo7iUH90QWA37VeXlcr8w5yOL92/wDW2n/BX3E62/rc09Y8T6ToM0UWqXLRPIN2Egkl2LnG99inYmeNzYX3qvdeN/D1lfS2t5qIt2iDlppYnWHKAl1ExXyyygElQxYYPHFJqOgX8niWLWdG1SKyla3Frcxz2hnWWMMWG3DqUcFmweRzyprLk8C3pSW2h1uMWK3E15aRS2W94p5A+SziQb0DSMwUBT0G7HFRrbz1/r+vwK0v/X9blpfiV4UaFpl1NzGsMdwX+yTY8qT7so+TlOxf7qnhiKkPxC8L/bWtU1QSyrctaHyYJJFE6ruMW5VK78dFzkkEDJBFcu3wt1p9Gl05vE9j5cmiRaMGGkPkRoch/wDj4+9gkenT05twfD3xAl8tzN4l053/ALXXVXC6O6guIhFsH+kHA2j3Ofyq3y30/rX/AC1J1/r0/wA9Don8c+H00m31H7ZK9vchynlWkzyAIdrlo1QugU8MWACnrimL4/8ADEmoLZQ6tHPMZooCYY3kRHlGYwzqCq7u2SOoHcVjaT4A1rR4YXtvEdr9rRrlZHOmHy5IZ5fNZdhmyHVycNuxg4KnrVY/DPU7bzYdK8QWcFoZrGSKObTGldFtcbFLCdQ2SoycDvjFCtfX+tf8gd+h6LRQOnPWipGFFFFABRRRQBg6/e3OnTS3tjaNe3NvplzJFbKcGVgYyFHXr0rmJPHesDwDquv6dcaJrBsrYSiSESQKkgY74pIizOrKuOCQSeu2ut1S2kvNUW3guZLSSSxmVZ4vvRnfHyM9653Vvh7faxb660+sWcV/q9otkbiHTSqLCGJy6ebmSTBI3bgB2XsWt9R9DffxhokOqf2dcXvlXIB3M0TiIME3lPNxs3hcts3bsc4xVT/hYnhfciPqTRzSSiKO3ltpUmlYgldkRUOwIBwwBB7E1iN8KLK41TUbm+/su4XU1Y3Ep0pftccjR7HMVwXJRDyQpDEZOGrG1LwZP4Vg0GHSILFbs6vCftWk+G2ULGkcih7gRMd3LjJ3IOTjHJo7fL89RdPv/I9Is/EGl32htrFveILBFdpJpVMfl7CQwcMAVIIIIIBGOa5ay+Ikd5rGrQXFxa6daQXFnBYy3NtMJJmmJ+Vo3CMGO35cDABDZYcVqp4NRvBmoaHc3ztLqLSy3F3FGE/eyMWLKmSAAegJPA5J5NYd58OtdvZby6m8WQteXktnJLu0oeSv2Z967UEoYEkDOXI5bjkYatza7af8EP6/yOrTxVo7xXUn2plS1JEjPBIoOG2/ISvz/Mdo25yeBzVAfETwvmBDqTLcXEjxR2b2sy3JdF3MvkFPMBxg4K85GM5FUG8ATy/bt2rpAJ2jmhW0tPKSOdJRKJXTeVdt45wFyDg5PNL/AMIRqb+ItN1q41u1e6t7xrq7C6eypOfJ8kKg80mMBCeSXJJz0GKUbdQfWwah8QraDxhpum2skB0+T7QL67mSVBGYoyxCOVCNgghsMSp4IB6Xx8Q/DGYkk1Jop5pTDFbTW0sc7vt3YETKHORgjjnIxnNc9qPwnl1aJLC98STjSYJLpoLaG1QSbbgNuR5GLbgNxwQqnBwcnmprL4a3Gny6RJZXWhWJ0++W6lFhoItxdBUZAGCy8Ntkf5uRnGFGCCKz3Dv8/wAtPxO+RxJGrqGAYAjcpU/iDyPoadRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDJ0GNom1JXkMhN6WyewKIQPwBx+Fa1Zukf67Uf8Ar6H/AKKjrSoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA52a3S58eMkjSKBp+f3crRn/WeqkGtX+ybf8A56Xn/gbN/wDFVnr/AMlAf/sG/wDtQVu0AUv7Jt/+el5/4Gzf/FUf2Tb/APPS8/8AA2b/AOKq7RQBS/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qrtFAFL+ybf/npef+Bs3/xVH9k2/wDz0vP/AANm/wDiqu0UAUv7Jt/+el5/4Gzf/FUf2Tb/APPS8/8AA2b/AOKq7RQBS/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qrtFAFL+ybf/npef+Bs3/xVH9k2/wDz0vP/AANm/wDiqu0UAUv7Jt/+el5/4Gzf/FUf2Tb/APPS8/8AA2b/AOKq7RQBiSaZAPEFunmXWDaynP2uXPDR992e/SrEVpps9xPBBezyTW5CzRpqMpaIkZAYB8jI557VW1vVbLQ77+0tUuI7a0trGZ5JZGCqBvj7n1PA9zXn2gao/hr4hWWoa4+kWNt4utTslg1PzjcTq2+NiCiAZWQoNpccIM9Mi1dgeiuemT6fY21vJPc3NzDDEpeSSS/lVUUDJJJfAAHenLpdq6Bkmu2VhkEX0xBH/fdePP4+1oWfiDUF8aWkL6dYTuLWaSxdDOJMLsjT98FxgYlIYOwyG6Vp3niWS01jxBfxeKriNLmPThasi27xRxS4/eKzLtVclgHYsoyTtYgChapPuD0/r0/zPT20q1VSzS3YAGSTfTcf+P0y3sLC7to7i1urieCVQ8csd/KyupGQQQ+CCO9eR6d4q1a6udM1XU/Ews5odJ1RGaRYmt2mhnVAXGxc/KAxxs+6D8oJB1G8d399pNncW3iCO3vW0q3urG3SKJk1icg+bHypJIYBdsZVlJyeMCq5f6+bX6Cvrb+un+Z6Z/ZNv/z0vP8AwNm/+KqG6s9PsrWS5vLue3gjG55ZdQlVUHqSXwK830f4hTt4qs4dS8X6dKkut3WnvZIIY18pYiUbqX3Bwq53YO7GOldH8UL7Sb34Oa1ePc2dzZS2m+Ccurxu2RsKt0J3YwR3xilbRPvb8RrV2OhePSI5jFJqMiSKyIUbUpAQz/cGN/Vuw79qlexsIp4oZbq4SWbIiRtQlDPgZOBv5wOeK8v1/wAQW2t3d2r61p9zDous6fcQXNusbGwgZQXkLfNwMnLnjFXLbx1q1nqlpavrFtqUcyXxsVkjjSbVBGitC4K4BBO9RsUBtuRS6N/1sn+pKbbS72/X/I9DFnp5u2tRdzm4VA5hGoS7wucbsb84z3qb+ybf/npef+Bs3/xVeNWnihLbxbd6paazLeve6VafbdUSwXbZAzsJNxVNo8sHAEmSuPm3bTXpXhXVb670PUpjef23FbTuthfqqD7dH5asDlAEPzFl3KADt6UNWi2+l/wZXWy8vyuav2PTheC0+2T/AGkoZBD/AGhLvKA43bd+cZIGfepv7Jt/+el5/wCBs3/xVeGz+L7yHXBrukXx1LVbrRkS8nNmI005jcJ5iO6RNsEa7ziQOy9TuziuotfFWsPFp1rrPjLTdOiuFma21izeK5hu5FZdkLyvEkbHDHIRULY+UjBFUlt8/wBRX1f9dF/n/melf2Tb/wDPS8/8DZv/AIqj+ybf/npef+Bs3/xVeW3PjXX307xJd2PiG1uf7O1hbEeVHHDFaW7iMmWQlJWUqd67iCAdxZTjC19V8c+IdO0rT2fxLYzXcUf2lmsnhe3vYfPVc+a0Q8whDhhEiAHksowKSV7edvxVwbsm/wCt7HrX9k2//PS8/wDA2b/4qmtpdqiFnmu1VRkk30wAH/fdefa7401nTrrW49NvUv7hEeS3gi8tktohIib3ATzEwC5yRIrbSR021nN4o1K50OCx8R+I9Nk0y/W6C6rYvFeJcbVTZbOxgSNnbdICFjBIUKMNmpv7t0Wld2PT7exsLu2juLS6uJ4JVDxyxahKyup6EEPgipf7Jt/+el5/4Gzf/FVzfwu1Kzn+HXh+xSdReQaXAZbVwUlQBdu4ocMFJU4OMHHBNcJr/wASNX0zVdce08SW8dvFbX/lJewwgW88DoEjCDDgsGIG9yWyGCgYBua5ZuPr+AoJzSt5fiev/wBk2/8Az0vP/A2b/wCKqJ7GwinihlurhJZsiJG1CUM+Bk4G/nA54ry5/HV5cT3VlpHju0vNTSW0nsrVWtB9t3x7pLfO04XgkOPmXdyTwKs2vxFkNpop0fxPb69PdWF65tpkhSee6jUFI8R4AAOVAAycZ3Gpel/L/IUfetbqem/2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVXkEeveINW0exudS8WWptP7Xs98umXMU8kBYndHLm2RVw2zahUtngluK7HTr7VrXxHdaVq+vX3laZI1/Pe3ENvHHLZsv7tGYRKFwwfJGD+7JJAIAdu/wDWif6/gK/9ff8A5fijrv7Jt/8Anpef+Bs3/wAVR/ZNv/z0vP8AwNm/+KrmfiD4mk0bQdJvtM1uysIrzUrWE3EoR1lhkcBthJ2j5SWzzwD06jh5/iDrtxZWtrpXifTCi3l7BJrN5cwwRu8coEEbsIZEyyHOAqFgPlYd1v8A16f5ldL/ANdf8j17+ybf/npef+Bs3/xVH9k2/wDz0vP/AANm/wDiq84sNa8TeJU8VRWfiyOPUNGdPIt9KggIJMKuUbzkdiN+5QcKcqc/3RdvPFEr29pqLeKLnStC1aRvK1KWK3C2oRFCruePavmPvOX3fdAXGRTt/XqI7r+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iq8r1jxh4isNPuHu9elsrqbQnu7ONbWL97PFKRujRkLHegVmU52hsjHZ3iT4g6lp2m67c2niCCCZLV7m0WaCMrAoZFVXjYJJG7EsBv3hjyOm2hK/wCP4Owr62/rZP8AU9S/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qvKNQ+IOpxrqNnpPiexvUi1SKOTU3nghWzge335Z1ikRV80FAzRt6E5+ati18V6xBfaVHq+uWMr3MCps05lljlf5i0u1o1d0wE+eMkDccrjDUv6/C4zv/AOybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiq5nwX4pW8hlttY1mG4vFnW3VzLCUlmKlmjjZAu4jB+QqrqF5Hc9nTasJO5m6R/rtR/6+h/6KjrSrN0j/Xaj/wBfQ/8ARUdaVIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBz8k0dv46mmnkWKKPTCzu5wFAk5JPYVPpvi3R9WuI4bKecvMxWEy2k0Sz4BYmNnUB1wM7lJHTnkVzHj3R73X5NX03SwrXU2kjZGxwJcTKxQntuAK/jWnc69d6xoN0nh7R76HVLe3kMQv7J7dbebYQoVpFCucnGUJXGecdTuO2qR1tFePanLq8SQT6FP4xi06S9sjPFLb3Ms2/zD9oHzo0gj8vBO3CZACk5IqoNQ1i0W3aCXxoqrqGoW+82N7MyWpjcwNteNgx3mPDsGbqM4BAOl/X8LfnfQX9fn/lr5ntlFeEm78QLoE7K/jRr4eHraYBrW+51FWwQPkx025UfI3JYHk11V1cavfa1JNF/wkNtf/aoZLVkhnW1NiQnmbkK+WJAPM+V18zdgAYwKpqz/rvb/g+mor/18r/8D10PTKK8r+H99qw17R01JvE8r3OnXC3ranZ3KxCYTAxZ3II0bZv5GM8A/wANeqUmrJP+t7AmFFFFIYUUUUAFFFFABRRRQBnyf8jJbf8AXpN/6HHV91DoynIDDBwcH865rxc2pJBcNoayNqA02cwLFjeTuj+7njdjOM98Vz0zCPRbI2X/AAl0uhy3ZN8JRdi9hUxkBVyBcFA4BJXPXg7cgG9xnWaN4ZXSDEJNV1DUY7fi1jvDERbjGMKURWbg4y5Y+/Jqe48SaVba5DpE1yRezHaiCF2UMQSFZwNqsQCQpIJAOBXk2qS+J7eO+juLnxdI8WkyPYLbW1wR5wuD5G5ok+aQxhNwYnqdw6ipruF7rU9f1nRbfxfDdLeWN1HlNSgWWIPGJwImwr4G4bNpOPujFPdq/wDWtv8Agk+X/DHs9Rx3CSzTRqJA0LBWLRMoJIB+UkYYc9RnnjqK8tmk1yOxvWjh8SLFDqVxLapJ9oZrlGVfLUMjNIgDMcCRCg53DjIk/tDWZbzWIbpPEkmmLrKmcrbXEcy2jW4GIGRVZlWYYJiy2BnnOSlqr+X+X+ZX/B/C/wCfQ9SIypB7+hxVYm10rTnd3WC1t0aR3kbhVGSzMT+JJNeOao3iKKSaGS78YPbDSLxrJYLe5LCTzgbXe8abjIVByHbOANwGWB0IdU1yXxvaan5HiNLAu8d3DNa3bI0ZtNysItoRR5gxjaz7jywyFoa0uu3+Ydf68j1LTNStNY0u31HTZhPaXMYkhlAIDqeh55qwZEWVYy6iRgSqE8kDGSB7ZH51wnhuG9PwR020RNQ0+8SyjgdTaSpPEwIVvk+R8deVIOOVPSueeDVH1ax1s6b4jeSLRtQihEM9xvMnmL5fEgG0smSolQnIXIZlFVJJSa7X/JhbQ9ceRI9vmOqbmCruOMk9vrTq8UsdN1u5nsvt0XiG4tbPX4p4N73quIHtD1aRt5Al4JbAGTkKpIrb8FXGvaXfXupeLtT1JvLiYXtkdJu2jSTeNskcjO6MoGf9Sqrg5YDFFtbf1sv+GE/L+tX/AJHqFUbTWdOv9TvdPs7uOa708oLqJDkwlgSoJ6ZwM46/nXNfEf7fNpdjbaYNUUzzMDNp7TDyz5TFS/k4kK7sdGQZxubHB4y2tfEM229kh16DXL7TdOa1ljSaOM3EakTC4wNoA3HKy9f4QTiktbik7WsezUV4tY6h4njZHs38U3OqSTalAhv7K5WApybZmBjES8hcNgYyQcDgWtWl1iHSbi48Pz+MILN57LcktvcTXAl80+eFEiNII/L5O35MgBTyQRK9vO34lNWbXa/4f191z1+ivHNbl1aw1vVI7K48Yyx22o2H2LZbXcqCEkfaACEIkUKW+/u5xjnFU9YuvEM+j3+naVH4tWW1ub97Cdo74ZACtCpbAeTPz7d77OMEN8opLVX/AK6f5/gwSu0v66/5HrdpqekXviK/tLS5WbUrCONbqMMx8gPkqPQE4yQOeBntWpXE+GJ55/iNrc09nfRLNpliomnspYo3dfMLgOyhSR5i5AOevocYjvrrXFxKsniO11KNrsaiVjmkg8nZJ5LW6lWiZ8+VtEYLddwzTl7v3Cj7x6jRXiOpprcnhXw9D9u8TJeXumFrxy2orLb3AEaeaVgjZ8rhsRsERuWznk6tzPq48bafPpDeIX06KWOFn/0qeKa3a1YiRQf3Z/eYyX3yburKMCm42/r5f15AtVf+v6/U9ZrPstIW0Fy015dXk9zxJPMyq+0Z2qPLChQuTjAz3JJ5ry97nW4J9ItZpPFJtY9S8q8mtra8YXERhbezAo0kYEhUfK5X5vlJC/LZ8EX2rx+INAW8/wCEndJrW8gujqFrd+Wu2UfZy+9dqtsDfOcMf4iTikld2/ra4f1+Nj0l7/TtNkisWmjhZYWkWPn5I0HLH+6o9TUej6/p2vxzPpczyCB/LkEkLxMpxkcOASCCCD0IOQTXG6vEZo/iDFfR3ks8kUS28dkJTM0JgAjCiL58eb5uccfezxmuft7TxAdW0mOy1HXtK02G1t2sxJp99cs7Anz45d0gVCTwPPRgFI2EYpLV6+X43/IGrbef6f5nslIzBVLMQABkk9q8S0y51iRbEajP42kMkOpJeM9peoWAkLWx+SMBGI6FAG6L0wtWNO1PxNd6l4cv5oPEsUtuLKO/We2uwkqmNlmPlBVQYfqWDtwCNq4Jdv0/G/8AlqJu34/h/Wh6xo2taf4g0uPUdGuku7OVmWOZAdrbWKnGeoyDz0PaprW/trySeO2mDvbSGKZMEMjdcEHnpyD3HIrxWCHxNc6Vp1vaXGs6DYtcXzecmkXryJO90zxs0UbRttKMCC4aPqGGa9Ak1BNM8eG5uWlKLo8Yv2it2chzLiIsqBiOsuT0A5JwM07Xfrf+vw/FA3ZP+utv1/BnZUUUVIyKa2iuGjMylvLcOo3EDI6Ejocdee/NS0UUAZukf67Uf+vof+io60q5r/hJtB0C5vE17W9O0xprnMa3t3HCXAijyRuIzjIroLa5gvLaO5s5o54JVDRyxOGVwe4I4IoAlooqKW6t4ZoYZp445Z2KxI7gNIQMkKO5wCeOwoAloqI3MC3SWrTxi4dDIkJcb2UEAsB1IBYAn3HrUtABRUUtzBBLDFNPHHJOxSJHcAyMAWIUdzgE4HYGpaACioZry2t5oori4iikmz5aO4UvgZOAeuACfpTre4hu7aO4tZY54JVDxyxsGV1IyCCOCCO9AElFFRXN1b2Vs9xeTx28MYy8srhVUe5PAoAlooooAKKKKACiiigAooooAwl/5KA//YN/9qCt2sJf+SgP/wBg3/2oK3aACiiigAooooAKKKKACiiigAooooAKKKKACiiigDPk/wCRktv+vSb/ANDjqPUvEFnpWr6VptylwZ9VleK3ZIiUDKhc7m6LwpwOp7Dg4zfF9vdXdtd2+nWq3lzLpdykdu0hjEhLRjbuDKRn/eX6jrXCWPgXVbWwjjuPDhutPs9de+TSz9lTzbeS1MZRI1YRDDscqSAQDy2clx1buPp9/wCR7DRXh194A12G3voB4bu9RL6VJFY7L2ExWkrXBeFEEkw2+WmwblUfd4zxXTR+HNUvNcF5e+HpodQ+1/aRrAuIRJ9lI5tCVk37gDs2j93n5w2aOn9d/wCmT/X4X/4B6XRXjNl4IvoNO8Jtd+Db64ltZbr+1YnvYJDJGySBFk3T4lyZBjJOBuHGcGvZeFPEtlptlFH4MuGlbQ5LG+828t8TP5ylAxWcM4CK4UZwNwXIBbBbX+vP+vmHT+u561qPiC00zXNK0q4juGn1V5EgdIiY1KIXO5ug4BwOp9MAkL4i1+18M6HPqt/HcSQQbdy28RkbkgDjsOeScAdzXnfh/wAM69o+o6DbjQbkWNlrd3db1ktUSCCWFlXCI4AAaQ/KqnAB68Zs/EPwtrWuX+pC00GLVzc2cKadcyXKRiwkVyZM7juXcCPmQHOMNgYo00C71/rqenA5GaK8fn8D61faX4jdtFuLW7udXW4TfdQXElzalY/NiieUuoDNGTtkVVI2AgDha+q+ANXOlafaaZol9MLKLzrOa9ms2uLaTz1cxYVhFEMA7fKB4+Xco4oS2/rpf/gA3pf+tz2imSwxzx7J41kTIO11BGQcjg147B4S1Vtbtbi58F6hIn9uXU88k95bSs1nJEVEbFpySpYqSnIwv0FXvDnhvXbVdAkufDc8NzZ7LZ/tU1tIkEKzM+VKSF0+UqAFLBiqhlAANC1t52+X/DA9L/P8/wCmer0Vzur3Fzr/AIF1T+zdNeS5lhmhjtJ5VXzSMr9+OTGD2w49CV5x5ZF4WuNF1nS7TU/Dc93aT6pdvbaV5tskcsL2gJUQq4hGHDcN78nOSlrcb0R7rWMfFWm/2/Z6RE001xdtMqSRxExK0X31L9MjpgZNeaaj4G8Rumip/Y4uZ9NS2kguo5oneELdb3g3SOCu2IgZRRv24ZsAAtHge+s9RW3fwP8AbLEXupTzG2ktVW4Wbd5QKtIpOAQPm6Y9ADQ9Ff1/AdtF8v8Agns1FeVjwpcNo/hdrzSba31e7sRomqJeeXJK8Hl/Owdd24gRkgbuj88jFeoW1tDZ2sVtaQxwQQoEjijUKqKBgAAcAAdqqSSb/r+un9IlPb+v66/0ySiiipGZOo+GdM1TUor+6S4S6jUIJba8mty6g5Cv5bLvXJPytkcn1rUjjSGJIokVI0UKqqMBQOgAp1FHkAUUUUAV3sLaTUI75oR9qiQxrKCQdp6qcdR3we9WKKKACiiigAqpFpVjC0zJaxlribz5Wcbi7joxJ9MDHpgYxVuigAooooAKKKKAPKPGOoG38R+HbYavpum6jJ4hdoHul8xdn2MqCY96Fs7lXhh8zD2FXFjuPAMuk6NFreYJZd0kcUcSPNNPOWbZE6nKDLYVH3IASQ4rudI/12o/9fQ/9FR1pHp6U72QPU8zudW8T6bDq1qNT1G8vNCSa4llktISt3G+PI4SIZ2rvJCYOUOTggVj61q2lS6x4Suf+E7sr5ze3Jg1hltllgiNq4ZdwAjJD7f4eMqGBPJ9W0zSxpqSl7u4vbiZt0tzcld74GAMIqqAB2AHc9SSb1LoB4zb/FSSXTLOSXxXYs83h4zyfZoonlS5Eqo0hBbb0LHBwq7WJyBxDJ4l1a7tdGuNQ8VNafYdbvLeS8HkSRsq28jxGXEaq2Rx8oUEE45ww9sopt/187/8AXX+u1v+CeS6L481KTTvBt7ceJbG9m1yKYy2eyJPMlWJtqIRyBvAUjkliBkfdrqvAOstrVk10/iZdYkliR5rTyI0ewm/jiOwAqASAFcFxg5Y9uwop3V2Fjw7V/FHm+LNO1a71iODVbOTUYXgmsVZNKCxusZcqA4VsIxLvtbqMAV0eneOb26fQblNWivV1Cxh2Wtq0RaacoWkLIVDYyFG6NiFydyjg16dRU9Lf11/zC2t/wCun+R43qfj3WLTwnqGqaZ4pt7hl0w3Fwbm2ixpl2HQC32jaQW3OAsm5gVzz0qP4jauZ9H1DS9S1x54xZwXlhELSKT+02eQklNqEkR/Lt8vDKMMxbNe0UVV+wNX0PEbr4g+KktfEGo/23pGmrZw3LLp16+biAIT5LfZzCjLvAXl5GBLjAB+WurXxJeWur6H5viNb231GOApHCsGZnkbJKpsBaMKOCjkoNxYNwR6HRSVlYb1VvX9Py/UKKKKQBRRRQAUUUUAc7Mtw3jxhayxxv8A2fyZIy4x5noGH861fK1X/n8s/wDwEb/45Wev/JQH/wCwb/7UFbtAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAFLytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyrtFAGJJHqX/CQW4N3a7/ALLLhvsrYA3R5GPM+ner3lar/wA/ln/4CN/8cqOdlTxDA7kKq2cxJPYb464jwf4pubv4i39td3GoyWur232uyjvLOaCOExsVKRGRVDAxtGxKkjO455FC1dgeiud35Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlcXp3xMvNR1DUo4dCglt9Ps5rmUW2oGW5jZCVEMkXlgJISM7S/TkZqDT/ijqV8EePw9Z3VvNfw2EF1p2rieF3kXduLGNOF6HbuOQRgcZFra39a2/MHpe/T/K53flar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOVxtt8TLq51i5s4fDN9cxW/nxNPaRTyJ58Sksm8wiPaWUqrByxOMoM1bPj2dbO1nbTbbbI7pPKL1vJhZVX5S5jG1yzYCyCPhSc9AWlcHpudP5Wq/8AP5Z/+Ajf/HKPK1X/AJ/LP/wEb/45XNQeLZnub2107SXOpyapLaRW97flY38uJXMm4B/LUrghVU8nJAJbGddfFC8jRhaeGnklh0+5vZxNepGim3l8uWNSFYsQc4JAB49SQb/15X/IFrt6fjY7bytV/wCfyz/8BG/+OUeVqv8Az+Wf/gI3/wAcqxFcJJZpcnKo0Yk57DGa8tufH15b+KLPxDdpcRaFNoNxd21nDc+Z54EkIR2QICsh8zGMuACMYORRbW39bN/oC1V0eleVqv8Az+Wf/gI3/wAco8rVf+fyz/8AARv/AI5XF2PxI1e+urOwTwfcwXt3NLFG93LJbW7FIvMBDSwrKQemfK4IPXjMVt8WTfalaWun+HL+65jS+8iKaU2rs5QgFImQhSpJLvHxyAelFnewro7nytV/5/LP/wABG/8AjlUrrQTfX9rfX0WkXN3Zkm2uJtN3yQE9djGTK/hWDB4/1C50l9RHh77PbR38lk5uLvmIxuyu7+WjhV+XAOcbiAcD5qnm8dzjdc2ukx3OnWs0MF9Ml6vmRSSqjDy0ClZFHmplt698A0lrqhtWumdJ5Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlchpXxHutQVJbnw/9jgmt72WPzL+PfvtpNjI/ARQcg7t5A5zxyc1vGl/4hGnSIsulz2XiCC0uYLS5MkV0jxhwNzxoxXDDsAcdWFPrb0/F2/MHom/X8Fc7gaVcLqLagp0wXrxiJrkaefMZAchS3mZwCTxVnytV/5/LP8A8BG/+OVyen+OGXTdMmGky20N9LOJGvr1j5LiYp5fmFWUsWPCllAGQpOAKo6l8Tr2I+ILa10q2WfT9Pury1l+2GRZBC+xg5WPaGyQdqs5HRtppf8AB/DcaV39347HdeVqv/P5Z/8AgI3/AMco8rVf+fyz/wDARv8A45XJWfjG6imu0v8ASnTVFjsYUT7eWguJJt20rxhFBzltgY4+6cLlX+IGpJqFrpX/AAjgOqTXktlKv29fs8UiQecv7zZuZWUjnZxzkZwC2rNrt/X6kppq51nlar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOVF4d1f+3/AA3p+reQbb7ZAsphLbvLJHK5749a4vRfE+qaX4o1axvUm1Kym8QSWkd1PdKHt82qyqiptAKDDDquMg/NyaLatPp/ml+o+l/62b/Q7nytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyvNdQ8fX3iDRblYEk0e5sL7TZN1ld+alxDPOF2lzGoIxuB8ssuRw5Ga0NK8TarpXiXUNPlD6rFeeI5bKKa6u9jW3+ipMiqojIKcMOxHB+Yk01F6/12/zDpf8Arq/0O68rVf8An8s//ARv/jlHlar/AM/ln/4CN/8AHK5fSPHWpa39nj0/w/HJcLCk1/Eb8L5CtK8Y8slP3hzExOdgx3zxUC+ObuO7t7Wx8O3D3Goand2g+1agAkckKFuT85UME4CggDPfgz1D+vwudf5Wq/8AP5Z/+Ajf/HKPK1X/AJ/LP/wEb/45XF/8LRfzNBb+x0EGqra+aftm6SBp2KqNioflDDBZygOfl3HIpmkeNtQur63/ALf00RxNqd/DDc2l63lxrbq4w6bVLkhWwCGHG7ggCna179L/AIA9Pw/G9vyO38rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxyuO1H4k3mk6RPf3vhxnRtPOpWSW96rmaEFA3mblURsBIpIG8YzgkjFdH4e1651i51S2vtPWxn0+4WIqlx5qurRrIrZ2rg4fBGDgjqetHK/6+4C95Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlXaKQFLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8cq7RQBm6R/rtR/6+h/6KjrSrN0j/Xaj/wBfQ/8ARUdaVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnnxFsItSs/ElvPbJdA+HpnSN0DfOpypAPcEAg9iKnvtK0Kaw8Imz0vSrme1UzaejxLtQLbuwKkKdq7/LJIHB2nrit5Rnx+4PI/s3/ANqCrNp4W8P2BuzY6Fptt9tUrdeTZxp9oBzkPgfMDk9c9aNUnb+tx32+f42/yODs/iTrn9k2d7qEOlqNS0+2uYAiuFtmlnWImRi3zIN4bgL0Iz3rdu9d8R293Do32zQ01UW8109w8MhhlSMrhRH5gKMQ4JO5towcNnjYt/BHhS0Yta+GNGhJiaEmPT4l/dtncnC/dOTkdDmpm8K+Hn0+3sG0HTGs7V/Mt7c2cflwv/eVcYU+4pu3Tz/4H3fj1F1/ry/P8Ohwk3xI8RSJdXVtYaZb29tbabdCGdpHkkS6YqykjaEIPQ4bgdDniyPG3iZvEEeiImj+c2rXGnPdtHKANtsJ0YRbueuD84zjjGeOuvfBnhfUrqa51Hw3pF3PPgyyz2MTtJgYG4lcnA6ZqE+AfB7XLXDeE9DM7Es0p02HcSepJ255outdP60DX+vQ4+z+JesJYWV5qcGneXfaSbxFhV1EEizRxEuxY5T95uPAKhTy3Wr934u8T6ffRaXImj3dydSt7Vr2NJI4ykylgRFuY7xtORv6FT3wOmtvBfhazmjls/DWkQSRI0cbxWESsiNncoIXgHc2R3yfWnnwf4aNhBYnw7pJtLaQywW/2GPy4nPVlXbgH3FDt/Xrf8tBd7f1p/nqR+ENXu9b8OJd6kLf7Uk89vKbZSsbNFK8e5QSSAducEnGeprcqlpei6Xodq1tomm2enQM5dorSBYlLHgkhQBngc+1XaHuMKKKKQBRRRQAUUUUAYusaZbaxqC6ffiU21xZTJIIpniYjfHxuQhh+B9qS+8I6VqD6XJOt0ZtJ/48pBfTqYzgDLbXBk4GDuzkEjuayfiFq9zoOi6hqtjeQWdzaaVcSxTXCB0DBo8DBIySeB7kcHpXD3PxIntJb6VPHFlcQ2s2myqP9G2us7BZoyQPuKuWGPmHdiOKIq7svIb2T9f0O4T4fJBpLWltql0sk9u8F15txcSwSBxhtsDzFYxySAuMcYOMgvn8EaFbS28upX+oNbQzxSWyXWs3TbLgEqrBnmJJO4KE6E9jmuA134larp+pa1NY+JbZbVLW+MC3cUIWCeB4wiKgw2WDEAu5LbgwUDANv/hZn2TUVtj440u6DX+nk+YYNzQzKPNRNpACg4O4hiAcZ6GnG7afe35/0/xFP3U7+f4LX+uux6QfCOinULq8+zSh7wHz41upRDISMFjEG2biP4tu73qnd+EfDFvZ+Vfq8cc8+GefUZg1w7lRsdy+ZA21V2MSCABjHFcp4c8ezP48u4dV1+F9Ha3upP8ASmghFs8M6ptwoyg2sPvuzHrhOla/xUu9LtND0W71S4s4Fj1yxkhmuHVQmJVLMrHp8m7JHbPaiP2X3t+dgb1l5X/K5dTwl4QneeGKRpJru9e5JTVpzKtwmVdo2Em6NgPlIQjjg8DFOvfAnhS/vVguIpVuBYvbiCHUp4ibdmy+USQZDN95iMk9Sa8+t/EMWuX+i67eeJrO3kgl1Swl1yzjh2oBIvkJlg6jcoBVWzuzxknNaEnxD1q0UQ6jqFrFeNpFrcTWqwATWpeYLLOyEk/LGd+3GF7g0uy/rZ/ovu8tRtWbt/Wv+f8AVz0PQNNstNa8t9Pv5LqON0iaCS8kuDb7UACkyOxBIwSOM8HGSScx/h54LshLeXOk2wjihlUvdTO8dvE4zIFDsVjTGeFwBk4xk15/4e1230q616G116Sz0y813dP4hFrEibWtUKuHMfkZeRSC+3BznA3qa7DUvE2rWHwb1HXJ9QtrXULaGYwXs8ICTBXZY32EgZkUKQOmWGARxVST38l+KCKvLlXf9S7d/D3Sr5tIMF1eLa2EkkvN9cSSyB4ygCzmTzEA3ZGDjGRxmtJfBegx3dtc29m9tJbRCFfs1zLErxjOFkVWAkAyeHDdT6151d/Eto9cu5V8a6X9jt7/AE5IbePyAssM2PNDMSScAltylcbfTIp9/wCO9Qt/B9/q8fjSyttTTYtxpd1bRH+z5DKF2gAqwG3PMm7djIOOKNd/66f5kaW/r+uh39v4H0K00uXT7eK8jgkuHuSRqNx5gkfO9lk8zeucnOCByfU04eCfD63kNzHYGJoUjRY455EiYRjEZaMMEcrgbWYEjAwRiuLufEniW3+ICaXFrdglpE8LRJf3CJJqULjdI0UaQEyFclV2SLjaNwPU5ej+PNYvv7TT/hJoWge1t7uC5uDbwtCrSyLMoxGyxlVTpJ5m0/eYZ4S7l6u7/rU7mP4YeFIkRBZ3jxxpNGscmqXTrtm/1oKtIQdxOTnvz1FJc+AvCXmw29x9qinnnWeIDWLmOWWWOPaHBEoZmCDryeM1yP8Awm3iTUPE2mQ2Op2NhayQwTRR6lMkLairMfNCIsUnmkAYXy5F5wTuBFMtdcXVvih4dur69km1KK9vraXT0sgTp6BWVAWVN6hxtbLsVb7wwBTSf9eX/BIcrK/9a/8AAO7tvAHh20sY7OG2uvs8chkCPqNw+4ltxDbpDuUsSSrZUnnFLH4B8NxSyutg586KeB0e6mZPLmO6RApfAUkZwBgHpiujoqStjmU+HnhpPtebO4f7ZHHHN5t/cPkRnKEbnO1lPIZcMCSc5Jp83gPQJ/sZkgvA9k7yQypqVykm912s7OJAzsV43MSccZro6KAsYmg+FbLw24j0mW6js44BDFay3k0yoNxOR5jsB1wMAccHPGKM3w38NXF3JczW160kt2b1x/al0FaYrtLbfMx935cYxjjGOK6mijfcDk2+GfhZ7U25s7zyysKnGp3QYiElohuEmflLHHPHHoMWR4B8PBp2+zXRee9F+7nULgsJwCu9W8zK/KdpC4BHBGOK6Oind/1/XkgObt/h94Ys5YJLDTPsTQ7gDaXEsPmBm3FZNjDzFJJOHyOelQ/8K38Ni5ScQ6iJUuJLlGGsXY2yyDDsP3vBIJH4muqopAcpa/DPwrZxxJb2V0qwmIorajcsAYn3xnmQ5Knoew46cVZ/4QPw9/asWoraTpcw3Elymy9nVBI+d52B9pBy2QRj5m45Oeiop3YbnMt8PPDLaVc6abGb7JdJ5bxC+nGyPcG8tDvzGmQPkTC+1PtfBGm6dqX27TJtQgmknSa4L6lcy+cVXaAQ8pU8YHIPAHcAjo6KLsNwooopAFFFFAGVokqTPqTRncBeFScdxGgP6g1q1m6R/rtR/wCvof8AoqOtKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnJ7lLXx4zyJK4OngYiiaQ/wCs9FBNaf8AbMH/AD733/gFL/8AE1SX/koD/wDYN/8AagrdoAz/AO2YP+fe+/8AAKX/AOJo/tmD/n3vv/AKX/4mtCigDP8A7Zg/5977/wAApf8A4mj+2YP+fe+/8Apf/ia0KKAM/wDtmD/n3vv/AACl/wDiaP7Zg/5977/wCl/+JrQooAz/AO2YP+fe+/8AAKX/AOJo/tmD/n3vv/AKX/4mtCigDP8A7Zg/5977/wAApf8A4mj+2YP+fe+/8Apf/ia0KKAM/wDtmD/n3vv/AACl/wDiaP7Zg/5977/wCl/+JrQooAz/AO2YP+fe+/8AAKX/AOJo/tmD/n3vv/AKX/4mtCigDEk1OL+27afybrb9nmTb9lk3Z3RnO3Gce/Srf9swf8+99/4BS/8AxNUPEM93ayy3GmvBHdQ6bcSRNcRGRMq0Z5UMpI47EVyXhH4oPqCtNrN/pd/ZDTo7uW70i3kxayuyr9mdN8haQluAp3HGNo4yLV2/rr/kD0/r0/zO8/tmD/n3vv8AwCl/+Jo/tmD/AJ977/wCl/8Aiax3+JHhRIEkbVG3PFLMIBazGYJGxWQmIJvXaQQQVBGD6GrD+MdGivLvdq9vJFa28EjwRQu8qmUnyz8udxcY2oF3fXIFAF2fUrW5geGW3vyjjDBbSZSR9QM05dXtkUKttehQMACyl4H/AHzTYfEelT+H5NbW626fEjvJLJGyGMISGDIwDKQQQQRnIxisWb4kaGs2mx26ahcG/vHtNq6dcB4XWMuQ8Zj3A4xwQODu6AmjrYDd/tmD/n3vv/AKX/4mj+2YP+fe+/8AAKX/AOJrn7P4n+HbjR7bUbp7uzjuWl2JLYzlgiPtMjYT5U5XLn5QTjORVnXPG1lZQ6jbaXLHcarbW8skUc0cqwO6IWKecFKlgBkqDuA7DrSeiuwWrsa/9swf8+99/wCAUv8A8TR/bMH/AD733/gFL/8AE1U8P+JINahhixN9sFrFNcbbWVYVZ0VtqyldhPzD5QxI71S8Q+LZPD3inS7O6gB067t7iWSWKKWacNGFOFjjUkjDZzz0PA61UlyuzFF8yujY/tmD/n3vv/AKX/4mj+2YP+fe+/8AAKX/AOJrEm+JvhGKG4lTV/tSWsKT3BsraW58mN1LK7+WjbVwMknGOM4yKs3Pjzw9aNMLi6uE8ieK3lP2GchHlGY8kJja2R833c8ZzRZjNL+2YP8An3vv/AKX/wCJo/tmD/n3vv8AwCl/+JrOh8Z6PeXVqLfU0iWRJpTFc2ksbyxxj5nXdtwoP8WCD2psvj7w3B9nWa/kjmui4gtntZhPIVTewEWzeflIPTnIx1FIDT/tmD/n3vv/AACl/wDiaP7Zg/5977/wCl/+Jqpo/jDQ9euo7fSb3z5Jbf7VH+5kRZI84LKzKA2CQCAcqTggVZ1nxDpPh9bY6xex2pu5hBbqwJaWQ9FVQCSfpRsA7+2YP+fe+/8AAKX/AOJo/tmD/n3vv/AKX/4mqA8b+H/tTQPevE6xtITNbSxp8q7mXcyhS6jkpncMHIFV7jx3py6jplhZw3k1xqTSJEHsp0ETKgbEmY8p95c5AwDk9KAujX/tmD/n3vv/AACl/wDiaP7Zg/5977/wCl/+JrntF+IFm3hnTb7xJLHaXd2jPKltDLJHCBIU3MwU7EyMb32jPp0rXfxfosYuS1zKRbMUfbaytvYMEIjwv7w7mC4Td83HUEUxJ3LX9swf8+99/wCAUv8A8TR/bMH/AD733/gFL/8AE1lXfxD8L2Mjx3OqBZY4vOljWCR2ij37N7qFJQBuCWwB1PFWpvGGhW2rNp0995c6g5ZoXEW4LvKebt2bwo3bN27HOMUhlv8AtmD/AJ977/wCl/8AiaP7Zg/5977/AMApf/iapnxlogto52nuFV2K7Wspg64UMSyFNyqAQSzADkc8itppESIyuwVFXcWPYetGwFH+2YP+fe+/8Apf/iaP7Zg/5977/wAApf8A4mqI8a6Gfsn+kXC/bJhBBusZxucglQcp8uQCQTgEdCahtPHGhajcQNaaxbpE1tPcyQ3EEkcojifYznft8sKwYEMvPbGDkDc1P7Zg/wCfe+/8Apf/AImj+2YP+fe+/wDAKX/4ms2Pxpo169rHZ6ksE092tusN3aSpJKSu7aqMFYZXkPgrjnmsu8+ItnB4wt7COWH+yltbma7vHjlG1odudhKhHUZwSpbkY4NH9fhcDpv7Zg/5977/AMApf/iaP7Zg/wCfe+/8Apf/AImufn8crc3+hDQkSa0vtSewvDdQywTQMImkAETqpB+X+LHBGAc5HYU7MP6/T9DP/tmD/n3vv/AKX/4mj+2YP+fe+/8AAKX/AOJrQopAZ/8AbMH/AD733/gFL/8AE0f2zB/z733/AIBS/wDxNaFFAGbpH+u1H/r6H/oqOtKs3SP9dqP/AF9D/wBFR1pUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcV4pvNR07VtTv8ARpbWO6tNGedftUDSowRtxXCuhGcYznj0NR2HjDVdXl0eOA2OnXIu2tNZsbmB5XhdYmk+RxIoAIX5WIYEMD2INnxBplzrOu6jptldRWct3o7Q+fLAZlQM+G+UMuTgnHPX16VPdeB7fUNc03Wr24xqNtbNb3b2yNHHdq0bJyhY42l2KkliMkZ5zQtLjdrL+uxHqXxK0Cw0q9vIpLm5a0jWQQpZzAzKzBVePKfOhJA3ruXnrVvxD4hu9MXQ5rGCJrfUL+K3na5DxvHG4JyEIB3cdGxj0PSseb4dXd7o5stR1xJ5LezNlYTrZbDFHvjYGUb/AN42YkBI2DGeATmtHxl4QuPF2j6fp8moxQx29zHPcM9szmfaCNo2yLszk884pvS1u6+6/wDkTrr6P77f5jZPib4UhDefqE8TpAblopLC4WQQggGXYY92zn72MYBOcA40bvxdoljqEVlc3jCWVlUMsEjxqzDKK0gUojNkYViCcjAOa5jUfAXiXVJmku/FWnyOdKm0vedHfcUl27nbFxgt8g6ADnpV6HwNfKzxT61FJZXckE9/AtkVaWaIIA0bGQ+WreUmVIc8HBGaFb+vX/Ib/r8P+D9xfi8f+Hpo4njnvNs0M8yE6ZcjKwkiTrHwylT8p+bpgcjK2nj/AMNX19HaWuos88k4ttv2aUeXKV3CNyVxG2AflbByCOvFZV58NkutWkvRqjR/6ebmGMW4/dRSKRcQ5zyJCSSexxwcU248C63Jrl7fQeILGOK61WDUvKbS3Zl8pAgj3eeM5Crk4HOeOcAVtL/1qv0/FegS2dvl/X9bndUUUUgCiiigAooooAKKKKAMLXbO41C6ezsriO2nuNOnjWaWEyqmWjGSoZc8e4qqPC+pD4fWvh5daSO7tooohfQ2zIrrGRgNGJM4ZV2thxnJxjpVnX9Rh0ieTULkziG2064kc28fmSABo8lVwcn8MVzvizxtd2Wiwr4e+1yTxvZm6vXt43SJZXQbX+YYdlbOVVgO4GRQt7en62Ds/X9P+AVrb4Xapp8yf2Z4g0+CCOO+jjibSGO0XT726TgfKQoAx0B9eJk+HGsm4WebxLaCaG0tIbd4dKZdj2zFkdszNuB3uGXjIIwRjJvQ/Fbw5ca9e6RatNc3VqsxCW5jleZovvosauZAwwcblUHHBIqCH4nxaheaVDpejXsv2rU5dPulMkDNbNHEZG5WUqxxg/KTwGH3sKXG+lv61/zY5db+f+bX4HSXul6pqHha60+fV1h1C4hZPt1pAYljYjGVTeWA/wCB568jjHN6V8NZdLvobqLVYEaLVW1LZBY7Fy9v5MigGQ9eWDHJyed3Wr1p45tX0a2urG01jV3uPPmEIgiSeOJJCrMykoAFOFC/fIxwTmmQ/EzRrq8WKztNSng862ha7FttiQ3A/dN8xDFSSBlQcZHuaavfTrp+P+ZLtaz/AK0/yMnUvhVd6j4dTRZPEKNZpDcRLFLYl1Uu+9JAokA3p/eOc5ONla3/AAh2sQ2Or6fZa9bRWOpCZ/Lk04u8Mso+chvNGUySdpGefvY4rqdQvodM0y5vrrd5NtE0sm0ZO1Rk4H4Vzn/CeweZaRjRNUZryCWaHb9nYOY0DsgYS7SSDwQSucjdxUO1mnsVrdFfQPDHiHwloSadpmrWV5BHsEUMunsNhyu/DGfhT85xyVLcZA2nW17w/danqen6npmoJY3tgsqI01v50bJIFDAqGU5+UYOeO4PSsu1+IWk3Rlu0OphRY2c6Wj26gObliIgh6s7HCn5igI6jBNWv+EwtTf2MeoQarpEjxXE0kF1boECxAbt7jcDjII2Mc+4qp3v7wkraIyrL4aNZ2+tWI1cPYanpUemon2U+dEEVx5hffhiTI5I2r26Y5lHgLU5PtQvfEENxFqEdvBf2x08LFLDGpVlUeZuUsDjJZsc8elS38eah/wAJVqL3GnaidMj02C4tbIWsYmcvKyeZu8wgKQAfnKbRncBjNW7HxjLr+t+FrvRrjZpGqJdiW3kiRpC8Qx99WYYBB+7kHrkijV6v+t/6/MTdv67pbfh+hDYeBPEdvNpwvPFFld22nRTwQo2kN5nlyLtCl2nYNtAUAlTkDnOc0L8PtXgvdOuLHX7OBdPu5bmK2Omu0KBoTEqIvn/IoUkkA4LHICjipJvGV5ovjHXoNXinu9KtRaMktrAgWySQMGaQl9zDIGSoOB/CME1neIfi1pklnr2m+G76OLWLG1uJIJZPKlR3gBMi+WJN6kYIBdVB6jcBSv1/ruOK5ny/1qWdI8Ca/wCH3025ttesbqTS9MmsYo/7KYebvcOGObgDgqnGRkA8jIx0Ov6FqOu2+jGO/trKaxvIrycNbNMsrIDlV+ddoyTzz2rOT4gww6TcTXGkaq9xZ+Ss0flxKXDx7xLuaQIiYB5dlwRjGSAZbP4gWuoW/n2Wj6nNA2mpqMEo8gC4RsAIgMoO/JwQQBx15Gad727f8F/8EWjV+/8Aw3/AKMHwxs7XXtRv4V0llvZJphLPo8ct3HJKDuHns3KfMflK9DjOOKsWfga+s7jT7lNajE1jczSoi2jeSkciBfLRGkJUDaD949WwBkYsxeM7TztQEUOp3N1FfCyTT2hjRzMIRIUjyVBG3LbmbHXBxiqcnxP0+NLg/wBjauzW9jNeyR+XEGAhkCTR4Mg+dCcnsR90tU20t5fhuU029f6bMRvhZaafZ2d9ruo6Fef2fbtDcz6ro6yQeT5jSblDy/unG9vn3EEYyvFbo8EyT3F5PFqVm1peR5W3WwBikJcPvkUPtc8ABlCNgk5JwRNc+Ko9cTWdH0fStSurq3tcSfukiTMkRZAGkZQ2emRkZPXHNb+iJNHoFgl1A9vMltGskLlSyMFAIJUkHHsSKev9ed7k3va39WtY4e8+Gut3VtcQjxTbYudLbTXabTXlZVaQuSpM+cDO1Qc4AGSe9q0+Gcdtr11qkkmjzz3eZZLiXRUe4jmKBWMcrOdsZxnYwYjJG6u8oov/AF66j/r9Dhn+Ht22mPax6tbRHzme3KWLBbNSqqPIHm7omCg8qwXLE7cfLXUWcWpNFewX0kRTcUtpBFhtm0DLjcwY5zz8uf7o76NFLdWDY4hfAF3FYCG21i3geDUIby0RLJvs8AjGAnlebxkHnayrnBCjkGivwtvGmaO68Ri4sJIL+CSJrALKBdPvbZIrgDawUjKt/F6gL6LRTTa/ryt+QLR3/r+tTkbnwx4jvrfSlvfEVhJLp94lwXGlMolVQRjHn8MdxywOOmFHOce4+F+qyJaxWvjG5sotPhuILH7PZqJESXbxI5YlsbcZXY2Mcg8n0ail/X6AtP6/ruee2Pw0vtOvrae01mxjji1j+1ZIU0xgGYwCJkB87jI3Nk5OSM5wc+hUUU7tq39dg/r9f1CiiikAUUUUAZukf67Uf+vof+io60qwdJ0iwebUfPtIbhvtZbdNGrEbkRiMkdMsa0f7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBdoql/Yulf8AQMs//Adf8KP7F0r/AKBln/4Dr/hQBnr/AMlAf/sG/wDtQVu1xWry6HoHiG6vNUtI006207zZRFZNME/eAbtiKTwOpxwOvFX21DwssOlSnTxs1dgtmRpMp3EjI3Dy/wB3xz8+3gE9jRuB01FUv7F0r/oGWf8A4Dr/AIUf2LpX/QMs/wDwHX/CgC7RVL+xdK/6Bln/AOA6/wCFH9i6V/0DLP8A8B1/woAu0VS/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KALtFUv7F0r/oGWf8A4Dr/AIUf2LpX/QMs/wDwHX/CgC7RVL+xdK/6Bln/AOA6/wCFH9i6V/0DLP8A8B1/woAu0VS/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KALtFUv7F0r/oGWf8A4Dr/AIUf2LpX/QMs/wDwHX/CgChrmmjWLptOe5ntUutPniaa3271UtGDjcrDOPUGsa7+F+m31sbe41fWPKljgS5WK4SP7S0JHluxVAQwCgZTbkAZGQCNS+s9GsNUWa8tbK3tIrKaWZ5IkVFCsnzHjHAzz9aNJn8Ma2WXT7KAyKgkaKfT2gcKSQG2yIpwcHBxg44oW+gdCq3w/sv7P1HTY9V1SLTL8SbrFZIzHE0hJd1JQvkkk7WZlyT8tMtvh1YWtwlxHqepGdL77csm6JSJDB5LDCxgBSg6AcHpgcV0P9i6V/0DLP8A8B1/wo/sXSv+gZZ/+A6/4U7tBuc5Z/DqCwt7ZbbX9ZS4tzMPtYeASSRyvveJh5W0qW5B2hgTwwqCX4X2Rkm+x67rFjDJLayrbwG32R/Z8eUF3Qs2BgHknOOa6r+xdK/6Bln/AOA6/wCFUJ/+EZttatNJnt7BL+8R5ILf7OpZ1QZZunAHqaLu+n9df+CLSxbtLC8/seS01K/nmmkLj7QrKsiqScAMiqMgd9o/HqcNfh5Yo0MianqSXEdzLcNOhhRpPNQI6ECMKFKgfdVWyM5yST0H9i6V/wBAyz/8B1/wo/sXSv8AoGWf/gOv+FIZydr8KdLtYZIU1jWXgNpBaxxyXEbeQIX3xOj7N+5WJIyxHOMYAA0bnwQl/dWc2p67qt79mimheOb7OFuVlXa4cLEMcAD5NvTPUknb/sXSv+gZZ/8AgOv+FRXGmaPbQ+ZJpduy7guI7PzDkkAcKpOOeT2HJ4FNvm3BabHLS/CbS7i4iubjWtcmuYY4YoZZLpCESJ96KY9nlvgnHzqx79ea0NO8AWmmX2l3Ftq+p40ya5mihcwlHM7FnDfu8kZJxggj1re/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KLsVkZep+C7DVdXmvZ7m7jS6SNL20jdfJuxGSUD5UsMZP3WXPQ5FU7n4fWs2m6ppkGs6raabqQl32cDQ+XEZSTIULRlhuy3BJA3EgA4I6D+xdK/wCgZZ/+A6/4Uf2LpX/QMs//AAHX/CkNaO6OXPwzt3v1vLjxFrU8qvC4En2bbmJCi8CEDlWbP1yMEAi/Z+BNNsrXQ4I7m8YaIpjgZnTMsfB2SYUZAKI3GDlBz1zqPpmjpcxwHS7ffIrMpFnlQBjOWC4B54BIzzjODUv9i6V/0DLP/wAB1/wp3YbaGA/gC3kvr+9OtaqLq7vVvoplMANpKE8vMf7rGNmFIfcCB65JZe/DjTb1EDahqUTm2uba4lilQNdLOQ0hclDg7gCNm3GMdOK1EHhqTXJNGjt9PbUYoRcSW4gUskZOAx44yavf2LpX/QMs/wDwHX/Cl0/r0/4A7u/9ev8Awxm+HvCMHhzUL26ttS1C6F3HFG0V3IkgQRrtXDbQ5OOpZjmt+qJ0bSgCTptmAOp8hP8ACqOjf8Iz4g01dQ0a3sLy0Z3RZo7ddrFWKtjI5GQeehp6sVrI3KKydQtfD+k6dPf6la6fbWluhklmkhQKijqTxUlrp2i3lpDdW2n2bwzIskbfZlG5SMg4Iz0NIDSoql/Yulf9Ayz/APAdf8KP7F0r/oGWf/gOv+FAF2iqX9i6V/0DLP8A8B1/wo/sXSv+gZZ/+A6/4UAXaKpf2LpX/QMs/wDwHX/Cj+xdK/6Bln/4Dr/hQBdoql/Yulf9Ayz/APAdf8KP7F0r/oGWf/gOv+FAF2iqX9i6V/0DLP8A8B1/wo/sXSv+gZZ/+A6/4UAXaKpf2LpX/QMs/wDwHX/Cj+xdK/6Bln/4Dr/hQBFpH+u1H/r6H/oqOtKue0rW9Ph1m70y8vrS21G4uS0Fk9ynmyoI0AZUzkggZ4HHPpWpba1pd5qdxp1nqVnPfWvNxaxTq0sP+8gOV/EUAXaKKKACiiigAooooAKKKKACiiorm6t7OEzXc8cEQIBeVwq5JwBk+9AEtFRw3MFx5n2eaOXynMcmxg2xh1U46HkcVJQAUUEhVJY4A5JPao7e5gu7dJ7SaOeFxlJInDK30I4NAElFFFABRRRQBz8kMdx45nhmQPHJpZR1I4YF8EVh+GLbXY7S70y4tZkl8Pxy2unXE64S7yP3UgJ67Y9qk+patqZrhfHjG1ijkf8As/kSSFBjzPUKf5Vq+bqv/PnZ/wDgW3/xulbfz/r/ADGeOW6+LLbR7ae41rxO802oWYvLS30e7VoSH/fnfI0pZCpP+q2x/KMYzg9idBuLDxgujW1xrEumagqXnnyaxcu1t5Bw8YZpCwDl4+B1BfPQCuy83Vf+fOz/APAtv/jdU7awurS+uLyKxgae5OXeXUppMD+6u5DsXvtXAzzir5tf68rfJWuTbT+vv9TD8U/aX8V2sV6+uw6Y1uDazaMsx2XQc580RA8FduPMBj+9ntWFfNrr3d1IJPElrqsU9z9oa3jlktjZ7ZPKMS7WiaQfu8BAZN2cgjNei+bqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43UdLev9f10Kvrf+v66+up4sbvxAugTsr+NGvh4etpgGtb7nUVbBA+THTblR8jclgeTV+HUNWuda8+Wbxm0cniDC7rC8iUWLwAMNojVQok4BI3LjIIOSfWvN1X/nzs//AALb/wCN0ebqv/PnZ/8AgW3/AMbq3K7v/W9/+B6aE/1+Fv8Ag+p5fpl5qt3oljBrUfixLJDeQpLBDeR3IlE2bcyYAkZfKIwzZQnO/kVUF74mtL+SXV5vFU97b3emEJbWVy1vjA+1ACKPY6YL5zu5xjnFet+bqv8Az52f/gW3/wAbo83Vf+fOz/8AAtv/AI3QnZ3/AK3v/wAD0sDVy6DkUVS83Vf+fOz/APAtv/jdHm6r/wA+dn/4Ft/8bqRl2iqXm6r/AM+dn/4Ft/8AG6PN1X/nzs//AALb/wCN0AXaKpebqv8Az52f/gW3/wAbo83Vf+fOz/8AAtv/AI3QBmeJIY7hpoJ7F9Qil024R7RDhpgWjBUHsTXIQt4htLPVLbSW1fUdOtlgVLi9s3hvkQS/voY3ZVMwEeSrgE5PDMenaSS6l/wkFuTaWu/7LLhftTYI3R5OfL+nar3m6r/z52f/AIFt/wDG6OoHmV0+qW91pYtLjxb/AGFNqxAQ291JP9mMHz+YxQzqolwF3kNyxHABGDPqXiW30CE2knjQXkul38LMbC8kYSrKPsuQ0ZCsVBBfG4g/M2cGva/N1X/nzs//AALb/wCN0ebqv/PnZ/8AgW3/AMbo/r8LDTs0+3+dzzGC/wBTF3c24TxZNpDy2st47296k4QwMJPJYqHH7zyyyx4I+bA60zVv+Elit9HXTINVuNQji1L+z7i5tZJGjRlIt/OcrhWIx/rCD03c5r1HzdV/587P/wAC2/8AjdHm6r/z52f/AIFt/wDG6HqStLeX9f8AD/I8pgXXrXS9OMms+JrmCbVoPOih0i9ieKLafNVjK0spXODkMFycKccCbRLrUrtbS31o+MIbGJpo7OeK3u1mEouHMZmyu51MJiwZAU+9u5Feoebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43TTt/Xlb/hvMLaf13v+PU898Ov4jtPGOoah4i1HU1jgkuTLYJpV3LE8GSYmSQSNESF2/LFGHJJDA9a6Hx5qNzH4YsL3RpNUJa/tZMabayTPLD5imQMqIzBdm4np0A74O9L/AGjPE0U2n2MkbjDI90xDD0I8qnCXVAMCyswP+vtv/jdLt5WK6t9zyvQ9R1kXtrJPN4wlmluNRhd7nTroKITk27FGjWMN90g4HUgkDgaEUuprYQW+qw+I20eO5kiubizN6LiRhGux1X/j4Ee/fnBYZwclDx6L5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdAut/wCtTx3U7jxXbpqcV3c+LZLmHTLeSx+y2k5UTiVuN0Ue128vyywYspJYHpgXLnUtVTWprGCXxill/b0Eisun3jh7Vol80GQxlgok3fKGGM8DFerebqv/AD52f/gW3/xujzdV/wCfOz/8C2/+N07/ANfO/wCgPW/p+ljyfStc12OSKJY/GE6RadqcQim0+5QlhLutm82WLmQxZAZi3QAjJwei+H2oXumjULXXG1cwz30S6e97b3b4V4UODJMCwG/cMuQN3GFyFrtvN1X/AJ87P/wLb/43TH/tCR0eTT7F2jO5Ga6YlTjGR+644NO/9fO4PU86+IpvB4n1GfT4NfW4h0HbazaXaXJV7jztyLvjUg9sqTjBORTEk8U3HjG91GS91iGNA0tpYRaZc7bm2MPyr5jP5Ecm45w0YkDDHI4r0vzdV/587P8A8C2/+N0ebqv/AD52f/gW3/xupWkbev4u/wDXkHW/9bW/rzPJ9Km8R29vNDep4kk0eS7tpLghb1rpIGgYOEd/3pIlCbggUgE4UCsmBPFFpoyW1ppXijT5rS6uLqBz5zLcBr0uQUhPzN5Z5844PO1G617d5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdVza3Fb3eX+v61PP7+S7dvETakniVtRWO6WCC3t7iSzuLdkIiCqFMe4ZHAxJuznIrmxN4jiszp+jHxJDaG109rqS60++YxAI6ziIDy3znycpEyn7xUcNXsnm6r/z52f/AIFt/wDG6PN1X/nzs/8AwLb/AON1K0VvT8P8+o3q7+v42/K2hR8Hw3kHhWzj1G/n1CYBv9JuLV7aR13ErujkZnBAwPmO44yea26pebqv/PnZ/wDgW3/xujzdV/587P8A8C2/+N027u4krIu0VS83Vf8Anzs//Atv/jdHm6r/AM+dn/4Ft/8AG6Qy7RVLzdV/587P/wAC2/8AjdHm6r/z52f/AIFt/wDG6ALtFUvN1X/nzs//AALb/wCN0ebqv/PnZ/8AgW3/AMboAu0VS83Vf+fOz/8AAtv/AI3R5uq/8+dn/wCBbf8AxugC7RVLzdV/587P/wAC2/8AjdHm6r/z52f/AIFt/wDG6AOC8WW+katrGn6NqepRWN1cao0lm3nKkqSrarskQE8kOV+ucd6yr3xP4o06y1SS5t49O1KK8trG+v5JFihSMI5+0q5SQKjfLyyMFLEEcZr03SP9dqP/AF9D/wBFR1pUdLf1/XT/AIYOt/6/rr/w55XoGveINc8SQaDe+M9PjlfSftSvoqwyvI3nEK4eRCrgoATiMDkkY4q1b+ItaTwxLfvqt5NNpix2GpF7aHak3nbZp9qxg/InzAA7dpBIPNelUU7/ANfN/o7CWjPKP+Ep1ODVNNP/AAl73OhT6hLZJqghtttyGtS6HeI9rOso2goArH5SpINSaB421G6h8MzX+sSN9uggikg+zpFLPMZCHcxOillwvWI4UbmKkYI9Top3X5D6WON8Q69dab40sLT+1PJtrnyoUtIhGZHd3OW2uu5htA5RvkG4spGCMoXviWGTUtMbXrz7Xo4lle7ubeFYrlJcfZwxWHgD58lBkFDnIIFejnp6VR0zSxpqSl7u4vbiZt0tzcld74GAMIqqAB2AHc9SSZW39f1oHW55ZP4m1O41PR9S0/Vr298qz1EQQAW7x308Yj2KGjXa+7LHcm3oeFwwqtaePPEEdpp82oeMdCW2vdTt7dnimjuJog4YyxsfKiWMrhcBlZhzkng17VRT/r8b/jsD1VvX+vkeS+EPH819rmhwXfi211Bb25v7Joc248zyXPkyfIAd7LjphSGGFHUx/FHWhLdX2n6jevbixuLGay09bRZWvAZULzL8pclTlfkIx3zuFevUUdU+wdWeUHx/dTaNcXcfiWzkFpqV1FK1sIkZ0UgRIqyAqT8w+QsrMT8rdqvt4r1CXxE0cWti3vI7wwyaHPBHhbTHF0eBJgDDlt2z+HAPNekUUun9eX9fMHr+P6/18jyPT/F15qXhHRbrWfFEYs9YaeK6v4LaAwxMhYJCAysAZAcHduztwMFs1geDvFfiBLHw/pemahYaRaW9pB5UOqE2324bm83ZG0DNJgDACSJg4J3A173RT63DpY8j07xnq1x4Ih1+fxbaz4vbiKcwC3hjKRSOECF1YbmzH8rOMqV2sCct6rYzfaNPt5iXJkiV8umxjkZ5XsfbtU9FFxdQooopDMJf+SgP/wBg3/2oK3a4Dx5rd14dm1bVNPwLmDSQI3ZdwjLTKu8juFzu/CtOextPCOm/21NrWpyxWqSXFytzevOLvEbHCq7bUP8AEAmF46dCAPJHWUVwuofEDU9Iuo7TUvDX+lTT2yRfZb9ZI/LnkMauzMqkEMMFQp6jBIyRHF8SL8GEXXhzBe5vLMpb3yuxnt0dyF3IoKMEPzMVIP8ADjmjpf8ArQDvqK84/wCFp340qTUH8NosSaTBq+P7Q5+zvkMD+7++MHA5BHVl6VtXvjW4tryWSDSBc6XBeJYTXC3QWYTvtC4iK4K7nVSxcHJPGBmm007f12/MV1/X3/kdbRXH+FvHNz4iv7KG50U6fFfWct1A5uhI48qURsrqFwPvKQQx79Mc9hRYL3CiiikMKKKKACiiigAooooAxdXsRqWpx2bTz26y2koaS3laOQDzIiQrqQVJHGQQRmuJ0wf8I3pHiPxIJ9c1JtEv7pVtJdYnmWSBFHylZpCvGd27G7jv0r0CX/kZLb/r0m/9DjrMj8BaBFpWqaaIb1rTVmLXkcmp3LmUnqdzSErnodpGRwcilrdtdv1X/BHppfv+Gph3vxLvLLVoNP8A+EaurqcwxXFxHZia4aGKViE/1cLLu+UkhmQccM1La/EXU764to7bw0I/tdxd2kQuNQVWWa33ZDhUYBDtPzAsQf4SOa6KTwdosk9pM0NyJrOFbdJEvp1Z4x0SQh8yr7Pu6n1NUIfhr4Zt5Y5IYNQR4ppZ4yNXu/lklBEjD971bJ59z61T628/+ALp93/BM+L4ky3ehJq+n6KJrSCxivtRD3eySCOQE4jXYRIQFJOSnGMEngbPh3xPd+INV1SD+yTZ2um3TWrTTXKs8jBUZSqKCMEPnlgRxwcnbFa/DnwxZR2sdtYTKlrH5KKb6dg8YJYJIC58xAScK+4DPAFWF8H6fax340yS8s5dRulurmVb6dmaQEcr+8+XgAYHykAAggYp+7d/11X6XE/L+v6/qxHr/iW/0zXrDR9L0cX1zfQTTRyzXQgiBjxlSQrNk7h/Djn64w4Pih9p1LRY4dIH2XVPJQubrM0MkisQDGqEAArty7pkngGtHxT4UuvEXi3RLmSOI6ZZRTrcMl/Nb3GZAoGzy1Bx8vPzjIYj63G8BeHDcpOlg0LRtCyLBcyxIrRDbGwRWCggcZxkjg5FStlf+tSntoYB+JOpN4YXWY/DkMSyXEtvHb3OpASFomkD/LHG5Y/u+Agckk5wo3FLP4rLqWq2NvpmgX93bzJbG4lhhmkNuZo1deViMeFDgsWkUjqAa3ofAHh23023sYrW5EFtPJcRBr+4ZleQEP8AOX3ENuOVJ2nJyKktPA3h+wmtZLK1ngNrCkCLHezhXRBhFkXfiTaOBvDY7U9BP+vv0/A5688ea1cWtj/Zul2cFzNqUFtNBcXjK8SuWO1lMW5GwoByuOTtLYzWbovjy98OaVdN4gjuNQsorrU8X8lwGmb7PIxCeWFAwVGAQRyPu45rtP8AhB/D5jdGs5HDyxS5e7mZlMedgVi2VUZPyDC/M3HJzTi+GfhaF42Fnduscksojl1O5kjLS/6zKNIVIbJyCCDk+tHf+ui/W4/+B+v+a+4zLX4kXsumtc3fhq5svLnCSS3S3ENuIyhff5klup4wR8yhd2BuwQaty+MHt11u4i0siezltoVW61ILDN5iqVZT8wVfn/hUs2OFJwK1E8E6ImnfYgl8YRwpbUrkyKP7okMm4LjjaDjBIxyaiPgDw6XumFrcqbp4pH239woVoseWUAf93twANmOOOlGlyS14R8QjxT4ZttW+zG0aVpEeEljsZHZGGWVT1U9VB9QOlct4p8R6ndazp8Wk+ZbWFnr9tZXU8d2FadyVLRmPYSY8MOd4JI+6V5rqdL8L2WiXUTaU09vbRrL/AKN9pldGaR97MQzlepJ6ZGTg44qvqHgLwzqmqPqGoaUlxO8qTuHlfy2lQYWQx7thcDjdjOOM4o05k+n/AAf8hNNxa9fyOfbx1qkGiw3mk+HUme6v57UWl9q7LM06zMmxMRyA/dZiMhUUcHA40bnxbr8Hij+yU8O2dyqwNcSm31QmaKMLwShiCjcwKqC4JwScAHCx/C3wtDcLPDFqscqNIyOmuXqlTIcyEETcbjyfU9anHw48OJczTxxajG85UyiPV7tFYqoVTtEu3IAGDjjAxjFLp/X9f18y3bmbRgJ8Sp7XRIJrHw7PLAmiR6u73Oo5PlEgMoYhmdwM/exkjr3q+fiPLJ4quNLsfDuoXtrbyPA93bwTNiVY9+CfK8oL0XPmbtxHy45qz/wqvwn9l+zfZL/yfsv2Ly/7XvMeRu3eX/rfu57fh0rSi8FaFDdSTx29wGmiEcym9nKTALtDOhfa74AG9gW4HNU7fn+en3IXX+u3+Zjn4gTrpcN2+l24zK0dwftjCO3wgfDsYgY2OcYkVBwckcZ7Ga5jgs3uZTiOOMyMRzgAZNYr+CNCkt5Ynt7lhM7NK5vp975xlS+/cVwqjYTtwMYxxWjYaWtkbsGWSWO4k3CJ3dljXaBtUMxwOOgwvsOcy9nYFurnm154w1VNYvdavLO7OmP4akvoNNttRA3R+Yv7zIVfLk2k5wz4x8pJ4rpdU8Z3lhJf2trpsIe2tGmtmu7pkM5WEyEgFDuUcLlWZs5yABkyN8LPBzQyRnSGxJAbbcLuYMkJOTEjb8onUbVIGCRjBIrRTwZoayxyNbTSmOMxqs93NKpBTyyxVnIL7Pl3kFsEjPJolZxsvP8AWw46O7/rRf5M5W0+IevW+ly/2roVk9za6dZ3zNBqTETRzMUJ5gG1htJ28jnGai1rxZreqx202n2U+lx2XiKKwkRr1A12Q6gqwVWwhDZ4bPAGCCa6eb4eeF7mGOG401pYktRZmN7mUrJEG3BXG795gkkFskZPPNSW/gTw9a6Tc6bBZSi1uZ/tLo15MxSXs6MX3RkYGChGMcVTa57rb/gr9PxIs+W1/wCrf5/gc1q3xUuNI0+Sa50OE3FnLLHfwrqG7y/LKZMW2MtIMSA5Koo53MvGb9v8QbmbXWtJdBa3s49VfTJLiS7UuGEHnK4jUEFSP9oEZHHUDTuvh94avbZYLiwkaMQyQNtu5lMqSEF/MYODISQDliTnnOaij+HHhuK7W5SC/wDNW7+25OrXZBnxt3kGXBO35eeMcdKWlv68v0uV/X+X42M6f4h3lr4bj1u40A/ZL4Q/2Z5Vw0zTmU/KsiJGXQ45IRZOOmTxWnB4pnvPh/d67c6HfW80EMzSWDh4ZG2ZyUMiowBAyGIU47A8VKngLw7Hp89itlL9lmbcITeTFYTu3Awgv+5+bB/d7eQPSr8nh7T5dAm0aUXL2c6GOXdeTGV1PBzLu8w8cZ3ZxxSlrFpfIa+JN7HLQ/EC5jvBapoEi2lvPY20txNfBnxcgBHUYYvglc7ipPJ68HvK5Bfhd4WVGUQakQ8kUjZ1q8JLRf6s5Mv8PGPTA9BXXjgVTat/Xl/wSEmgoooqSjN0j/Xaj/19D/0VHWlWDpmsabFNf+Zf2y77gMuZRyPKQZH4g/lV7+3tJ/6CVr/39WgDQorP/t7Sf+gla/8Af1aP7e0n/oJWv/f1aANCis/+3tJ/6CVr/wB/Vo/t7Sf+gla/9/VoA0KKz/7e0n/oJWv/AH9Wj+3tJ/6CVr/39WgDQorP/t7Sf+gla/8Af1aP7e0n/oJWv/f1aANCis/+3tJ/6CVr/wB/Vo/t7Sf+gla/9/VoA0KKz/7e0n/oJWv/AH9Wj+3tJ/6CVr/39WgDQorP/t7Sf+gla/8Af1aP7e0n/oJWv/f1aANCis/+3tJ/6CVr/wB/Vo/t7Sf+gla/9/VoA0KKz/7e0n/oJWv/AH9Wj+3tJ/6CVr/39WgDOlt4brxxPb3MSTQy6WUkjdcqymTBBB6iprDwhoumxyx29tLJFKjRGK5upbiNEbqiLIzBFI42qAOlUl1XTx42a4N7b+SbDYJPMG3dvzjPrWx/b2k/9BK1/wC/q0AZEnw78NS2aWslrdNHHNHMjHUbnerRkmMB/M3bVJJVM7QeQBUD/C/wtIiq0Go/LPJcqRrN4CJZBh2yJc5IyD9T6mt7+3tJ/wCgla/9/Vo/t7Sf+gla/wDf1aAMD/hVvhM2r2xtL4wvaLYtGdWu8eQpyI8ebwoPb6+prRTwToUd8LtbafztqBibyYq7KoVZGUvhpAAMSEF+BzV7+3tJ/wCgla/9/Vo/t7Sf+gla/wDf1ad2Bl6R4A8P6Hf2l5pkF5HNZRPDB5mpXMqojnLLseQqQTzyOoHoK6Ss/wDt7Sf+gla/9/Vo/t7Sf+gla/8Af1aLsDQorP8A7e0n/oJWv/f1aP7e0n/oJWv/AH9WkBoUVn/29pP/AEErX/v6tH9vaT/0ErX/AL+rQBoUVn/29pP/AEErX/v6tH9vaT/0ErX/AL+rQBoUVn/29pP/AEErX/v6tH9vaT/0ErX/AL+rQBneJdSOjmbUEeBHt9NuHVrjd5YYNHjdtBYjPYAn0riT4y8VajHYwC7sNNu4vED6fcSyWLbJEW2MysYxOSo9Rvz0zjla7W9v9FvtUSO8uLK4s5LOaKVJWV0cM0fysDwcgHg+9EMPg23j8u3t9FiTzUm2pFEo3oAEfAH3lAAB6jHFCtfX+tQe33/kcFpvjvxkNL0uy062ttd1a5iuLyQiJIwUWXaIv3lwm08/fG7aCvyHrW1YeN/Ed3rYing0q2tf7abSzGheV8G285H37gpIPBAGDng8ZPQz2vgq5t44Lm10OaGKY3EcckMTKkpOS4BHDEnJPWoP7I+H/wBr+1f2X4d+0ed5/nfZYd/m5zv3YzuzznrTXn/Wv+Wn4h6f1p/nr+ByGh+NNWtLGzvddi0/VpV0vUb9biGJkuFMcq5iAJbapDA5B5AAwNuTqap428SaPFKhXRdSkLWUsVxD5kUaxXE3lYK7nLMDgg7gGGTgYwehjsvBEOoJfw2ehR3kZYpcrBEJF3ElsNjIyWbPrk+tMbTfAb6c2ntp/h9rJ5fPa2NvD5bSf3yuMbvfrRdaX/rX/L+tR6bf1/X+fkXPC2q32p2uoJqptmubG/ltS9qjIjhcFTtZmIOGGeTyK5vxZ411/RtX1uCwt9M+z6VYW9+pnMjvOryMjIcFQh+U4PzY44OcDWtdM8EafqUN9psGjWM8Tu4a1ihiLMwwSSoyePfnvnAp2oab4E1a8lu9U0/w/e3MyhZZrm3hkdwMYBZgSQMDr6Cl2F0f9df8tDG/4SrVJdc/s3UrPSroW2vQ2ZmCMuxXgEyMqMW+cE7d2R0yAOlZl5478aRf2xf2tjpzafpltdTyJNY3EagxPtRFud+yXcoZsopxt2nBO6ulOg/Dv7WLoaP4aFyGDif7HBvDDo27bnI9axdM8HeF4byWXW5/DOpKzMxddKiinuN2c/aJNzCXkg8KoyAccUL+vuS/4I9L3fl+bHa3448QaNd6cpOl3Ac2j3kEVtKWjS4mEY+cyBVxzg4YsQfkQDNMj8WeIP7TFjp1jodlJdXmoJJMRJIA8AyrFRt3EjGTkHt710slp4JmEImtNCkFvCIIQ0MR8uMEEIvHCggEAcZAqn/wjnw2ErSDQ/DHmNnc/wBit8nPXJ298mh+Xn+lvuF2+X/BMKz+IniXVtR05NH0OKeD7FZ3eofPGoCzjLMrvMhUIM9I5NxGMr1r0HWr8aVoV9fl4Y/stu8u6csIxtUn5ioJx64BPtWNFY+B4TZmGy0GM2GfshSCEfZsnJ8vj5MnnjFT2T+GrDS5NPhubA2srO0kJMYR95JYFQAuDk8Y5pys728wjo1fyON0/wCIHii4vYNNnttMFxJq4057l4ZIgA1t56uIfMY+owXB6cAk4hk+JXiW10VL+W10id5NMvrkRKJIwJLWQIx3bm+VgSQmMgjG45yOqbRPh65iL6T4bYw48sm0gOzAAGOOMAAfgKjbw58NnjSN9D8MMkYIRTZW5C5OTgbeOaNP69Lf8EaaTTf9amFqPj/xLYXB01LKyu9Rubm3jtmtofljWWBpcMskyBmBQgfvEzkcZGDrQ+LNfW400atY2mmiZIo7mNiJtk7ylNheORvLzt4yrAlsbgVObiaN8Po4Z4o9K8OJHcIqTItrABKq42hhjkDAwD0xVto/B7tas0OjMbNdtsTHF+4GMYTj5RgkcUaEq9rM4e9+IOr6R4Qtr7TrHSIJ0W7uryyggeQER3Gxip3Iqgkkl2JJPRDk49YVtyBvUZrlU0f4fx26QR6X4dWFN+yNbWEKu8APgYwNwAB9cc1tJrWjRRrHHf2aIoAVVkUAD0Ap3Vg1NGis/wDt7Sf+gla/9/Vo/t7Sf+gla/8Af1akZoUVn/29pP8A0ErX/v6tH9vaT/0ErX/v6tAGhRWf/b2k/wDQStf+/q0f29pP/QStf+/q0AaFFZ/9vaT/ANBK1/7+rR/b2k/9BK1/7+rQBoUVn/29pP8A0ErX/v6tH9vaT/0ErX/v6tAGhRWf/b2k/wDQStf+/q0f29pP/QStf+/q0AaFFZ/9vaT/ANBK1/7+rR/b2k/9BK1/7+rQBoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z" alt="" width="559" height="370" vspace="0" hspace="0" border="0" style="width:559px;height:370px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RD+RXhpZgAATU0AKgAAAAgABAE7AAIAAAARAAAISodpAAQAAAABAAAIXJydAAEAAAAiAAAQ1OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE1vaGFtbWVkIE1haG1vdWQAAAAFkAMAAgAAABQAABCqkAQAAgAAABQAABC+kpEAAgAAAAM0NgAAkpIAAgAAAAM0NgAA6hwABwAACAwAAAieAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMzowNjoxOSAxNjo1NDoyNAAyMDIzOjA2OjE5IDE2OjU0OjI0AAAATQBvAGgAYQBtAG0AZQBkACAATQBhAGgAbQBvAHUAZAAAAP/hCyNodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIzLTA2LTE5VDE2OjU0OjI0LjQ1ODwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5Nb2hhbW1lZCBNYWhtb3VkPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAuMCMwMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoHSpru705ZbqSNZt7o4jX5cq5XjPParmyX/nr/AOOiqeif8g0/9fE//o560KAI9kv/AD1/8dFGyX/nr/46KkooAj2S/wDPX/x0UbJf+ev/AI6KkooAj2S/89f/AB0UbJf+ev8A46KkooAj2S/89f8Ax0UbJf8Anr/46KkooAj2S/8APX/x0UbJf+ev/joqSigCPZL/AM9f/HRRsl/56/8AjoqSigCPZL/z1/8AHRRsl/56/wDjoqSigCPZL/z1/wDHRRsl/wCev/joqSigCPZL/wA9f/HRRsl/56/+OipKKAMSC81K81rULOC4t4UszGAXgLlty57MPSrf2fVv+gha/wDgG3/xyvPPiBptjqNlrp1K0guYoNR02Q+fGGEa+aodueg2FgfYmtPxqdP0bU28Q6ZpWl3WraPolxPE0yBTGimPb8wBIG3zAoGOrDIBJoX+f5XKUbtJHYfZ9W/6CFr/AOAbf/HKPs+rf9BC1/8AANv/AI5XGf8ACaa8mpDSJ20mK8urm3it7ryZDFAJYHlw6bwXbMZUYZc7h06GbVPF2u2S3wjbSDPotnHdX8G2Rvte4sCsLbhsxsIBIfLHbxjJdnexCd1odb9n1b/oIWv/AIBt/wDHKPs+rf8AQQtf/ANv/jlcQPG/iWXWnt1g0mGFdeOkBGEkj7WgEqSFsqMjPK7ec4BGMmgPiN4omtH8mDR0kh0y/u3lZZWEklrceWwEe4bVYDI+diCe+MMdL/1tf8h7u39b2/M9G+z6t/0ELX/wDb/45R9n1b/oIWv/AIBt/wDHK4tfHerjUJtOuP7NinuBYm0uPLcxW/2lZDiQbwXwY8AgpuLKOOtD+MfFDaha6XFFo63LSXkEt6yytGzwIGDJEGB2ncAQXJBBGTjNJ+7e/T+n+Yk07ef67HafZ9W/6CFr/wCAbf8Axyj7Pq3/AEELX/wDb/45TPDWqPrnhXS9VmRI5L20indEOVUsgJA9ua06ck4tpgndXM/7Pq3/AEELX/wDb/45R9n1b/oIWv8A4Bt/8crQopDM/wCz6t/0ELX/AMA2/wDjlH2fVv8AoIWv/gG3/wAcrQooAz/s+rf9BC1/8A2/+OUfZ9W/6CFr/wCAbf8AxytCigDIjbVn1Ce1+22o8qNH3fZW53FhjG//AGf1qf7Pq3/QQtf/AADb/wCOVz3jKyGpWuqWRv4rFp0s0R5wTFI3mviKQAglHPyEZ5DVjWOpaho2g6v/AGRplno15pNzEdSs9jXVsIfLUsbba0e0bPm2kDBBG3nNC/r+vmB3X2fVv+gha/8AgG3/AMco+z6t/wBBC1/8A2/+OV59qHjvxVFe3r6e2hS6a2l3Wq2EzwS73ihdQFYCTBDKchwR1zt4wd+18VarqGqX8lr/AGfHYaW8aXNtKrm4l3wrIHRgcDlwoUqd2D8w6UbK7/rp+egen9bf5nRfZ9W/6CFr/wCAbf8Axyj7Pq3/AEELX/wDb/45Xn+o/ETxDpulW1+kei3sOoWkd7AyGSNbVGljjKyHLeYf3oww2A7W4GKXUvH/AIptNal8O2On2uo6qt06R3NtCBDIixJIF2SXCYf95g/vCeNwU9A7Nf123Ba7Hf8A2fVv+gha/wDgG3/xyj7Pq3/QQtf/AADb/wCOVLpVzcXukWlze2wtbmWFXmgEiyeU5HzLuUkHByMirdDVnYS1VzP+z6t/0ELX/wAA2/8AjlH2fVv+gha/+Abf/HK0KKQzP+z6t/0ELX/wDb/45R9n1b/oIWv/AIBt/wDHK0KKAM/7Pq3/AEELX/wDb/45R9n1b/oIWv8A4Bt/8crQooAz/s+rf9BC1/8AANv/AI5R9n1b/oIWv/gG3/xytCigDP8As+rf9BC1/wDANv8A45R9n1b/AKCFr/4Bt/8AHK0KKAM/7Pq3/QQtf/ANv/jlH2fVv+gha/8AgG3/AMcrQooAz/s+rf8AQQtf/ANv/jlH2fVv+gha/wDgG3/xytCigDP+z6t/0ELX/wAA2/8AjlH2fVv+gha/+Abf/HK0KKAM/wCz6t/0ELX/AMA2/wDjlH2fVv8AoIWv/gG3/wAcrQooAz/s+rf9BC1/8A2/+OUfZ9W/6CFr/wCAbf8AxytCigDP+z6t/wBBC1/8A2/+OUfZ9W/6CFr/AOAbf/HK0KKAM/7Pq3/QQtf/AADb/wCOUfZ9W/6CFr/4Bt/8crQooAz/ALPq3/QQtf8AwDb/AOOVDeNqllZTXMl9bMsKF2C2ZyQOf+ela1Z+vf8AIvX/AP17v/6CaANCiiigChouDpYZWR1aaZ1ZGDAgysRyPY1frO0JFj0rZGoVVnnCqowAPNfitGgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDl7a6sIfEmvRanLAkc3krsnIw42HIwevWlg0/wLa6XPpttY6DDYXJBntY7eFYpSOhZAMN0HUdqtaP/wAjVr3+9B/6Aa3aAOTTRvh9HDPFHpXhxI7hFSZFtYAJVXG0MMcgYGAemKtvH4OeSykeHRmfTxizYxxE2w9Izj5PwxXQ0UAcm+j/AA+kujcyaX4dadpjOZWtYCxkznfnGd2e/WoV8NfDVN2zQvC67htbFjbjI9D8tdlRQBysek+AIRMItM8PIJ4RBNttoR5kYxhG45X5RweOB6U6403wJdw20V1YaBPHaxmK3SS3hYQoeqqCPlB9BxXUUUAY+n3vhzSbGOy0ubTbK1iz5cFsUjRMnJwq4A5JNWP7e0n/AKCVr/39WtCigDP/ALe0n/oJWv8A39Wj+3tJ/wCgla/9/VrQooAz/wC3tJ/6CVr/AN/Vo/t7Sf8AoJWv/f1a0KKAM/8At7Sf+gla/wDf1aP7e0n/AKCVr/39WtCigDAa/wBIl1a6N5cWklvNbw7PNZSr4aQHGeDiq0g0Wz0YaZ4Zv9H0W2Zj5iQW6bQjA7tiqyqrnOdxDD1U1LrWvW3hu41HULtJJf3VrFFDEAXmleSRURc8ZLEDnirNjqusfaFj13SLexiaN5ftFvemeOMLtwrkom1iCT3Hy9TRuh6mfc6X4EvfKN/Y6DeNDAtsj3MEUjCJeiZYE7fbpU8Nv4Lt7u2ure20SK4s4xFbTJFErwIP4UYDKjnoOK0YPEmh3WnLqFtrOnzWTP5a3Md0jRlv7oYHGfaoo/FnhyV0SLX9LdpLc3SKt7GS0IzmQc8oMH5unBp67k2WxzniLQ/Dup+Hr3TtBvND0aW+uI57mdbRHExRw/zKrJuJIHJJ71qGy8FPosekz2mgyWCNvFp9ni8kP13CMggHPNXLXxl4Yvo0ey8R6TcrJMtuhhvonDSsMrGMNyxwcDqaraH4zsdT0wXWp+Vo8j3s9nHb3dym53idlIBzgn5ScDOB3pK+39f1sV0v/XX/ACZpJrWjRRrHHf2aIoAVVkUAD0Apf7e0n/oJWv8A39WmS67Y2Vve3WqX+n2dpazeU073i7U4XiQsAEbJxtyeMHPOAs/iPRLWOKS61nT4UmVWiaS6RRIGIClSTyCSAMdc0bi2Hf29pP8A0ErX/v6tH9vaT/0ErX/v6tTajqmn6PZNeavfW1haqQGnupliQE9MsxAqpb+KvD95DFLaa7pk8cxxE8V5GwkO7bhSDzzxx34oDzJf7e0n/oJWv/f1aP7e0n/oJWv/AH9WorfxR4fvLNru01zTZ7ZJPKaaK7jZA/8AdLA4z7dag1fxfpGl+GTrSX1ndQSRlrTZdxKt22CQkbswUk445pN2V2Nauxc/t7Sf+gla/wDf1aP7e0n/AKCVr/39WmafrtrdeHdP1e9kisY72GKQLNKAFaQAhNxxk5OPeltPEmh38kMdjrOn3L3EbSwrDdI5kRThmUA8gHgkdKppptMlNNXQ7+3tJ/6CVr/39Wj+3tJ/6CVr/wB/VrI1Lx1psNjZ3eiSW+uQXGpQ6fLLZXcbpbtI4XcxBPTI+Uc8joOR09Lpf+v61H1sZ/8Ab2k/9BK1/wC/q0f29pP/AEErX/v6tYK/EnQB4lvNNuNQ0+3tLWFG/tGTUIRE8jMymIfNwwKnIJB9u9bbeJtCS6a2fWtOW4SXyWiN2gdX27thGc7tvOOuOaFqroHo7Mf/AG9pP/QStf8Av6tH9vaT/wBBK1/7+rWXpHjWwvjLHqjQaPcDUJbCC3u7qMPcNHjlRnknI4Geoq6fEulWtlHPq2q6XZ+YpYE3yFCu7aCGbbkZIHTqcUbpPuHWxP8A29pP/QStf+/q0f29pP8A0ErX/v6tOOt6UNUOmHU7MX4i842n2hfNEf8Af2Zzt98YqOPXLG8S0k0u+0+7huJvLDrdrhvlJOzaDvbj7vHGTnjkAd/b2k/9BK1/7+rR/b2k/wDQStf+/q07T9b0rV5LiPStTs757V/LnW2uEkMTf3WCk7TweDUGr+JtI0K/06z1W+htp9SmMNskkirvbBPc+wH1ZR3oAl/t7Sf+gla/9/Vo/t7Sf+gla/8Af1aii8U+H7iyubyDXdNltbRtlzOl5GUhb0dgcKfY1EPGGgNrkmkjVrT7XFbfanTz0+WPJGevtk+g69RQBa/t7Sf+gla/9/Vo/t7Sf+gla/8Af1an0/UrHVrJLzSry3vbWTOye2lWRG+jKSDVmgDP/t7Sf+gla/8Af1aP7e0n/oJWv/f1a0KKAM/+3tJ/6CVr/wB/Vo/t7Sf+gla/9/VrQooAz/7e0n/oJWv/AH9WquqapY3uj3ltZ3cM88kDhI43DMx2ngAda2qo627R6DfPGxVlgcqynBBx1oAvUUUUAZ+if8g0/wDXxP8A+jnrQrP0T/kGn/r4n/8ARz1oUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcHrWv33hq817UtP0631ArcWkbxT3ZgwH+QEERvn5mHGBxnnsdXQ/GSXja1Fr0NrpU2iSKl5Kt4JbYBk3hhKyp0B5BUEH86wvFGial4jXxFpWk21hcNcT2ZmW/naOPy0O8j5Y33Z27cEAYJPbBfL4S8Q6fo9xonh210WPSpJEuYI55mBtX3q7xIPJYFcg7H4KZGF+UULr/Xb/g/1Yemh16eI9DktYLqPWdPe3uBmGVbpCkoztypzg8kDjuamsdY03U5biLTdRtLyS1fy50t51kMLf3WAPyn2Ned+H/h1rOleKrG9uYNKa3txqCtdi7kkugLmXeuN0XJXkcvzvY/XX8AeBp/Cj5vYo3mhtRZpeLqlzcNPGDkZil+SH12oWGScEDq9P6/r+r+QpabHc0UUUgCiiigAooooAKKKKACiiigAooooA5TxN4ebxLJe2kNz9luYfsd1bTFdypLFI7ruGRlcjBHoaNQ0vxL4h0C6s9T/s3TZSo8pLWZ7mOVlZWBctGhCnbgqAeCfmrRutStNJ1LUbzUJvJgS3twW2liSWkAUKASzEkAAAkk4FYXh3x6NYmMV/c2VhNJq81na25hl33EUcYcjD7WRxnLFlwMbcZ5oWt0vX8l/kD0s3/W7M/U/BOt6lqFrrEmm6F/aH9p295NAbpzHGsSlcpJ5OWdsjJKrgKo5xmptL8HeIbbS7MSf2ZZ3sN7diX7PO8iNaXMhd1VjGpDqSuOMHZ1GeNbUfiLoljZW1zEt9dJc3Mdugh0+dmO8nDhQhLKQrEEA7sDGc5qRPiL4Xa2juJNRkghkWdhJc2k0Kr5JxKGLoNrKf4WwfQU07J/10X6Ctr/AF5/rcx9d8Ga5ea3qEukSaXDbXVzYXUclwXZo3tmBK+WoAIIAwd49Md6qW/grxMmlyIyaTDfNe3csc0d7KypHPKJCGUxbZAOhRlwcAhlrRf4l2UfiREfnQpNNN5Hex2tw8jneg3bQn+rCuDvGR1yRg1ry+PfDUF9JazaoqNHG0jzNFIIABH5hHnbfL3BCG27s45xQrpff/k/yC6ei8v6/E5208IeI7C+ub60tNERk1mXULe0FzIIpkki8tt7CH92/wDFkK4yzD3rIvfhjrkf9prpdloLnUNKmszLLcPE0byztKcAQtlEDbV5ydo6du5s/Hvhq/tZ7i21LdFBDFcMzQSJujl4jZNyjfuIwNueeOvFJL498OQWMV3LezJFIXBBs5t8IQ4dpU2bolUkZZwoGeTRqml1X+Vh2/r53MP4jTywaFob3V3Y6VfR3Syfap7wQw27iJ1bE7wugzu2jfGdwJ4B5Gf4b8JX/wBu/tGw0zRrS3/sN9LhnNw1y7uGJV+YVEkZ49MjoMYr05WDqGUhlIyCO4paXe/9aWDovL9Hc8lj+HHiSPULa7ktNEunS+s7xvtF/KxjMMZRlT9xgA8YACgAYxVq28DeLILH/V6EJ5ItQtmha4lkijjuZfNEinygSyk7SmAGAB3DpXqFFD1TXf8AVW/ISVrW/q2v5s4LWPBmrXfgXw3pCRaTf32kXNpLJLcl4Y8QkE7PkkIJA29uCT7Vkf8ACDeLhJDJFaeH4nXVr2/Ym8kkG24jdACpgAcr5hJBwCFA78eqUU2222+t/wAbf5IEkkkun6X/AM2eVR+APFUEMnlrpckk99p13Ismoy4X7Njcq/uMAHaAAFUAHpxz3zJea5oGo2l1F/Z0swmt45InZ/lIKrINyqQec4x1HBIwTr0Upe8mn/Wy/QI+6010/r9TzA+GL6wluL3xdfaJpljLpEOlILRn3mVHYxOjMFw2SCEAY5wAeMnRl8L6/feHtOnD2n9tSRM13cTO8QR5ShYeXtdZEAUDYw52r8y9a76inzO9/wCv6dx2W39dvyR55onhjxZo+uavey2+j3sGp3MztbS30m2NGIwVPkHBIzuXkHC88VhR/DbxMlnFGNK8NLLHoNxpG9b2XnzHBU/8e+dqgEY/2jXsFFJaJLyt+Fv1GnZ3Xe/43PMLD4baguqT3WrW1ldtMxuY3bV7spbzND5bJ5ACxuuMjf8AK2G6HFWf+EM8Rrqmj3SwaTKNP1J51ae8keWKAweTtEnk7pCc7iGPG1V3N94ejUU7iWn9dzzjw34a8SeFNQn1S4t9PvZZ7K3s2gt7qRV3JK+WRRDtjXa+QoAUEYJ6tXR+K9C1HV73RrvSpLVJdPuJJGF0GKlXgkjzgD5sFwdvGcHkV0lFDd1YfW55jo3gDX7Fb2S9Gnyyz21mESLUJkCTW+/lCsSiJTlcBV2jkbT3fffDvXdRtZ459QtFe60u3tpZI2dCJIZ3lABRV+Vt4BcbTwSF549LoobbYlpt/XX9Dn/B2gNoGmTpNaR2lxdTmedE1Ke+3PgLuMswDEkKOMDHv1roKKKG7iWgUUUUhhRRRQAVn69/yL1//wBe7/8AoJrQrP17/kXr/wD693/9BNAGhRRRQBn6J/yDT/18T/8Ao560Ky/DkbQ6HHFJIZWSWZWkbqxErc/jWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBhaP/AMjVr3+9B/6Aa3a5uwtI7rxVrnmtMu1oceVO8f8AAeu0jP41r/2Tb/8APS8/8DZv/iqALtFUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+KoAu0VS/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qgC7RVL+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iqALtFUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+KoAu0VS/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qgC7RVL+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iqALtFUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+KoAxtd0STXry7t7a8Njcwi0ube48vzAkkckjLuTI3LxgjI4PUdax4Ph5q9vqVvejxPFM66s+qTJNpoKl2iMRSPbICg2sfvF+i+h3dFHp1sutXoeW5VEt4WLG8lGOZM5O7px36Umm3Hh/WN39ka0t/sYq32XVnl2kYyDtc8jIz9RQtNv62/yQf1+f+bMWP4f3UcYCazFF5V7b3VvHDZbIYvLzn935hG5txyV2rwvy8HNW8+GuozRzRWniUW0ZubyeBf7PD4+0ht6uS/zAFjgrs/rXaf2Tb/8APS8/8DZv/iqP7Jt/+el5/wCBs3/xVD1Vv66f5Id9b/11/wA2c3L4IvzDprW+txQ3Vtpp0y5l+xFllhOMlF8zKP8AKMElx/smsy4+F10NTt7uw1yGP7EWWxF1YtO0ETWxg8rd5q5Xo2AF565PNdv/AGTbf89Lz/wNm/8Aiqht7PT7uMvaXc86KxQtHqErAMDgjIfqDxim3e/n/X6/iSklt/X9W/A4y2+GOqx2sMFx4ktmW20+0tLdodMKMj20nmRSHMzBvm+8uBkdCKu6z8PJfEGoWGp6zcaNqF/bxtBKt7oontnjJB+SJpS0bgj729upyCMAdPDZafcSTJBd3ErwP5cqpqEpMbYB2th+Dgg4PYipf7Jt/wDnpef+Bs3/AMVQ227v1+8fS39af8MWoYhBbxxLjbGoUYUAYAx0HA/Cn1S/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qkBdoql/ZNv8A89Lz/wADZv8A4qj+ybf/AJ6Xn/gbN/8AFUAXaKpf2Tb/APPS8/8AA2b/AOKo/sm3/wCel5/4Gzf/ABVAF2is02WnrdJatd3AuHQyJCdQl3soIBYDfkgFgCfcetS/2Tb/APPS8/8AA2b/AOKoAu0VS/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qgC7RWZc2en2cJmu7ueCIEAvLqEqrknAGS/rU39k2//AD0vP/A2b/4qgC7RVL+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iqALtFUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+KoAu0VS/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qgC7RVL+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iqALtFUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+KoAu0VmzWNhbbPtF1cReY4jTfqEq7mPRRl+SfSkez0+O5jtpLudZ5QTHE2oShnA6kDfk4oA06z9e/wCRev8A/r3f/wBBNMms9Pt5Iknu54nmbZEr6hKDI2M4UF+TgE4FRarp1rBpN1K/2qVY4mYxtey4YAdDlu9AGxRRRQBn6J/yDT/18T/+jnrQrP0T/kGn/r4n/wDRz1oUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcbP4k0vwxrut3muTyW1q0tuhnFvJIkZKkAuyKQgyR8zYHvW+/iDT01630ctcNeXMJni2WkrRMg6nzQvljt1buvqM8f4mkiEmtxXFndXsct9p4eG2spLklFkDPlI1Y7dqt1GO3UgVU/sbxR4fv72y0eKS6sLXSrg6PcZzJHveM/ZzuGNy7TsJ6jAP3SacfPz/K42tL/1uemSSJEoMrqgLBQWOMknAH1JOKpz61p1trVppM92iX94jyQW/JZ1QZZvYD1NeYX+l3WofZprOPxPNocWp2UyRXUl4t0j5cTYDES7B+75Pyg5IIGTW18SJtRj8QeH20uw1C58tLo3D2dvMxSNowCFkQEJIRnbkj5sfWl/nb8E/wBSdb2/rc9Dorxa8u7621fUpNLl8cSWVu+nvYRy2l+2CJT9oU7k3SLs67y2c8ZwuOgit9W1XX/JnfxBbXsl5PHdlZLiK0NiwfyzG3EauAY8FMShs54zTt2H/X9f1uek0V5HpWn+JJ9Tsba/TXltbmEadczG9ulKSW0ilrjPmfKJUUgMMEkdTuqTwlf6rH4k0w30niu4aS/v4JmvrK6WHyNxMDMDGI16LhsDqRkDgFr/ANf1uD0V/wCv6R6xRRRSAKKKKACiiigAooooA4H4jW91c6bfrbQy3ECSWEl9DCpZpLZZ2MqhRyw2g5A6jIqzqfifRZ9Im1fwnJa6ndWNuYxdWIEwtY2ZN4baeoHzeX1+XpXS2/8AyMN9/wBe8H/oUlMsPEWl6oJDplybtYrtrORoIndUlUZZSQMADpuPGeM54oW1vn+S/r1Dz/ruec3njS+sxZraeNLS60q41a3t4tXnigLTxurGRFZdsZKED5gv8WDyDS6R4u1G706w1IeKZdQtp5bzSSbWK2KtdK7C2kJEZwzIBx90koduDz6xRT01X9bW/rz1F5/11/4H3Hk+p+JdX8Oave6beeKry7ltL/TnSOSzgeae2lYLMNkcIJTJPzKMggDPY5+h+J7fSPDbNoesWltp8Wr6iGgszEWcmc+UqKylW4fIjVkdsrtyMg+tDW9ObX20RbtG1Jbf7S1sMllj3bdx7Dn86vU4u2/9bf5ffcfTl/rr/meWjx5LO+oW114otrW1h1yW0m1S1SICxi8oNGrb96Ll8oXcEEhhwcYxNU+Iet2Md8t74ssbGS00mS7t18iFHunS4KRswfPEqKp2qBw/HY17bVC71vTbDVrDTLu7SO91AuLWA5LS7F3MRjoAO546etJbr+ulv+CK2jv/AFrf/gHJWPjOP/hLplvNetZNNkha5i8uWIxQwqgO9yQroCS3z5dDgYKnIOr401iXTNEtr2y1OGyhMweWZpI03xBS2FeRWQZwPvYBGQGBINdJLEs8LxPuCuMHaxU/gRyPwqh/bWkWupWejpeQLd3CP9ntkOSVj4bgdAuMc9+KT10Q1pqzzNfG3iW58TMg1nTNKtYoo3SDVXEUlxA0Cs04g8osxDE5xMqrtIIGN1TaX4wv77wp4evtV8Xrp8Gr2jyzarFFbiKG4XaFgG9WVc5fIbJJUgFeleqeen2r7PiTfs358ttuM4+9jbn2zn2oe4RLmOAiTfIrMpETFQBjOWAwDzwCRnnGcGnp/Xz/AK+XbQP6/r+v8zyb/hIdftdcm1K9u7pLpvD1tMLEW6+WpaVxLKI9u/5FAcru6kA5+UUl143vbTU9MtYPG9ncaNeaiIE1eWO33zIYXZwrqFiOx1UZCdZFB5Bz69RR/X43H1/rtb/gnh5+LF1/Yc0lv4z0ea5h0K4mUskTM1zFMApYBgNzp0UADknDDAruPAnikazrGr2DeI7bWjBFbXEZiMWYxJHlgPLxlQ3TOSN2CTXcUUdP67t/16E2f9eiX6fieZQ65ruo6fqostfnlvdMMd3ItlHbyJJHuYtCN0W5GKAYRlDg7TuYGszWPGepWmqQF/Gi6ZZatpt5qNtFdQW6TW6qQYACyjhlOdrKW4YZ9PVNU09tTtRbi9ubRC37z7MUBlXBBQllJAOeq4b0Iq1HGsUaxxqFRAFVR0AHap6f12/4b8e5V7O/9f1v+B4h4u8XR+INBja+1RQI1026tLOC2SYX26SMyTLhWclG3L+7I24Oc7gK2NJ8bahf+G/7TvPFUQtJNYnsLnULSCFI7CFS+yQhw+0tiMZclQHHHc+s02SRIYmkmdY40GWdjgKPUmq01/rt/kJaRs/60/pniup/EDWbOSa2uPGFnapHo95dW0/2eFJLpopgIZDvypEi5GFUA4Yr1BC3nxK1VZru003xFY3nmRWNw90ZoYlsElRzK24RyBUBEXLo+3zBk4Ix7WSACTwB1NZmk+ItL122hudHuTeW85kWOeKJzGTG21vnxgc9MnnBxnFHS39bt/8AA+Qef9bL/JlDwhrMt3oljDrOq6XearLE8oaxuBIs8QbAkX5V3DBXLKoXJ44xXG3finxBJ481SzufEGnaJp9m7o9vNcILgW4jyLmOJoCWIY53mQpgEFQRmvT2tomukuGUmRFKqSxwAevHTPv1qWh6u4LRWPEbjxTqGpeD9fstR8YTf2pbWkEqxwLbKJbVmU/ahhCRvRsspPyA9MEE6o8Z3hg8Vu/jFXi0i6gtoJLe2t9yJKsf7yXdwCCzDedqghiVIGwelW2uabea1eaTa3cct/Yoj3MC5JiD5K5PTJAJx1/MVfo0/r+v6/ANnr/X9f13PE7Hx5rU0lra6z4vt9MhaHUI2ulhgaQzQXCrHl2TY25XAwI1z25YY6P+0/FR/s1b7Ur6yn8QWMPlJHbQFNNuF2tN96MnGzcwDk/dYdcY7C58OR3PjCy8QtqF4ktnbSWyWqeX5LK5BYtlC+cqh4YfdHqc210sf2y2oTXdxOQu2GBygjgyAGKhVBJOOrFsc4wCRTurL+u//A+4Hvp/Wx5NbeM9ZuPAVlf/APCZia+u764s0nt4LWOJjEZSg3MrhC4CHGHJG0KoJLVUvfilqR06e5Pi3TrKWHQrHUYrdY4cvO5xJG+4ksDwcLtIDLgjqfcqKL63Dp/Xe/8AwDySH4keR4obS38YabcomuxW4ErQebLbyQBiq7cABZDt3YJ7E55rD1LxgIvEljr93qc51OOw1COeCHTFmbSnGzbG20AgDrmV9v8AFlVNe70VP9fhb/gjvrc8Ts/E8eo6z4eHiDVbO6vbHxQ1va3MssJkeB7QsPmREU5aRB8qgE7RluCfXNe/5F6//wCvd/8A0E1oVn69/wAi9f8A/Xu//oJqm9Lf1shf1+Lf6mhRRRUgZ+if8g0/9fE//o560KwtFm1M6YCllbAGaYkPdEEHzWyOEI4OR1rQ83Vf+fOz/wDAtv8A43QBdoql5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdAF2iqXm6r/z52f/AIFt/wDG6PN1X/nzs/8AwLb/AON0AXaKpebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43QBdoql5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdAF2iqXm6r/z52f/AIFt/wDG6PN1X/nzs/8AwLb/AON0AXaKpebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43QBdoql5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdAF2iqXm6r/z52f/AIFt/wDG6PN1X/nzs/8AwLb/AON0AXaKpebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43QBn6P/AMjVr3+9B/6Aa3a5jSpL8eJNaMdtbNITDvVrhgF+U4wdhz+Qra83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAF2iqXm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdAHOeL5b+Jb9tNjvJB/oYuhYAm4+z+a/m+Xt+bdtz935uu3nFcbosuq6XrVoILLxRa2M/iKeQ+bayzfaLZrfajythnGHCY8wr1yc7SV9Hgl1L+3bwi0tS/kQ7gbpsAZkxz5fPftV7zdV/587P/AMC2/wDjdEdG/wCu3+X4sHr/AF5Nfr+CPOIJtbisjb3cXiGfT4rmIahcxi6S4kRkkLeWnMgIcx7vJZlxwmMEUzS4vED+LrO1uLvxI9kLC6e1S4SZI9yzhrbzpQoO8oDkO2SAAwyxB9K83Vf+fOz/APAtv/jdHm6r/wA+dn/4Ft/8bp31v/W1vw6B/X43/HqeLXKeK3uY7zRtO8SrevpSw6ld3screTKZ42nESl1Y/KrYEJAORsIPNdBptvrA1bw3ZXms+JL3T5nuvOaPT7u0QJtHlrIzlplw2QC8gJx+J9J83Vf+fOz/APAtv/jdJ5uqH/lys/8AwLb/AON0X/r+vwJcb/15Jf8ADmdreqG88C6jfaNHqEr/AGeQRJbxvDc7hlSFV0LKwIP8JPoDxXlLzeJYJ9PgWy1y8e01qeW3llsr19tq9pjiWQMwbdIyqXbhuoABA9li/tCCJYoNPsY41GFRLpgB9AIqf5uq/wDPnZ/+Bbf/ABuhaNlPVWPLNQl1Ia5pbeHI/FsdnbS2ZYXn2+TzInmInBDY5AIyZC5AA2BQN1ULTS5dOGl2l3ZeKIvJu9WkuJoIr2Vl3swj2yKGZdw2kFSMnnkk59i83Vf+fOz/APAtv/jdHm6r/wA+dn/4Ft/8boeqt6h1v6fgeXWGpa7qNtDBdTeKIXm0O1E5k0u6RY7hZB5wyqo25lHJVt2OV54qS/1nXo2s3itfFG2bRb0NbQQTMFl8wGJ/MMJKuVD4Dgso2jbuPzem+bqv/PnZ/wDgW3/xujzdV/587P8A8C2/+N027v7/AMb/AOYR0/r0/wAjj/AGoXmm2d9aa82qMr6p5VhJd2122YniRlBeXcwG4sMuw544JC1kfEW41lNd1dNOm8TFV0TfZJp1rcGEXgf5AGiT5ieMhiRjOeM16I/9oSOjyafYu0Z3IzXTEqcYyP3XHBp/m6r/AM+dn/4Ft/8AG6Teqfb/ACt/wQWn9ed/+AeZrf6p/al/b+X4pl0V7m2muXNveLMImgbzPJbaHGJfLJSPBAztA5FaC2es2Vjpeqka7feXPcWiWz3U6yNbybhBJLGDyynaCzDcFbcxyvHeebqv/PnZ/wDgW3/xujzdV/587P8A8C2/+N0af1/X9agrpf1/X/DI82i03xLZeOmt59a1iCztGjW0C2d3eLc24iAfdN5piD795/eIXyBgkELWFZ3WuS2Nqt3L42aWbRr37UzWt8h+0LIDb/dQBWxu+5jPAOQQK9m83Vf+fOz/APAtv/jdHm6r/wA+dn/4Ft/8bpdP67W/4PqC0dzyiyl8W6jra3uo6prmmoIInhii0a7kMsXkASA/MIkk8zecPEXyBt3AgVlsms6r4T+x3sfi64urnRYpLxbi3vUH2mOYFgvygBtm75V+9gdTiva/N1X/AJ87P/wLb/43R5uq/wDPnZ/+Bbf/ABunfX+vP/h/UVvdt/XT+vQ5/wAWPdwaHpC2kOqnTTcImoCzaZrxYPLbGChMpO/ZuKnfjPvXBeF21+wuU09rbxPp8UsGq4D2TyIJHuPMhlLDjeVLj52HK9twLeu+bqv/AD52f/gW3/xujzdV/wCfOz/8C2/+N0J7/wBdLFXskjzpJtSktbaHVIPEiaMsk8TzWTXv2hpAsYifGPtAj4kHzZG7kkqQahtf+EvfUtRimn1uXULfw/FLaRyxvHam9AcEb1URu2DGSpZgWLcHb8vpfm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdF/wCv6/rYE7f153PF7qDxF/bd9deHrHxLb6fd21kt3fX8NzLMqo0xlVUEiTk7nXiMjADbeNoPUeFLfWD4xsrTV9Y8Q6haR6Z5qSy2NxZ27SibKhs5bcEwCsjknuOSK9A83Vf+fOz/APAtv/jdHm6r/wA+dn/4Ft/8bp82t/62t+HQmSuv6/rXqXaKpebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43UjLtFUvN1X/nzs/wDwLb/43R5uq/8APnZ/+Bbf/G6ALtFUvN1X/nzs/wDwLb/43R5uq/8APnZ/+Bbf/G6ALtZ+vf8AIvX/AP17v/6Caf5uq/8APnZ/+Bbf/G6pau+ovot4s1vaRRtCwZxcu20Y5OPL5oA2qKKKAM/RP+Qaf+vif/0c9aFZ+if8g0/9fE//AKOetCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDC0f/AJGrXv8Aeg/9ANbtYWj/API1a9/vQf8AoBrdoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOM8badNqljq1vaaheabcmK08m6s7h4XjYyOucqRuHP3Twa5nXvE+pa54N0q2ju7iwvYdQtLfWjayvC6t9pWBow6kMoc72yDnaB613OpaJZeINSvbLUxcGDyraTFvdS27blaQj5o2U9ecZxkD0o1LwPoGrW8sN5aTBZrlLuU295NA0kyBQrs0bqWI2rjJ6gHrzTjo7va6f3f1+Q+n3me3i7ULK+utOn0uzSa0uUjRW1J2aS1MbOZ8mHOQEYbecsCC3Qnlrzx5rOn+JP7dn065m0+fRVuLbTYb9GUq88arIwKqFfD8jL47HrXeWmiPJ4ik1XUrS0WSG2NlamORpnaEtuJdmUHJwvy845+Y54y5fhP4LnQLJpDfKnlo4vJw0SBtwRGD5RAeiqQo9KFum/wCtGv8AJ/f5EyV00v61T/zX3fNlz4uurHU9YS60cRXthZ28iiTVMW8yyyOq4JGFwQdx27j0AbC5g074kS39hYXL6QtstxPNbzvNcOkcckcvlbVdogCzNggP5ZIzjJGK2b3wH4f1C/ub28gu5bi5iiikf+0bgfLGwaPAEmFKsMhhg5JOck5VPAnh9ITElpMsZmadkF7Ph2Zizbhv+ZSxJKnKk9qFYqW2n9af5mT/AMJtJaWMt0ujyxL/AGjcQTm8vW2ReXxkuA6pux8qkqnqwPB1vEt/P52j6VaSvA2rXJiknibDRxLG0jbT6naFz23ZHSmp4C8Ppb3ECwXmy5leaXOpXJLs5BfkyZ2ttGV6HuKua3opv4LKSxaOC802cT2jODsBClSpxztKMy+2c9qS2V/IXV28/wDgHNy/EG7sdVhsL3SrSE/2hLYzN/aEjGILGJI5D+55DhlHJGCyjJzxlW/i3X9M8Wanc6hZtPbywaW8tmb/AClh58jxnyv3Y3nO0nIXPPzcAV2l/wCDtC1aa7m1LTkmlvlhFyTI+H8ptydCMYIHTGcDOcVW1P4feHdYv7u8voL1przyvPMWp3MSv5RzH8qSADaeRgDnnrTi7b/1/wAOJ+WxmxeMbp9SvbDSdEkk1Rr+eJbe91EojLCkZZwwDhAQ6YRRjJycEtWfB4o1fSfGGrfa7a4urOW70+Fori7UGwM67dqKqkPh2GeRxzuOMV0A+HfhweawgvhLLc/ajP8A2pdeaspXaWWTzNyZXg7SAQAD0FNufhx4au7ieea3vvMnlimk2ardIGeL/VthZAAV7e/NCtdX8r/hcGm/x/WxN4j8T3mjavYabYaP9umvop5I5ZLlYYlMa7trHDNz6hTWJafEu4utPF0NFiiE+lw6jaCbUFQOsjhNshK4TBIPy7yR0G75a6XWPCek69e2t3qSXRntEeOF4L6eAoHGG/1brkkcZPNZS/C7wmscEa2d4Ft4Ft4R/at1+7jV96hf3vGGAIPUYGOlJef9b/8AAH/X5f8ABKmm/EK6vrDTL+bSbe1srm6uLO6mlvHH2aWIuBgGEFlYocFthGQCM8UvirU9Xk+H+nam7Po9699ZNJDZ3HmDY9wimNnKKSCrc4A54yR1v3fg+2OnjRbGwtf7Iubn7XeG5uJJX8zzFkO1GBB3EHJ3DB5wa19d8P6d4k05bHV45pLdZUmCw3MkB3qcqd0bKeDg9eoB7CmrXT81/wAEfU5KD4oNdX2orbaBdvY2q3IjvWEkcTPCSGDyvGsKAlSAwkbpyFPFFh8QrvXbN7Gy0uOLWHuZrXyxeMkaiNEdpVkeEMeJFxmPkkfw/NW/J4G8Pym+D2k3l34b7RCLyYRMW+84jD7Vc/31Abqc1Gfh/wCGyrA2U5Zrj7SZTez+Z5mwIW3793KqAwzhh1zS3Vn2/H/hhddO/wCBz1l4j1fTvgBHr8T/AGzU4dNMxkvJclm5yxIByR1x0OMcCtVfGl/HNG1zpEP2KO7isLy4hvSzRXD7B8qGMb4wzqNxKnqduK2LfwloVn4Wfw3a6bDDpDxNE1rHlVKt97kHOTnrnPvUcPg3QrfVF1CGzdZwVYj7RKY3dRhZGj3bHkAA+dgW461V1zX6C6WRneMvG8nhO6tUXTo7uGQK0zG6KyIpkVMrGqMWxuyS2xRj72eKbd+MNW8nVLzStBhu9P0/7RGZ5NQ8p2khzuBTyzhSQQGBY5xlQOa1dZ8IaJr90bjVbWSWRoRAxS5liDoG3AMEYA4bkE8g9MZoXwhoq6hdXi20okvFIuI/tUvkykrtLNFu2FiON23d71GvL56/8ArS/lp/wTktX+IeuCNY9L0ezjleTS3jea+bDx3TlSDiI7SCpXPPB3dRtrU8P/EF9f8AE8mnQaHeLZCSaJNQEM5j3xMVYMxiEYBIO0rIxOOQp4q5H8OPCsaADSyziOKITyXMrzBIn3xgSFi4CsBjnsB0AFaFh4X0nS9TmvrCCSCWZi7RrcyeTuPVhDu8tWPdgoJyeea0bjf7/wBLEe9b7v8AgmHe+O7u08RXVgNCb7NZ31paTXMl2qki4OFdEAOQCRkEqcZ9MHL1D4sS6bcaxHJoH2gafazXUX2a9VzKkUojfcSoRSNwbaruQOCA3FdDf/D7w7qd/c3l5DfGe6mjnmMeqXUatJH/AKttqyADb2wB0FQ3Xwy8KXkckc9jclJFkRlTUblBskcO6DEgwpZQdo49uTUxtpf+tP8AMr+vx/yKlx4+v7HVNQtNQ8PiBdPtEvZZRfKyvE7MqBRtyXyuCDgA5+YgAs+58batYSTQahoNtFcWs9t9p2agzxpbzuUEyt5QLFWU5UqvTO41r/8ACGaGb+5vJbaaeW7s1sZxcXc0qSwgYCsjOVPfnGcljnJOXQ+D9Eh0W70r7LLLa3sflXHn3UsskiYwF8x2L4AJwAeO2KNP69f8g/r8P87/ANaGX4a8Z33iDUPsv9l2kPk3FzDdMl67mIRbNrKDCu7fvBHQbeQTUWr+PptK8YxaKNIW6ilcwpLFdgymTyWlAKbdqghcDfIpJ527ea6LT/D+l6VfXF5p9mkFxcxxxSurH5ljXagwTgYHHHXjPSqF94G0DUdQlvrm1nFzNKJmeG9nixIIzHvARwFbYduRgkYz0FJ9LDVru5g2fxMuLjR21KfQDBA+lrqduBeBiyF9rCT5cIFyGJG75cnqMVny+MdT1yw0vVGMWnWsOvx2xbTNQNzDfRbSWbeYkymemOpBz0xWrqHwx0u20jy/DcE0d1FAttCl1q155fkhw5jB8xinThgCVOCBwKt6f4HhubOEeIRdFoLlLqC3XXLy6WCVQRu852V3zn7pAUenJJOt1/Wt/wAtCXfVev5W/PUTwV48k8YTSf8AEjvbG1aBbi2upIZhHKjHgFpIkXfjBwhdcHhjXQa9/wAi9f8A/Xu//oJqLR/DWl6A0n9lQzQo+cRNcyyRxAnJEaMxWMZ7IAOlS69/yL1//wBe7/8AoJpu3QfU0KKKKQGfon/INP8A18T/APo560K8t1nVtQ07xXptoviDW7DTruC+leHStMju3EkdwADj7PK4BEhyTxwvTv0sHi7+zLeG1vbbU9Qf+y21BL1kt4/tSrglQodf3mGXI2quT1GaFqr/ANdf8g2dv6/rU62iuO0z4n6BqfiuPw6pkg1By0flyTQMVlRdzxFUkZwVAPzFdhwcMag8d+MLzS7eS20BJ/tFvc2y3d0sCSRQLJIq7DuYHcytnIVsd8ZBo7eYdzuKK5KPx1p8ce5E1K6ae+ntkieKON1MX3wqsUJAxwPmc54BHSe78c2NnetHLYai1osrW5v4oVeLzwCTFgMZC2RjOzaW4znijpcDpqK5KPx5BqWhWt7pOm6lJJqSFrCMwx75VC5MmxpFwq8Z3Fc8bc5Gee0L4waVbaRoNt4luzJqt9BE9xInlR7GkYqn7ouHOT/cVtv8WOtHWwdLnp1Fcfa/EnTryxtryDTNTEF1cNbQNNHHCZHRnDgK7q2VEZOMZPQAkEDro38yJH2sm5QdrDBHsR607AOooopAFFFFABRRRQAUUUUAFFFFAHlnxA02x1Gy106laQXMUGo6bIfPjDCNfNUO3PQbCwPsTWn41On6NqbeIdM0rS7rVtH0S4niaZApjRTHt+YAkDb5gUDHVhkAk10GmRRz+JPEMU8ayRv5KsjrkMCh4IPWrMHhLw3a6XPptt4f0uGwuSDPax2UaxSkdCyAYboOo7Uapaf1pYpNXVzk/wDhNNeTUhpE7aTFeXVzbxW915MhigEsDy4dN4LtmMqMMudw6dDNqni7XbJb4RtpBn0Wzjur+DbI32vcWBWFtw2Y2EAkPljt4xk9CngjwpHDPFH4Y0ZI7hFSZF0+ICVVxtDDbyBgYB6Yq2/h3RHkspH0ewZ9PGLNjaoTbD0jOPk/DFPS5CvbX+v6/A4keN/EsutPbrBpMMK68dICMJJH2tAJUkLZUZGeV285wCMZNAfEbxRNaP5MGjpJDpl/dvKyysJJLW48tgI9w2qwGR87EE98Ybun8E+FJLo3MnhnR2naYzmVrCIsZM535253Z79ahX4eeC03bPCGgruG1saZCMj0Py0un9drfnr+BXW/9b/5aHOr471cahNp1x/ZsU9wLE2lx5bmK3+0rIcSDeC+DHgEFNxZRx1ofxj4obULXS4otHW5aS8glvWWVo2eBAwZIgwO07gCC5IIIycZrqY/BfhaETCLw1pCCeEQTbbCIeZGMYRvl5X5RweOB6U+48IeGruG2iuvD2lTx2sZit0kso2EKHqqgr8oPoOKcrO9v6/r8b+RKvpf+u/3/p5kvhrVH1zwrpeqzIkcl7aRTuiHKqWQEge3NadVtP06y0mxjstLs7eytYs+XBbRLGiZOThVAA5JNWacmnJtArpahRRRUjCiiigAooooA5bxNq13okeq32nRxyXCRWiKJEZwN0rqSEUhpCAchFILEYHJrk/t2s3et+EtW8TmGKdNSvVgCW09mptxbSkO8MjsQTtB+YAqDj1z12v6G3iGXUdPWWCMPFbMVurUXEMgV5DtkjJG5TjkAg+9GjeAdD06GFrrR9GmuYZPNia30yOGKByACYk+Yx5wCfmJJ79MC0uD2scfY/EfxJNNtnXTNq3mmguLOVFlgu3KfJmXcCpGQzKuR/AvFaGmeOdZ1m6j0awvND/tYXF9G87Ru0J+zyKqx+WJNyuyuGzuOACdprr18H+GktJLVPDukrbyoI5IRYxhHUNuCkbcEBiSB6nNS3PhrQr2zW0vNF064tllMywy2iMgkP8AGFIxu9+tVdf18vy38w/r8/z/AAsczL4x1Y30k1r/AGbJZ2uowadPZgOZ3eQJiVZN2AuZAQpQ5UE5HSsnT/HXivUFsspotu19HqAVRHLKIXtZCuc718wMOMYU98/w16A2haS+qLqTaXZNfpH5S3Rt081U/uh8Zx7ZxWUfBXgi3nhhPhrw/FLIHSGM2EKswIO8KNvPBOQO3Wp6W/rb/PX8Og+py1v8RNT1G/0DZBYSafqYtIryBYXZ4XuIi/MhdVHbChXJByStdT4RuJFl1rSmdpIdK1AwW7MxY+W0UcoUk/3fMKj2AqzF4N8N2qqbHw9pFu8YHlMlhGNhUllxgDoxJHuTRZeFbG2+yyz/AOk3cFw90bmRF3vM4wzZxleOMKRwAORVXV3/AF2/LX7yLOy/rv8Anp91zN17xTfaLrzI8UP9nJGuCIi7ySkM2zcrfuzhcAMmGLDDZGK5eD4keLF8Nf2leaBEov2txpkqmHa3mtggqLk7guV+Zni3FsYU16JqFpotvMNa1W3sIpLNWYX9yiBoFIwT5jfdGBzzVew0PwxPpc50vS9JksNUHmTm3t4jFdg/xNtGHz6nNSvP+v8Ah+/Qp/1/X6FKx1rxA3ge4vtU0uG11qBZF+ytLGFdgfkJxKyruGDtMhxnG7vXMX/xA8TNd2ul+H9Lh1LUxHLLcIYBAGMbKpj2yzp5ZO7JYGXAK8MDmvQ7fS9Ps9OXT7SxtoLJBtW2ihVY1HoFAwKpv4U8OyWNvZSaDpjWtq/mW8DWcZjhf+8q4wp9xT+1cOhy7+KfEOo6VrOo6bPpNnbWS3MHkTRtJcRSxoSrlg+1gxGQuB8pDbj0qjZeLr/S7OOfVI9NvJ4dCtpxforK7NJKEYSZLFUU4LcnOCeOld7/AGDpH9qPqf8AZVj9vePynu/syeayf3S+Mke2cVBB4V8PWtwLi20HTIZhB9nEkdnGrCLGPLyBnbjjb0pf1+D/ADuJr+vmv8jkbjxf4ostetNDkXRrmaa+S2bUI45UjCvC8qkQ7mO4eWcjzOhU8buNvT/FF5L8O49burbzr0oUeOwtpZlMgkMe5Y13OVyNxAyQM9avnwZ4Xa0t7VvDekG3tXL28JsYtkLHqyrtwpOBkir+maRpui2YtNG0+10+2DFhDaQrEmT1O1QBmjpYfVM434WX8VxYa9GsmoTvHq07vLe2c0LPux/fVeeD8o5XgYHFUPDuvrqXxfkknTVo5LrSiscFzplzCkAEuQPnjAGQMls4LHAJwBXoX9l6f/z423+v+0/6lf8AW/8APTp97/a61L9lt/tn2vyI/tPl+X52wb9mc7d3XGecULRxfZW/Cwmrpru7/jc818WW8Vl4k1XXp7e21ixhEUN2UkKX2lfKv+pJBDIwYMUG0nJ+992p4fH+uI4u722017VdUutNeytd7TgxI7Bw5Iz9zldnQg57V3Nzoek3t7DeXml2VxdQPvinlt0Z42wBlWIyDgAZHpWN4V8GRaBe6hf3v9n3uo3d1NOt5FYCGWNJG3GIsWZiAc9x9KS2t5f5f8Ep23/rZ/8AAOY0rx/4qvNPtZtQ0yz0+PV5YE06+m8sxJ5gYnckdw7OBhQGzHuLgYWtHUPEmqaTqkn9rQaF9qtdEnuFvk8wjzFlVSuAC6ocoSo3EnjsCepTwt4fjtbu2j0LTFgvm3XUS2cYW4Pq4xhj9c1H/wAIf4ZLo58O6TuSA2yt9hiysJBHlj5eEwSNvTk1V1f+u1v67k6/l+ev3/gcBDrt/wCINY8PPrSLFfab4mksT5KtAkq/ZHk3GLzHAPK9WJGO2SK6bxn4i13QdQSPTXsDFd2coskmtWkd7xCpWPIlQEOpYAcYIznHFbI8HeGRLDIPDukiSCQSxMLGLMbgABlO3ggKoyPQelac9nbXUkL3NvFM9u/mQtIgYxvgjcpPQ4JGR2Joeqsv60t/wSk9bv8ArVv9bHnU3jvXZ/DsWp6VcaXL9sKi0jNjKzsUt/MlG3zgD8+V+ZkCAHJY4BpT/ErxVNoep6pp9jo0cVhpFnqYjnaVmlWZGLLkY2kFePvZAxn5sr6PL4f0ae1htZtIsJLe3lM0MT2yFI3JJLqMYDZJ5HPJqmPA3hJY5o18L6KEnRUmUafFiRVIKqw28gEDAPTAp3V3oLsc1c+J9X86Wz1Sz0e9+za9Z2rNsdVSOVY3VgrFsyKzAA5A43YHSo9N8deIZ5o5L220lYpJtRthbxu4Iktt21vNYgbTtIPyjHBz2rpz4C8Hlix8KaGSWDk/2dDyw6H7vUZPNQ3Xw+8MSWkqafoOk6fdMr+Td2+nQiSB2GC6/L1qX8Nl/WiX6At/u/W/5r7jnNM8V+NLy0nu5be0Nu0kCW5bSJ7eQlgWkxHLODLsAx8uN2SwzjbXQ6l4lnj8EWmq6dPZ/arwwJC8kMrxs0jAfLGMOx5OFJX3KjJFfQPh5pemW00eo6boMwnTy5IrDR0tYJV9XjLPvbqMk9CcAZOekudI02900afeafa3FkAoFtLCrRjbyvykY4wMemKbt/X4iV+p5hF8SvFN3pazQ2mk28iaTe30jTrI26S2n8tk2K+FDDvvfBPfHzR+O/Ez6pCjzXdlYWGk61pqypLI6SSM7RSb928LsCuwwysDtLZG2vQJPAvhGaRpJvC2iyO4IZm06IlgTkgnb3JJ+pqyvhfQEmglTQ9NWS3jWKFxaRgxIpyqqccAEAgDgEVSklJO2zv+N/y0/EfR/P8AJf8ABNUHIyORWfr3/IvX/wD17v8A+gmtCs/Xv+Rev/8Ar3f/ANBNQBoUUUUAcYvhB9V1KHW4PEOq6bc2/wBqtoltFtiio85LcSwuckovftxjnNi88OvfXuj2N3HfXkWmTi7bVLqeMGZsN8mEIJ+YqSuxUwBjpitfw5Otzocc8YIWWWZ1DdQDKxrUoB6mJp3hiLStXuLux1G+itriV5304NH5Hmscs4+TeCTk437cnOKz9f8Ah7pviG8upri+1K1jvTC11b2lwI0meJgUcnbuDDaBlWGR16Ajq6KO3kByA+HludKvNPm13V54LyeSaUSmBs+YQWXHlYwcdSCwycEHmrB8CWa3UzwalqMNtJIbgWSvG0Udxj/XLuQtuz82CxTdyVJrp6KAOTt/h/Z2uh6Pp8Graokmjq0dreq8Qm8thho2xHtKkYH3c8A5yM1Fofw20/w0YRoOraxZosSxTp9oWUXQXO3eZEYqRkgbCnHHauxop3d7gcnb+ALe38LPoP8AbOqSW7yyyPJKLdmbzW3OpXythBJbquRuOCOMdPbW6WlpDbQ7vLhRY13HJwBgZPepaKQBRRRQAUUUUAFFFFABRRRQAUUUUAYWj/8AI1a9/vQf+gGt2ubsJ5IPFWueVaTXO5oc+UUG35D13MP0rX+33H/QJvP++4f/AI5QBdoql9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlAF2iqX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5QBdoql9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlAF2iqX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5QBdoql9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlAF2iqX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5QBdoql9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlAHJePdZ1DQY577Tb6KyxcafFPLJAJP3Uk7I2MnAOGzkg9Dx3HPReMNXl17SNLi8WwNp9/qtxa2+oGGAzX0Itw6ujYEZ2ykoCqEMdvXkHp/EGkv4nup7SaPVrIRtaXGbNrbfuikd0z5m4Y3AHjn5eeOvTC/ucf8gq8P8AwOH/AOOU4tJa/wBbf8EJbaf1ueVWnjbxcX1i6n1HTiLbzEn0wSCW7sQJQol8hYFZQI9zHc7hjjaQODL4r8Z3ul+Gon8P+NxqcrRXVzbXiQ2oW5ESqfKaQIUYjLfLGgY+q7ST6j9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOUug01e55kfGepR6vPbSeI7hiusWnlwQ2sUjtaTwqThVjLFA7Nh+vy4JNV/DXi6/0mz0WyGvpqV1cw6i72N0IxPLcIxKICAv8AFuGMZznnjA9V+33H/QJvP++4f/jlH2+4/wCgTef99w//AByh+X9aW/4IuqbPKNU8falYaWLzTfGVpd2kj2ouLm7t4R9jleZVktxt2BSELNtcM6iM5PORbPju4Gl3bQeLLe7XTtSuIpJ42txLNGAvlqBs8tjltu0FGfAw2Qc+mfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45Tv8A193+X4h2/rp/TOO+KN7aw6Bosl54gbRFk1W1IkLQoWHmKSSJVYfKPm9BjnI4rFfxPeaeZ003XLWwntp7qKfR5bWHyrOBRIyXZChXAOEYsW2NvIABr0v7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKXRpef5L/IFun/XX/M5TRNR1XVfg8Naj1yS41K70wXSXNvDCRFKIgSqLsIPzA5DbjkkccAczb+PL+6knMHiZWtpLGxuxcNHFHFFlZPtCrP5RjBygOJM87gCvb1H7fcf9Am8/wC+4f8A45R9vuP+gTef99w//HKpu8m11/DcSTsk/wCtv6+Z5pa+M/Euo+MdPt4dRsLG1ZbZ47bUZVgl1CJ0BldIhC5dgSwGyVQCOQRzXrFUvt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHKV9LB1uXaKpfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlIZdoql9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOUAXaKpfb7j/oE3n/AH3D/wDHKPt9x/0Cbz/vuH/45QBdoql9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOUAXaKpfb7j/oE3n/AH3D/wDHKPt9x/0Cbz/vuH/45QBdoql9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOUAXaKpfb7j/oE3n/AH3D/wDHKPt9x/0Cbz/vuH/45QBdoql9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOUAXaKpfb7j/oE3n/AH3D/wDHKPt9x/0Cbz/vuH/45QBdrP17/kXr/wD693/9BNP+33H/AECbz/vuH/45VTVbi6utJurdNLulaWJkBZ4sAkY5w9AGxRRRQBn6J/yDT/18T/8Ao560Kz9E/wCQaf8Ar4n/APRz1oUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcBr+pa5o95rt94cWzmuUubNDbXUTET7yECq4ddhy33iGHtVyx8Yy6pqdleW97ZW2iNZTzXsNzbMLi3lhZVdGfzAq4L8gofunk7gQ2+0m/wBZ1bWrbS7+3sZEurOcyXFq06kRneF2iRMZZRznpn1yJ9S+HdhqGtalqUdzNayapYta3Kw/dMhKETAHIDYRQeDkBc9OWtN/P8tPxG7W0/rUdefEfQ7aGF4RfTyS3sVm0A0+4WWNn5DNGU3gYBIOMNjirGveJZ9E8S6VbSxwDTLqG5luJjvaVDEm4BUA5/U9gKoz+B7++ljv9R1qGTV0ntpPtMNj5cWyAuQvlmQnJ8x8tu644wMGTxj4Lu/FOqaTd2+rx2A0zzHjBtTI/msBtcMJFA2kA4IIPQ8Gl/n+Fl+tyevl/wAEmT4j+F3uvs39oSpcLJFHJDJZTo8DSnEYkUoDHuPTfjqPUZtXPjXQrS/ks5rqbzow/wBy0mdXZAS6I6oVdwAcopLcHiucv/APiTUb3UbqbxPpiy34tA23Rnwgt5DInH2nuTz+mK1rHwbcWuoRCfVEn0y3vZL+G1+y7ZFmfcWBl3nKbpGIXaDyAWIGKen9f1/XkMnXx94fdC8c946i2huxt025O6KUgIy/u/myWAwMkc5AwcS6X448O63fxWelaiLqWbzPKZIn8tzGQHAk27SRkcZzjnpWNpnw2TTdWsL4ao0htHkQp9nAElvvDwwdeBGygg9/m6ZpujeBdb0vVbG5l8QWM8Nrf3V40S6W6NJ9oJLLu884xuODg9uPU0/r8P8Agg9tP67/AI/md1RRRSAKKKKACiiigAooooA5PxXd65p1trV94YFo99a2kMwiu4GlWVVMpKgK6kN6HPtjnIkn1+7STTryPVNLXSBp7XuoXMls/wBzaNro3mYRTknBDcKea2IQG8QXwYZBt4AQe/MlYui+DJdB8PapptlqYka6MiWkk9sGW0hOdkW1WG5U3NjkE57UtUnb+v6/roPS6/r+v+CW4vF+lx2lubm8e5le0S5MlrYTlHDLkEABtpbkhCS2PXFMh8e+HLi2a4jv5PJFiuoB2tZlDQMcBlyvzHPG0ZbPGKzdO8CXtm2jNLq9uz6dBHBLNb2JhluEjUqqFhIfl5JKsHGTldtUbb4aapa6bDbQeK5IWtdOOnwNBZBB5fmBlL/PuJwMHayZzxirla7t/W//AAPxJV+VX30/4P6mo/jX7Zrfh6PRUjl07Uru4tbp7iKWGeGSOJ32+W6qVOUOd35c5B498br4V0mf7B5VxqaIsghljlZEQtt3OyKQmedu4qGIwDVDTfhzeaXqenT2ur2SW1lqc+om3TTWXeZYyjICJflwGYg4PJGc4ObXinwHd+ILrUjZa82nW2q28UF5GLUSsfLYlWjYsAuQSCCGyOmDzS00/r+uwau/9dTUTxbpSy3m/Uo7lYb0WXlWttJI8cuwM0bbd24jliQAFHXoTWefiZoEetz6fP8Abo0ia3Rbr+z7hoXeb7g3iMqoOVwWIzu9qqnwFqbnVzca1Y3Jv7tbqIzaWcxOsQiBJWUEttVTuTYc57HaFvPh5dXNvfRrrzl7qOyYSz23mN51sykSOdw3Btoyo2nk89MGl1fy/wCCM02+IHhwzi1jvy168k0MVo1tMJnki++BHs3kD1APtms/w38R7C+0RZvEM0en3yxzyzIsUoh2RSMrbJGUCQgKCQOec4GcU2x8CapZ+LbfWX8RR3EaXU9zJavp4GWlRUYIwcFR8o+9uqNvh1d/YmtI/EDwxWwuG0x4rcpLbPPu3M7h/wB5jcwG0JgHqTghLbXe34i15vK/4GoPiL4X2Q7tRkSaeSSKO1ezmW4Z413OvklPMyFIP3ecjHUVYbxx4eEVjIL8vHfxJNC8cEjgI5wjuQp8tSeAX2jPHWuYs/hlqmm6pDeabrunQLFqEmoeT/ZDlTLJbiFhxOOPvN3JJ5J6m94f8C6x4eNm9p4htmkSzjsrstpp2zRxsxjZB5vyOA7AkllP92q0/L/ghrZ/1/Wh0Nh4p0fUtXl0yzume6jDMA0MiLIFO1jG7KFk2kgHYTgnBxWvXHeFfh7aeFtYnu7ZNLdGeRopl0tI7wB2LFZLgMTIMnj5VPAyTXY1PRD6sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9e/5F6/8A+vd//QTWhWfr3/IvX/8A17v/AOgmgDQooooA4m21nwtolqlp4h8UWlleh5CyXOr/AGdmHmuN2wyDrg8/WujtLTTb+ziu7G8nubaZQ8c0OoSujqehDB8EV5pr2vW+mfETRli8S6HolzHZal5kmqgOihrlNoK+bGQTtJBz/C3B7O8QeOriwuNI/sPX7fykjtZbiOGOFLe6WS48qWRWZSzrnJ+TYFyGLHIFNK6Xn/m1+g2rP+vL/M9P/sm3/wCel5/4Gzf/ABVH9k2//PS8/wDA2b/4quY+G2vXXiXS77ULvXrfVPKvri1VbOONYlVJCEbjLZK4PLYwRx3PAXvxM1e0j1WaLxVapC8Cy2r3sUAMTi5MbxiNQNpCkcO7sMZOOlLql3FL3U/LT8bHsp0q2VSWluwBySb6bj/x+qxj0hdNOoNqTiyC7zcnU5PLC+u7fjFecjx0Ly7vtGuvFkEunrqUtvJqiR28hEZhR44WG0x4d2kQErk7Cud3NQyT6e37KZN8sccUem7EF1CYgJA3ybVcDndjaR7YppdfT8Q62PVH0y0SMyPPdKijcWN9MAB6530kOnWVxAk1vcXMsUihkdL+VlYHkEEPyK8t1nxZPqviqXR4dTi1HSL0TWMmnukBQ5szLGVUKzvuYcOWAbOFQ43VY8M3evaj4dXTvDfiOab7PosL+ZHDbn7DdoAv2UkxkfMAchwzrjOeQKLfp+v+RN9v67f5/gem/wBk2/8Az0vP/A2b/wCKqKGxsLjzPs91cS+U5jk2ahK2xh1U4fg8jivPJfFOrXWveHZIfE8um6f4jupIorO7tYFnjRIDhkLKCCZR/EG5ZMYHymk3xEuZtRsLF/HGlW6SatfWl1NEkIdYo42MbAsSq4IXkg5JHbgm39ehX9fn/keoXNlp9nbPcXd3cQQRjc8suoSqqj1JL4FSDSbYjIlvCP8Ar9m/+KrwbWvESa/4T1S/1vxBHdR3HhaF44nWHyHuhK6swG3IZXVDwwwzAf3QPU/BHiUarf8AiGxTXrfXDp88ZgaJotyxvCrbf3eAQH3AE88YJJFNqyd/P8HYHo7f1sv8zeuItJs5Cl3qMkDiJpisupSKRGv3nwX+6MjJ6DNTrpdq6Bkmu2VhkEX0xBH/AH3Xhep+MpINUTxPHrUaa1/wj14JvOsUKafcB4mFqxVQQchgBIxO5gedwU9zeeNr+LVLhtL1GPVTNZtPYWVr5cgfbb79zKAHwWP31ZkPyr8pPJy+7f1/N/5FOOtv66f5ne/2Tb/89Lz/AMDZv/iqhubPTrONXu7yeBGdY1aXUJVBZjhVyX6knAHevM9W8dahpuk3F3pXjK0vrEz2QGoXdvDiJ5ZSssGU2LlV+fBBZQDu6gir481dnvvsOqanPPNpOr6fJZ2Rs45JLuLfGzXI2R7yQS6ZjwBjaQSwoSu0vO35f5/0tRdL+X9f1+p65/ZNv/z0vP8AwNm/+Ko/sm3/AOel5/4Gzf8AxVeOP8QPFsfhfX9WuNf0Wymt7RnNlLKstxYz+YAqGLyo/L3DI+d5MtggkcV2a6/d2fi3TLSXxD9vtr4IIo4xBukL5dm2BASgGwB0ZsA/MD96kk3bzJbtc7D+ybf/AJ6Xn/gbN/8AFUf2Tb/89Lz/AMDZv/iqu0UhnLadZWw8Q655008cUPknf9rkXA2kks27J/E8Vd0yfQNaj8zRtZGoJz81rqryjjGeVc9Mj8xXHeMobiW71BlhknsIdUsJdSijUsXtlyW+UcsAdpI7gGtbWPFGkS6VJrXhWe3vpIESCXUbLbMlrA0qBySuQSq5fbzjbyADyLX+vx/rzDrY6r+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iq8tuPG1/bazplj/wAJxaHR7u9mhj1aSK3ElxELbfvV8CI7JPl3BMEkA8gg4d18WNStvDMN2njPTTeXegy3QWWOAqlxHKqAIoIO51L8EkZXIUAEU0ru39dX+gf1+Nj27+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiq8om+I0llqd4f8AhN7K5trTWbGFVJtgJYZwvmKxA+6mXIIwRtO4tg1b1Hxvq0MN5d2niGGO8h+1re6Xc28ZXTEjWQxSkDa+GKoMuxVvMyuOlJ6R5v62T/UFq7Hpn9k2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVXF/D3xe2t65d6fceJLbWH/syzvVWPyQ0TurCVQIwPlBCHnJG/ryK9BqpRcXZkxlzK5S/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qrtFSUUv7Jt/+el5/4Gzf/FUf2Tb/APPS8/8AA2b/AOKq7RQBS/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qrtFAFL+ybf/npef+Bs3/xVH9k2/wDz0vP/AANm/wDiqu0UAczeNo+j6he3Os6n/Z9pHDADPdai8Sgs0gwXZx6cAn6daSx1rwhqizNpvie1vBbqHmNvrZk8tScAtiTgZ4ya0Jfsqa1fXN8YkitbeGbzZSAsWPNyxJ4GATzXnWmeJ7LTvgtZa3pWs6bBNa3H2Z7l2SQKHuAXjznAYrg854wcULcHfoen/wBk23/PS8/8DZv/AIqo59Psba3knubm5hhiUvJJJfyqqKBkkkvgADvXlUnxKni1u6aXx1pEcEeuS2McZSAQiA229XbLbjtkwMhwCcg9QBTt/iler4UmvX8aaZJqE3h37ekciQbYLlXwUVVIJLDjaxOCM47UJX/ryv8AkVbW39b2/M9jXS7V0DJNdsrDIIvpiCP++6d/ZNv/AM9Lz/wNm/8Aiq8o1HxJeWPii/1i28WTpZmfSnaMi3a2a0lYK7ljGSqfM2GDDnPJxxbTxvqMWl+dP4glZLXULy3eSS2jilugsgWEIGjVJcK33UKsxxgnBFUot/16f5kLa/8AXX/L8j0z+ybf/npef+Bs3/xVH9k2/wDz0vP/AANm/wDiqug5APrRUjKX9k2//PS8/wDA2b/4qj+ybf8A56Xn/gbN/wDFVdooApf2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVV2igCl/ZNv/z0vP8AwNm/+Ko/sm3/AOel5/4Gzf8AxVXaKAKX9k2//PS8/wDA2b/4qj+ybf8A56Xn/gbN/wDFVdooApf2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVV2igCl/ZNv/z0vP8AwNm/+Ko/sm3/AOel5/4Gzf8AxVXaKAKX9k2//PS8/wDA2b/4qj+ybf8A56Xn/gbN/wDFVdooApf2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVV2igCl/ZNv/z0vP8AwNm/+Ko/sm3/AOel5/4Gzf8AxVXaKAKX9k2//PS8/wDA2b/4qj+ybf8A56Xn/gbN/wDFVdooApf2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVV2igCl/ZNv/z0vP8AwNm/+Ko/sm3/AOel5/4Gzf8AxVXaKAKX9k2//PS8/wDA2b/4qqmq6dawaTdSv9qlWOJmMbXsuGAHQ5bvWxWfr3/IvX//AF7v/wCgmgDQooooAwtFv5jpgKaZdurTTMDmNesrHBBcEEdOlaH2+4/6BN5/33D/APHKZon/ACDT/wBfE/8A6OetCgCl9vuP+gTef99w/wDxyj7fcf8AQJvP++4f/jlXaKAKX2+4/wCgTef99w//AByj7fcf9Am8/wC+4f8A45V2igCl9vuP+gTef99w/wDxyq1/Le3toYYbbVLFiQfOt2ti4API+dmHPTpnngg81rUUAZlrK9lZw2tto94sUKBEBkiOABgcmTmpvt9x/wBAm8/77h/+OVdooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAOY0q7mXxJrTrp9y7OYcorR5T5T1y+OfYmtr7fcf9Am8/wC+4f8A45XG63rtzoms6hHp3li81LUbKwhklGViMitlyO+FBIHc4rcJvvDEP2rVdbudVswnl7ZoIlned3VY1Xy0RSCSQAQME8k9hah1t/X9aGt9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOVzjfEexS8g0+XRtZTVJppIBYG3QurpH5uC4cxfMvIO/B9sHFZ/ixokWlnUJ7DVo7Y6edQjb7KGMsYdUcBVYkFWZQSwC85BI5p2bA6z7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8AxyufHxEsRfPaz6VqkDR30VjK8kUe2JpQPKY4c5Vtw6ZYZ+YLS3fxD0yxaSS6sdSWyxKIL1IBJHctEGLogVi+QEb7ygHaSCRS2Vw3djf+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcrP8PeLLXxHcTwwWd7aPDBDcAXaKvmRSglGXax/usCDggjp0rdptNOzEmnqil9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOVdopDKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooAxIL2ca7eMNMuiTBCCgaLI5k5+/jn+lXvt9x/0Cbz/vuH/45XK+Pr6/0vQvEGo6Tfz2F1aWcEqSwRRyMcPJldrqwOc+map6R4u1XSrLVLvVrfW9W0uKWJbK4u7COzuXypMm9XEKKi4GHYIDnHJxk7h1sdt9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOVxEvxHjttS/tqWaebw7NocV/DbwWe6ZWeULliCc9R6KOcnvWw3jizl1CHTprbVdPvvt0dv5DQRsW3KXUswLKEcKechuCODTs/wCvWwrrX+ulzf8At9x/0Cbz/vuH/wCOUfb7j/oE3n/fcP8A8crjI/ipHbeFX1zWNA1K3gW6uYmMZgKpHFIV3ljKBnjG3O5iG2qwGank+ICPfanbXNlqNlbWuoWllDeW8cUnmPNsYZGW2qd4BJUYB4O44Ak27f1/WpVjrPt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcrEu/H2n2Vw4msdSazDyxJfxQCSKWWMMXiVVYybvkYDKAEjAJNVbb4maXc6dNef2fqUMaWlveRCdI0+0RzttQqS+F+YYO8qB16c0twsdL9vuP+gTef99w/wDxyj7fcf8AQJvP++4f/jlS2N2L6yjuVilhD5wkoAYYOOxIxxkEHkYNWKBFL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKu0UAUvt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcq7RQBS+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrtFAFL7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKu0UAUvt9x/0Cbz/vuH/wCOUfb7j/oE3n/fcP8A8cq7RQBS+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrtFAFL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKu0UAUvt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcq7RQBS+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrtFAFL7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKu0UAUvt9x/0Cbz/vuH/wCOUfb7j/oE3n/fcP8A8cq7RQBS+33H/QJvP++4f/jlUtXuribRbyI6bcx74WXfJJCFXI6k7+lbVZ+vf8i9f/8AXu//AKCaANCiiigDP0T/AJBp/wCvif8A9HPWhWb4fj8rR1j3s+yaZdznLNiVuSfWtKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkn0Sy8Qax4gsdRRmj8y2kRkYq8bqCVdWHIYEAg1ak8Gw3mmS2mr6tqWpyNt8u7uGiSWAqwZSnloqghlU5KknAzkcVk6lq2j6JrWs3uvyXkVv51vCrWsdxJ87qQARCCeTgAnuQOprWefRI9ctdIc6sLy6iM0Q23mzYOpMn3FxxkMQQSB3GReQFOb4exT3tnfHxBrC39rO9wbofZy80jR+UC4MJXhMgBQo5JIJ5rMn+D9jPpsFi3ibXlghsZNPAU2uWhdw7KT5HcheRg4Ue+ey/sSz9br/AMDJv/iqP7Es/W6/8DJv/iqdwOZuPhnFcy3MsvifXDJc3dvduwFqP3kAHl4/cdPlXPrtHvmzL8O7GW3uLb+1NTS1kMzW9uHiKWbyhg7RZjJyQ74DFgNxwBW7/Yln63X/AIGTf/FUf2JZ+t1/4GTf/FUt1YFpqZfh7wanh7VJL5Na1O+L2cNmYrryNgSLOwjZEpyNzd+dx9sdJWf/AGJZ+t1/4GTf/FUf2JZ+t1/4GTf/ABVNtvcSSWxoUVn/ANiWfrdf+Bk3/wAVR/Yln63X/gZN/wDFUhmhRWf/AGJZ+t1/4GTf/FUf2JZ+t1/4GTf/ABVAGhRWf/Yln63X/gZN/wDFUf2JZ+t1/wCBk3/xVAGhRWf/AGJZ+t1/4GTf/FUf2JZ+t1/4GTf/ABVAGTr/AIfj8UNqukXF9d2UNxb24kktDGHKhpDty6sAD9M+9W9W8MRa1Y6dBeaheeZp8yzJcJ5e+RgpUlwUKHIY9FGDyMYFZus3mjeHZry81qS+isreGBTJB9pmZdzSct5eWx7ngdO9WNHu/D+uzTQWE2orcQANLb3TXdtKqno3ly7W2nBwcY4NG+gbanLeJPhrJYeEbmLw7cavqlyulrpdvZGW2RTHvDBizKhyOud34Gt9fAcdw1rez6zrCXy3Md5LK7W5kdkUhI3xGV2qGYYXGckkk81v/wBiWfrdf+Bk3/xVUZRoUGt2+jy3k66hcxNNFb/bJizIvVvvcDnvTv8A1+P/AARNX1/rt/wDHu/hbpN3am3Oo6nHCRdrsWSMgJcktIo3IcYJyCPm7EkcVNe/Dizu47hY9a1a0+0z29xKYGh+aSAIEbDREf8ALNCeP4eMAsD0H9iWfrdf+Bk3/wAVR/Yln63X/gZN/wDFUJtbFXZjP4Cs2ecR6pqUVvJJJPHao8Xl288gYNKmYyd3zscMSgJztqtpnw5h0pkMHiLWnWOwisERzb4WKM5TpCMkZPXIIJBBrojotmASWugB1P2yX/4qszSp/D+uWcF3o93d3ltcPJHHPDPcNGShIb5s4AyCATwe2aXoLz/rv+lzT0PRoNA0eHTrWSSWOLcd8u3cxZixOFAUck8KAB0AArQrP/sSz9br/wADJv8A4qmnSbBZVjMlwJGBKob2XJAxkgbu2R+dPcDSorP/ALEs/W6/8DJv/iqo2v8AYV9q17plpezTXunhDdQpeTEw7wSoJ3YyQCcdfzFIDeorP/sSz9br/wADJv8A4qj+xLP1uv8AwMm/+KoA0KKz/wCxLP1uv/Ayb/4qs15tATVLrTRdXUt9aQrPPbw3FxI6IxwpwpJ59OvegDoqKz/7Fs/W6/8AAyb/AOKo/sSz9br/AMDJv/iqANCis/8AsSz9br/wMm/+Ko/sSz9br/wMm/8AiqANCis/+xLP1uv/AAMm/wDiqP7Es/W6/wDAyb/4qgDQorP/ALEs/W6/8DJv/iqP7Es/W6/8DJv/AIqgDQorP/sSz9br/wADJv8A4qj+xLP1uv8AwMm/+KoA0KKz/wCxLP1uv/Ayb/4qj+xLP1uv/Ayb/wCKoA0KKz/7Es/W6/8AAyb/AOKo/sSz9br/AMDJv/iqANCis/8AsSz9br/wMm/+Ko/sSz9br/wMm/8AiqANCs/Xv+Rev/8Ar3f/ANBNH9iWfrdf+Bk3/wAVVfUdPtrHS7q5iWWRooXYJNcSSI3yngqWwRQBsUUUUAc6niHTdD06NdQmk82a4uPKt7e3kuJpAJmyVjjVnIGRkgYGea2NP1G11S3M9jL5sauUJ2lcMOCCCAQQeCPWuA0+S60fxePEt/p97Np97YvbZtLaS5ks5VuZHKmNAXw28cheqc4qt8RbnXLm2jl8PWOt2c32aa5ga0WcCSRSm0SRwgHeyg4EjbcdVZuA462/r+tAe+n9f0z1Ksyw8RaXqgkOmXJu1iu2s5Ggid1SVRllJAwAOm48Z4znivOoZtcmtPEV75nii4EesIqI8M8EgsG8rzfIj2ruI2uAVBcAHactlqOlz6vpGpQG1sPFUFnN4guJNr2skpubdrbajyNhnGHCY8wjrk52kqLz7f5fo/vT7Bvt5/k/1X4ruezUV4xo8/iiLT9TE0fiR7KVbCd0dbprlELMLlY3kw28AKSIwnB+RRwT3N0b23+HFwfDbavczKuYDeq4uzGXBYASgPuCFgu8bsgZz1I1a/8AX9f8OC1djbg8RaXdXF5BaXJuZbG4S2uUgieQxSNjCnaD6jJ6KOTitOvGbaXUdM1W+uNNsvFkFjNrdhJFLLazzSXMAjVZVk3BpgowSd2OgGT92teWfXoDqcUcWuXUHnJLczItxHIIWl+dIkbI3iPHMDdA2FVzgltF/XRfhqK+v9eZ6fVGXWtOg1u30eW6RdQuYmmit+SzIvVvYc9683tIdXk8WaTaG88UDQZ7i58lZEuVPk+Umzz5SvmIfM8zG9g2AM1i6kvi6TULW80vS/EEuvR2t9HdzTBjbwSsU2mLeypt2g7fL68Z+bJC7f1/XmNa6HuFFeP2kOuwJoELa34mu7K61YidY9LvbcxQGIgpI0pkmCiTbhi4A3tg4XK9b4Z+32/i6/tZxqk9vtkkE9156xp84CJiTKMdo4aNugJZQzZNW1/rtcHtf+t2js6KKKkAooooAKKKKACiiigDz7xNYXWox+I47CB7iaG60+58qPlnWKRZGA9ThTgU3xXq97rOhanqHhy2120ltNLnjhlXTZoZ2ndoyiRxyR72+5gsFwAeDxkb9g90virXPskMMvzQ7vNmKY+Q4xhWz+la/m6r/wA+dn/4Ft/8bo6W/raxSlZpnlqX2p/bJrcL4ul0d57WW9c216s+xoGD+UxUSAeb5ZZY+R82BjNaOrDVS5t7STxM0q2UZ0K4AmCvMC277UFAUE/JnzwBt6fNmvQfN1X/AJ87P/wLb/43R5uq/wDPnZ/+Bbf/ABunfW5CVl/X9ep5S1zrP/CSS/abjxfIB4jMe5LO7WL7E0IDY2RhNgk4DdQBuB5LHJTUPENxaywyyeNlWHSr9IUFjeofPFxm1O8Rh3Yx45ZjwMN1YH2zzdV/587P/wAC2/8AjdHm6r/z52f/AIFt/wDG6XS39bW/4PqV1v8A1vf/AIHoeXQalrX9oXkPleKZtNmgsZ7xmtrtJQCri48klQVbJhykeDjdtGQaW7OrRXWmQz3fi06O/wBtKLDBdNN5PljyfNdEMofduChmDYAyM16h5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdOWt/wCv6t0+ZKVreX9fj1+RQ8F3d3e+B9Hn1Jbpb02ca3IvIXil80KA+5WAOdwPOOeo4rcql5uq/wDPnZ/+Bbf/ABujzdV/587P/wAC2/8AjdOT5pNglZWLtFUvN1X/AJ87P/wLb/43R5uq/wDPnZ/+Bbf/ABupGXaKpebqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43QBdoql5uq/8+dn/wCBbf8AxujzdV/587P/AMC2/wDjdAHH/EgyN4b8RW9vb3txPc2cEUSWVq9xJuLSHO1FbA4PJGK4/Vz4gK+Ir/RbnxVfb9JWKDUrjSmt7uOYSArDFGIULK2SWYRjGPvenqUEupf27eEWlqX8iHcDdNgDMmOfL579qvebqv8Az52f/gW3/wAboWjuH9fqea67/bNt4o0yTRf+EkaCCWyldpDdyxzRySnzsoAFBAYbhJuKgAKiAZqCwsNU1fxhpP8Aadj4lW5eC+g1S682WKG2dtmxoXLKFXA4MXXvk7seo+bqv/PnZ/8AgW3/AMbqG6j1G8tJbaa0gVJVKsYdQlicA+jqgZT7gg0/+D+ILe/oefJb63/Y0d3djXDHZTx6XfJZ3txLLPBEXEk8aq5bczbMsP3m1SAe1V/EL6zHeaX/AGC3iqSK0W2ljmnW6bzozc4kV0VVywj6+dubbjC53NXpFnDe2FqltaafZxxJnA+2OepySSY8kkkkk8knNT+bqv8Az52f/gW3/wAbovrfzv8A1+fzYf1/X5fceY6dLrL+HVur5/FVzC2tTQ35eK5huhZZcxNHGqq2MmMlo13YJGRjAreGp9c0ZbG3fTvE0CeZqzm2+zMwl3yM8LtIFYBzkgbyOecYIJ9X83Vf+fOz/wDAtv8A43R5uq/8+dn/AOBbf/G6XSy/rQpu7v53/P8Az/I4T4fajfaZJfx66dZ+y3Mtr9ia+t7yUo0keGUvKCR845J2KCeigjM3jOxvIvHVvq9paaxc+Vod5HF/Z00gAmyhVccoGI3EblIJA4JUV2Un9oSlDLp9i5jbcha6Y7T6j91waf5uq/8APnZ/+Bbf/G6bet/62sTHRW/re55Rpb67DbzW2rDxPJof9oqzvAt99pWF7ZSu1mzOVEud23kHqoXIpurPeWnibUbyzTxY8kEOlJBPHYXWbny5XMpfy49sn7t+QeOem4ces+bqv/PnZ/8AgW3/AMbo83Vf+fOz/wDAtv8A43T5tb+n4COG1XS9YTXdQ0/SJtTdLqM6tazyalOBFIqMogwXyFMjI2zG0jcCOAKrO0reEsWI8YGS6urdLxLo3avbvzvZTt80oTjPknZ0wVG4121np91Y3NzcQWFuZrlt0kkuoyyt1JCguh2qCThRhRk4FXPN1X/nzs//AALb/wCN1PS3p/X3afK43e/9f1vr8zyvw1J4purqGC9n8RNd22hv5cd1BcQW7XiSHZukK/MSoUkM7Ag85rOuJNYtb+51DTrHxlGZNOs0luZLaaaQzrclpowCC4Ugt9wbAPukAjPsvm6r/wA+dn/4Ft/8bo83Vf8Anzs//Atv/jdNOzv/AF1/z/BCto1/XT/L8WcDptxrUnxVjuhHrkWnSzXME0dyly0O0IpicAgRIpwcYUtkkM2flr0uqXm6r/z52f8A4Ft/8bo83Vf+fOz/APAtv/jdLol2Dq2XaKpebqv/AD52f/gW3/xujzdV/wCfOz/8C2/+N0DLtFUvN1X/AJ87P/wLb/43R5uq/wDPnZ/+Bbf/ABugC7RVLzdV/wCfOz/8C2/+N0ebqv8Az52f/gW3/wAboAu0VS83Vf8Anzs//Atv/jdHm6r/AM+dn/4Ft/8AG6ALtFUvN1X/AJ87P/wLb/43R5uq/wDPnZ/+Bbf/ABugC7RVLzdV/wCfOz/8C2/+N0ebqv8Az52f/gW3/wAboAu0VS83Vf8Anzs//Atv/jdHm6r/AM+dn/4Ft/8AG6ALtZ+vf8i9f/8AXu//AKCaf5uq/wDPnZ/+Bbf/ABuqmqnUptJuopbeyiR4mVpDdthAR1/1YoA2KKKKAM/RP+Qaf+vif/0c9aFZ+if8g0/9fE//AKOetCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDC0f/AJGrXv8Aeg/9ANbtec+KrGe9k1z7BqN5pt4t7YJBc2tw8ZjLyKhLKpAkGGPysCPaqtv4pVfErXOvveQavoenT/2hp8N7IsMrhoxHKsW4IyuHYqSOM4JynDSv/XlcHornqFFef6t428RWt9baWujWNtqRv7WORTfs8TQSl8FX8rOSY2Ugrx1GetWfGmtT6F4w8OTreTCK4W5hFkZfLhuJig8sMdpx8xAyeBnOKX/Dfhf9RdbHb0Vwc/xA1ey1S6sb/wAMxRvYPZi6kj1IOm24kMYaP92C2COQwTv6Ddcl8a37XCvYaLDcWNxczWNrcNelGe4j3jDp5Z2IWjYBgWPTK0bK4zsKK8/s/iTfX9xFbW+i2f2i4sbe6gjbUJBueSRUeJj5GAULc4ycbcgZ4u6D47u9Z1W0t59CNjb3U93aiR7tXkSW3OGBRRjBw3IY8jp3p2f9eQPRXf8AV9Ts6KKKQBRRRQAUUUUAFFFFAHHeLteufD7XU2nrEbu7exsoGmGUjeWV0DsMjIGc4yM4xVbUJ9f0TxBp2it4hmvE11J4orqe3gE1nMibwyBECsm0NwysQcZJHFbep6LY+ILvU9O1SIyW8tvbn5WKsjB5CrKw5DAgEEdCKy9H8J61pvi1NR1bVR4hiRXitrm8YQzWMZAyqpGmyRmIGXO049elONuv9af5g9tCDwlFr914g1f7Z4q1C9t9K1M2v2e4t7ULNH5CNyY4VbcGkzkEDAxitbW/Gtpouryab/Zup311FZm9cWsA2iEMFYhnZVYjOSqkn2zgF+leDrbTpdZ+1X11qsGszGa5tb9IGiyVCkBVjXIKqq4bIwPUknnr3wUzeObW20bT7rRNBTS5beS40r7NDEWeRWMew5YAgHLKgIJGGHJpb8q8vxt/mLa78/wv/katr8RtIvhePZW2oTQWckcTz+QEV3kCmJU3EFi+9cEDHIJIBBNTUvGF3cNpZsFm0mSPWYrLUrK+gRpQrqWADKzIARg7lLccZBzVu3+HemW9vqtuL2/aDUZYZli3RqLR4gojMRVARtCJjcW+6PU5fceAre7it/tGs6o9xFepfS3RMG+5kRdqhx5W0KF4wir69eabtdW8v0v+v4eYfZa8n+RDP8SdKtLOa8vLDVIbNbRr22uPs4dbyFcbmjCMWGNwOHCnBz0BNTDx/ZfZLuV9M1KOW3mgiS2eOMSTmcDyinz7QGzj5yuCDnFQS/DbT5dHuNMbVdU+yvayWdsnmRH7FC+N6REx9CAFy+8gcAiszX/AV1Dpd39kvdY1z7ebeO7t2ayDeVF0KK8SxsexVztIJ7gClp/Xr+dvkV6ef/ALMvxX0620NdWvdE1i1tfPlhkaZbcCExuI2LHztv3yQFUlztJCkc1JbePPtmvXOnXdhqNgsOsJp9vPGkUiTnyhIQ5y20EHPRTgrg5yBUh+GsWsaLFBq93qVnGlrLZwwKlnHJHBIFJRhFF5asGXgx4GMAlq1Zvh9ayaj9sh1rVbZjfpqDxxNCUeZY1jyQ0Z4IUZA98YqtE/67r9L/eS72dv60/zHS/ELTbcSS3Fhqcdp5Mk9tdiASJeLGMv5YRi+QMnDKuQCRkc1e8PeLLXxHcTwwWd7aPDBDcAXaKvmRSglGXax/usCDggjp0qh/wr2xFnPZrqmpratFLFaw74itgJAQ/lZjz0JA3l9oOBio7HwLc6NfC80zxJqrytDb2rrci2KGGEnAwsAOcMw4IJ3HkYGErdfL9f+ADv0/rb/gm3qOujTda07T30+7mGoF1S5iMXlRsqltrbnDZIU4wp6VzL/F3w9b6raadfR3Npd3PlgwSyQGSJpOY1Mayl2LAg5QMBkZIrqNe0K28Q6etpdyTwhJVlSW3YK6MPQkHGQSp9iaqP4TiTXJtS07U7/TjchftNvamLypyq7VYh0YggAD5SucDOaQznb74sWi+HbrUtN0bU5GXT5b61+0RJEsyxuI26vuG1ipIIBweMnird58RbOOw1fz9N1y0fS7dZL6SO1Rmtd6FgRksrkeq71HU/Lk1AnwnsPscdpP4g1q4to7GexEUjW4Bjmbc+SsIOdwUg5/hHbIN6b4fQXFtrsMuvauV1yFILk5gyiqu35D5XGVyDnPXjHGHpb+u/+QL4lfb/AIYtyeMI0vJbSz0rVdT+zgJNcW0UZRJTGJBG2XXDFSOcbAWGWFYWr/EJ7/wZqF54ehurC7/sM6vaXF5BG6FP7u0OfnHTngZB+bpW9YeDo9O1Jru31nU8TKn2uAtF5d26IEEj4jBViFXOwqDgZFZP/CqtL/sprAaxrIj+wPpsbC4QeXbsclAuzaeOAWUnHfPNJ2/r0f62+Q42Vr+X5q/4X+ZZn+IFlpuq2Wl6jZah51zEClysKFJXERkKogbzH4B5VCuflznitTRvFNvrnhv+3LSxv1smh8+HfCPMnXGfkjUls9sEDPbI5rGf4Z2b3i3Y1zVluUkjmWUG3yJEhMO/mLHKn7v3c8gDnOrYeELSx8C/8Iob29uLIWrWgmkdBMIyCMZRVGQDgHHbnNOVrOwopK1/mZFp8U9JuzFEmm6oLyS+NgLVYo5GEwjEm1nR2jXKnu4xg5xg4o638Qbq50+C58P2l/ax22tQWN6bqzXL5lRHiQFshjv+8FI4PI4NX4PhlZ22pWt7FrmrLJb3cd4UAtgkkiQiEFgIeAUBGFwOSRjjEsvw7glsZrY6/q6rLqo1YuPs+4ShgwUZhxs3AHBGeOuMimrKSb20/T/g/gKV7af1v/wPxJ7Tx3b3cmnqNH1KEXtxPal5vIUW80W7cj/vep2NjbuB9a5fWfiVrNzZat/ZWj3mj/YbS0u1uLyOCVmWWQjbtSVsFlHy8HGGyBwDs3Pgry9JfQA+p6pBf3xvpb65mhjFq3mB3AMYRst82AFI5IJAq9r3gCx12e9lOo6hYG+gggmWzaMArC5ZMB0bn5iPTHbvSXccuqX9a/5ELfEiwW9SxOkax9vku5bRbUW6FjJHEJcF9/ljchBGWHXnGDitL8UNIl0Wa7Nvq9pC+lvqEU62yM7RqwRyi5b5kZhncu3vkrk07/hWaf23/av/AAlWvfaBdteAYtNolaLyiceR/cwMdO/Xmqz/AAjs30+CzHifXkhhsJdOAU2uWgkbc6kmDvgDIwQAMd8mml/60/zGt/67/wCRtS+N7G08UWOgXNpfLLekJBdyLGscj+WZMAbg54HLKhQHjOeKTX/GOn+HtUuBfNqRWy0176WKC13xvGHVdwO3cWHoDgAkt2NQQ/Duyj1mDU31bU5riG4iucyGHDyJCYsnEYOCp5AIAPIC81L4k8Cw+Jr6e4uNb1S0Wewk094LUwBPKcgv9+JmycDnPbjFD8vP8v8AMStpfy/PX8PxGp8QLNzJEulap9tEscUFkY4xLcl4zIpTL7QNqsTvZcbSDjisvUvHV3o+uXN/e217Jo8ejLenT1tkjuIW83azNvcZwOwPTpu4q3/wraA3jXj+I9be7BheG4zbK0DxIUVlAhAOVZgQwIIY8dMWNR+H9rq1xdS6jrGqT/a9NbTpkZoQGQksX4jyHyc8Hb2244o05k+n/Af6i1as/L81+hM/je1WW9t107UDe214LKK1Cx77qRo/NBj+fbt2c5YrjBziua8MfEKT+y0k8TT6hLewx6jcSpb6eBG8UFwY8YAY71GPlVj1JYng1tt8N7Bp5bw6vrH9pSTxXK332hN8cscflhlTZ5QyhIYbMHPsMUo/hNp9uT9i8Qa9bo0V1EyCeKQEXDbpTmSJiCSFPBAyM4yWJOjt/Wn+Zatpf+u5fi+IunSWN3cvp2pQm3jtpUhkiQPOtwdsRT58DLZX5iuCOcDmpbfxGviXwjrFwmmXunfZzNbPHe+VuLoCGx5buMA8defpzWJq/wAPZ7PSbv7BqGsau1zbW1lNau9mpMELZG0NEqM2Cw2udrByGyMCtPSdLudI8A31pOk8MCwP9nt7mK2jkhXbyrC2VYhznG3P19G+W7sRrZX3/r9TsaKKKkZn6J/yDT/18T/+jnrQrE0jV9Ni08rJqFqjefMcNMoODKxB6+hzV7+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAHPPoVj4h13W7TUxcGFJraZRb3ctu29VJU7o2UnB5xnGQD1Ardu/D+lX9xJPe2MU8klq1nI0gzvhYglG9Rkd/f1NZOlanYR+JNalkvbZY5TDsdpVAfCnODnmtr+2tK/6Cdn/AOBC/wCNAXM2PwRoKWAtDaTSxrNHMHmvJpJdyH5P3jOXwMkBc4wSMYJFS634Q0XxHdW9xrFtLO9vHJFGFupY1CyDa4KowByOMkGrv9taV/0E7P8A8CF/xo/trSv+gnZ/+BC/40Ac/L8MvDE7XDTRanI1z5fms2tXhL+Wd0fPm/wk5HpWpa+E9Gs9XbUre1dbkuZPmuJGjEhGDIIyxQORkFwNxycnmrn9taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NFwKNt4N0Czure5ttORJrW4muYX3uSskv+sbk859DwMDAGBVSx+Hvh3Tb+2vLOG+Wa2nkuIi2qXTqskn322tIVO7uCMHJ9a2f7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GgN1Yu0VS/trSv+gnZ/8AgQv+NH9taV/0E7P/AMCF/wAaALtFUv7a0r/oJ2f/AIEL/jR/bWlf9BOz/wDAhf8AGgC7RVL+2tK/6Cdn/wCBC/40f21pX/QTs/8AwIX/ABoAu0VS/trSv+gnZ/8AgQv+NH9taV/0E7P/AMCF/wAaAOZ8Z61qWgQ317o0NvNcs1hABcSlFAknZM5Ct/e9OOvOMGZ/Gl4l4rDR0l037YdPa4ivAZBcg7ceWUA2b/l3bgc87QOamvjoOs3l/a6pdWstpLDbn/j52ZZHdgVZWBBB2nIORxTU0jwdHqj38U9vHO/JVNQZY923b5gjD7A+ON4G73o/r8v+CN7aGbb/ABDv5tAstZl8Ppa2l2z4a4vceUELA72WNkQnA25YKecsuBkvvibHpfiK7stR09FsbeC4lF1Bdea58lFdgyhNi5BOB5hbjlRmrkWgeDINEh0iK6VbKDeET+15SwVyCyl/M3FSRypOD0xg0f8ACO+B/tjXBa0LM8rlG1BjHmRdsgEe/YAw6jGCecZ5o6iXQ5WTx1q+geNNXbWLaaaS7t7FbDS4riS4ijd/POR5UJcZWPLYRzkcEjGO1h8Xj/hBx4hvtLu7J/umyuI2ik8wv5ar84UgMxGCQOCCQOlZaeDPh5HvcJaGdo0jF0+ou06KpyoWYvvTHbawwAB0AradPDU2hPo9xeWtxYyRmORLi981nH+07MWJ9yc+9NtW0Drc4WLx3rHh7XddttTsptQ1Ge/jjtbCKeW4igX7OsjBWigZ9vP/ADyzk8nvXX6n4zl0/wAI6ZrY0O9L389vA1nORBJbNM4QeYG5GGYDABPPpkiivg/4fo0kiC2S6kdJGvV1OQXRZV2g+eJPMHHH3ucnPWm+N7S31rwnBpGiXulPsvLeZxeak0eUjlWQ/Oodix24z15JzkcitovNfd1Dr95NB441C6uJdKg0a3/t+G5kge0e/KwYREkLibytxBWVMDy85ODgDNZ938Sfs9lfasnh+/key0sXTRfbFVW/elHTbu25RkOXxkjoDmtZtC8GyabFZtcRKIpjOs6apItwJCMF/PEgkJI4JLcjg8VXv/CfgTUzJ9qnQLJaraPHDrE0SGEHITYkoXGeTxzk56mjS6/rp/mH9fj/AJFO98da6NWtNPh0i0t5f7ZSxn8y9LBomtzOGBEXB28EY4IwCQdwbpvxSudWgurix8MX8lsIRNaXBhuFilXeE+dzBheG3fu/N+UE9sVoxeGfBEV09x9pWWWSdLhnn1iaUmRFKK3zyH+ElT2I4ORU8Gi+DrZbhbe6jjjnbeYl1SQRxtu3ZjTzNsRzzlAvNGn9fIO39dze0fURq2lQ3qiMCXOPKlEq8MRww69PYjoeau1j6ZcaBo+nx2Wn31rHBHkgNdh2JJJLMzMWYkkkkkkk5NW/7a0r/oJ2f/gQv+NDtfQSLtFUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GkMu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aALtFUv7a0r/oJ2f/gQv+NH9taV/wBBOz/8CF/xoAu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aALtFUv7a0r/oJ2f/gQv+NH9taV/wBBOz/8CF/xoAu0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GgC7RVL+2tK/6Cdn/4EL/jR/bWlf8AQTs//Ahf8aALtZ+vf8i9f/8AXu//AKCaf/bWlf8AQTs//Ahf8ao61q+my6Fexxahau7QOFVZlJJx0AzQBt0UUUAZ2hIselbI1Cqs84VVGAB5r8Vo1zOleKNLg1aHw9LJcDU7h7iaKMWcxRkEr5bzAuwAcA5bgkDqRWtpmt2WsTXkVibgvYzGCfzrWWEBx2BdQGHQ5XI5HPNAbGhRRRQAUVRk1rToteh0V7uMalNA1wltyWManBb2GTjmr1ABRUN3dwWFnNd3kyQW8CGSWVzhUUDJJPoBVfTtYstXtba506R57e7txcwzCFwjxnodxGAeeh59qAL1FFFABRVDTNc03WZb2PS7uO5awuDbXPl5xHKACVz0JGRnH0q/QAUUUUAFFFFABRRRQAUUUUAcHrWv33hq817UtP0631ArcWkbxT3ZgwH+QEERvn5mHGBxnnsdXQ/GSXja1Fr0NrpU2iSKl5Kt4JbYBk3hhKyp0B5BUEH86wvFGial4jXxFpWk21hcNcT2ZmW/naOPy0O8j5Y33Z27cEAYJPbBfL4S8Q6fo9xonh210WPSpJEuYI55mBtX3q7xIPJYFcg7H4KZGF+UULr/AF2/4P8AVh6aHXp4j0OS1guo9Z097e4GYZVukKSjO3KnODyQOO5qax1jTdTluItN1G0vJLV/LnS3nWQwt/dYA/KfY1534f8Ah1rOleKrG9uYNKa3txqCtdi7kkugLmXeuN0XJXkcvzvY/XX8AeBp/Cj5vYo3mhtRZpeLqlzcNPGDkZil+SH12oWGScEDq9P6/r+r+QpabHc0UUUgCiiigAooooAKKKKACiiigAooooA5PxTrt54ah1bVrGwhv2tre3aSGa5MGU3SAkMEfJ5HGB9albxNqkHjKw0S70uxjhuNPe9nuxqDHydhVXUKYhuG51wSy5GSQMYNTxro+peINN1vSNHhspZry1gib7bM0capukJPyo5J4xjHfrWNP8Pr61143fhnw/4X0eGfRZ7GdYehmk2sCYxAFkRWTHzEZDE4GNpFvr5/k7fjYP6/H/I7RfFvhxtIbVV8QaWdOV/La8F7H5Ib+6Xztz7Zqe51/R7No1vNWsbdpSgjEtyily/3MZPOe3rXmx+GOvNNJdyyW8khvluxarrN1CJM2ywupnjRXXBXIwuCDjaB0TUvhjq6jVbfQtK0CG0vdIt9OjEt9NvQxuWyxMLFxghQSckIvToHpf8Art/mHT+u/wDkejt4k0NNOn1B9a09bK3kMU1ybpBHE4OCrNnAIPGDzUkmvaPEsJl1WxQTqrRFrlB5gY4BXnkEnjHWuIh8J+KoPEt5rMVvooJv0u4LRr2UpIPswgZWbyfkIA3BgG6kY71BZfDm/sNWvrhdN0O5hutJuLUiSRlJkllaXyyPKP7obtmck4H3e1J6L+u1/wA9A/r8f0OiuviHotr4jt9Pe7s/sUtrJcPqZvYhDEV2fITngkSI3OBhhjNbj69pEWqQabJqtkl/cJvhtWuEEsq+qpnJHB5A7V58vgXxJBpvh22hsdCk/srQ7jTZVe9kVTJIqrvX9weMJk5wfnI7ZLl8EeJje6TdXv8AZaJpr2cpW3upBu8mMo4IEQMhIOVLdM7QB9407J2/rd/krMTel0un46afM7dPFvhyTUJrCPxBpb3kAZpbdb2MyRhRliy5yMd89KvafqVjq1kl5pV5b3trJnZPbSrIjfRlJBrxjRNDbxTY3lhZX1nK0sJiha01Uu2noswmEMsSQRvCGZdp3SO6ngHqa9Q8HaA2gaZOk1pHaXF1OZ50TUp77c+Au4yzAMSQo4wMe/Wklpr/AF/X9dwe+h0FFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUdbdo9BvnjYqywOVZTgg461erP17/AJF6/wD+vd//AEE0AaFFFFAHBazDqFp4f07xFYWcl7qWj3szy2tmm57iF5WWaNB1PBDAeqCqnja11iPwzp9pYJqyXtytxPLNpzzhUuChYB/Jw5G44UFlTgbs8A9xon/INP8A18T/APo560KTV1b+v66jT1TPLJLrxSxeXTk1ebUbrTi0azRTQx28i23GQ+YjmQng7X3EZDKvE0ytHpWmajpD+MGih1SB7uG6F4ZVRgVlXy2G+Rc4J4ZR1XAzXptFU3d3/re5Nvdt/W1jxi0n1u1vLH7RpPiaS4s7LWIopZIpJZWDSq0AE5DgMVTC7+flHByuYtNfxFHqljYXFx4rWwl1lSdtvesDavajO+WRWkUCU4yWXBLHC4+X2yimnrr/AFrcq+lvX8TivG/22O6023EOsTaS0Eyyf2U0pm+0AL5Icod2w/Pkk7c438VyPhn+3YNFtNInj8Racy+HbaDy2sZWjgmV9rlWjwMlcE4feB0wwwPY6Knpb+uv+f4IO39dV/keWTT6rd2NsuoW/ia2tnt5RYyWLXRlFyJG2GX5Q4UrsKiYbRzvycEwWz+KjbeJJrmXxBc3trdWwRBFLEnkMsf2n7OAqrIQRKFxuIwCOTk+tUU/6/G//AfkL+v6/re54a1p4hibVV0q38Qadot1rAme9ntrue4kh+yoqHZHKl0QHTk5yMruz8wG3pdrr8+qa1a3+s+Jbl7fTLb7JdPYzW8TTbXWR1RdoY4ZGKlyckngqNvq9FF9Lf1tYNf69bmB4LmuZ/D+buG7iKzOkf2tpS7oOFbEwEgBHZ+evJ6nfooobuLYKKKKQwooooAKKKKAObsEum8Va59kmhi+aHd5sJfPyHGMMuP1rX8rVf8An8s//ARv/jlcF4w0Ow1063b38Klvt+nLDOAPNt2aVVLRt1RsE8jms06r/ZPiqa58S6Vb3HiHw7o9w39oNAF+1Q74xFMJMccFwwH3Tv7HlxV/x/BXG1ZXPT/K1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcrgNa8S+KIdQttLOpaWki39kz31vaSeVJDKXOwqZcqR5XJ3fMrDpVvx/qC6N4w8M6khIm8u7iV3LtDHmMYkkQEfIpOWYchc80v87fgn+pN9bfM7TytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyuEvPGPivTdXv7O6OiTRaa2ntJNFDKpuUuZTG2FLnyyMZHLjj/a+W6fFeu3d4j6c+mLbXV/caZFbywO08E0YfEjkSAOp8vJQBSFYHcadv6/r1H5/13/I67ytV/wCfyz/8BG/+OUeVqv8Az+Wf/gI3/wAcrz3TvH+v6jf2tik2lxz3tpEIi1i5VLtZEW5iP7/LbAxbHBwepwc6Phvxjr2p6zYx6pDpkVtdXd9ZtFb+Yzq9uxAYOxAIO05G0djntRb+vQHor+n4nY+Vqv8Az+Wf/gI3/wAco8rVf+fyz/8AARv/AI5V2ikBS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxyrtFAFLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKu0UAUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcq7RQBixR351y6CXNsJBbw72NuxDfNJjA38fmfwq75Wq/8/ln/AOAjf/HK4/4iXdzZ6ffPBNLbwNJYR3s8LFWitmnYStuHKjaTlhjAyay/EKweC/Emny+ArOxgd7C7ur+zibyoJokjDJLIEB+bfgB8ZOSM+hdJXfn+CuO2tkeieVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OV5jrWreJNSeGLVtUsYLC/8M3V9Ja2kMsTK22LAEvm5LBm4baOMjbzkXdH8X6xp9na6NcNpqSva6clncmJ9kHno4/ejeN+DFgYKbi6jjrVcr/r1a/NEcy0fz/J/qeg+Vqv/AD+Wf/gI3/xyjytV/wCfyz/8BG/+OVxsvjPXLa1zdJp6/Yp7iK+u44neJhHtw6oH3onz/M37zaVIPXIy28X+JLG21cx6jpt1eNq9xDawPZSMyxRRlsKolAOdo5ZkUfMSWJAqbq1/K/5f5ldbedvz/wAj0bytV/5/LP8A8BG/+OUeVqv/AD+Wf/gI3/xyvLZfGmuXtprWpzDS7qwOgWN2ul3cLbP328vzuIbADZG35vlGVwSe203XNV1PxJeJbyaZHpmn3f2Oe3kDi4z5YZZAwbaMlgAhXkc7u1U4tPle5Kknqv60ubnlar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOV55qeo6h4f+I/iK+0trdoSmki6ju2kkLLJLJERH8wEZwQehGR93kmtC/8UeJ7S91LS4ZtHl1Wyka6WKS0lRJLERlg2RKxDF/k3YxkH5TUuyV2XZt2R2flar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOVwNv8QtZSGx+3HSmbVrK1ubaeGNxFZtM6piXLncMtlSCmcFeOtJfeKfEi65pNnNeWMJttXmtb2SG2fy7tEtTMNoMmU4O3aS2GAOSBgvlavfpf8NH93/DEpp7f1pdfed/5Wq/8/ln/AOAjf/HKPK1X/n8s/wDwEb/45Xmlr8SfGM+gRaw+gWUVnevbG1luJUQBZZljK7UlkZyN6ncRH3yoIAOu/jTXbaKb7V/Zu2xu7mK8uY4HKBI9mxvL8wugw43ON4G3oNwILO9v66f5jen9f12O08rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxyuOg8T37X93YWkGk6bqF3rctmlyY2libZAsis4BQySMoAxlcY6nbzmXfxC8T+W4tbTSIWg0q9vXll8yRZJLaby2CqCuEYcg7iefbktt9/4X/IFq7Lvb8bfmeieVqv8Az+Wf/gI3/wAco8rVf+fyz/8AARv/AI5Vi0m+02cM+APNjV8A9MjNS0NWdhJ3V0UvK1X/AJ/LP/wEb/45R5Wq/wDP5Z/+Ajf/AByrtFIZS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxyrtFAFLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKu0UAUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcq7RQBS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxyrtFAFLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKu0UAUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcq7RQBS8rVf+fyz/8AARv/AI5VXUo7tdKujf3ML23kv5qw25VyuD0JcjP1Fa9Z+vf8i9f/APXu/wD6CaANCiiigDmNL8VaNb2RjmvNredK2PKc8NIxHb0Iq5/wmOhf8/3/AJBf/wCJq1oSLHpWyNQqrPOFVRgAea/FaNAGJ/wmOhf8/wB/5Bf/AOJo/wCEx0L/AJ/v/IL/APxNbdFAGJ/wmOhf8/3/AJBf/wCJo/4THQv+f7/yC/8A8TW3RQBif8JjoX/P9/5Bf/4mj/hMdC/5/v8AyC//AMTW3RQBif8ACY6F/wA/3/kF/wD4mj/hMdC/5/v/ACC//wATW3RQBif8JjoX/P8Af+QX/wDiaP8AhMdC/wCf7/yC/wD8TW3RQBif8JjoX/P9/wCQX/8AiaP+Ex0L/n+/8gv/APE1t0UAYn/CY6F/z/f+QX/+Jo/4THQv+f7/AMgv/wDE1t0UAYn/AAmOhf8AP9/5Bf8A+Jo/4THQv+f7/wAgv/8AE1t0UAYn/CY6F/z/AH/kF/8A4mj/AITHQv8An+/8gv8A/E1t0UAcFLP4Y1LV9UHiO1tb2zmeCWCO9s/NUkIRuCspwcN1x0NbjeJvDLuHeeJmEZiDG2YkIcZX7vQ4HHsKzrnXoPD2sa3czRSTyTXFrb29vFjdNK4IVRngc9SegBNbFjq2qJJt8RaXbacggeZ7iC9M0KBSPlZmRMHBJ5GOOCecH9f18gMuC88C2unCwtrTT4bISiYW0en7YxIDkPtCY3AgHPXIp+oaj4J1a5iuNVt7G9nhVkjlubAyMisMMAWQkAjqO9a6+J9AfTY9QTXNNayk3bLkXcZjfaCWw2cHABJ9MGnJ4k0OXzfK1nT38mFZ5dt0h2RN91zzwp7E8GgDlTp/wvIcHQNCxIcv/wASdPmPv+75rTh1XwZbam+pW8VnFfOgje6SyKysg6KXCZI46ZrWi8TaFPNHDDrWnSSyTtboiXaFmlXlowM8sO69RUg17SG1C4sF1WyN5ap5k9uLhPMhX+8y5yo9zQBjx6z4PhkjkiW0R4pHmjZbMgo753sDt4ZsnJ6nPNULaP4c2V3FdWekaPb3EMhkimi0oK6OerBgmQeOorqrDV9N1UyjS9Qtb0wkCUW86yeWSMgNtJxkc89quUbBuYn/AAmOhf8AP9/5Bf8A+Jo/4THQv+f7/wAgv/8AE1t0UAYn/CY6F/z/AH/kF/8A4mj/AITHQv8An+/8gv8A/E1t0UAYn/CY6F/z/f8AkF//AImj/hMdC/5/v/IL/wDxNbdFAGJ/wmOhf8/3/kF//iaP+Ex0L/n+/wDIL/8AxNbdFAHML4l0YardTT3P7i4t4lQtC+Hw0gbjb05xVW2m8A2dhc2Npp+mQWl3/wAfNvFpu2Ob/fUJhvxq3r+parpMuqX2h6TFq08NtC7Wsl0YCyjzSdpCPlvYgZ9exNN8U3er3Gny2FnYTaZNZJdXd8t+2LcsCQqgxAP06kqQAcgcAm/9f12HqitLdeBJ7OG0mstOktreJoYYX07KRxt95FXZgKcDIHBxVeKL4cW6zCDR9HiFxF5EwTSlHmR8fI2E5XgcHjgVvweL/DVzHDJbeIdKmS4dkhaO9jYSMoywUhuSByQOlLD4t8OXEcckHiDS5UljaWNkvYyHRW2swIPIDcE9jxQIyXvvA8lnbWklrYPbWhBtoWsMpCQcjYuzC4PTFE994HupGe6tdPmd5hcM0mn7i0oXaJCSn3gOM9ccVtrrljdQxTaZf6fdxvc/Zy4u127gfmVSAcuP7vH1FOg8QaNc3T21tq1jNPHGZXijuUZlQEqWIByACCCfUYo/r9QOdmf4fXFqLa403S5YBEsIifTAyiNTuVMFMbQeQOgNTRX/AIIg1GK/gtrCO9hiEMVylhiRIwMBAwTIUDsOK2dJ8S6FrzypoWtafqTQgGVbO6SYx56Z2k46HrU+oatY6Yn+mXVvFIVJSOWZI2k5xgbiO5A+pFDdtQ3OWvl+HWp3c11qWlaRd3E5BmmuNLEjyEDA3Epk4HrUUuo6dNa6mZNctReXdsbW3kTTZBHbxfNtGzdlj83J3AHAwFrU0LxvYa74dN9HLZ2l6tu08lhcXqBoFDMoMhGdqkr97BHpmtZte0qG7hs7nU7GK8mZUS3Nyu9mIyFUEgkkAkccgUON1ygn1OS8ODwfofhWPR5zp1zvgWK9kj0sxLeFV27nTDZJAGck1qRar4MhtLW1hiso7ezcSW0KWJCQMM4ZBswp5PI9atyeMNItNQsrDUNQsIrrULiWG1jjulffsJ6k4weACozhjjnrVyDXbArapd3+nxXF3u8iKO7VxKAcfISAW7ZwOCcU223cSSj7vY5yZfh1cLOtxpOkSi5lE04fSw3muM4Zsp8zcnk88miJfh1Bu8nSdIj3SiY7NLAzIDkP9z7wPfrXa0UthnGFvh6be7tzpulGG9kEt1H/AGYNs7g5DONmGOSTk5ovD8PdRkSTUNM0q6dIRArT6YHKxjogJThfbpXZ0UAc9aeJvDNhaRWtjNFbW8KhIoYbZkRFHQBQuAPYVN/wmOhf8/3/AJBf/wCJrbooAxP+Ex0L/n+/8gv/APE0f8JjoX/P9/5Bf/4mtuigDE/4THQv+f7/AMgv/wDE0f8ACY6F/wA/3/kF/wD4mtuigDE/4THQv+f7/wAgv/8AE0f8JjoX/P8Af+QX/wDia26KAMT/AITHQv8An+/8gv8A/E0f8JjoX/P9/wCQX/8Aia26KAMT/hMdC/5/v/IL/wDxNH/CY6F/z/f+QX/+JrbooAxP+Ex0L/n+/wDIL/8AxNH/AAmOhf8AP9/5Bf8A+JrbooAxP+Ex0L/n+/8AIL//ABNH/CY6F/z/AH/kF/8A4mtuigDE/wCEx0L/AJ/v/IL/APxNVtR8SaVqOl3VpY3DT3E0LrHGkDksdp/2a6SqOtu0eg3zxsVZYHKspwQcdaAL1FFFAGfon/INP/XxP/6OetCvEfFWixz+JNLmk8N6Xr18dL1I3QuEG5glxGPMX5CXZdzbV+XqcEVvP4l17QtL8O6B4QQeJ7k6WLk3kpj/ANLVNq4BeePbnPLZkK8ZU00rpPv/AMH/AC/qwPR/15f5nqFFeb674/13SbHU7pbXTgYYnltYZy21kRkDN5yM6uRuOVwhBGOR81TXvijVUvn03UrTSNREGr2MTTiNljWOZsrhCW/eowXncOobA6UJXa8/+GJckk7/ANWPQqK83Xxr4luNBe7H9j2t1Jqc+nwW6wy3BcxNJuI+dNxIjPBKADLFv4azLH4ia3Ndwapcz2UNrc6PYSraNCwWOa4mZC5ff91dpY8fdGMjkkSb2/q6ujRxav5f52PW6K89m8X+J7XVrXRmj0ee5k1X+z5b5FkSPDW5mVlh3McgAgqZPTn5uLsWu+Ik8Tv4fu7zSzfGeOaEpp8gV7LaS7YMx+YMNmc4BK8HdwJXJem/9b/5Ha0V5L8TrzU55vFmnS6hGmm2+gR3MNuoeNzKXkx86uM/6vkbSCOMdc7cXi3XBqk2gyS6VDftqAtbe7aCQwqpthOA0fmAs/JXhlzjOBjFFtL/ANb2G9Hb+tk/1O/orzrTfHWv3+pSQXEOkWVtaWEt1cXDtI4cxTtE2AMbUbYSGyxAPQ9Kq6X8QfEF3MdMul06C+nvYba3vXtHjgVZLdpgTEZSzHKFQCyE5BwOhS12/rWxOzs/60uen0VwGseK9Q0LUnm1Sw0maa00Oa5NzA7ZEiyorrkjKR/dJ6njn7vPUaVc6nFptxJr11plxJEPMSeyV442i25DMrMxXnPRmBAzx0A9I839b2/Qa1dv62v+pr0V5Pa/ErxPJvia00uaQ3WnKkxilgQw3bFcqpZmbBHBbyyRztHAMmqeL9U1XQb7Rry50u0uVt9RN1dYljjkjt5PLxGBIGRiCCW3tt9GzwSTim/X8Fd/cNav7vx2+89UorB8C3EVz8PtAlt5UmjOnQAOjBgSEAPI9wRW9VSjyycexEJc0VLuFFFFSUcLqvh6TxDrGqLa3C217Y3tne2sjqWQSIrYDAdVIJB+uav6npXiXxBoUkOof2bp9zHJFLDBbzvcQyvHIsg8x2jQhTt24C8Ak5PAE9hBJP4q1zyrua22tDnygh3fIeu5T+la/wBguP8AoLXn/fEP/wAboWm3r8/6QdbnA3XgfXZvFen+I00zQDeR3sl3cQm6kATNv5IVJPIJYk4dmKr91Rg4zWDe/C7xXdeGrTSvsHhtxDo82nOZL6XaHeZZBKB9n6rsB7HJ6jHPrn2C4/6C15/3xD/8bo+wXH/QWvP++If/AI3TTa26f8N+oHnl34L8Vz3t/cw6foETXOpWF4gGoS/KtsFypP2fvsGPTcfTmbUvAGs6jpMmmXEOj3ENq93LZzyyuHuDOsg2TL5ZCgGTJYFtxReF7d79guP+gtef98Q//G6PsFx/0Frz/viH/wCN0nrHl/rZL9AWjujl/BnhzXNF1uWfU7TSoLVtLtLNfsV28jb4A3JUxIMHee/G0evHa1S+wXH/AEFrz/viH/43R9guP+gtef8AfEP/AMbqpScndiSSVkXaKpfYLj/oLXn/AHxD/wDG6PsFx/0Frz/viH/43UjLtFUvsFx/0Frz/viH/wCN0fYLj/oLXn/fEP8A8boAu0VS+wXH/QWvP++If/jdH2C4/wCgtef98Q//ABugC7RVL7Bcf9Ba8/74h/8AjdH2C4/6C15/3xD/APG6AGQ5/t+/2gE/ZoMAnHeSuW8P+Fta0/wd4h0ye00azudRuLqe2EEjXEIM2SBIrRLkDIHQgjt2regspzrt4o1O6BEEJLhYsnmTj7mOP61e+wXH/QWvP++If/jdLuO+3rc4Sx8CeILSx1GVJrGLUpdRttQtHe5knWN0jSORWJRTgqHAwAMMBgYqK++G+qP4T1XR4jp2oiS4Q6d9vmf93H5vmuXbYxDl2YDAPAXntXoH2C4/6C15/wB8Q/8Axuj7Bcf9Ba8/74h/+N1V/wCvu/yFurM4B/B/iiTWHvG0nw8R/bi6nHnUJconkCJkH+j9SFz6c47ZrGfwVrfh/wANAX2maBHYWlnqccy291M3y3T7lARYF+VcKp5HHPGK9Y+wXH/QWvP++If/AI3R9guP+gtef98Q/wDxuld2sv60t+Q07Sv/AF1f6nCeAry7ghmltFstba9uYftGo2mrC6RlC7PvR20aBkVR8uBkdWzgHd1bw7f3PxI0nxDaWWmSQ2VjcW8ks0zJOWfBXGI2G0bSPvD/AFjcdjvfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdN6u/wDW1hLRWPKbj4b+LZ/D8emtpvhp/wDiV3djIz6hLjfNKsgkx9m52lAcep6jHOhceCPFTX2oXdvpPhuOW8vNPuzjUJRzbkFskW3JYrjPoc+1ejfYLj/oLXn/AHxD/wDG6PsFx/0Frz/viH/43Rdq3l/nf8weqs/60scJongnX9Oh0zzbPRIvsV7fyfZIrmRoTDcbmCgmFeQW2424xz/s07SPBfiCx0rRbfytKtZ7FY4ZXt7uR08pJS+PLaLa/GAAQpUkkN2rufsFx/0Frz/viH/43R9guP8AoLXn/fEP/wAbovrcHrfzLtFUvsFx/wBBa8/74h/+N0fYLj/oLXn/AHxD/wDG6QF2iqX2C4/6C15/3xD/APG6PsFx/wBBa8/74h/+N0AXaKpfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdAF2iqX2C4/6C15/3xD/APG6PsFx/wBBa8/74h/+N0AXaKpfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdAF2iqX2C4/6C15/3xD/APG6PsFx/wBBa8/74h/+N0AXaKpfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdAF2iqX2C4/6C15/3xD/APG6PsFx/wBBa8/74h/+N0AXaKpfYLj/AKC15/3xD/8AG6PsFx/0Frz/AL4h/wDjdAF2iqX2C4/6C15/3xD/APG6PsFx/wBBa8/74h/+N0AXaz9e/wCRev8A/r3f/wBBNP8AsFx/0Frz/viH/wCN1U1WydNJumudTvZIRExkQLDllxyPuDtQBsUUUUAc/pPh/Rp7hNYm0ixk1OKecR3r2yGZB5rjAfG4cE9+9Tt4O8MNHsbw5pJQzm5Kmxix5x/5afd+/wD7XWvMfEvjy70eXVY7HxTZ6fHb6VPqNrbmKLzJJvtDbVYyZyGHG0AHng55qXUPiHqcf9q2mleIrK+2XNoxvWmhjWygmiLM25Y3CoHCgMyPjeNxPWhbXX9a2/MHvZ/1pf8AU7fxl4U03UfDeqiB9M0W4u4RHc6pNZqxWINuIY7kJHXq2BnODVu38M+FrvTk0yTSNDu0s5BK8EdnEY45mUHeI+djEHPrg9TXlfjLxBqOp+BL7SvEusWRZ9Ha4tGsES4h1eTe4ARmjG4oqxsfLVSCdw+UYrU/4WFPd2epWlr4migmj1aK1tXghijeKNrcOsb+aGEZ3hlLMjEspUKD0q1k/wCuth8t9f62PSYvCXhyCz+yQeH9LjtvPFz5KWUYTzR0k2gY3f7XWlGjeHraWKzGnaZFJJbvDFAII1LQ5BdFXHKZIJA45Ga4DQ/GmqapD4fe71pVk1OyiQw2ghMnnlSZHMbJkgELyhIXJ3J0NYeleO7zRfDek20ni6zWaTw9dXTjUI4zIl0hUgHBXcOZFC9co2SxBAUla9+l/wAE/wBEOKbZ62PCnh0Q2cI0HSxFYP5logs49ts2c7oxj5DkA5GOlNtbcR+JJZtR1C1nvnhYWtvFGImjt9wJ4LMzHJUFuBwvA7+YQ/Ead0lsj41hmnuLfTpY5oFtQ0DyhvNQEjYi5VPmdXKlwMEsoq54K8QQaz488OXeo3dlJrdx4fuY7ooyCSRkuEABAAJ+65AwP4sAc1XK+a3r+Tf6WMuZcv3fmv8AO56Lrek+Hb1PM8R2GmXCyBbfffwxsGywKplxzlsYHrjvVW28J+Dp7W6js9A0OSCd/LukisoSsjRnG1wBglTng9DXnvxG1tbnWpLTU7x4X0rWdPks9NW0WVp4t8TNcjCmQ4JdMoQBjaQSwqe1+IN5c+H7fUG8TWcwhvbyCdrIRBpisu2EIjAhvlIIjDq7ZUgtyCoxvG6/rb/M1krf16/5HpS+HdES+F4mj2C3Qg+zicWqB/Kxjy92M7cfw9Krnwn4Zi0+a2bQNJSzkRVliNnGI2VeVDDGCB2z0rjW8W6k+sSbNejtruO5uYbrR7iCMpZ26LIY7o8CQDCoxZn2HdtGDWRF4tutW8E6HLrviJBZ67YTPc3aWsDxGZQoFoFKsPny+VOWJUhdp4qHflb/AK6v+v8AMFH3rf1/X9bHpVpoHhq4e21Ox0nSpWFuIre7htoyfJIwFVwPuYJ4Bxg1b07RtM0eyNnpGnWlhakkmC1gWJCT1O1QBzXivgzxb4jFnoGm2uo6do1ra2NrGlvqshga7j8sea6RNCXkKkMAVkQfLkgg5rbsvGWqyeBdM8QXHiuCbzzMZxbpBGpKMVVYwykMSWXKF1ZuNpHIOko2bX9bkLojvm8C+EnRFfwtorLHjYDp8RC4JIx8vGCx/M+tSR+DPC8UKwxeG9ISJZvPVFsYgokxjfjb97HGeta8T+ZCj8/MoPzDB6enan1ILXUbFFHBCkUKLHGgCqiDAUegHanUUUhhRRRQB5X8RdPtb/R/Ev2qxtb14rvT2gS6UFQ5kVepB25DEEgHgng9Kd4dlk8L6H4kubVdP0e7a/ihTRQjvbWDnai7FQAv5m4ONoQMSB8vzEdBNp2i6p4h1m38Q6TDqkAkgdIp7H7UqsEIzjawBwev1q9d6V4U1CVZL/w5b3Miwi3VptFZyIh0TJj+77dKFpfz/wCB/l/XV32OX0Px94l1a906zktNOhaZL43EpRy261mCELEHIG4Ef8tGwSeuPm1fAHi3xD4oxdavo6WenXdsLmznVogevMZCzSM2AR8xWPngqDWnBpXhS11KPUbbw5bw3sRJjuY9FZZEznOGEeRnJz9TVmxj0LS7m4uNN0j7HPdNvuJbfSnjaZvViEyx5709P6/r0+7zFLXY26Kpf2tb/wDPO8/8Apv/AImj+1rf/nnef+AU3/xNIC7RVL+1rf8A553n/gFN/wDE0f2tb/8APO8/8Apv/iaALtFUv7Wt/wDnnef+AU3/AMTR/a1v/wA87z/wCm/+JoAu0VS/ta3/AOed5/4BTf8AxNH9rW//ADzvP/AKb/4mgC7RVL+1rf8A553n/gFN/wDE0f2tb/8APO8/8Apv/iaALtFUv7Wt/wDnnef+AU3/AMTR/a1v/wA87z/wCm/+JoA474i3lzY6dfPbzSW8DyWEV7PExVorZp2Erbhyvyk5YdASatajB4c8E2Tapodla2k8cBKxWw2ROsjoplkCjBAO0lzzgHmtePULZ9avvMhuXjkt4VKmzlOeZM5G3pz36803T7Tw5pNrPbaXoaWUFwSZorbSHjWUkYO4LGAePWhaL+vuH2Ofm8VeI7DVbfT7uXSZ2XU7e1muYbWRUljnRiu1TKdjqV5BLAgg8ZrHk+Ivie60SD+xF0u+1PdeRP8AZbGa6SSWGby0jKRyZhDKQ3mOxUZ56g12q6d4YTRxpKeH4V00PvFkNHYQ7s5zs8vbnPOcdaw9f8LabrGpWs8dnp7WsKFTZ6j4Ze6RSzbmeP7ux27k7gcDjrlq19e/6f5i/r8X/XyMnRdR1jQ/F2sDzbSaG4161trxZBIWLy20ZYxZkPlgOchTuGCQMYpbbxt4h4tdP0/QrCSWPVJ5HAkkUS20+05UbM7sglsgkknAxg9HD4V8ExRIsnha1uJF2s082hl5JHUYDsxj5brz70L4T8BIxZPBmmqzAgkeH8EgjBH+q7ih7W/ra356lJq+vl+t/vuZOo+MvFV1qWnW3h21tB9qt7SZvM0+a6XEx/eFpEkRYtigkBz8/Y5r0YdOetec3vgnR7nWhPFZWCWAjWOKCTwwzTWiqDgW8wAEQyd3KNgkkdsdwNWtgAPLvP8AwCm/+JptprTuzNJq1+xeoql/a1v/AM87z/wCm/8AiaP7Wt/+ed5/4BTf/E1JRdoql/a1v/zzvP8AwCm/+Jo/ta3/AOed5/4BTf8AxNAF2iqX9rW//PO8/wDAKb/4mj+1rf8A553n/gFN/wDE0AXaKpf2tb/887z/AMApv/iaP7Wt/wDnnef+AU3/AMTQBdoql/a1v/zzvP8AwCm/+Jo/ta3/AOed5/4BTf8AxNAF2iqX9rW//PO8/wDAKb/4mj+1rf8A553n/gFN/wDE0AXaKpf2tb/887z/AMApv/iaP7Wt/wDnnef+AU3/AMTQBdoql/a1v/zzvP8AwCm/+Jo/ta3/AOed5/4BTf8AxNAF2iqX9rW//PO8/wDAKb/4mj+1rf8A553n/gFN/wDE0AXaKpf2tb/887z/AMApv/iaP7Wt/wDnnef+AU3/AMTQBdoql/a1v/zzvP8AwCm/+Jo/ta3/AOed5/4BTf8AxNAF2iqX9rW//PO8/wDAKb/4mj+1rf8A553n/gFN/wDE0AXaz9e/5F6//wCvd/8A0E0/+1rf/nnef+AU3/xNUtX1CK40W8hhhu2kkhZVBs5RkkcclaANqiiigDP0T/kGn/r4n/8ARz1oVn6J/wAg0/8AXxP/AOjnrQoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4DX9S1zR7zXb7w4tnNcpc2aG2uomIn3kIFVw67DlvvEMParlj4xl1TU7K8t72yttEaynmvYbm2YXFvLCyq6M/mBVwX5BQ/dPJ3Aht9pN/rOra1baXf29jIl1ZzmS4tWnUiM7wu0SJjLKOc9M+uRPqXw7sNQ1rUtSjuZrWTVLFrW5WH7pkJQiYA5AbCKDwcgLnpy1pv5/lp+I3a2n9ajrz4j6HbQwvCL6eSW9is2gGn3Cyxs/IZoym8DAJBxhscVY17xLPoniXSraWOAaZdQ3MtxMd7SoYk3AKgHP6nsBVGfwPf30sd/qOtQyauk9tJ9phsfLi2QFyF8syE5PmPlt3XHGBgyeMfBd34p1TSbu31eOwGmeY8YNqZH81gNrhhIoG0gHBBB6Hg0v8/wsv1uT18v+CTJ8R/C73X2b+0JUuFkijkhksp0eBpTiMSKUBj3Hpvx1HqM2rnxroVpfyWc11N50Yf7lpM6uyAl0R1Qq7gA5RSW4PFc5f+AfEmo3uo3U3ifTFlvxaBtujPhBbyGROPtPcnn9MVrWPg24tdQiE+qJPplveyX8Nr9l2yLM+4sDLvOU3SMQu0HkAsQMU9P6/r+vIZOvj7w+6F457x1FtDdjbptyd0UpARl/d/NksBgZI5yBg4l0vxx4d1u/is9K1EXUs3meUyRP5bmMgOBJt2kjI4znHPSsbTPhsmm6tYXw1RpDaPIhT7OAJLfeHhg68CNlBB7/ADdM03RvAut6Xqtjcy+ILGeG1v7q8aJdLdGk+0Ell3eecY3HBwe3Hqaf1+H/AAQe2n9d/wAfzO6ooopAFFFFABRRRQAUUUUAcd401jUPD+ma7q+ky2cc9naQSk3kLSRld0mQQroR165/CotJ8cWcFrLea34u8O6nZNNFbQz6VC6Dz3z+7/1soYkYPBBHOR3q34o0K68SwaxpFlfQ2DXVtbq80tsZwF3SEgKHTnjrn8K5/wAc6f4kh8OB768i1GeTULIxro+gzZTy50dpHUSSswVVPdR25JFOO9u7QbnUJ410W7ksVtdVhge4uZIPIuraRJmMaFnTY21o2Aw2WGMdvmBqK7+IGj27aaIlvZ/7Ru1tYwljOCpKswYjZnGFJBxyOenNZsvgHU5Lu1vk1y0W9/tFtRvJG0wlZnMHkBUTzf3aiPPUuScE9wXwfD64gNqY9Xjh+x6gl3bRQWZWGJRE0ZRYzIQpKuTlcLkA7OoJp+X/AAQdunZ/rb9C/N8R/DEFvezyXtx5Viu+d10+4YBNxTeuI/nQMpBZcqMcmrA8YaTcyW8dpqCwPNffY0FzZyr57rkske4Lu4B+cblGO9c/a/DjVLS+uLyPxFbyXV1bG0uJ5tOZ5JojLv8AmbzsltpK56DOQB0qW28B61ZW1jZWviGyXT9O1IXdlbvpjsYIQCBAG8/kAMcMR+GOKS2V/wCtf8tf61T62/rT/P8Art1ema7p+sNKNPleTyuTvheMEEkBlLAblJBwwyDjg1oVz/h3w1NoV9eTPfRyQ3AUJb29uYI1IJLOV3ld7FjkqFB44zzXQUD6hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWfr3/IvX/8A17v/AOgmtCs/Xv8AkXr/AP693/8AQTQBoUUUUAYOjafcPpuW1W6VvOmDeWsYUkSsCcFTjPXr3q9/Zs//AEF778ov/iKNE/5Bp/6+J/8A0c9aFAGf/Zs//QXvvyi/+Io/s2f/AKC99+UX/wARWhRQBn/2bP8A9Be+/KL/AOIo/s2f/oL335Rf/EVoUUAZ/wDZs/8A0F778ov/AIij+zZ/+gvfflF/8RWhRQBn/wBmz/8AQXvvyi/+Io/s2f8A6C99+UX/AMRWhRQBn/2bP/0F778ov/iKP7Nn/wCgvfflF/8AEVoUUAZ/9mz/APQXvvyi/wDiKP7Nn/6C99+UX/xFaFFAGf8A2bP/ANBe+/KL/wCIo/s2f/oL335Rf/EVoUUAZ/8AZs//AEF778ov/iKP7Nn/AOgvfflF/wDEVoUUAZ/9mz/9Be+/KL/4ij+zZ/8AoL335Rf/ABFaFFAHFSahp2j67q8us+Io9Ii3wRie4uIYhK2w8EuMZ4JwMd612ubFdSt9PbxURe3Ufm29sZ7fzJkwTuVduWHB5HpWXfaKniGXxXpjkK0yQ+U5GfLkCko/4MAfwrKi8UajqvgrUPFdhYE6pp1m1okDxt+7uFI+0Y4yVDKBwDnYeDRfe/T+vzHba39f1+h2/wDZs/8A0F778ov/AIij+zZ/+gvfflF/8RXluneL/EE2o+H9PufGujSQatezQrcWMsV1M8fkEgeYYo496yADAi/iQHPRuq0WXXR4ql0G+1rUrh7CY3kl1Jb26rcWzqBFGSsQAO4Pnbhv3ZOQCAK5WTdHUf2bP/0F778ov/iKP7Nn/wCgvfflF/8AEVzF5r9x/wAJ9Np0+vrpTW7RGz014oyNTjZcuQWG8sGyvyMNuMsCDXHav4/1uz8L3mqWPie3+1DT3mvrW5tYiNJuVZAsIA2kFizKBIWJIDDIBFStf6/r+tyra2PWP7Nn/wCgvfflF/8AEUf2bP8A9Be+/KL/AOIryq5+I8ljqF63/Cc2M9tZ6xZQrv8As22SGcL5gYgD5Uy5BBBG07mbBqtpnxGvb1bH7V4+sUa7h1ITGBLZBF5Eh8qRAwbbuUfxFgVHAz81HS/9bXEtWkevf2bP/wBBe+/KL/4ij+zZ/wDoL335Rf8AxFeZxfEDUNU0OyvINeitL99Kt7qytIoomTV7gg+bENwJJDLt2xlWUnJ4p2i/EC5l8W2Vvf8Ai3T5xPrl1pzWMawopjWImMjkvuDhVzuwd2Mciq5Xzcvr+Gn6k83u839bXPSv7Nn/AOgvfflF/wDEUf2bP/0F778ov/iK0KKkoz/7Nn/6C99+UX/xFH9mz/8AQXvvyi/+IrQooAz/AOzZ/wDoL335Rf8AxFH9mz/9Be+/KL/4itCigDl9Qu7HRdQuZ9Z8RDS4FhhT7TdTwxCRi0pAJdcZ4OAMVY0m907Xonk0Pxb/AGlHGdrvZ3FvMFPoSqnFc98T7+zsPCviNr+6gtlls7eOMzSBd7l5CFGep4Jx7Vi+LfENjf8AiC217wRqdm8uk6fdyahq0O2a2RPK/dxSOCFdi+0hd2RjPflXsm3/AFpcNW7I9L/s2f8A6C99+UX/AMRR/Zs//QXvvyi/+IriH1fWrPw9oPiX/hIL3VLS9hRLm3tbe3MZlljxGyYjLY80hcbsZYEnAIN3xbrOoeFtI8NwXHiWG3mutQitbu7vIot8ysDuK/dRceu09qpqzs+9vn/X5kqV1zLtc6r+zZ/+gvfflF/8RR/Zs/8A0F778ov/AIivJdP+JeorDZyweJbXWrmY6nbR2YEH+kPAW8h/kAJdwF+6QrBhhQea0b7xZqcOl3V/pHi5tS021lsp5b7yLfEW+fZPA5EYUKEO7oHT+JqLa2/r+v63K8j0ltOmVSzaxegAZJPlcf8AjlMgtDdQJPba5dTROMpJG0LKw9QQnNeXTa62peIrRdX8R3UmlQalfwu09tEkFxF5IZFJMW112lxlf4cnPen/AAu8Y2FjY6Pp934qsHsv7ASc28ksKLaOj7SNwwenUMTyvGOlKOq+78m/0B6Jvzt+Nj1H+zZ/+gvfflF/8RR/Zs//AEF778ov/iK5rx74km0TUPDcMOvWmk2+pXzQXEkqxlmj8tmDIznaMEKOQeWX6Hhf+Fm6hPZ6PNY+KIrmWEwC8VUt1juUa7MLuTtJY7cEhNgXIJJyFpx1dvOw3p91/wBD1/8As2f/AKC99+UX/wARR/Zs/wD0F778ov8A4ivNX8Z6pY6wtpJ4jlnlt9YvLOaFrNJMQmBngeRYo9ygMFwwxkZznGRW1Hxzr6adawWet2sK/aZIbrWby6gjt45FRCsYnWB0ILFxzGh+Ur8pGSt0n3t+IutvX8D1P+zZ/wDoL335Rf8AxFH9mz/9Be+/KL/4ivOIfGutL480eyudZgZXuIbTULONY0hDPbNJvj3L5rAuOHJRf4QpOTXq9NqwGf8A2bP/ANBe+/KL/wCIo/s2f/oL335Rf/EVoUUgM/8As2f/AKC99+UX/wARR/Zs/wD0F778ov8A4itCigDP/s2f/oL335Rf/EUf2bP/ANBe+/KL/wCIrQooAz/7Nn/6C99+UX/xFH9mz/8AQXvvyi/+IrQooAz/AOzZ/wDoL335Rf8AxFH9mz/9Be+/KL/4itCigDP/ALNn/wCgvfflF/8AEUf2bP8A9Be+/KL/AOIrQooAz/7Nn/6C99+UX/xFH9mz/wDQXvvyi/8AiK0KKAM/+zZ/+gvfflF/8RR/Zs//AEF778ov/iK0KKAM/wDs2f8A6C99+UX/AMRR/Zs//QXvvyi/+IrQooAz/wCzZ/8AoL335Rf/ABFV9Rs2ttLupri9uruJIXLwSFArjaeMqgI/Ctis/Xv+Rev/APr3f/0E0AaFFFFAGX4cnW50OOeMELLLM6huoBlY1qVn6J/yDT/18T/+jnrQoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5uwnkg8Va55VpNc7mhz5RQbfkPXcw/Stf7fcf9Am8/77h/+OVn6P8A8jVr3+9B/wCgGt2gCl9vuf8AoE3n/fcP/wAcqhp0VxYPPLJaape3E7fPPcPbbtoJ2oAjKoUZOOM9ySea3KKAKX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5V2igCl9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlXaKAKX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5V2igCl9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlXaKAKX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5V2igCl9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlXaKAMSC9nGu3jDTLokwQgoGiyOZOfv45/pV77fcf9Am8/wC+4f8A45XN+M9V1TQ7DWtU0SS0S5tba3kIvIGlR13SAjCuhB565PTpUc/inVPC+sWtn4xudNks76KZ4dStYHt0gaJN7LJG8j8bQx3Bu2MDrQBs3cVxe39vPNaap5EBDfZFe2ETuDlXb5txII4G7HqCcVf+33H/AECbz/vuH/45WTH430SBtOtb3UhLc3kMMiyw2cywnzPuFjhhFvIO0O2T05qGL4leEZ1tzb6wsq3TtHbNHBIwuHUkFYyFw7Ar0XJ5X+8uXZrQN9Tc+33H/QJvP++4f/jlH2+4/wCgTef99w//AByua8OePrfULy5sNbaGzvVvri3gSOOXy2SJQ3zSMoAfblipwcA8cZrTh8ceH54bqVb2RBaqrOstrLG7KxwjIrKDIGPClAwY8DNLpf5huaX2+4/6BN5/33D/APHKjnuJbmB4ZdJvijjDBZYlJH1Emay5/iD4at7WC4mv5VSYuMfY5i8WwhXMqBN0QUsoJcKBkZro3kWOJpDuKqpY7VLEj2A5P0FHS7DqU1vZ0UKukXYUDAAaHgf9/KX7fcf9Am8/77h/+OVmweNtDuLO3u0nuUt7hJXSSaxnjUCI4fcWQbOeBuxk8DNRjx/4a8mN5dRMDyXItVguLeWKcykZCeU6h8kcj5eRzQHQ1vt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcrHh+IXhm5iDxaoI0aCWYST28saKIuJAxZQAy90JDD0rPn+I+lW2+0uL9YZU0yG9/tKTT5hanzTtQhfc9F35PQEkHDs27f1/Wgf1/X3nUfb7j/oE3n/fcP/xyj7fcf9Am8/77h/8AjlZqeOPDr6v/AGZHqSy3YuvsbiOJ2VJ9pPls4BVSQDgEjJGOtFn430HUNfXRrO4uJbxxIU22M/lMIzhyJdnlkA/KSGxnjrxSWuwbbml9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOUmraxY6JaLcajKyK7hESOJ5ZJGwTtREBZjgE4AJwD6VnTeOPD0EdtJJft5VyiyLIlvKyRqxwrSMFIiBIIy+3kEdjQBpfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlZcXj3w1Pqh0+DVElnFw9qxSJ2jWZE3tGZAuwMFBOCecHHQ1BqHxA0eysrO5jS9uFu7uO1RY7GfcC54Yrs3YwCRx83GOuaP6+8Hpubf2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVhQ/ELw6sMbSa1DevcNO9uljayyO8cblWwi7mbbggsBg4JAAq03jnw6t3ZW66gZGvkjkgeG3kkjIkyI9zqpVNxBChiCSOKAelzT+33H/QJvP++4f/jlH2+4/wCgTef99w//AByuf0j4gaVrrWf2e6+wNNdXMQt721kSSdINwZkLbQoGAS2GA5U4bpYb4h+F4rW5uLnVBaxW2wubqCSEsHOEZA6gurHgMuQexp2DY2Pt9x/0Cbz/AL7h/wDjlH2+4/6BN5/33D/8cpuka5p+uQzyaZM0gt5mgmV4niZHABIKuAehBBxgggjisL4geNU8IeHb2ezEc+pw2zTxW8kcrIFH8TmNTsHBALFQTxkUuthpXehv/b7j/oE3n/fcP/xyj7fcf9Am8/77h/8AjlZcPjfRpLeR3e8DQXK2kw/s64G2Vl3Y+5yuOd4+UAg5wRTZPH/huIW4lv3WW6LC3tzazedNhSx2RbN7cDIIHORjORkEtTW+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcrLk8d+HI7O1um1AmC6XerrbysI13bS0uF/dAMCCX2gEEHkU238f8Ahi6uBFb6qkgLyRiZYn8kvGCXQS7dhYAE7c5wCcUAa32+4/6BN5/33D/8co+33H/QJvP++4f/AI5WaPFulXNzp0NtqKW8t5O0aQXVrIks22MuVCttKnBVtxBGO3INT6J4r0fxFPPDpFy8zwKrsHt5ItyMSFdS6gOhKthlyDjrTsBb+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrtFICl9vuP+gTef8AfcP/AMcqpqtxdXWk3Vuml3StLEyAs8WASMc4etis/Xv+Rev/APr3f/0E0AaFFFFAGfon/INP/XxP/wCjnrQrP0T/AJBp/wCvif8A9HPWhQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBhaP8A8jVr3+9B/wCgGt2uA1vXbnRNZ1CPTvLF5qWo2VhDJKMrEZFbLkd8KCQO5xW4TfeGIftWq63c6rZhPL2zQRLO87uqxqvloikEkgAgYJ5J7C1Drb+v60Ojorj2+I9il5Bp8ujaymqTTSQCwNuhdXSPzcFw5i+ZeQd+D7YOKz/FjRItLOoT2GrR2x086hG32UMZYw6o4CqxIKsyglgF5yCRzTs2B3NFckPiJYi+e1n0rVIGjvorGV5Io9sTSgeUxw5yrbh0ywz8wWlu/iHpli0kl1Y6ktliUQXqQCSO5aIMXRArF8gI33lAO0kEilsrhu7HWUVheHvFlr4juJ4YLO9tHhghuALtFXzIpQSjLtY/3WBBwQR06Vu02mnZiTT1QUUUUhhRRRQAUUUUAFFFFAHJ+KdCvPEsOraTY38Ng1zb26yTTWxnwm6QkBQ6YPA5yfpUUvg3VtRvDqOt67bXV/BbSwWAh09ora2Mi7WkMZlZnbHH3wME4A61p6lqq6Ne6letaXN5sgtwIbVQXYl5B/EQoHOSzEADJJArl0+Itzfa7pF9o9tdX+jX2l3U5sLaKI3AlhlRGO8ybCBubhW5xwWyKLX09fyf6D8/63CT4Y6lPDpS3PiK3mOlpZ/Z9+nMVje3fO5F87C71wGxyf72Plq3Y+AdXtLLQ4H1+zkOl6rNqLsNMZfO8wuSgHnHbjzX55/h44Oa3iP4hSXFjp0/hFpnt5L+xS6vfs6NEsczx/ujuYMrlJAchWA6HBINbMvxC023EktxYanHaeTJPbXYgEiXixjL+WEYvkDJwyrkAkZHNW5SSbfd/foyVFKyXa3y1RkTfDfVbq4IuvEFm1pJqVzeyxJpjq7LNG0TRh/P4wrthsdcHHGDNqHw3l13SXtfEWrQ300cMcFrKLAKiokiyDzYy7CUlkXd90EcALnNWP8AhZ2mhZGfSdWRYo7ad2aGMbYJzhJf9Z93IIK/f4Pykc1J/wAJ9p1vePAIdYvJrjVJNPhh+xhdsqRhiqkhQFIyQXOTkkHaOJs1p2/TT9Qunr/Xf9LmRqnwpfUtDGlx3+l2Fs8EqS21jo/lW3mttKzJEJcB129WLnk4K13OmDUlNwmptCyLIBbtFEYyU2jqN7Z5zzx9O55uX4maXBb6TcTadqUcGpsiCWSONFgd5PLCNlwWbcDkR78Dk4GDVnwzrd6+la7c65Obs6fqNzEptrYg+UmCFVFyWOPqSfyou7Pyv+av+f3Bbb+t0/8AIbL4HE1vq9u2pSrDey+baBIwDZMXErEZJ3ZkAbBAHaql74I1i+lt72XXrMamt7BdTzDTG8qRYQwRFj87K/eJJLNnPYcVLafErT7y1SeLSdWxcWS31mhhTdeREqCUAfjaXXO/aADnO3mmWnxG0jUorK7gGqRpJFdymCO3WUN5B2yKWTeGYHoI2OfcUmuXfp+n/Da/iPf5/qZkPw48QW8VqIfE+m+Zbz3s259Gcq32okuMfaexZsc+menL7j4Z6nLo5tIfEVtHNLpEOlTStppZXWJmKuF80bThzkZPIB4GQei8NeM7PxRMY7SyvrXdZw3sTXUaqJoZc7WXaxPVSCDg/UEGq/jrWtU0q00630e1vZJdQvFtmns/s5eEEE/KJmC7jjjII4Oe2W7xdvT/AC/Vho7v+uj/AERlnwH4gOpXN4fEenE3Gpwai6DSH+9EipsB+0dCFHP1rI8L6fq0GtXt9YQMt6/2jMV9o91H9j3szgI73AgcFgu4QhQ3BJ4yb2k+NdQ8M+E76fxfNd6/PY6hcW0t5bW0NuBHGoO9gzqi9+NxJJwAelXH+Jqw6zdxSaDqMmmwvZxpfQmAqDcY2symUNtO5eikjnPaheXl+KX6WFfvv/k2buuaHe6za6ZPBfRWGq6fMLmOUwGaLfsZHVk3KWUh2HDA9Dms7UPBmoahPdmTW4xDqlqttqkX2LPmgbhmE7/3RwxHzeZxjvyad740uZfEWim3aTTtPGo3dlqNvdQoXcxQPIGDqzAL8ueOTkdOQYbL40eF9QU/ZFvJ3+0QQJHbrHOW85isbkxuwQEjGHKsOAVBIyK7tbrr9+33j2+X9fgOf4fa3/aU1zb+IrCOOTVzqYjbSWcr+58kR58/BGzvjk84xxVmPwBcxWKww6vFAYdQhvLVIbMrBAIxjaIjIQCQedpVc4IUcg24/H9pPZwvbaRqs95I86tp8cUZnjED7JWPz7CAxH3WJORgGo4vid4el8Zx+GVlcXsj+UCzxjEuzf5Zj3+aDj+IptzxuzxQr6JeX4Wt+SB+fn+t/wA2cu3hzxDonivQrK21NZrh5NRuDfx6FM1tB57K+yTEhAO7fgl16LkHvq3HwtdpNNS31ofZdMNo9vFc2plaOSGTezKRIqrvyQcLn3x8tdjrut2/h/SzfXaPIvmJEqRsil3dgqjLsqjJI5JArH1bx7Y6Lcacl9p+opHfvGizmNFSNpH2IDucFiTzhAxA5OARRFu6tvf8eg5Nu9/67mU/w3vGjs7T+3ITp9vdXkzwtYnzHS58zcgkEo2kCVvmwedpxwQX6h4A1bVNHltrzxDbPeeQlpBdf2aQEhWRXO9BL8zkouWBUeiim6P4svBqL2GrT3d5enVr2G2SytUSOWOGPcImZ+FODx84JI5O3Na9v42S40qG/TQtW8uW1kuTGEhaRNjbdjKsh+YnpjIHOSuDSvon8/w/4cnRtrz/AF/zItG0PxDo2t3lxLqdhfW+p332m4WPT2hMQ8oJgMZ2/uJ/Ce/TPEPizwLc+IrjUXstaOnRarp4sL1DbCYsilirISw2N87A5DAg9jzTLL4n6ZqP2SKx0vVLi8u5LiGO1ijiciSH76mUSeUD6fPjmtLSvF66tLaxJoupW8s808MiTGDdbGIgMZAsp4JIA27jyDgAg09Xb+tNhp2bt/XUz9P0P7V4pe7invylpZi1mkurbykuLlQUEwUqu4hCwyo2EMMZxxzms+GtU0LV/DkOmXLuzauZYjbaRNJaWMYt5IwWjVyFBLqDho17gLgmvVaKE3e/9dw8v62sedS/COwa8tbwtpl7cKrrd/2rpS3aS75WlZo1LDym3SNg/MMYBBxVTwx4avtcOofbLiazsLbWru5trW50l4pGdtwSTdJgPHtcnaE5PBbHFeoUUv6/FMbbf9eTX6nCp4B1SG4017bXbWGGx1A3i266e5jVfKMQjjBm/djazE9RuIIUD5S3RvBGs+Gb641Oz1a21DULm3htpnmsWBm2SM3mOxmyWKuQTzjAIXHy13lFO7F0t/Xf8wooopAFZ+vf8i9f/wDXu/8A6Ca0Kz9e/wCRev8A/r3f/wBBNAGhRRRQB5zDNPrvjp/DVzeXdnp1tZy3vl2dw9vJdSNdSL/rEIcKoUcKRktzUI+IE+iaDfS2uk6hcm0vZoSms3qLJiKPcyRmIzPJjHHy98k9TXTjw1pWv2EMmpW7me3ubjyLmCeSCaLMzZCyxsrqDgZAPPenN4C8OvaQ27WUxSJpWDG8m8xzKMSb337pNwxkMTnA9BS1tp/Wt/8AgD0bv/W3+epmXnj26EN0bLTIUK2P2q1N3ctEZ/3PmkgbMMo4XKsxznIAGTV074h6jHasms6MqNY6PDql7dpdgo8bq3+rAUEtlDwQoznnABboovBWgxPERaSOIYjEkcl1K6AFPLJ2MxUts+XcRuxkZ5plh4F8P6ZdSXFrZzb5bMWMizXk0qPCOiFHcqep5xnk88nNaXdv63/4Alsr/wBbf8H7zI1LxlfWtpe22taA8c0Yt5EWx1EkNDLJsD+ZtRlKn7ygH2Lc0tt4+v7rVVtR4f8AIikv7nT0kmvV3edFEZASqqwCMFIzuJHHB7ab/D/w7JpMumvbXRtpihf/AImFx5hCHKKJPM3hFJyEB2jsKitfhx4bs7q3uIYdQ823uWu4zJq93J++YYZyGlIYkcHOcgkHqaX9fl/wRf1/XzOW0/4r6kui6Qbrw/LqOo3dkl9cRacs8+yF2IXaI4GG84PyuUXj75rS8QePdVttI1k6dptvBeWZxCt3cskhTzFjEhjMecHcSCNy4AyQTit6PwF4dhW0W2s5rf7GCsLW95NE2wnOxmVwXTp8jZXAxjFST+CtAuTdfaLOSQXUTRSK11LhVZgzbBuxGSwBJTaSQD2FPT8/+AN+Rh3vji60q8vBJ4fuJLpNQs9PkVb8NFmYDEi7uigtjhQzdSB2qap8UrrStFW+udCh8yKW5S8hXUCxQQSiNjGFjLSZzuyVRQPvMvGdy4+HHhq6uZZ5re+3yzRTvt1W6UGSP/VttEgA28YwOwqP/hWHhQxzo9ldutwJVmD6ndN5glILg5k5BIB9jyOeaI26/wBbf8EOn9ef/AHeErm6l8R+LYbq9uLqKDUYxAJmB8lGt432KAAAAWPv6knmuX1Lxlqc3iDT9XhtbltGl0y/ngtLa+Aa7WMLh2XauxuTj524x0biu+0nw1pmh319d6dHcLNqDrJctLdyzB2AwDh2IXjA4xwAOwrJuPhj4RupWkm0klyJQpF1MvkiX/WCPD/u93fZjqfU5l+Xb8bWKTV9SI+Nk06eKG7svs9ktks4nnuWMjjyjIdm5cS4C4JDls8lcc1T1H4i6hoyL/aXhpmkn8mS2W1vkkDxSyLGC5ZV2sGdMqNw+YYYjJG/B4M0O3e2ZbaZxbLtjSa7mlT7mwFlZyHYL8oZgSBnnmqj/DnwzJpxsWtLr7OZEcAajcBk2Hciq3mblRTyEUhQQCBkVenNfp/X9f1chbJHOeL/ABPrNwsMNgn2FdP1qxttQmtr7lnkkjJiCmMF0KSDJyhzxgjNE3xflS01S+tvCmo3VhZwyyw3KJIiSCN9rbnkjWNc8kbHkyFPQ8V1OqeAvDOtXz3eq6Wt1JIYzKryyeXKyfcZ4921mGMbiCccZxxTLn4feG7u1vrWW0uBa37Fp7aK/uI4iScsVRXCpk9doGcnOcmkmrWf9aL/ACKe42PxVfR+ILbTNR0uG0+0AFJGu2+csWwqExhXYKuWUNkEgAMPmrp6yW8M6W97a3UkU7y2u0x77uVlJUYVnUth2GOGYEg5OcmtajQnUKKKKQzkn0Sy8Qax4gsdRRmj8y2kRkYq8bqCVdWHIYEAg1ak8Gw3mmS2mr6tqWpyNt8u7uGiSWAqwZSnloqghlU5KknAzkcVNo//ACNWvf70H/oBrdoA5Cb4exT3tnfHxBrC39rO9wbofZy80jR+UC4MJXhMgBQo5JIJ5rMn+D9jPpsFi3ibXlghsZNPAU2uWhdw7KT5HcheRg4Ue+fQqKdwOJuPhnFcy3MsvifXDJc3dvduwFqP3kAHl4/cdPlXPrtHvmzL8O7GW3uLb+1NTS1kMzW9uHiKWbyhg7RZjJyQ74DFgNxwBXW0Ut1YFpqc34e8Gp4e1SS+TWtTvi9nDZmK68jYEizsI2RKcjc3fncfbHSUUU229xJJbBRRRSGFFFFABRRRQAUUUUAc3rOgweI768srmee3VVtJ1kg2FgySSMvDqykZHQg1Uh+HNhaw2q2mqapbzWzXG24SSPeY55PMliOUI2lsc43DHDCqfxAur2xtbm60y6uLeeO400YgYKZla5KNGSRwCG7Y+uM1Zj8a6kGga70a0t4F1N9Ovpm1BiLdh9x1/dfOGyBztwSB70Lb+vJfqkN6K/8AXX/hxlz8K9CnUwW9zqNjYM9vI1jZ3AjiaSAKI3yBvDBUUcMAcA4yAasD4eWK2U9mmqamLUxSxWkO+IiwWQEP5RMZPQkDeXwDgYrHPxM1aKPUZLrwvHHHplnFqFw66luD2sm/54x5eWYBCdrBOhGehLrf4qteT6g9j4b1G6sLWO4aK6iilVZGhJDBneNYlBKttIkY8cgHinK/K+bbX+v69As018v+AWJPhXbTQXMUnibXStzZ29k5/wBFyI4W3R4/cdck899x9sSp8NVW7jun8Va9JNHf/wBoh2FpzN5flkkC3xjZxj8etSxeN70HS3vtGhs4NRijlWSS8OFD7QE3eXsMnzHK7hkY2liSBl6f8WDqEck0fh2+FrN5YsLlopkinZ5ViRXkeJUUkuD8jSDaCc5GKfvOXn/X6kK1rrb/AIFvy/AsxfCbTo41STXdZn2iMbpGt8/JP569IRjDk9MAg85wMdBo3hpdDtNTih1C7vTqFxJcsbvy/kdxyF2IvHTrmsuTxjrFrrNjpN/4bWC7ubee4aUagrQIsTKGIYLvPDAjKDqBxyRzkvxW1bUfD8t7o3h2W3Ej2ptbm8WeKGSOaZY+XeALv+YHCb1wchjjBm3MuVdf1f8AmvwL1Wpo6P8ACuJPCdhp+vareT3trZQ2ySxSRlLXYyOREDGNyl41J8wNkADpxV5fhpbxSI1r4h1q2Eb3TqsZtiN1wSZD80J7nj0pYvGEo1DULSDSXXVTqYsIoLm/PlSuLcS7wwDeWmwE/KuSeSuSazrn4n38LTwR+F2NzaWNzd3Ikv0WMG3kCSIjBSW65BKqDkdOdtSvJ69dfv1YJNaf12X/AADQsPh/NoaiTRvEmrefHYRafD9o+zFEijbK9IOSMt9cnpwRteIPDh19tPY6tfaebG4Fwn2MQ/O4GBu8yN+Bk8DHX6Y1reYXFtFMoIEiBwD2yM1JSd76kq1tP60t+RxUnwysZjKZ9Z1aUy3NxctuMHBnXa6j91wMYwfvDscEgzSfDjTZLO4tzqOpKJ4bWMuskYKtbkGOUDZjd8q5yCvH3eTnr6KS02/q2w+t/wCtdzjW+GmnPqUV4+q6s5W7ku5YpJo3jneSPy33KyHaChYYTb94+gw6X4exzaRa6a3iTW/s1lcRT2q7rcmIREMiZMJ3KCF5bLcfexnPYUU07bf1bb7hWT/rucfa/DuGzkS4t/EWspex3E863ebfeBMQ0kePJ2FCwDYKkgjgir9t4TXTtQu7vTNW1GBLomSWzEkZiebaB5uWjZwxwCcNtJ6qcnPQ0Uv6/r+vMe7uzLfSrm70CKxvdSuBciMCS6hEYZmxjJBTYfoU2n+7jiuem+F2kypbol/qMKwQQwhUaLB8qbzUbmM7Tuzwu1SOMcDHa0U763A46z+HcdlrkOpr4k1qUxX0l8LeT7N5ZkkBV84hDYKnGN3Hbnmrk3gXTZtM1ixFxeRxarL5rlHXMB3b8RgqRtLlmIYMCWIPHFdLRS6WDrc5Gw+Htrp2vW2qQa1qjNb3E1wIG8jy3eVQr5xEGwQBwCMdsVq6d4fisvFGq6xsVZL4RqAshYYVcFsHhSTgHHUIpJ9NmijYVkFFFFAwooooAKKKKACiiigArP17/kXr/wD693/9BNaFZ+vf8i9f/wDXu/8A6CaANCiiigDO0J1k0rfGwZWnnKspyCPNfmtGs7QkWPStkahVWecKqjAA81+K0aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsL21s/FWufa7mGDe0O3zZAu7CHOM/Wtf+2tK/6Cdn/4EL/jWfo//I1a9/vQf+gGt2gCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igCl/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jV2igDkdXtvDviO8urXWbyN7TbbSJ5V+0GXRpCPmjdScHBxnrg+lU7vQ9ATT7rSdNnsJNP1aYy6k9/q0k7ZyDlEcsCTjGdy4wDhsYrW1vX7XwzPqOo3iSSgRWsUUMIBeaR3kVEXJAyWIHJA9asafqutm5VNd0W3sImjeTz7e+89IwuOHJjTaxyemRwfmoXf+v62/AHrY5ifQtN1P4iX2q6xc6VJpMllb28EcWqurs0bO2JIlCoyHzPuszD5Acc8a0uh+DZWv8AN1GiagHFxFFqskcbFxhmEayBUY5OWUAnJ55NbEHinw/c2CX1trumTWjyiBbiO8jaNpD0QMDgt7dagj8Z+HZNau9KGsWS3dmIzMjXCDG/7o69en/fQ9aN1YL63/rTQpf2V4RMFlCbuJo7JY0hVtTkIKxklA+X/eAE5Afdzj0FRDQPBItry2Mtu1tef6y3bUnMSHO7MaF9sRzzlApzzW5F4i0Se8t7SDWNPkubqITW8CXSF5oz0dVByy+44qNvEml2lq8+q6ppdnGryAOb5du1W25JbbgjjI5weMmh+YLTYybfRfCFtqlnqSX5e8so3ihlm1maU7X+8GDSEPnA+9n7q/3Rhsfh/wAFRWE9ik8P2SZg3kHVJCkRDBx5QMmIsMAfk29B6Vpjxj4f/tq80ptWtEurG2W6uFedAEjbPzHJ6AAEnoAy+oq0niLRJIbWWPWLBor3P2V1ukKz4GTsOfmwPSnqBz48NeCB9txcJm9nS4lb+15dyyKMK8Z8zMRA4ym3gAdABUV14T8CXrAzzqD9me0PlazNHuidtzhtso3Fm5ZjksepNbGneL9J1pv+JLqFjdLHePaTZulUhlBJ2gA7jx0OMjJzxzcTxJocjTiPWdPc20XnThbpD5UeSN7c/KuQeTxwaXT+u3+X4D1v/Xf/ADG2V9oun2MFnbalb+TAgjTzLzzG2gYGWZix+pJNT/21pX/QTs//AAIX/GsmXxnZvqug2+kiLVLLWZZYl1C1uUeKMxxs+OCdxO0jjgYOT0Bdd+MLPTfFr6NqoisIRaLcJfXVyiRysz7BGoJznPrjtjNPVvXdk6Jf16Gp/bWlf9BOz/8AAhf8aP7a0r/oJ2f/AIEL/jTU13SJNVl0uPVbJtQgTzJbRbhDLGv95kzkDkckd6jh8TaDcWP22DW9OltNzJ56XcZj3KMsNwOMgA5HakMm/trSv+gnZ/8AgQv+NH9taV/0E7P/AMCF/wAaZZ6/o+ozrDp+q2N1K0IuAkFyjsYj0fAP3T69KZb+JdCu7aS4tda0+eCOYQPLHdIyrITjYSDgN7daAJv7a0r/AKCdn/4EL/jR/bWlf9BOz/8AAhf8axdf8eaVpGhnULCe11ZsoVhtryPLKxUb+vKgMCcAnBHFaMvivw7Bp/26fXtLis/OMH2h7yMR+YOqbicbhjp1oAs/21pX/QTs/wDwIX/Gj+2tK/6Cdn/4EL/jVfU/FPh/RZYo9Y13TNPkmXdEl1eRxGQeqhiMj6VYtdZ0y91C4sbLUbS4vLXH2i3inV5Ic9Nyg5X8aAD+2tK/6Cdn/wCBC/40f21pX/QTs/8AwIX/ABqldeIgl7qFvax27Lp8Ia4uLm5EMMcrAFYy2GI4IJOOAV65q2Nd0k6imn/2pZfbnZlW1FwnmFlALALnJIBBPHQigB39taV/0E7P/wACF/xo/trSv+gnZ/8AgQv+NZGu+NtP0vR7680x4NYmsJkiuba1u490BZgvz8/LjPTGfatGHxNoVzcR29vrWnSzSTPbpHHdozPKgy6AA5LKDyOo70bgTf21pX/QTs//AAIX/Gj+2tK/6Cdn/wCBC/41hHx3ZTeKL3R7E2cy2di9zJeNfRiFJFYKYn27ihGQSWHHYGtoa9pQvIbKXU7FL2Y7EtvtK72bbuKqM5PHPTpzRukw62H/ANtaV/0E7P8A8CF/xo/trSv+gnZ/+BC/41BF4o0CfWjpEOuabJqYJBsku4zMCBkjZndwOelTz61pdtctb3OpWcMyglopJ1VgApYnBOegJ+gJo8w8g/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xqBvFGgLpcOpNrmmiwnfZFdG7j8qRs42q+cE57A1VXxv4aN1qcEmt2EJ0oot40tyiLEWAxkk8dQM+vHWgDR/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xrNh8VRXXi610e0gE9rd6c9/DqMc6NFIFdV2qBkn74OeB0xnnG/Ts7X/rsBS/trSv+gnZ/+BC/41R1rV9Nl0K9ji1C1d2gcKqzKSTjoBmtuqOtu0eg3zxsVZYHKspwQcdaQF6iiigDP0T/AJBp/wCvif8A9HPWhWfon/INP/XxP/6OetCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDg9Z8QX3hm/13UrDSl1RUntUmgFwY5SH+UeWNjB2yw+UlfrWxZ+K5NT1jTV0y3tJ9HvrJ7v7c12yyR7CAV8ryyM5dRy4x82RxzlapZarf6nrMGiQWc063ljMwvLloV2xsJDgrG5ydoHTvntgx6h8OZZNV1efS79bS01SxljNoy7o4bmRkLSKMD5X2fMMjJyerGnG3Xz/AC/zG9tP61N278eeFrSwgvW17TpLa4ultI5YrqNkMpONu4HHHU+gqTVvEyaR4i03Trm22215FPK99JMqRwCJdxyDz05zwAO/auduPB+u398msTJpdpqIurORraCeR4GWAvli5jUliJOm3ooGe4s+OvDGva/rGjXOivZRx6eJndrid0LuygKhQRsGQkYYEjIJxS/z/RfrcnW/9dzei8WeHJxAYNf0uQXLKsGy9jPmliQoXB5JKtjHXB9Kln8R6Ha3k9pdazp8NzbQmeeGS6RXijHV2UnKr7nivP8AUfBXiq+1jWdRj0jw3BNqRsT8uoS5zbS7yzH7NklhtHtgdcVt2fhDVBqVvFqA097C11GbUY7pZGa4cy78xFSgAA8wjfuOVUDaOtP0H/X9fl+JvHxh4ZCyMfEWkgRxJM5+3RfJG+Njn5uFbcuD0ORjrVuDXNJur8WNtqllNdlWcW8dwjSbVOCdoOcA8H0ritJ8BazY6rp089/byW1sDaTQh3Ia0jkD2wAIxvBHzH0YjnAqDwz4K8Q6JqumO2m6DBaWuo3ty/2W8k3CO4Jwqr5AGVBAxkA7R07Gn9fgD0V/68/68z0qiiikAUUUUAFFFFABRRRQByXijw4fFDX1lFc/ZLmIWd1bTlN4jljkd0LLkZGRyM9KxtT8Fa34i14azq2meHLbULXTLizt5lZrrzpJAArOHhXaq4b5cv8A6xvfOt4t8QXXhlrrUrSK3kUPYwzGd2ASOSZ0LAAckbhxx9exuz+PvDtvpgv5bufyfOkgKrYztKrx5Mm6IJvUKBkkgADnODQtv67W/JorVWZylr4B8Q20GpSf6Ebu6uFuYW/tObMTm3WFgWMWGHDHaUKkYG1cDC+IPAGu6jqnnwwaJextd6fds127xMjW/DhFETgbgMDnoxHbnr5/G3h61vBb3GorGdgYzGJ/JXKbwrS7disV+baWDY5xVP8A4WX4TMDTrqbvEtuLrelpMwaEnBkUhPmUH7zDIX+LFVd8yfa34bfkQ1df11Kl14T1W41i5jb7A+m3Gpw6mt0zsLmJ49n7sLtKkHZjfuBCsRtNcrZfDnxPaXiTJo3hhFit9RgjCX8oIW6kLqv/AB7cKmSuO4YnjofRZvF2iQapHp8t6VmkZUD+TIYQ5GQhl27FcgghSwJBHHNUIviX4SnW3a31hZlunaO2aOCRhcOpIKxkL87Ar0XJ5X+8uZ+zbp/wLfloWpNbev5v/NnMXXw61+/0+aKe4sbeSaw0+NlguphmW0dm271VWCMCPnGGXsD1q7F4F1K0tbdtKtrOwuWmLzltWubvbudWclpkPn5KA4ZUIJOGHU3/AAp8QrbWIXh1porLUFnu18pI5fK2QOVb94ygbguGKnDYOdorTt/Hfh650ue/iu5/Jt5EjdXsp0lLOAUCxFA77gRt2g7s8ZquZ35vn9/9WM+VJcvbT7jl5fA2vQ31hJBaaJex2es3l+HubiSN2hnEmU4ibr5vI6fuxyc/Ll2fw98XWWmWFpa2XhuAWmnXFoSt07qxknSUYU2+AAExk5wWzg4we0j+JHhiXT1vVvblYGd0LPp1wpTYcOzKY8qinguwCg5BORWlpmsvc61faVeLGLi3VLiF4ids0Dlgrc9CCrAjnoD3wBXX9eVi5Pm1f9a3/M47S/BPiPTtY0uYjT5La11m51CVn1CZ5Nk0RTaN0XzMC7HkgHA6Z4n8beEfEGvatqc2l22kSQXejNp0T3d3Ijo7PuLbVhYYHsecdq9BopX28v8AK35E238/87/meV6h8OfEmuXk0moXGn2YnS7iY2dzIQizxBQQgjUMwYcsTuYc5X7tEfw51W3vtG1G20fR/t1nfrc3L3WtXd00irE0Y2ySxMVzuB2jgbF5PG31SiltsCVvx/E8os/h14m+zWVncJo9nClnqNrPNaXkjuv2pw4ZVMKhtuADkjOT6VZ1vwFruuTWuoXWm+H/ALdBcWWYhPJ5Zjt5GcuGMJIZgdgXGFBPzN0r06imm00+3+dxvVWPNdQ8C63Na+MorKw0OP8At69hngJuXXcihA3mYh4J2FuN3Ln6mvfeBfFeoz6sskOi2ttqFzNLiC9l8xRJbrCMP5AIwUBIUjcGxkY+b1Kiptpbyt8tP8h31v8AM8Z1G3a28WWljczae1zaWtiLjTv7UNvLfSwZdTGjW7PNtPIKNHk5Vs846rwf4Dn8P6693exxztEZxb3x1S5kdklfeym3b91Gc4yVJztzgZrvKKvme/r+JPKkrLbT8DznXNAvL+08WeHYLazlu9WuVvrJ75mSJl2RqTuCN86NHnGM8r061TsfA3ia31M3P9l+HrVZtdOqyfZ7+XKKYPKZV/0cZbJZs8ZJ9816lRU9LfL8v8kPrf8ArW/+bPOJfBviT/hAm0CKz0E3NvBDaQXv2iRGniSQNl8QkocL90FwWYnI7reeB/Edzq9xJb3Gl2sE2srqYmLSSSIDbeS6BdqgEdQ27nPIGMH0ainvdvr/AMB/mg22/rp+TPJL34b+Kb3SZLSZfDjBNBbRo4yZQJfmBWYts+QjAbaFbBHDc5Fiz8E+KrbULm7Gk+HITcaxbak4h1CUkCOMIw/49hliQWz/ALZ+p9Top8z3/re/5it7vL/W1vyR5P8AD945fGLXEE1leIrXMUUFvqW+XTkkkMhElv5CtHuZRnzJHIPC4BIrV1PwBqGp3ni8rHp9jHrTWz289tM4ldocEiXailQxHJViRn1r0Oip6IfW55zY+BdT0u6ttSsNN0x52+0JfWF7q1zdRyiURgyCeWNm3YiUbSmCCRnvU934N15b3UZNPbS/JvL+2u9hZo2UJCkbKjbG8sjZlWGTzj5etd/RTv8A1+IHnvhHwdr+g61oj3g057LTtNuLJ5I7yV5WMkwkUhWj5ACKOWzyeuOfQqKKLtq39b3/AFElb+vkFZ+vf8i9f/8AXu//AKCa0Kz9e/5F6/8A+vd//QTSGaFFFFAGfon/ACDT/wBfE/8A6OetCuX0jw+02nhpNY1NWEsqsIrjapIkYZxg9cZ69TV3/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoA26KxP+Ea/6jWsf+Bf/ANaj/hGv+o1rH/gX/wDWoAbo/wDyNWvf70H/AKAa3a4GZtI0nWNUbW/EkmjwRvDGtxPqCw+cxQnDM/3jwTj61r6ZYabrVmLvRvFV9qFsSVE1rqKyoSOo3LkUAdPRWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AG3RWJ/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61AGb4o0C78SyXdhY38NhIDZXBlmtjOD5cryBdodOrKOc9M/UZd58OdW1K3vLfUPEVrLb3l1PPLAumssbCWMJgqZjuK4BBOR1yp4Iv6hDpejXk8mteJrjS7dIoV+1XOoLF5jMZMAs3B4HAHvT420CbUbewh8bTSXt1GJYLZdWjMkyEbgyr1YEAnI4xStdNf10/yQ7vTy/r9TLsPhXHp2qfb4ZtHnuWjjJuLzRVmnjmjiWMPFIZAUX5FJTnvhhnIqx/C3Wk0ZNObxPYtGmiSaMG/shwdjkHef8ASPvAAD07+1dl/wAI1/1GtY/8C/8A61H/AAjX/Ua1j/wL/wDrVTbf9eq/US93by/D/hjGtPAt/F+4utbhnsZLiG9ngWxKsbiPYQUfzDtjLRqShDHqAwFQWXgHVrSy0SBtfs5DpeqzaizDTGHneYXJTHnHbjzX55/h44OdybQoLbZ9o8QapF5jiNN96F3MeijI5J9KH0KCKeKGXxBqiSzZESNegM+Bk4GOcDnijmf9f16C0Wn9a3/4Jztr8PdetpISPFFoqx3V7c7odKZJAbndnaxnIBUsSDg9s1map4Iu/D+gX+Lo3j6lPaG4mstKmkaFousxWOYzMTtHKNvBOc46dz/wjX/Ua1j/AMC//rUf8I1/1GtY/wDAv/61L/gfgN6u78/xOJsvhumsW+n3tzBpLm0DxIup6HJLHcROwkLmGeUyxy7y2XZyTySOa6/R7Cd/FN7qckLwW0NrHp9qjoEMgRmZ5No6KSQB0+6TjBFT/wDCNf8AUa1j/wAC/wD61H/CNf8AUa1j/wAC/wD61O4jborE/wCEa/6jWsf+Bf8A9aj/AIRr/qNax/4F/wD1qQzborE/4Rr/AKjWsf8AgX/9aj/hGv8AqNax/wCBf/1qANuisT/hGv8AqNax/wCBf/1qP+Ea/wCo1rH/AIF//WoA26KxP+Ea/wCo1rH/AIF//Wo/4Rr/AKjWsf8AgX/9agDborE/4Rr/AKjWsf8AgX/9aj/hGv8AqNax/wCBf/1qANuisT/hGv8AqNax/wCBf/1qP+Ea/wCo1rH/AIF//WoA26KxP+Ea/wCo1rH/AIF//Wo/4Rr/AKjWsf8AgX/9agDborE/4Rr/AKjWsf8AgX/9aj/hGv8AqNax/wCBf/1qANuisT/hGv8AqNax/wCBf/1qP+Ea/wCo1rH/AIF//WoA26KxP+Ea/wCo1rH/AIF//Wo/4Rr/AKjWsf8AgX/9agDborE/4Rr/AKjWsf8AgX/9aj/hGv8AqNax/wCBf/1qANus/Xv+Rev/APr3f/0E1U/4Rr/qNax/4F//AFqgv9Djs9OubibUdTu44omZoJbs7ZBjocDNAHRUUUUAZ+if8g0/9fE//o560K8qlvZ4vHWg3dha65qMV3Z38z2FlqPlISs6BXaN5kj4EjDuckHBwCK3h/xnP4Z8PbFsNY1TU7/Ur4R2l5dXN3JDFBKV2ExicggFV4BUnq3en0v/AFvYbT/r0uevUVwMPxKu5vtE7eGbm1srOe1iuzeTiO4jE4UqwiCnO0uMhmUgZ78Vn658UdRtofEFtYaVapc2NjcXVrMbwyKwikEbb9sewMCQ2xWf0baeKLO9v67i6XPTqK42fxnqEXmb9Kia3s5obTUp4L3L280iocxo0YEir5i5JKnrhTjFc9ofjXVdI8IwLrNjcaqk0d95F2t8PtFw8LyEqy7VCfIpwyt2xgcUnom/6/r+kJO7S7nqdFeY3/iC50vVNcun/tK/sF0CyuUsEvShg3vIrFZMhgcKCWyXODjsK1dT+IkumeLG0caMLmPEqxPBeBpXkSDztrLt2JkAgbpA3GduOabVt/P8B9fu/FXO5orirPxzqc1hoeqXmi2dnpWrorCeTUWLwbot67lEO3kgj73p3OK0pvEt9a+G9Ou7vTIU1TUpEhgsVuyYxI4LKGlMYIAUEk7CRggA9xpp2foH/DnR0V5l4S8SajFKLTVrbUNQu/tupsswvN4HktgQ7V2h+DhcqAOvBrbtfHF5qFvBBp+mWkurXDOFtXv2SNAiqz72MW9GG9RtMYOT6c0ugdWvNr7jsqK4e3+I8lzdbF0OWCCLTm1C6nnuUAiVJCkiAKGLMpVsdAcdRnNYNx471XRvFl5e6paTNHdadamw0yG5adN8srqpxHEWDEDLALIRj5S1HX+vP/IOjf8AXT/NHq1FcLZfELUr+602zj8KXkF3fW88xW7kMCr5LhWADoJCCGUqTGudw4HO3e8L+IX8Q2css1tHayxMFkhWYu0ZIyFdWRGRsEZBUc9MjkuzA3KKKKQBRRRQB5X8RdQtbDR/Ev2q+tbJ5bvT1ge6YBS4kVuhI3YCkkAjgHkdarR6/a+GrTxHPqWvQWPiXUZ4ZZHt1jEckPypHPAjtt2FD8zsXCkHduCgHubCeSDxVrnlWk1zuaHPlFBt+Q9dzD9K1/t9x/0Cbz/vuH/45QtP69P8h32PKvDnjrW9U1/S9GuvEtr58i6gssMawtcTNBNiL5toX5lz0jGQrEf7O78MvEfiDX7i4k1zUtNuFaAPJZQ3Ae4sZs/NG6CGPyx22uztkH5iK7j7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKdxPXYu0VS+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcpAXaKpfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45QBdoql9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOUAXaKpfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45QBdoql9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOUAXaKpfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45QBxXxSvrWx8I+JTeXdva+bZW8cTTuAGcvIQBkjJ4JwPQ1z+q+JNR03xwlz/bWia3qn/CM3cumwafbmHzGLROg2maQvuClhjGQpxmvR4L2ca7eMNMuiTBCCgaLI5k5+/jn+lXvt9x/wBAm8/77h/+OULR39fxTX6h/X43PJbbxp4hjj0qTUfGejrpN5fmCa/tJYriSBTbyPh5TDHEhVk6GMkZG48fMar491+z0jTpf7ZMN1GjTkPDDEl/brdeWsp3ISd0Y3bYwmN24sBgV6DrWlya3qmkX0kOsWraTcm5ijt3tdsrFSnz7ixxtZhwR9498EbP2+4/6BN5/wB9w/8AxyqutGJ7W/rc8ws/Es+i6zNHceKlH2vxS1tNDeiHd5Jj+QIwVcZGzru424xnJr+GfFd5pVza6bc+KopZrmbVjJb36RmVJY5W8v7qgkcFtuCcnjjCj1f7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKlaRt/WyX6XH1v8/wAW/wBbfIxfAuszavpl0Lq+N/Naz+S84aJ0LBVLBXjCqwBJH3VIPBGRz09Uvt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHKb1Ei7RVL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKQy7RVL7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8AxygC7RVL7fcf9Am8/wC+4f8A45R9vuP+gTef99w//HKALtFUvt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHKALtFUvt9x/0Cbz/AL7h/wDjlH2+4/6BN5/33D/8coAu0VS+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcoAu0VS+33H/QJvP8AvuH/AOOUfb7j/oE3n/fcP/xygC7RVL7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8AxygC7RVL7fcf9Am8/wC+4f8A45R9vuP+gTef99w//HKALtFUvt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHKALtFUvt9x/0Cbz/AL7h/wDjlH2+4/6BN5/33D/8coAu0VS+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcoAu1n69/yL1//ANe7/wDoJp/2+4/6BN5/33D/APHKqarcXV1pN1bppd0rSxMgLPFgEjHOHoA2KKKKAOY03wvpd1qcWvTJdf2jA9zDHIt9MqKhlbK+WHCYOAT8vJAPUCiH4d+G7ez+zQ296gFw1yso1S685JG++yy+ZvXd3AIB75rX0T/kGn/r4n/9HPWhQBxGmeBAPGmraprFpbtayzQSWKxX8zf6pAoMsRCoxBUMCd+CeOea0v8AhXvhkmfdp8jCeKeB1a7mK+XMwaRApfCgsAcDGDyMV0tFGwGH/wAIboX9ox332N/OjCZH2iXZIU+40ibtsjL1DOCQec1E3gTw6y3ifYpFS8R0kRLuZVRXOXEYD4i3H72zbu75roaKNwWmxyk3w08MXCTLNb37LNax2cg/ta7+eFDlUP73oP6n1OZJ/h34buJWkltrvzGcyb11K5UhzH5RYEScMUOCRyepyea6eigDmbzwpC2h2Phqysrc6FDs8z7VcSTSRrG6sqKrBt3TGS428YB7bGr6NYa7p/2LVIDLDvV12yNGyMpyrK6kMrA9CCDV6ih67htsctb/AA18KWl0tzaaY8EqtK5MV3MokaUYkLgPhyw4JYHoPSrMvgfQZoDHJb3O7zzcC4F9OJ1fG3KzB/MUbflwGAxxjHFdBRQBiQ+ENEt9UF/DaOswtPsW37RJ5Rh67PK3bDySc4z71nL8MPB67mOjK8hiWFZpLiV5YkVtyrG5YtHtPTaRjAxjArrKKAMFfBeiDULS+aK8kubSF4IpJdRuHJRxhg25zvJ45bJ+VeeBi9peh2GjNO1hHIrXDBpGlnklY46AF2JCjsowB2ArQooAKKKKACiiigDgNf1LXNHvNdvvDi2c1ylzZoba6iYifeQgVXDrsOW+8Qw9quWPjGXVNTsry3vbK20RrKea9hubZhcW8sLKroz+YFXBfkFD908ncCG32k3+s6trVtpd/b2MiXVnOZLi1adSIzvC7RImMso5z0z65E+pfDuw1DWtS1KO5mtZNUsWtblYfumQlCJgDkBsIoPByAuenLWm/n+Wn4jdraf1qOvPiPodtDC8Ivp5Jb2KzaAafcLLGz8hmjKbwMAkHGGxxVjXvEs+ieJdKtpY4Bpl1Dcy3Ex3tKhiTcAqAc/qewFUZ/A9/fSx3+o61DJq6T20n2mGx8uLZAXIXyzITk+Y+W3dccYGDJ4x8F3finVNJu7fV47AaZ5jxg2pkfzWA2uGEigbSAcEEHoeDS/z/Cy/W5PXy/4JMnxH8LvdfZv7QlS4WSKOSGSynR4GlOIxIpQGPcem/HUeozaufGuhWl/JZzXU3nRh/uWkzq7ICXRHVCruADlFJbg8Vzl/4B8Saje6jdTeJ9MWW/FoG26M+EFvIZE4+09yef0xWtY+Dbi11CIT6ok+mW97Jfw2v2XbIsz7iwMu85TdIxC7QeQCxAxT0/r+v68hk6+PvD7oXjnvHUW0N2Num3J3RSkBGX9382SwGBkjnIGDiXS/HHh3W7+Kz0rURdSzeZ5TJE/luYyA4Em3aSMjjOcc9KxtM+Gyabq1hfDVGkNo8iFPs4Akt94eGDrwI2UEHv8AN0zTdG8C63peq2NzL4gsZ4bW/urxol0t0aT7QSWXd55xjccHB7cepp/X4f8ABB7af13/AB/M7qiiikAUUUUAFFFFABRRRQBx3jPVdU0LT9a1TQ3s1ubW2t5Ct5A0qOu6QEYV0IPI5yenStrUtUGi+H47jV9Ss7ac+XEblrdvKaViAAse8tyTwNxPuayvFWg3niaHV9IsL+HT2ure3WSaW2M+F3SEgKHTnpzk/SotV8M+Kta0eexvvEmlL5hjKGDRXVVKuHyQ1wxJ+UAYIAyeDxgQO5qr4x0ZmuVEl5m1vBZTZ0+4GyUjIByn3cYO/wC6AQScEVUPxH8KIoM2rLBuljhRbiCSJpWkJCFFZQXVsHDrlTg88VLP4T+1a5c3tzesba7tRHcWkce0NNsZPNDZJB2MVxz0XniuYtvhRJp+k21lpl5olk9vd28/2m30FY5J0hcOqylZRvbKjLDA6/Lk5Dja+vl/wf8AMHtp/X9bHR+LPF6eH/CsWqwW9zI11NDDCrWM7lDI4Xc8arvGAc7TtJIC9SKp6L8Q9MfS4Dr18kV4bmW1lddPureJZETzCGEqAxHy8NhjjqAWxmtTxfoN/wCItHistO1G3090uobhpJ7QzhvKcSBQokTGWVcnJ4yPcYV58PtTuNSuLq28RpaCXUl1NFTTwxWYQeSyks5yhwDgAEcjd0IOj/rt/wAErTT+u/8AwDasvHnhrUYZZbTU1aKK2W6MjQyIjRElQysygOMjHy55461Tn+JOgxXVhErXey7eZHkksZ4xbeWm5jKGQFMZX72MA7ulYtn8MNUi0+1sbvxJbSQWmmrYxNBphjkDJIskcmTMwyGRcjGDg9M8bl74Y1zUH028uNdsxqVgZgJU00iF1kTbjyzKSD0JO855xjIIUvInr/Xb/O5P/wAJvotnpFjd3+prMl1Ak4ubazl8sRt0lYAN5SH+85A96lTxz4cl1b+zYdTWW5+1fZGEUTuiTFdwRnC7VJAOMkZxjrWBp/w61LT9IgsYvEEPzaaml3zf2ecTwJuCFAZT5cgDsMncpznbSt8P9Yj1S5uLPX7GK3m1O3v1hfS3dkEKKix7vPGcqi5OBznjnAp25vL/AIP+Wv8AkD2dv60/zN7U/GOnaT4ot9FvRPG81nLeNcmB/JiSMjO5wu0dTySAMAHlhki8b6DNB5iXNxkSiJomsp1lUkbstGU3hdvzbiNuOc4qr4o8EReKNQ86e+eCCTTbjTp4kjBZ0lKHKsT8pBQdjkHtWVB8NPs+htZ2z6DaXG4MJ7HQhbDIUqHwkoYSAM3zK69emMgz08/+D/kPr/Xb/M6LRfFdlr2tapp1lFchtNdFkkkt5ERyyBvlZlAPDDjOe+MYJxfEfxGsrPRtVk8PPHd6hpyGRo7mKaOJkWQJIyPsxJtJwQp68EitjQvDcuiatqd2dRe6TUDE7JJGAwkSJIyxbPOQgOMDBJ68Y5mX4Vy3eoXt1qGuCZru1uLV5RaETFJJVkTLtI2dhXAGAuDwFp6XX9a/8OS78um5vn4heGUlWGXUjFcvMYFtZLaVJ3cLuwsRXecjkEDByME0+Tx54ci0+1vmv3NtdRiVZEtZWEaE43yYX90uQRl9oBBHase58Bavc6tZaw2v2f8AacN2lxO50xvKkCRvGiKnnZQASOSSzEkjoBiodP8Ah1qtjZSQf8JHbsbu3a0vmXTSBLCXdhsBlOxx5rjcdwIIyvFA/wCvx/yNu6+InhSye7FxrMIFlKIbl1R2SGQ4wjMAQGOeBnJ5x0NSW/jvw9dXqWkV7IJ3uTabXtJk2SgbgjFkAQkcruxuH3c1iXfw91KbT/EVnb67awx6xcQSxE6czG3WJUUKf3w35WNefl5yccgCOT4f69LfXN0fElgr3Grxaodukv8AK0cYj2D/AEjoQq8+ufXhf8D9P+D9wPZ2/rf/AIBa1j4iWjeHr+88KvFeXNkYWkS7hmhUxSSbPMTKjzFOGwVO046121eaH4Val9lv1XxJbNdX9rBb3F1LprO0nlStIHb99lmIOCc444AHA9JjDiNRIys4A3FVwCe+Bk4/OnpYH8Wmw6iiikAUUUUAFFFFABRRRQAUUUUAFFFFABWfr3/IvX//AF7v/wCgmtCs/Xv+Rev/APr3f/0E0AaFFFFAGFoulQtpg3zXbMJplLfa5FziVhkgMBnj0rQ/sm3/AOel5/4Gzf8AxVM0T/kGn/r4n/8ARz1oUAUv7Jt/+el5/wCBs3/xVH9k2/8Az0vP/A2b/wCKq7RQBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAUv7Jt/+el5/wCBs3/xVH9k2/8Az0vP/A2b/wCKq7RQBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAUv7Jt/+el5/wCBs3/xVH9k2/8Az0vP/A2b/wCKq7RQBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAcHeapo3hrVNYutbnv4bVZreJZIBczNuZTgN5WW5PALcZIA61uvcaRHrVppTy6qLu8haaFd13tKDqWf7qkccMQeRxyKpSaVDrl74q0y5yI7qOKMsOqkocMPcHBH0rIgm8Wal4C1PUPsM9n4igtTZQJJHgu6H95LGCeQ55XkZCryOtHf+v61/Afb+v66nbf2Tb/89Lz/AMDZv/iqP7Jt/wDnpef+Bs3/AMVXlWnWuuDUfD9rPrnii7067vZhcImm3tqIYzARtkklZ5gPM2kM0gA3EqcKCvUaJpF3aeMJ9Hkn1SSx0+X+0YbqbVJ5DIso2pCxaQlwpSQ7W4wEOCSTVWJudb/ZNv8A89Lz/wADZv8A4qj+ybf/AJ6Xn/gbN/8AFVyt4bt/H0y37a7HsaJ9KaxExtHXb+8SbaDHktnJkwcY2kGuO1d/E48L3lxp0viu31cae66kiRTyA3e5Nn2cMrDBO/mEbQvJIODUrX+v6/4cq2tj1v8Asm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qvJ7nUNTtdQvZ7NvGTww6xZSWwayvnBhYL9p+Up8y8P8AKQVU42gZGa2mXOsSLYjUZ/GzmWHUkvGe0voyVEha2OEjARiOhQK3RemFo+zf+triWrSPYf7Jt/8Anpef+Bs3/wAVR/ZNv/z0vP8AwNm/+KrzCK88R6lodk12niSHVTpVudOeKG4iT7YoIlFyoAUZYL/rhtK8ryadot/q8Pi2ye7l8VXBbXLqGUz2V0Lf7KYiIyQIxGF8zZhscDJzjNXy+9y+v+RN/dv/AFtf+vM9N/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qrtFQUUv7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+Kq7RQBS/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qrtFAHM3h0vSL3ULrU7u5gtoYIMv9qmLEszgKMNuYk4AUZOTwMmreltpOsRSPYXN+3lMFkSW4uYnjYgNtZHIZTgg4IB5FUPE1lBqH9o2t3Z3V3FIlpkWblZosSORKhHIKEBuOePwrm4xr0nh+5vy+sXyaXfwzWkv2eayu9QgG0SpLCoQyEDcFyo3YHHci1/r0BnoP9k2//PS8/wDA2b/4qj+ybf8A56Xn/gbN/wDFV5hFpvjCDw/q0Nu2rLqOmbhbSy3VxKs8c7pI20NJmVoo9yA5zkcEE8Z+rQ+J4/CSW9hqHiS+mZLqezuIrK+tTE6ouyJ0Z2mc537TK+w5IIf5RT/r+v68hpXdj1ia0sIFctNfOUZVZIrq4kZdxwMqrE4564wBkngVP/ZNv/z0vP8AwNm/+Krym7TVdKvNZ1GCLxLHcXeq6dODbW9zMssGyLzVKANtHEucAEbQpwCql9jqWrQ+IIZ5p/Fsm7WLyJnuLC5EK2hhPlsV8tYwBJswxAxzyBmi2n9eX+f4MXRPv/wf8j1P+ybf/npef+Bs3/xVRQ2NnNJMiPqAML7G33NwgJwD8pLAMORyMjOR1Brg/hb9rl1a5utWvdW+0S2cYjtb6TUCjEHMkwFwiIGYsmUj3BMcNhqz7rUdYfXEt5bjxcbQeIphMY9NuVD2Zh4wyRAhBINoKkcEnn71Nqzt/W6Qk9P67N/pY9R/sm3/AOel5/4Gzf8AxVH9k2//AD0vP/A2b/4qvMvD11qd22nR66fF0UEVuqWUsdvdI5mWaTcLgbfm3R+VhpRsI3cg5NRXKeJrjRdUntbzxAXXXJIpXura6DpYnoYoYzEzjcF5jO7GcHkgz1/rul+v3D/r8G/0t66HqX9k2/8Az0vP/A2b/wCKo/sm3/56Xn/gbN/8VXk+of8ACUW40hYLvxFfTWgtpRdraXcMdxEbrEitCCTuWMgHz2ZioyFB3NVvVpPFItNUt9LOsODMks900F1uSJpfmWOLcCzBNv8AqJBwG4VjguwHoWpppWjaXcajql7c2tnboXlmkvpgEHr96p4NPs7m3jnhmvGjlQOjfbJhkEZB+9XlWr2uvnwrJp9/N4i1m3k0u5FhNaWdzbvJcNu2pMjM0mAhCjziQ2DnLYJ9W0Dzf+Ec04XNvLayi1jDwzY3xkKMg7SRn6E0W0b/AK6/5A91/Xb/ADH/ANk2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVV2ikBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAUv7Jt/+el5/wCBs3/xVH9k2/8Az0vP/A2b/wCKq7RQBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAUv7Jt/+el5/wCBs3/xVH9k2/8Az0vP/A2b/wCKq7RQBS/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqrtFAFL+ybf/npef8AgbN/8VR/ZNv/AM9Lz/wNm/8Aiqu0UAUv7Jt/+el5/wCBs3/xVUtX023g0W8lBuX2Qs2yS8mKtgdCN/IrarP17/kXr/8A693/APQTQBoUUUUAZvh+TzdHWTYyb5pm2uMMuZW4I9a0qz9E/wCQaf8Ar4n/APRz1oUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3YTyQeKtc8q0mudzQ58ooNvyHruYfpWv9vuP+gTef8AfcP/AMcrjdb1250TWdQj07yxealqNlYQySjKxGRWy5HfCgkDucVuE33hiH7Vqut3Oq2YTy9s0ESzvO7qsar5aIpBJIAIGCeSewtQ62/r+tDW+33H/QJvP++4f/jlU9PiXTFlFpo+oZmcvJJNcpM7H3Z5S2B0AzgDgYFZDfEexS8g0+XRtZTVJppIBYG3QurpH5uC4cxfMvIO/B9sHFZ/ixokWlnUJ7DVo7Y6edQjb7KGMsYdUcBVYkFWZQSwC85BI5p2fQDrPt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHK58fESxF89rPpWqQNHfRWMryRR7YmlA8pjhzlW3Dplhn5gtLd/EPTLFpJLqx1JbLEogvUgEkdy0QYuiBWL5ARvvKAdpIJFLZXDd2N/7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8Axys/w94stfEdxPDBZ3to8MENwBdoq+ZFKCUZdrH+6wIOCCOnSt2m007MSaeqKX2+4/6BN5/33D/8co+33H/QJvP++4f/AI5V2ikMpfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45V2igCl9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOVdooApfb7j/oE3n/fcP8A8co+33H/AECbz/vuH/45V2igDFiu5l1y6cafcszW8OUDR5TDSdcvjn2Jq79vuP8AoE3n/fcP/wAcrlfH19f6XoXiDUdJv57C6tLOCVJYIo5GOHkyu11YHOfTNUNG8aX+lTTLraa5qVhdXkNrpdzdaV9nuZZHUl1dAkYCggYcqucnrjNC1E3Y7n7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8Axyubi+I9oWC3Oh6xaut9JYSo8cMjQyrD52CI5G3Bl6bd3IxxxktfHtnqv9jT2dprEUepLJNaA28apdKkRYqxYnZ7AlSSAeVyaOl/67j/AK/Q6T7fcf8AQJvP++4f/jlRXUzXtpLa3eiXU0EyGOSN2hIdSMEH950xXH6X8V1udDS91Hw1q1u7aW+qqsZt3WaFGUMUxNnIDg4YKTg8Z4rp9M8U2mravPYWlvcFrfAklOwqrFA+CAxZeGXllAOeCeafK/6+4NtSHSNNt9DUiw0jVWyMBrq/+0si8fKplmYqvA+UYHHStT7fcf8AQJvP++4f/jlXaKQFL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKu0UAUvt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcq7RQBS+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrtFAFL7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKu0UAUvt9x/0Cbz/vuH/wCOUfb7j/oE3n/fcP8A8cq7RQBS+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrtFAFL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKu0UAUvt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcq7RQBS+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrtFAFL7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHKu0UAUvt9x/0Cbz/vuH/wCOUfb7j/oE3n/fcP8A8cq7RQBS+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrtFAFL7fcf9Am8/77h/8AjlVdSnmutKuoHsZrZZIXUzTPHsTg8nDk4/Ctes/Xv+Rev/8Ar3f/ANBNAGhRRRQBxieKZrHVodDsLCK6uZBcXbCa7EJdBO4KxDafMfPUHaACMtzVm38d2cerala69HHocFhBaym6vrpERzOGwOSNuChXnBJzwOM5V94Vu9Y0EWMdjpeo2cbPHbi+kaKW1kE0oM6SIjHcBswBt5H3hVa38H+LtP8AGn9tQz6dfpFZWtqBd3kim6MasHkdRCQjkuSrAtjBH8Rw42tr/X9f15EvL+tv+D/Wp2h8Q6dbwSz6jqWm20KyuiSG8XaQoyck4AYDJI5wBnNWpNTsItLOpy31slgI/NN20yiLZjO7fnGMd84rzW28C+JIdU029OieGUNjqd3fKiX8vCzow8tT9m4+Ztx9do49N618M69B8KrPQdmlpqlqsSACQyQMscgPDNFlSVHB2HacEZxml9nz0/4IdTom8T6Cmmx6g2t6ctlKrPHcm7j8t1HUhs4IGOazvFPjfTvDVjbTB4Lye7kiEFsl1GjyI7qvmKCcso3AnaD1rkLT4eeINOvNPnistEvHs5tRkElzfS+YVuSSi7jCxON3OTz1qFPh14tXwyNKEuhq80Nisk0jyy+Q1qVACDYu9WCbsEqVYsOc5DVn+H/BDrb1PULzVLDTmhXUL62tWnYrEJ5lQyMBkhcnk4BPFZ8ni3RGty2n6nY6hcMsv2e1tryIyXDxjLomWALDvzx3xVHxZoOqasLaTSjaLdxxtEZ5pXQKGK7vk2usi/LyjDnA+ZetY3/CE69/bySxz6ZFZxazNqKyt5jyPHNC0bJswoVgWODuYHr2wZ1a+/8A4H+YbWf9df8AhjoPDfjXR/Efh+LU476zhf7LHdXVubpGa0V13DzOfl47nFWF8YeGWj8xfEWklPINzuF9HjyQcGTO77meN3TNcNH8M9abSNNgkn02K40OzjtbIxs7JehJopQ04KgoD5ONo343E5PStbVPCuuahe2eoQWei2c5tby2urdJ3aMeeE/eBhEDIcpyCq5z145udtXHz/4H3/h1HFK9mbyeOPDMl9f2v9uWCtp0KTXLvcoEjR+hJJ6dOenzL61bl8TaDDYR302t6dHaTR+bHcPdxiN0/vBs4I561xMfgfxPa2c8cdxpFxJKmn7mO+PLW+AwXKP5fAyr/Mc9AuAazrX4b+IrBrIw2Wh3TW1nqNqZri+l8xxcSl0yxhYkKDg5J+834qWl7f1p+uxMLu3Noem/21pY1OPTTqVn9ulj82O189fNdP7wTOSPfFVj4s8Or527X9LH2eYQTZvI/wB3ITgI3PDE9jzXBaR8MdTh1FJtXW3l8zyZfOh1i7X7HLHCsXyQhVjl4XIZtpG4ghgObNz4A1zUNDFtdf2TBd2WmjT7V7eR9l0FkjdXlygMf+q+6N+C7HJ6UWV/6/ry/EV21/X9f1Y7j/hI9D8l5f7Z0/y0uPsjP9qTCzdPKJzw/wDs9aZrfifR/Dtvaz6xfwWsd3OkELSSKodmPGCSBjHJPpXIzeDfEcratdFtLFxeXn2u3SG4liNuzQLE2ZNjCQYU/K0eDjkDPy9Br+h6jqOj6RHZyWrXmn3dvcv5uY45NnDY2g46kgY7Y460dvl/wfuH3t5/8D7zQTXrCONGv9Q06386eSGDF4rCUqTwCQPmwCSozjB5OM0lx4n0GzFwbvW9OgFq4juDLdxr5LHGFbJ+U/MvB9R61w1j4G8RWugLaxW2jWd1Hc3TQtb3kpjiinmEm0oYQrqOhjK4O0YZauap4H1nULPX7GGSxt7XULOeOAGZ5MzSPv3YZMxL/eCswJOQFxgmnUp7ux1s3ifQLe1ubm41zTYoLSbyLiV7uNVhk/uOScK3PQ81pI6SxrJGyujAFWU5BHqDXl+o/DzxJqWszatcS6dl7pLgadbX91a7j9nEL5uowH4xxhORnPXj0PQtMi0XQbPTbeFIIrWIRpEkryLGo6KGf5mx0yevt0otoIwX0Sy8Qax4gsdRRmj8y2kRkYq8bqCVdWHIYEAg1ak8Gw3mmS2mr6tqWpyNt8u7uGiSWAqwZSnloqghlU5KknAzkcUlhZWt54q1z7XbQz7Gh2+bGG25Q5xn6Vr/ANi6V/0DLP8A8B1/wpAc7N8PYp72zvj4g1hb+1ne4N0Ps5eaRo/KBcGErwmQAoUckkE81mT/AAfsZ9NgsW8Ta8sENjJp4Cm1y0LuHZSfI7kLyMHCj3z2v9i6V/0DLP8A8B1/wo/sXSv+gZZ/+A6/4U7gctcfDOK5luZZfE+uGS5u7e7dgLUfvIAPLx+46fKufXaPfNmX4d2MtvcW39qamlrIZmt7cPEUs3lDB2izGTkh3wGLAbjgCug/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KW6sC01Mjw94NTw9qkl8mtanfF7OGzMV15GwJFnYRsiU5G5u/O4+2Okql/Yulf9Ayz/wDAdf8ACj+xdK/6Bln/AOA6/wCFNtvcSSWxdoql/Yulf9Ayz/8AAdf8KP7F0r/oGWf/AIDr/hSGXaKpf2LpX/QMs/8AwHX/AAo/sXSv+gZZ/wDgOv8AhQBdoql/Yulf9Ayz/wDAdf8ACj+xdK/6Bln/AOA6/wCFAF2iqX9i6V/0DLP/AMB1/wAKP7F0r/oGWf8A4Dr/AIUAY2v+H4/FDarpFxfXdlDcW9uJJLQxhyoaQ7curAA/TPvVrVvDI1i20qK41a/jfTbiO5WWIQhp3QYBkzGRzkkhQvXtWbrF14c8NXN7e61Zxx2UcUAzFp7T7GZpBnbGjEZwBnGOg9KuPc+Go9TsdPfSyLi/j82Af2RLt299zeXtQjuGIIyM9aF5d/xB+fb8CnqHw6sNQ1G5uzqurWxnvV1AR206IsU4i8rep2bjlcZViV46YJBdZfD+3sLXw/bw63qrRaDuFurGD98GUriTEXICkr8u04OevNbj6VoyOEbT7IOVLBPITcwGMkDGT1H5ikt9L0i5to549Lt1SRQ6iS0EbAEZ5VlBU+xAIo6W/rsD13Ocb4YaWdPtbOPU9ViitrGfT/kmjy9vLjMZJTjG1cFcHjknJzp6d4Ns9O1azvkvr+4NlA0MEdzKsm0EYJLlfMbgDguV4zjPNan9i6V/0DLP/wAB1/wqIaZo5umtxpdvvVA5Js/kwSRw+3aTx0zkcccind/1/XqD13NKiqX9i6V/0DLP/wAB1/wpG0bSVUs2m2YAGSTAnH6UgL1FYmjDw14g0uPUdGt7C7s5WZY5kt12ttYqcZHIyDz0Par39i6V/wBAyz/8B1/wo2Au0VS/sXSv+gZZ/wDgOv8AhUUum6PDLDG+l25aZiqlLPcAcE/MQuFGB1OBnA6kCgDSoql/Yulf9Ayz/wDAdf8ACj+xdK/6Bln/AOA6/wCFAF2iqX9i6V/0DLP/AMB1/wAKowDwzc61daTbwafJf2kaSXECwKWiV/uk8cZx0oA26Kpf2LpX/QMs/wDwHX/Cj+xdK/6Bln/4Dr/hQBdoql/Yulf9Ayz/APAdf8KP7F0r/oGWf/gOv+FAF2iqX9i6V/0DLP8A8B1/wo/sXSv+gZZ/+A6/4UAXaKpf2LpX/QMs/wDwHX/CqOoDw1pU1nDqFvp8Et9MLe2RoFzLIf4QAP8A9VAG3RVL+xdK/wCgZZ/+A6/4UxdJ0dpGRdPsS6Y3KIUyuemeKANCiqX9i6V/0DLP/wAB1/wo/sXSv+gZZ/8AgOv+FAF2iqX9i6V/0DLP/wAB1/wqBrHREmljk061j8pVdne0CphiQMOV2k8cgHI4zjIyAalFZsemaPLNNGul24aFgrFrPaCSAflJXDDnqM88dRQ+m6PHcRwtpdvukVmBFnlQBjOWC4XrwCRnnGcGgDSrP17/AJF6/wD+vd//AEE0sek6PLGskWn2Lo4DKywoQwPQg4qtqumabaaTdXEWmWW+KJnXNuuMgZ9KANiiiigDg/EvjVPCHgu/nsxHPqcIuZ4reSOVkCiZ/mcxqdg4IBYqCeMityLxbpqvdmbUI5vs8kUDwWttJJJFKy7thC7i5xzgD5QDn1rntR8C3PiK21J7LWjp0Wq281heobYTFkWaUqyEsNjfOwOQwIPY81aHgTUi+pfadasrxLtoXjFzpW4q0UexWcrKuT0bKCMgjjA4o6DdtLf1/TNu58Z6DaTW0c96w+0hCsiwSNGgf7nmSBdse7tvK57VDF498OXNlLd2WoG7hjkMQe3t5ZQ8gJHlptU734Pyrk45xjmsweArxY5LX+3mmsb2GJNRjuLcySztGoXckm/5CwUA5D9OMHJplr4C1O20uJBr1v8A2ha6vNqlrcrYMI1Mu/fG8ZlJcYkcZDKenpy9BdP67P8AWwnhv4k2V34dhvvEckVpcS3FxGVtYZpI4kjmaMO7bcovy/fcKM+nStiLx54cuPNNnfvdiGc27ta20sw80EZQFFILc5wOcAnoCRyVv8GYIL1bu5v7HWJmklMw1nR4rlAjytKREuV8ttzt8xLZzyMAAbdv4HvY9H1GyuNTsLlrvUXvojJph2RFhwpXzcnBwQysh47UO39fL9Lg99P63/4Y662uYry1iubZ98Mqh0YDG4HkGpaqaTZSabpFrZzXUl5JBEsbXEpJaQgdTkk/qfrVuh2voC2CiiikAUUUUAFFFFABRRRQAUUUUAFFFFAHEaj4kTwrqmt382nXt/G1zaQFLPytys42qT5joMFiBwT19Mmuhk12SPxFZ6SdHvz9qgaf7UDD5MQXAZW/ebsgso4Uj5hgnBxzWuaRda23iO109Ve5S4sbiNHbaHMTiTbntnbjPvUPiq017xV4c1Ux+Hb+xm/s2a1tbZ7yFJ5ZpChDBo5SqopQZy4J5GPU6f120/EpJNpHoNFeQJ4Y1cXk2zwVcf2Q09rPd6bLcWpF/tgaOQFfNKswYo3zkBtnXOM6OreEr27cwQeG3Mb2Ucek3D3UbPokqluSS+4dVOYi+du08AGnbUhO6PTqK8cbwhqo8SS3MvhK/ulPiM3YupLy3ctaNCI3GWn3BWYZMfQrgEcAVkp4K8QTWstvdeCdRaNNKv7SCJ761aJHkuPMttqfaNq7FwMgAggYzgUul/62v/wPUrrb+t7f8H0PeaK8hg8Na+moXhXwncDTriCxkvLOa5tiNQeNXE6NiU7nO9Dl+H8sgnGCVu/Bl8LrTM+FLy70tftrf2Yt3B5dpHJGBHCY2mCE7tx+XKruwDgU5aXJTvY9dorD8Fw39r4H0e21e1ltb63s44Z4ppEkYMihSdyMwOcZznoecHitynJWk0gTurhRRRUjCiiigAooooA4/wAZ6fdanpOv2unwtPcG0tnSJSMuVkdtozxk4qprmsz63p13d6Ja65aG0024xP8A2bNDMszBdiRxyR7nbg8qpA9a6u3/AORhvv8Ar3g/9CkrQpNXTQ07O55C+j3cGoaRrRfxS00nhy4EtyrXUkkV0REOYTkKcBjs2YJAO0kCtDRrnUb280htd/4SmBhYWjWjQQ3CK0ygidLhduNxIAzMMYOVIPNenVXlvoI7v7IG8y68lplgUjcyggZ54HJA5I/nVuX9fe/1/AhRt1/rRfp+J4pe3fiqKLVZbZvF1sLuBWjRLa6uJY5hckMoJRkUGM/8s1VcAYLda6HV7rUbHV9fsrL/AISq6sXsbNoNkVz+7Yyt53ly+WWJ2uhYKS+MquNuF9QidpIUd42iZlBMbkZU+hwSMj2JFOqVorMpPVvv/wAA4v4faheW2ixaXr7agb83d0kD3dtcfPEsjFP3kmf4CCNzFiAeuDWT4kn1pPiTaT2UetpbWt1bLKI1uJLeWBlbeQkYEfBIyW3vkDG0c16OYYzMsxjQyqpUOVG4A9Rn04FPpt3aYPZrv/X/AAx41pB1FtES3u7TxPZWzPePZmxtrqCRbprmR0MqhQdpR0ILjy/vbuRUouPEUviLUrI32t3Gt293YtbCEv8AY4sxxtOj7AIwmC/+s56bctXsFZth4f07TNW1DU7OOZbrUmVrlnuZZFcqMDCsxVcDj5QOKOv9f1/wLIPP+v6/zZ5hpMfjeOw1a5udR1SXUvJxdaeun3CAN5q7mgmllaJm8sOFEKqDkEgGtK7vrjTrjRH0F/GV1ZO92Xt7i0uWbmEhAzyxlxiTAXzSRlieQAR6fRS6W/r+u3YOtzzjwBqN/pQ1P+3jrP2OV7VrRr23vJWQyIA4LSgtw4+Y4VRnOFFaXiD7dL8TNFtln1saa9jO08dnHItv5oKmPdKi/KTh+C4HAH8WG7KSGObb5saSbWDLuUHBHQj3p9N6u/8AW1hR0VjxnR28Ryf2mLl/Elva3NrbzgXEV7K8ciyyecm4FWBKhR+5CjlSisOsOpXOqPqV5qJsPFFrerpFmIfstpdvvmW4kYqXSMbxtcZVuzEEZBx7ZRRexT1v5/8AA/yMp9Ri1XS9QSwmu7WWKNkMjWzQyRMUyGUSpg9RzgjIx2IryKwPiLXPAQvdIuvEss7+HRNdSST3KGS9GxojAcjORvyI/lbIBya9qmsLee0uLZozHHchhKYWMTNuGCdykEHHcHPvUOjaPZeH9HttL0qN4rO1TZDG8zylF9NzknA7c8DiiLs2/T9f8/w8hdEv66Hlk11rc/jKGKFfGFvpF5rEcjP5M/ltA9qN4JIMkKiXHHyBdx/u/K/RE1TUNUayg1DxHdT2+r3ltczyzTLAbIB1A8xcRhw23BX94Dz05r16s3RfD+neH4rmPS45kW6na5l825lm3SN95suzYz6DApafh/l/l+I29F3/AOH/AB1/A8duLrxXD4btDEvjKO8/siG3upooZpCtykyhvkcMSSu7LopyMHdXR6oNWtfHuntpY8RfY7a6thIZGu5opoJFcudv3BhmGd+5hgYCKBXqNHWnfW/nf8b/APA9CWr38/8Ahv68zjfHerSXHwt1TU9Dvr6ykjjLJLFEYZgVfDLtkXK9COgPoRXKakt7LJD5cPiSXR31y1lgM1tdS3EW1W89uVMiR5K4JwMk7eMGvS9X8PaZrmhyaPqFuxsJAA8MEzwZAOcZjKnHtnmr8USwwpEm4qihRuYscD1J5J9zzS/zX6P9Aavp6/ieRWF3q13pMdtqS+L0t4xcxWE0UN3HceeJ38ozcBmXyjFhpMx/e38ipoLDXNMv9cnvrbWna6u7R7+Sylnbdb/Z0Ehg2n73mhs+X84UEDHyivWqKd/6+d/68tB/1/Xp087nl9wNbtdJtpoX8QXNvHPObK3ZbkXEsTbBGJXHzKwy+POUrjBfBGaxdRXxqi+JLqXVtct79EuhDZWOlXMquuT9nMcpdoemwHy41flt3QsPaqKXQadnfzv/AF5Hkcd5qJa/it5PFRgRra7U3Nlf/vWEJ8xAwUOoL7CVQEZ6oVLVBrKavrVpq9ncweJmRV0q4SF4518rbIv2hI5I1USMFOTtJJOSPujHsdFVfW/9aEpWseXqNUvF8Qyq3iZzpWrQ3dnDKLm3M9uEj8yFCNomGVlAHzZOCc7sluq22pnVlsom8RPDquj30ktuftLwwzyFWiXzekbBQy7d4AwAAN3PqVFS9Vby/S3+T9S1KzueWWmjXllYeH47A66kOsWKadPFcaldI9m4UOZQryZjOxJBwAQQg4BNeg6zGIfDF5GhYqlqyguxYkBe5PJPueamGl2o1ZtSKyPclAgLzOyIP9lCdqE9yoBPfNR69/yL1/8A9e7/APoJqpSuZxikkjQoooqSjP0T/kGn/r4n/wDRz1oVm+H/ADP7HXz9vm+dNv2Z27vNbOM9q0qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMLR/+Rq17/eg/wDQDW7XN2CXTeKtc+yTQxfNDu82Evn5DjGGXH61r+Vqv/P5Z/8AgI3/AMcoAu0VS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxygC7RVLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKALtFUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcoAu0VS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxygC7RVLytV/5/LP/wABG/8AjlHlar/z+Wf/AICN/wDHKALtFUvK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcoAu0VS8rVf+fyz/8AARv/AI5R5Wq/8/ln/wCAjf8AxygDj/iFpV9rFtc22l2F3fXCzWEvlWt0sDbFmdnyWkQEbQwxnqR6ZGS3gS/h+IM+ox2l8sKSJJpr2T2cNvBGIwpt5CV89VLbiVjJQ7geDk13EEepf27eAXdqH8iHcTatgjMmOPM4796veVqv/P5Z/wDgI3/xyl/X5f5DvdWPItH8EeILGK68zw0fsFwbKe60nzLZUuiglWaPAkIYktG2ZWO/b8zdhq6r4Ic3Et3pXg+SNZNAms4I0uYVuLWQuSqeZ5ny8NgbWKhQRnGAfSPK1X/n8s//AAEb/wCOUeVqv/P5Z/8AgI3/AMcpy97+vK35CWjv6fg7/meeXHhnWNRkhN54ec3b29t9g1Fp4d+jsigSKSH3DJBP7vcG3YbAFVtH8N6vp/jCzvx4U1BWTXbqaS+kvLeRhaSRlFGTMXK7irbccbemQBXpnlar/wA/ln/4CN/8co8rVf8An8s//ARv/jlVze9zev42/wAieVctv62a/Uu0VS8rVf8An8s//ARv/jlHlar/AM/ln/4CN/8AHKkou0VS8rVf+fyz/wDARv8A45R5Wq/8/ln/AOAjf/HKALtFUvK1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xygC7RVLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8coAu0VS8rVf+fyz/wDARv8A45R5Wq/8/ln/AOAjf/HKALtFUvK1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xygC7RVLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8coAu0VS8rVf+fyz/wDARv8A45R5Wq/8/ln/AOAjf/HKALtFUvK1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xygC7RVLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8coAu0VS8rVf+fyz/wDARv8A45R5Wq/8/ln/AOAjf/HKALtFUvK1X/n8s/8AwEb/AOOUeVqv/P5Z/wDgI3/xygC7RVLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8coAu1n69/yL1/8A9e7/APoJp/lar/z+Wf8A4CN/8cqlq8V//Yt59pvLYw+S2/y7Rt23HOMydaANqiiigDP0T/kGn/r4n/8ARz1oViaRq+mxaeVk1C1RvPmOGmUHBlYg9fQ5q9/bWlf9BOz/APAhf8aALtFUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GgC7RVL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xoAu0VS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8aALtFUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GgC7RVL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xoAu0VS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8aALtFUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GgC7RVL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xoAu0VS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8aAOG8VWM97Jrn2DUbzTbxb2wSC5tbh4zGXkVCWVSBIMMflYEe1VbfxSq+JWudfe8g1fQ9On/tDT4b2RYZXDRiOVYtwRlcOxUkcZwTlONm4stE1nWdXg1q7KW7S208Ri1CS23sqkqwaN1JAOD1xnB9K2LuLwrf3Ek97Jp08klq1nI0k6nfCxBKNzyMjv7+pprT8fysN2at/W5z2reNvEVrfW2lro1jbakb+1jkU37PE0EpfBV/KzkmNlIK8dRnrVnxprU+heMPDk63kwiuFuYRZGXy4biYoPLDHacfMQMngZzirceh+DEsBaG4hljWaOYPNqckku5D8n7xpC+BkgLnGCRjBIqTW9L8IeI7q3uNYuoZ3t45IowupPGoWQbXBVHAORxkg0v8AP8LL/gk9f67/ANf1qZc/xA1ey1S6sb/wzFG9g9mLqSPUg6bbiQxho/3YLYI5DBO/oN1yXxrftcK9hosNxY3FzNY2tw16UZ7iPeMOnlnYhaNgGBY9MrVWXwZ4Ena4aa9nka58vzWbxDdEv5Z3R8+d/CTkelalrp3hGz1dtSt7i2W5LmT5r9mjEhGDIIy5QORkFwNxycnmnp/X9f15jMWz+JN9f3EVtb6LZ/aLixt7qCNtQkG55JFR4mPkYBQtzjJxtyBni7oPju71nVbS3n0I2NvdT3dqJHu1eRJbc4YFFGMHDchjyOnerVto/guzure5tjYJNa3E1zC/2vJWSX/WNy3OfQ8DAwBgVVsfDHgnTb+2vLO8ZZraeS4iLa5O6rJJ99trSlTu7gjByfWjT+v66A9tP6/4f/M7OiqX9taV/wBBOz/8CF/xo/trSv8AoJ2f/gQv+NIC7RVL+2tK/wCgnZ/+BC/40f21pX/QTs//AAIX/GgC7RVL+2tK/wCgnZ/+BC/40f21pX/QTs//AAIX/GgC7RVL+2tK/wCgnZ/+BC/40f21pX/QTs//AAIX/GgDkPiP5qeGvEc9tPeW89vZW8sT2dy8Em4PJwGRlPOehOKNOvH8PWVzcxaPr1vcXE8Fpb2et6u1wssjn5WDmWYRrzyQSePu5xnR1i10DxDNfWWt3SNYXMEBxHfNAJdrScbkZSQD1GcVF/wjvgxrW4t7m9a8S4VVY3mtz3DJtbcpRpJWaMhgDlCDkA9hQtAZK3inXDdxafF4bjfU44RcXlsdRUKkZkZAYn2YkJ2kgME46lTxWJ4f8S6zZatdabPC+ppdazeWltd3d4FZHSMyJGVVCAmFI3Dkf3TnNbcmi+EJZLSV70efaArHcDV5RKykglZJBJukU4GVcsDiqieF/BdrdpfWdz/pUF099CH124CeewwWI8wjkcH5SMEjGCRTVk7vs/zQnrt/Wj/UqXPxI1K10RdQPh2GdoEP9oW8Go/PaP5xiVfmjUNkg5PHQ4DDBNmP4gXqao9rfaHHBHBqo0y5lS+37GeMSRuo8sbhhhuB24PTdTk0Tw5qelalD4hm05ZNXuVur2Kx1Bo13qqqo8xSjMBsBzgZPak/4RLwMZnmN5I0kl2l67Nr1wS0yDCuf33UDj0wB6Cj1/rb/gr7gfW39b/8Bj4fHl5JBHcvoLNa3ti99prW1wZpLhVCna6BMoxDAgLv79+C6Hxi15faaP7MkmeSG6kD2V95ke+JRuj2/KXYk4AdRjHQHirFpo3gyxM32aa1UTArsbUGZYlLBisalyIlJAJCBQcCoB4c8FC4t5zdhpLcSBWfWJm3eYMOXzL85IwMtk4AHYUn5DNjwzrza/p7zywQ28sbhHiinMmw7Q2GDKjKeeQyg/hg1k+I/HUnh/xPZaZ/ZsdzBcSwRSTLdfvEaZyikRhGwuRyzsgOcLuORU9vY+HrG6hm0/V1h23DTzbtSkkaYlduGLSHcoGMKwIGBtAxTNU0bwdrGoNfX9zC1w/lFmj1N4gTE26NtqOBuU9GxntnFPS67C6NFDRviJeao8TTeHZbaGe3vZIlF0skxe2k2NGUAxzkYIY85HoTnWvxLudYs5ZpNFgl09LuygF1pestIA00igbmEaYKEgOgJOTgjBJq5J4O8IWlkf7Ev0hvIYZ0tWudZuJo0M2d+5GlIYMTk5781V03wxpF5p/2bxLfrHApRltIPFd5dKXQgpJ5jsjLg9FAxnBOSBhxtza7f8H/AC0GzUvviH/ZySaldaYP7BWa4txex3O6USw7926LaAFJjYAhyc4yoBzVfTfiRd6hZtv8OXVrdzTxQWKXAnghuWkDEfvJYUI2hCW2qwHGC2a1E0nwamozXoltGkmLM6PfF4izLtZxEXKByCQWC7iCcnmol0DwWukvppuY3tWdXVZNWldoSpyvlOZC0WOwQqB2qV5+X/BB+Xn/AMA5DSfiNqmh2c9hc6bqGv6oL+8eWOMyzvHDHNsCqYoWBPZQwjXjkrXQR/Ea/n1HyIvDUkcf9qnSs3F4qSeYYRKjFArAKQeedy8cE5AsQeEvAFpIsliLWznWZ5jcWmovDK7OctvkRwzgkDKsSOOlN/4RLwKLw3K3TLKbwX3y65cKvngYD7RLjgcYxjHHSmrWSf8AW36XB7u3n+v62KNz8VJrbSbC+bRYissjx3cf24l4Slx5DGNVjJcZydzCNcY5BOK6fTvEkl74mu9Jms1tvJ3mMyTESSqu0b/LZRlTu4ZWYeuDxWFF4J+H0MLxJKpSQMHD61O24M/mHOZefnyw9CSRgk52raDwxaaqdRgvYPtJVlBfUGdV3HLFUZyqknqQATgZ6Uafn/wBanQ0VS/trSv+gnZ/+BC/40f21pX/AEE7P/wIX/GkMu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu0VS/trSv8AoJ2f/gQv+NH9taV/0E7P/wACF/xoAu1n69/yL1//ANe7/wDoJp/9taV/0E7P/wACF/xqpquo2V5o95b2d5bzzyQOEiilVmY7TwADk0AbFFFFAHD2viuTRfE2l+H7jS0TTtRkuVt7+OY4jlWV8RtHswoPQHcc9MVbufHlva+NbzSLqO1tNN0+1S4vNUvLwQojOxVUUFcNzgEll5OOSMVm6j4c1bxEk8MSWUNmI5xbXZuX8+G5W5Mkb+WI8YDIv8eevHaq974G165vNWgX+zfseoaG+nNdPcyec0zF3aUx+VjBeQ8b+Bz7ULZX8/1t/Xp5jsm38v0v/Xr5Hat4k0NFmLazp6iCVIZibpP3cj/dRueGORgHk06bxBo1vdx2txq1jFcSRGdIXuUV3jAyXAJyVxznpXFN4N8TS3NzfSjSRPJHAYoYbqaNopY4mjLCfZyCG6GIgjgitHQ/DGs6Tq0n2uLSNQtbp4LiS5cGOW3mSFIj5cYQqV+TKncu3ceDTtv/AF/X9IlbXZf1nx1pGn+Hr3UtLurTWZbaxa/W0tLyIvLCDgyDn7nB+bnpgZPFaa6/pYubOzudQtLe/vYxJDZyXCiWQYydqk5bHsK86uPh34rbRTY20mir5el32mJvll/epPIrK5YJ8hGOVw/TGecrsjwdrkzS290umG1vp7W7nm853ltJIVjBSIeWA6ny+GJQruJwelCtb+u7/TX8Bvb+vL9bm1rPjSy06K1fThFqvm6lDp8/2a6T/RWkfZufkng8bQM59OSLp8W+HBbtOfEGliFbj7KZPtse0Tf8885+/wD7PWuF1nwD4mvdMksLB9Pt7c3NrIgF/KGjWKQyMUcwsycnCoSwXqCPu1Y1fwNrut/2XLqcGnzGxgmspLS21a5s47iKTb+83RICp+TBjIZTnrwKFt8/0X63+/yB/F/Xn/X/AA51Nv4utf7T12DVEj0u10dog13dXCLHIrruD5zhR25OfYVJ/wAJn4dOsxaYNYsmuZrQ3qAXCYMQ/iznkYyeOyk1xmofDvXLy7vGiNnDbxz2c1nHDqdzE0ogiMZR5FXfHndkMrMcgZzzVg/D/VLS1ePRItMtVm0iaza3ubmW7WOV5TJ96VGMikscsw4/unOAv6/D/MWtv67/AOR0dx41sDdaGNHMOr2er3jWgvbO6jeKFlRn5IJ3E7SMD05I4zrXmt6Vp99bWWoanZ2t3dnFvBPcIkkx9EUnLfhXAWHgbxNY6nazgadLEmvf2rL5uozO4Q2wiZQTD8xyWI+6MAD5c8aPjXwfrfiHWln097AWyC1dfMmaGTfDceYQ22Ml1K9AWwpydpzkVZaf10X5D3+79X+ljrodc0m51D7Db6pZy3m1m+zx3CNJhThjtBzgHg+lZeleMrLWfF99omneVcR2dsszXkNykiMxcqUwpJBUqc5wfbvXGab8PvEltFb2v2PQrC3FzqEjy2V7IXiS5BA2L5CglNw4yAdo6dtLStB8VaFrg1me20aVU02300Wdm0oaTZIf3gfZhflbO0qQDwWAG6klqr/1o/1sEtL2/rVfmrnodFFFIAooooAKKKKAMLR/+Rq17/eg/wDQDW7XG3OvQeHtY1u5miknkmuLW3t7eLG6aVwQqjPA56k9ACa2LHVtUSTb4i0u205BA8z3EF6ZoUCkfKzMiYOCTyMccE84ANqistfE+gPpseoJrmmtZSbtlyLuMxvtBLYbODgAk+mDTk8SaHL5vlazp7+TCs8u26Q7Im+6554U9ieDQBpUVmReJtCnmjhh1rTpJZJ2t0RLtCzSry0YGeWHdeoqQa9pDahcWC6rZG8tU8ye3FwnmQr/AHmXOVHuaAL9FU7DV9N1UyjS9Qtb0wkCUW86yeWSMgNtJxkc89quUAFFFFABRRRQAUUUUAFFFFAGfb/8jDff9e8H/oUlaFcn4p1y/wDDkeq6ppelLq0tvBblrU3BhZ1LSD5TsbLZI44z60zX/H0Om+FtJ1fSbMak+sS28dpE0xiXErKoZ3CsVUFgD8p5IHeha7en37B/X3HX0VkR+K9BaNvM1zSw8c62syrexsI5z/yyJyPmyDhSATjpWfq3jvTLTSft2jS2+tol9DZTiyu42Fu0kgTLkE4wWHGM+3Ug62A6eisqbxT4ft9WGlT67pkWoscCze8jWYnt8hO79KSPxJpca6fHqOqaXbXeoKDbwLfK3nn/AKZE7TIOeoFG4GtRSEhVJYgADJJ7VmW3ijQLyza7s9c024tlk8pporuNkD/3SwOM+3WgDUori5fij4fluYo9GurbVIv7Qjsrm4gu4/Lt96bhITkkr1GQMZUjIwTXRL4j0R4beZNZ09orpQ0Di6QrMCwUFTn5gWIHHcgUb/18w62NKiuY1bx3plppP27RpbfW0S+hspxZXcbC3aSQJlyCcYLDjGfbqRpTeKfD9vqw0qfXdMi1FjgWb3kazE9vkJ3fpQBq0Vkx+JNLjXT49R1TS7a71BQbeBb5W88/9MidpkHPUCtagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqjrbtHoN88bFWWByrKcEHHWr1Z+vf8i9f/APXu/wD6CaANCiiigDmYPE+kaPHHZ6hdMk8txKdqQvIIw07qrOVUiNSeAzEAnjNWJPG3h6C8ntrjURAYEkd5ZonSEiP/AFm2UqEcrg7grEjBz0rOsPD9/wD2w+s6RqkVp9o8y2vIJrTzhIqTylWQh12MN7DJDDkccVGPAt6sf2ca1E1payTz6aklkS9vJKrqfMYSDzFXzWwAEPTLHFLp9/8AX9fgPS/9f1/XUtJ8SvCLW/nnWUji2wsrywyRiQTZ8spuUbwdp+7nBBBxg1ZbxzoC6d9t+1TtH50kBjWynaYOn3wYgm8BepJXAGDnFci/wt182dpap4p09Y7a0s7QZ0ZyWW2k8xD/AMfPUnr7dMdasXnwtuNTuGu9V1DR9QuVvZrmFLzRfOt1WUKHRommO4/IpDBlI56g4qna+n9bW/UXb+un+eh1D+NtAW6jt0vmneVA6Nb28kqHKb1XeqlQxXkKTuI6A1lWPxL0S+0601I3cltDJZSXslm9hO9wYVYL5gCjO0Z5O1gc5BwpNWtI8I3ehalOdK1K2g0u7KPPYrYAFXWNY/3TK4WNSqL8pVsY4Iqho3gG+0m+0QvrVtc2OlWEtgbd9PIeWOTb/H5uAR5afwnPzdMgKadP60f62GrdTcl8YaPBGXlku1/dRTKv2Cfc4kzsVV2ZZzg/IMsMHIFM1Txjpmn+CrnxPEZLyxghaQCGJizEHG0rjKkEYOQNvOcYrFvPhrHqHhS30m/v4r6a0ulngmvbMTxEIpREkiLfvAEOD8wycsMGtSfwdDP8PrrwxGbOxW5t3iLafZCCGNmzlkhDHAyc43E+/ejTWwlur/MfbeM9JnW5nF8ZY4pIoTbR2M3nxSOu7YyYLFsc7doKgHPtYbxdoyyFFuJpD5QmBitJZAQULgAqpBcqCdg+bHasNvA+qzT6pJe6xp119ukilRJNJO2N402qT++yexypVgR1qzaeC7q21Swu21jzPs0SxzyfZyJ7oCPYFeQP8y5LNh1Y5xhhjlPy/r+mC8y3D498OXEImiv5DG1pHeozWsy+ZE7bUK5T5mLEDaMtkgYrSsNd03UtJfUrW5xax7vNeZGiMRX7wdXAZCO4YAiuDl+ED3mkWmn6hr4ngsrRbWCIaenlOElEkZlVmbfgqAwBUN7V09p4MtYvBV74dlSxtor6KSOY6RYizjG9dpZYwzYOO5J59uKbtZ/110/APtW6f1+pjW/xJhuvE2pWMlza2FjELJbGe5tphJO8zupUowQ87DtIyMENkjium/4SvRs3W67ZRalhIzQSKpKsFIQlcP8AMwX5c/Nx14rkL34a69fXcl9N4uha7lWzR92kgwkW0plQ7RKGDE9Tvxy3HK7dK68AT3d3eTHWFthMyzRLa2nlgTrKsqyyLvKyEFQOFUkFtxYnIen9f16j/wCAaP8AwsDwz5cBfUvKkuJ2t47aW3lS4aVRuKeSyiQNgg4K5ORjqKztW+IMFr4r0XTLAwva3VxLFfXE8UqCHbC8mFYqELDZ8w3ZXoV5yFm8Eancapp+pza3am8h1Fb+6I05gk22IwqiL5uYxsLckucnPQYqhqnwrl1Yi0n8RTxaQl7cXkdtDbKJQZ1kEqGViQV/evjCggE8k4IX9fkPT+vn/wAA3f8AhYnhZQgl1TyJJJlgjhnt5YpZHflNsbKGYNg4YAg9jWnp/iLTdUu2trOSYzKCSsttLEDjG4AuoBILAEDlTwcHiuPsvhhNp1vYR6fd6FZPaX0Ny8lnoIga5WIHasm2UZb5j83T0UV0dh4amsvFc+rC+jEMyvut4LcxGVmYHdIQ+1yoAAOwN1yTmjT+vRfrcjX+v69DoKKKKQzhdV8PSeIdY1RbW4W2vbG9s721kdSyCRFbAYDqpBIP1zV/U9K8S+INCkh1D+zdPuY5IpYYLed7iGV45FkHmO0aEKdu3AXgEnJ4AvaP/wAjVr3+9B/6Aa3aFpt6/P8ApB1ueaXXgfXZvFen+I00zQDeR3sl3cQm6kATNv5IVJPIJYk4dmKr91Rg4zWDe/C7xXdeGrTSvsHhtxDo82nOZL6XaHeZZBKB9n6rsB7HJ6jHPtNFNNrbp/w36geX3fgvxXPe39zDp+gRNc6lYXiAahL8q2wXKk/Z++wY9Nx9OZtS8AazqOkyaZcQ6PcQ2r3ctnPLK4e4M6yDZMvlkKAZMlgW3FF4Xt6VRSeseX+tkv0BaO6OK8GeHNc0XW5Z9TtNKgtW0u0s1+xXbyNvgDclTEgwd578bR68drRRVSk5O7EkkrIKKKKkYUUUUAFFFFABRRRQBzGv2+qXdxfQ6HBZzXJW0YreXDQoFWR2PKo5zxjGO+e2Dzmo/D/WotOmg0ZrC4H9qQ3VpDd3MkSWkKzLcPGpEbklpAR0AC7fTFd1b/8AIw33/XvB/wChSVoULR3QdLHEw2f9qeNLybSr+1ktkh33sEf72OO/VTGAW6EhSdy4B+RCcZrmk+HXiyGxuljGkST3S6buV7+VY1NrKXbaBBhVYBQFVQF544yfW6KadtvL8P6+6wdTx60X7f421FbddL1Ii6uQmkyapseFpV8t5JLf7MXCN3LSFcHcFyQtWB8OvFMmi6PYzHSI/wCzrWyiPk3Ui5e3nD8sIQXVkHAbhGzwc7q9Zooi+VK3S34bfmO+/mZIfUdV0LUIpLWCzuXE0MHmFpY2GCFdgyKSD3XHrgkYJ87h+G/iFdStbq4tNFutl/Z3jme+kcxGGMowjzBgZ4IACgYxgda9aopLR39Pw1JaurPz/E881Lwb4gbVriWxj0q5tZtfh1bbc3EkbbUiRCuBGwzlMj+lUvDPgPxDpvimPU9Q0/w/CEtb6Dzre5klkzPOZkyGgXIXJXG7oxPtXqFFC0Vv62t+Q3q7/wBb3/NnkifDrxZDY3SxjSJJ7pdN3K9/Ksam1lLttAgwqsAoCqoC88cZMNov2/xtqK266XqRF1chNJk1TY8LSr5bySW/2YuEbuWkK4O4Lkha9hopt8z18/xt/kHSyPJh8OvFMmi6PYzHSI/7OtbKI+TdSLl7ecPywhBdWQcBuEbPBzur1kdOetFFNyb373+8AoooqQCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9e/5F6/8A+vd//QTWhWfr3/IvX/8A17v/AOgmgDQooooA4m11rwto1stlr/ii0s75Xk3R3Gr/AGd2/eMA2wyDGcfjXTpplpIivHNdsrDKst9MQR6/fryzxLfzP4602w0LUNMGqnTtUVrS6w7zK1wh8tRuG12CsVJDD5TwRkiG48VSadpfh/Q/AHiDT7PT7ez8kXeq3iRf6Qm0C3mzDJh8HJjHlsf4WGKaV0vP/g/5Dej/AK8v8z1v+ybf/npef+Bs3/xVQ3Nnp9lbtPeXc9vCv3pJdQlVR+JevMrD4iXY8TrHqXi/TmVfEDaebGGOJFaE2+4dcyZWT5c5GTkEcgDD1Dxn/a/hvXIvEGtW19Ym3s72ye7EEbRSG5ZWUKijYV2j5Szsvds8Att/Xn+Qnom/63t+Z7f/AGTbf89Lz/wNm/8AiqP7Jt/+el5/4Gzf/FVyHxL8SXek6TZ/2Lq5sLi6SaSCRFi2zlIywXfIrgZ4OFVmbtjk1yd58TLtNQuppfGGm2sNvFpU6WqLCN/nNidHLEk4U7srtI+X3yRV3b+tQ7ef9fqeqyWenQ3EME15PHNOSIo21CUNIQMnaN+Tgc8VN/ZNv/z0vP8AwNm/+Kryuz16PWfib4cvbu+e41CO8vreSxjs1P2BNrKgLKu8BxtbLsVb7wwBWh4t8WanoXibWbX+37iFYTp11aWq2sUjtG8zRzoqiMu64xzywJGDzgiV7ef9f8EW7a/r+rnf3Flp9pGr3V3cQozrGrSahKoLMcKvL9SSAB3JqX+ybf8A56Xn/gbN/wDFV5enj69SJ9QufGWneTF4mGmtD5MSI0BdeOSWDAZJJPTdx0Ip2fxPnj23F74ysbhml1O3NvbQQsMQ5MMioG3ljgYBfDBh9aX2b/1sn+o+tvl+LX6Hrn9k2/8Az0vP/A2b/wCKo/sm3/56Xn/gbN/8VXklj4/1jy4rWfxZZjfrttapczi3kkmtpYVfKlAkeck8hWHbJxk9dbnX7XxZ/wAI9ca/ql15kiX0V69tbD/RlUiSIlYQufM2g8BsOMEYNO39fJP8n+DFe39eq/NHUXNlp9nbSXF5d3EEES7pJZdQlVUHqSXwBSQ2enXEkscF5PK8JAkVNQlYoSAwBAfjIIP0Nec/GPVTLp+taHfXhs7c6Qbizg+zpJ/aM2XBQblJym1GwmGGd2cCi28f3F1Z6v5PiSyjj07Uo148u3eO2Nur+WfNVgrb9ykybclWUFGxgSum/wCt7FuJ6Z/ZNv8A89Lz/wADZv8A4qk/sm2H/LW8/wDA2b/4qvPpPGOpz3ieTrL2d6j2v2XSbi1jU6jBIkZklKkbwQWkzsYBNnzZFUdM8ZX9/wCFNPvtV8WRC0v9RuLG71G2t4BDaqjS+XjcrhTJhBlywwVAGTuI07E6HpVtZ6feQCezu57iJiQJItQlZSQcEZD9iCPwqb+ybf8A56Xn/gbN/wDFV4hoPifXtP0DRNK0C8sNGtVjlaCXVT9iiupftL/ugrQOWG3adiFD83DHBA6iz8Ware6Pq9+/i2y/0LV5LRvJEMMccK4b77rIFbCty5CkZHBwQaf16pfqK76/1pc9H/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qmaBfHUvD1hes0jNcQJIWkjCMSR1KgkD8CRWhQ1Z2GtUcUbvQ9F1zWJNd1ePTbcSQpHLdai0AZijHG4uNx4PBJrXa68OrqkGmNraC/uU8yC0OrP5sqYJ3KnmZIwDyB2Nct4wgea18RMkbSCC9064kCqWISOVXc4HXCqT+FHizxnZS6TqOveEta0+Y6VpNw325Cs8McjNEUjJDY3ttIC5yMgkHgFaW1/rQpRu0l1O6/sm3/56Xn/AIGzf/FUf2Tb/wDPS8/8DZv/AIqvLU+IUhvJrE+M7eS0ae1afVIhbk2EUkDMSMKUC+YqLucNjfgk8GtHVvFeo27mC38Tp9rgso59NVLaIJrshLblAIJb7qjERBG7dyCKdnexCd0eg/2Tb/8APS8/8DZv/iqP7Jt/+el5/wCBs3/xVeUt8QL7/hJJba48Z2EG3xGdN+zxxwKFgaEHPzZbcj/KGzjdnIPCjJT4p31zayonjrTozb6Vfy70S38154LjbCWJyv7xMfKqrkEkdQQul/62v+RVtbf1vb8z2z+ybf8A56Xn/gbN/wDFUf2Tb/8APS8/8DZv/iq8ug+I0zaheWbeKbeW3kgsbiS9hWAnT45lfzXUAEbFIi5cNt8wFiRS3fjXUoLrTLO58Z2dpY3P23y9SaKBZLuKOMNHMC37vGSRkJtbbkcHFOS5b3JTvbz/AFPUP7Jt/wDnpef+Bs3/AMVR/ZNv/wA9Lz/wNm/+Kqh4L1r/AISLwPo+rNcRXMt1ZxvNJCRtMm0bxx0w2RjsRitynKLjJxfQE7q5S/sm3/56Xn/gbN/8VR/ZNv8A89Lz/wADZv8A4qrtFSMpf2Tb/wDPS8/8DZv/AIqj+ybf/npef+Bs3/xVXaKAKX9k2/8Az0vP/A2b/wCKo/sm3/56Xn/gbN/8VV2igDl76bRNE1K7n1vVRp1qIoFE13qTwqWJk43s4z04GfX3qy154bW+tLNtdjF1fIJLWA6u++4Q9GRfMywODyM1kePbeS50DxCkMLTMtpayFEQsxCyuxwByeAar694x02+s7jVPC+tWE503TLqZr1Cs8Nu2E2q5DABjg/KSDxUt2Tb6DSu7HWPZafHcx273dws8qs0cR1CUM4XG4gb8kDIz6ZFS/wBk2/8Az0vP/A2b/wCKry688fX2mQae0vjLTGa/8OT6gpnihwtwqxldoUjKn95hc5yrcnGBWh+I07pLZHxrDNPcW+nSxzQLahoHlDeagJGxFyqfM6uVLgYJZRWji1df1u1+hN9E++v5f5nrX9k2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVXmHhrxfrPiXWNC0i48Vw2ct5o801wtpFAbjz45guQXUryobjyxwrcf3ep8IXWtXupS2uqanfSyaNvtr0ywQol3KzbkfKxggCMo2FwPnAOSDRy/r+Dt+f5oL6fd+J039k2/8Az0vP/A2b/wCKo/sm3/56Xn/gbN/8VXmM3jLXm8N67qNnr9rdvZ6y2nl4Vjihs4N6jzXbZKQVGfmIZRkkqccZt94h8UWVzp+ptrcWpXaaNevbJpzpPbXbCWLadwhUuwRtzFFAzHwANymY6q/9bXH5f1vY9g/sm3/56Xn/AIGzf/FU2TTLSKNpJZ7pEQFmZr6YBQOpJ315XD421q3t9DXUPGuhm11HVGg+2W08Vw5h8ktzKYoowyuMcR8b0B5+9TtfGV5cAa3/AMJjGZIfD1yY5HSFreWaOYqWZQo5IEZIDDkr2IBHp/XlcO3n/nY9fi06znhSWG4upI5FDI6X8pDA8gg7+RT/AOybf/npef8AgbN/8VXnlx41vbp4Xsdfjhuhb20un2CxxOmsh1BkIJG44O5f3bLsxlsiq/hPx/PqHiTTIL/xdp94bu/v7JrOFYUVhGx8p1AJcEgDHzEEMOp5Ncutib+7zen4npf9k2//AD0vP/A2b/4qj+ybf/npef8AgbN/8VV2ipKKX9k2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVV2igCl/ZNv8A89Lz/wADZv8A4qj+ybf/AJ6Xn/gbN/8AFVdooApf2Tb/APPS8/8AA2b/AOKo/sm3/wCel5/4Gzf/ABVXaKAKX9k2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVV2igCl/ZNv8A89Lz/wADZv8A4qj+ybf/AJ6Xn/gbN/8AFVdooApf2Tb/APPS8/8AA2b/AOKo/sm3/wCel5/4Gzf/ABVXaKAKX9k2/wDz0vP/AANm/wDiqP7Jt/8Anpef+Bs3/wAVV2igCl/ZNv8A89Lz/wADZv8A4qj+ybf/AJ6Xn/gbN/8AFVdooApf2Tb/APPS8/8AA2b/AOKo/sm3/wCel5/4Gzf/ABVXaKAKX9k2/wDz0vP/AANm/wDiqqarp1rBpN1K/wBqlWOJmMbXsuGAHQ5bvWxWfr3/ACL1/wD9e7/+gmgDQooooAwdC1KSXSVkg066ljklldXVogCDIx7uD3rR+33H/QJvP++4f/jlM0T/AJBp/wCvif8A9HPWhQBS+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrtFAFL7fcf9Am8/77h/8AjlH2+4/6BN5/33D/APHKu0UAUvt9x/0Cbz/vuH/45R9vuP8AoE3n/fcP/wAcq7RQBS+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrtFAFL7fcf9Am8/77h/+OVQs4ri1v7i8ltdUu5puFM72+IUySI0Csoxk9TljxknArcooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooApfb7j/AKBN5/33D/8AHKPt9x/0Cbz/AL7h/wDjlXaKAKX2+4/6BN5/33D/APHKPt9x/wBAm8/77h/+OVdooA5jSruZfEmtOun3Ls5hyitHlPlPXL459ia2vt9x/wBAm8/77h/+OVm6VIkfirXd7quWgxk4/gNbf2iH/ntH/wB9CsJYijCXLKaT9UOzZW+33H/QJvP++4f/AI5R9vuP+gTef99w/wDxyrP2iH/ntH/30KPtEP8Az2j/AO+hU/W8P/z8X3ofK+xW+33H/QJvP++4f/jlH2+4/wCgTef99w//AByrP2iH/ntH/wB9Cj7RD/z2j/76FH1vD/8APxfeg5X2K32+4/6BN5/33D/8co+33H/QJvP++4f/AI5VtZY3OEdWPoDmnVtCpCouaDuvInYpfb7j/oE3n/fcP/xyj7fcf9Am8/77h/8AjlXaKsCl9vuP+gTef99w/wDxyj7fcf8AQJvP++4f/jlXaKAKX2+4/wCgTef99w//AByj7fcf9Am8/wC+4f8A45V2igCl9vuP+gTef99w/wDxyj7fcf8AQJvP++4f/jlXaKAMSC9nGu3jDTLokwQgoGiyOZOfv45/pV77fcf9Am8/77h/+OVyfj/U9Q0XSdZ1LSGtlubW3gkAuoWkRgDLkYVlI+ufwqp/wmmi2Mn2HVNWge+geKC7aC3kEccrj5Q33hGCem5u4Gcmvls1z6rgK/soUOf0bv06cr7rqbQpqSu3Y7f7fcf9Am8/77h/+OUfb7j/AKBN5/33D/8AHK4k+PPDnyqL6QzMZALZbWYz/u/v/uQm/j/dqaTxjoMZtSb/AHR3ao8c0cLvEof7hdwpWPd23EZ7V5D4vxC3wb+9/wDyBr9XX8x1sl5dPE6Lpt9GzKQHVoMr7jLkZ+oNVdMWbTLUx/YdSupXbfNcTvb+ZM+ANzbWCjgAYAAGOAK5ODx3pMgvzKt5ELO8NoF+wzM8zBcnYgQlsfNnaDgDJwDTh4/8MPcCGLVo5nJhBMKPIqed/q9zKCFDcckjqM9RVf63YlN/7G//AAJ//I+gvq6/mO3+33H/AECbz/vuH/45R9vuP+gTef8AfcP/AMcrkm8W6Il7cWr3ux7dXaR2icR/J98CTGxmXuoJI7irWk63Y63BJLp0kjeS/lyxzQvDJG2AcMjgMvBBGRyCDWUuM6sY80sK0v8AF/8Aaj+rq9uY6P7fcf8AQJvP++4f/jlH2+4/6BN5/wB9w/8AxyuWv/EulaZqUVje3LRzylQMQuyIWOE3uAVTceBuIyeBmqR8aaLb6Quoz6kt1bSzzRxSWdrLJkIW3fKgYkKFOX+7xngVUeMa0kmsI9dveevp7gfVl/Mdt9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlchceL9Et7lYGupJHZAw8m2llXld4XcikBivITO49gaydc8f2sfhW91Dw28d3dxacNRhS5hljjeHON2Soyf8AZyDnAOOtXT4txFRpLCPW32tNfPlF9XX8x6L9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOVx03jHRrfUJLCW4lN1EpLpHayupZU8woHClS+35tgO7Haquj+N9M1mC0ukvI7RJdON/LaXMLpLHHkASFmwAg+YdDu4KnA5X+t9fl5/qjt/ifXb7HWwewX8x3f2+4/wCgTef99w//AByj7fcf9Am8/wC+4f8A45XFf8J14dVV83UGgkaZYFgnt5YpmduVAjZQ5yOhxg1o2eu6bfaIdXt7pRYBXZppVMewISG3BgCpBBBBAxiolxjWgrywjX/bz/8AkRrDpuykdJ9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOV5taePY7rVtUgnuLawtYJrSGzluLeYSStMT8rRuEYMdvy4GMENkjiug/4SbSd1yGumUWpYSM0LhSVYKQrEYfDMF+XPPHXitKnF1em7Swr6fafVJ/yeYlQT2kdT9vuP+gTef8AfcP/AMco+33H/QJvP++4f/jlcT/wnvhv9yh1BlnmkeKO1e2lW4Lou5l8kr5gOMHBXnIxnIqpeeN4V8Xabplk0L2kzTrd3EqSL5ZjjZiEYqEbBUhsMSvQgdiPFuIbt9Ua0b1k1ot/s+X3g6CSvzHoP2+4/wCgTef99w//AByj7fcf9Am8/wC+4f8A45XE/wDCeeG1C+bqXku8yQpFPBJHJIz/AHNqMoZg2DhgCDjg1vRzpLarcDckbIH/AHiFCBjPIYAr9DgisqnGdWn8eFa9ZW/9tGsOntI2Pt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHK4hvG+hzQn7PqsdvJ58MS/araRfM8xsLsVgpcPhgrrleM8gEVYHjDQjqFzZNfbJbVJHlaSF0jxGQJNshUI20kAhScE81b4vrr/mEf3v/AOQD6uv5jr/t9x/0Cbz/AL7h/wDjlH2+4/6BN5/33D/8cri4vHOgzTQwpPdCaZpESJtPuFfcieYylSmQ2z5gDgsOmapDxvC+uWjpJbDw/c6PLqS3jB1k+R0BypA2rtfPck+mOaXFuIbs8I16yt3/ALvk/uF9XX8x6D9vuP8AoE3n/fcP/wAco+33H/QJvP8AvuH/AOOVwj+P9G8/TorcXkpvrxrPH2GZGhdULnerIGXjHUDg7ugJqaLxjpEejw6hNqK3cFw0rRS2VpK+6NXILbV3HavAL/dzzwCBQ+LsQkr4R6/3n5/3PJh7CP8AMdr9vuP+gTef99w//HKPt9x/0Cbz/vuH/wCOVxg8ceHHvhaRapHNKZYoiYUeRFeUfuwzqCq7u2SOo9RXoFe9k2cVMz5+ei6fLbd3ve/ku34mVSChazuUvt9x/wBAm8/77h/+OUfb7j/oE3n/AH3D/wDHKu0V9AZFL7fcf9Am8/77h/8AjlVNVuLq60m6t00u6VpYmQFniwCRjnD1sVn69/yL1/8A9e7/APoJoA0KKKKAM/RP+Qaf+vif/wBHPWhWfon/ACDT/wBfE/8A6OetCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzPxXrVxo2s3y2AjF3qF/aWULyjKxmQHLkd8AE47nFXCb3w5F9p1PWbjUrQJsKzQxCZ5ndVjVfLVVIJJABHU8k9p9S0S38QazrdleQySR+ZbuGjJDRuoyrKRyCCMg0x/BZutOktdVvdT1J2C+Xcz7Fkh2sGUp5aKoIZVOSCTgZzX5RxDS58yqe47XV/dvdcsdnbpr1Xz6d9J+6v61u/wDgGe3j+zS7gsZdJ1ZNSmmeAWRgQurrH5gBcOY/mXkHfg+2Diu/xP0eLTTfzWOqR25sTfRt9mDGSNWVHAVWJBVmGSQF5yCRzV6b4ema8tL1tX1kXttO1wbkLBumcx+WCwMW3AQkAKAOSSCeazZvhDDNp8Nk2ua+IYbKSxAUW+WhkYMyk+R3IXkdAB758mGDwrtzwl56S872022tfW176l8z6F7/AITyyW8e3m03UoTHeRWcryRptjaXHlMcPyrbh0ywz8wWn3XjvT7Nne4stQFp+9EN4kIeO4eIMXRArF8gI3VQDtOCahuPhm1zJcyS67rpe5ube5dgluPngx5ZH7j2XPrtHvmxJ8PIZIp4BeaottIZXggGwraPKGDvHlCckO/DFgNxwBWf1Ohp7kvPSXZeXf5W8xqTvqzW8G+KLbxBqNxDBaXlq8drDcgXKKvmRy5KMMMf7rAg4II6dK6+uM8I+DD4e1qS9/tPU7rdYxWfl3SwhAkZ+T7kanI3N353H2x2dfp/DlOFPAKMFZXe9/Lv5nBUcnL3gooor6IzCiiigAooooAKKKKAOL8baNc+IbLVtKtLyKya6gt0aaS3M2FzLnCh1598/hXL3/gXXtQmvJZfEWnq93PZzvt0l8K1uQwx/pHQsBnPbj3rpfHusXWg6RrmpafbNc3FvaQsirt+U/vfmO5lBA6kZz7GsHTvFr6TqFpouvrqs11eOfIuLq3t0YExmTyiIn/eEAEb0QrnAzmvzLiSWLjjnKi1ZJaWTelm3qntZfodlHlcdSk3g7xLaeKbe9sdUs2D3F5cNObA7bcyrGAhQzZfO3ggjBHPHFXrf4ftZWzafY6rt0y6hjjvoJbffJKUGNyOGAjLAAEbWHpg81VbxjcxX2k31rJdXukXOmXd49s1vGly5iZMHJKqMK5wvB45JNaE3xG0y3kCT6fqa7/sflFbdXEguciMjaxwAVIO7HI4zkZ+aqSzBqKVnp0S6Sa1Vt09u2+9zf3Etev/AA7K2pfDddVnkZrqznJ1F723gvtPW4hUyIFdHQsN/qCCpHHvl1z8LtbaW9/s/VNNsoLmO0jWCPSsJCLeQyKFCzAYLMeMdMDryblh8R9Fl8Z2nh+US29/JKsRjklhJjl27/LZVkLZx/EFKZ43Z4r0mvqsgyyrjaMpYqUo2tayja299Yvqv6uYVpqMtDzh/h1qM+k6potzqKPpF+0sghW2AljeRi7fOXIZN5JClc9iSKs6F4P1Pw5FbwWNto8aSS5vPsGmraI6hTg4Epw+cc/MD0wvWu+or3ZcL4WUXCVSdnq/h37/AAbmXtpXvY861T4ajUPF/wDbpg06VpEjSVL7T0uXUpna0Llh5bc+jDgHFUW+HWr6nob2N3OtpE99fyy27oJkmjmkcoSA4GQGDDORzyM9PU6KuPDOGikvaz0tb4dLJr+XzH9Yl2R59ofgXWdCuCLbU4XtJ0i+1Qta/M0iRLHuR/M+QMqLkEN3wRmsWX4Saw+g/wBmJ4gVFXTX0xP9BUqYmYHLDzMlgBjIZRnnHY+t0U48NYeMudVZX0/k6bfYJ9s1Hltp8zzKT4aapdeI7fVr7VIp5LeYyKPsp3KrQGJ41YynapJ3AAdeu7rUMXwt1UW1nZ3GsRvZ22kNpeI7MJKQduHD+YQCCiHBU/xeox6nRR/q3Q0/ez0Vl8Hn/c82L2t91+Z5pd/D3X726t7+41i0Ooxz28kkosCI3SEuUUJ52QSZGJbce2AKtWXgLUV8G6hoOqX6XBvZJ3FzaweQY/NcucKXfOGY456YGO59BoqJcMYaUVF1J6NP7HTb7BXtne9jyu8+GXiO8ku7mXxHC15dvaPIW05fJH2d967UEoYEkDOXI5bjkbbl18OL+7uruVtRWBZiJY1trcRgTrKsqySDeVcgqB91SQTksTkekUVX+rWH0/eS0/weX9zyQe2drWPNz8P9ak17T9Xn1S2e5guzdXIWy2rN+58kKg83KAKW5Jc5OegxVWf4U393JFb3WtTf2ZBLcvFbRwIsm24DB0aQk5A3tghVIB7nmvUqKFw1h1a1Weit9jz/ALnmxe2d72/M8qtPhTfWFvZx2Eui2b215DcNJa6MsLXCxZ2rJtlGW5PzcD/ZrrV0nU7yPULbU44/s0rNHD5YCN5ZXByd7ZOSefl+gxk9RRWdXhXCVnepUm3/ANu/pEca0ou6R5LF8LLvR/D4stNtdMklF1Z4ltbCO0keKK4jcmVwx8xgqk5AXJzxk1PefCi+1DVrm9vdW8wzJdRK4tx5yxzFWVd5cg+WVGPlAxxjOSfU6K3/ANXaF+b2s7u+vu9bL+XyD2ztayscBdeDfEV9/ZNxeavatfabdGZZY7HbG6mN42BQykhiHJ3bsAgfL2rIh+Fuu2sNpFb+I2AtdLm09JTaASjzGDbwySKBgogAxnAPzZOR6tRUR4Zw0FaNSX3Q8/7nm/vD20u35nl+n/C6/wBOuo7mC/gjkj1M6iFis9qBmt/JdcGQ9fvZJJyed3WpNO+HniDTIreSDWrb7ZEbhHk+wfu5IppPMK7POyGDZw27GOCpr0yiiXDWHl8VWb/8A8/7nmxe1fY8ob4V61AssOmaxawWpksmiSawMjILXBQFhMoOSoycDvivVx0560UV62Ay6GB5uSTlzW35eit0ivxuRKXMFFFFekQFZ+vf8i9f/wDXu/8A6Ca0Kz9e/wCRev8A/r3f/wBBNAGhRRRQBwcvxA0vw9ctpl8boXG64nVYtNuZwYxK25t0aEYGRnnjIz1robPX11CyhvLGSCe2nQSRSx8q6kZBBzXlviKxvrrxlp1loUmo2LW9nfwrcxWTvBuaZCkTylGVQwjbJBDDA5BIBp6guo3Fpo2neH11jw1pdpbtbkLpl3M8FyCu0ERuhdQM4c74ic7q/MswxmMWJlGlXlH3peaSTklolfWytv8AlftjGNtV0/yPZP7Tm/ux/kf8aP7Tm/ux/kf8a8g06bV5tauoRqGu3N/a6wVaVlf7Otr5aGRSqjysjJ2rgtnGM8kyaZ/aB8LaVPrL+J5oJ5Jk1J1F0l0pDN5J8uMK6rzyY1GflzkA482WNzWK1xL6fim9Pu07vQaUG7cv9L+vuPT9W8V22habJf6tPBa2sZAaRwepOAMDkkk4wKuDVJiOFj/I/wCNeK+IbfxFc6Dc2OqWuu3s7WCDTltd22RvMbf5+3Cb9nl5EnHXb82auOdfttZkS0tfEUksetiWKNpZWiFvLajIZmfy2RZc/LuO0jgDIzf1zMuTTFO+vVWsrWt99m/VdNWowb+HT/h2euPq7xLul8pFyBluBknAHX1OKbFrbzSSokeDE+xt8TqCcA/KTww56jIzkdQa8hu9Om1TwjAzr4pkvFvbKTUbe4a5Uxusy+a0WMEjBJ/dEoNoIAIzV+M6jPDql6x8RTPpWtC4hhkFxAZ7YhAyKqhRKq4fCgNnaOu7Jj6/mSX+8yve35W++/l3Dlhp7u//AAf8j1P+05v7sf5H/Gj+05v7sf5H/GvI9T0/xLH4gtEi1LU7C0khSeFkgur7Fw0jNJG5WUKoAKKPNBQDONpBrpfGrX0Rs57H+0ZfLV/9HsllHmudoXLx52kZON6lOSWxgGsZZlmanCKxTfNf+u346Pcrkhr7p2/9pzf3Y/yP+NNbV3QqH8pS52qDxuOM4HPPAP5V51qGl30fiG80+KfVvst0p1NZ4r+ZmhZFKmFRv6F2Rgn3T8wPQYyDYaldXWhSS2+sTLp+quvnGW6UP/ozAOVc71TzMAliy8n5irYq4ZjmMlf609r9O3rvfS3zE4QX2f6/4bU9e/tOb+7H+R/xo/tOb+7H+R/xrw1D4utdAkubrVdfN+ZrcXdna6Vckq/mjzCrs0isuzf/AKkKnC8DODpWV5qNtr1s0X/CTyW8evvEontrx0+xtCeW3L8y+aRhmyV7ECtpYrNUm44pu1+j6LzXW+ndai5Yfy/1r/l957B/ac392P8AI/40f2nN/dj/ACP+NeY+O5dZHiK1bSE1hfswtpQ1qJ2hkU3AEq7YxtLBOT5hbj7q5yaydJ1DXUvIJYm8S3F69zqES/brO5SExkE25dTGI152fNgYyRwOBnTxubToqqsS/T5X+79dCnCmna3b8T12y8S2t54hk0ZbiFr2GITSwqDuRDnBPYZxW5Xkfw+juz8QxdNYa4IZdIRJ7nUw+FuA7l1HmHPfgINnpgEZ9cr7/h+rWqYWTrTc2pbu38sdNPO5x1bc2isFFFFfQmRhaP8A8jVr3+9B/wCgGt2vOvEeu2vh3VtXvr7RZNWjNxbQhIo4nZC42qf3jqMFio4PcdskX5NTtY9etNMPhRT9qhab7SIIPKiC43Bvn3ZBZRwpHzDB4OPDxee4PB1XSq3uv8k+/Zo1jSlJXR21Fc75Fj/0CtP/APAdaPIsf+gVp/8A4DrXnf635X3l9xf1eZ0VFc75Fj/0CtP/APAdaPIsf+gVp/8A4DrR/rflfeX3B9XmdFRXO+RY/wDQK0//AMB1o8ix/wCgVp//AIDrR/rflfeX3B9XmdFRWZbaVpk1usjaZZAnPS3X1+lTf2LpX/QMs/8AwHX/AAr6ehWhXpRrQ2kk16NXMGrOzLtFUv7F0r/oGWf/AIDr/hR/Yulf9Ayz/wDAdf8ACthF2iqX9i6V/wBAyz/8B1/wo/sXSv8AoGWf/gOv+FAF2iqX9i6V/wBAyz/8B1/wo/sXSv8AoGWf/gOv+FAGD4n0D/hJ11XSTdXNrHcW8CySWxQPtzLkAurDn6ZrGf4Zb9TXUH1TU2ulmjuPNLW+TKkRi3/6vup5X7ueQBzm74ovtN8KR6hqcmgrfW9vFAXit4IiUBMmWw7KOwzg56cU/Sr6HUWmW68I/wBltGFI+2W8BEgOfumKRxxjkEg8j1r4jPP7OjiHPE1Jxdre7y26d032udNNztaKRm2vwvFs1jv1XVLhLK2ntljle3xJHN98MVjB7DBBH3R75gk+EcUjW7nV9aE0C26CQXEPzLA5eIFPL2cEjnbnjry2er8ix/6BWn/+A60eRY/9ArT/APwHWvA+s5GndV6v3R73/l7s1cajVmkU7DwfJYeIZdRtby9ghuZhPcWSvGYXk4Bfld4JwMgMAccjk111cXBquj3HiO70RNHthdWkEc8jPZBUKuSBtY/e+6enHbrWl5Fj/wBArT//AAHWvXwGcZRlcXCMpvms/eS7abJdCJ06k3qdFRXAyeI9Gg8Zw+G7nQIYbi4gae3uHtY/JmC9VUhi24c8FR0NOt/EOjXfi+78PWuhQSz2UKTXNwLaPyot+dqkltxY4PRSB3Nez/rNgLX961ubbptf79PXQy9jM7yiud8ix/6BWn/+A60eRY/9ArT/APwHWsP9b8r7y+4r6vM6Kiud8ix/6BWn/wDgOtZukato+tS6hHaaPbodPumtJvOsgmXCq2QDyRhhg9+o4wapcWZbJOScrLfQXsJnaUVzvkWP/QK0/wD8B1qOVbOOSJV0OzlEjbWdLePEYwTubJBxkY4yckcYyRK4uyt9X9wfV5nTUVi2djp1xMUfS7EALni3Wrv9i6V/0DLP/wAB1/wr38Bj6OPo+3ofDtrpsZSi4OzLtFUv7F0r/oGWf/gOv+FH9i6V/wBAyz/8B1/wruJLtFUv7F0r/oGWf/gOv+FH9i6V/wBAyz/8B1/woAu0VS/sXSv+gZZ/+A6/4Uf2LpX/AEDLP/wHX/CgC7RVL+xdK/6Bln/4Dr/hR/Yulf8AQMs//Adf8KALtFUv7F0r/oGWf/gOv+FH9i6V/wBAyz/8B1/woAu0VS/sXSv+gZZ/+A6/4Uf2LpX/AEDLP/wHX/CgC7RVL+xdK/6Bln/4Dr/hR/Yulf8AQMs//Adf8KALtFUv7F0r/oGWf/gOv+FH9i6V/wBAyz/8B1/woAu1n69/yL1//wBe7/8AoJp/9i6V/wBAyz/8B1/wqlq+l6db6LeTQ6faJJHCzKwt04IHHagDaooooA4bT9atZdeu9FVZhdQ+ZcOzRkIUaZwMMepyD06VsV5xr/hm/wBYvp7qXRYr97qxktEbzUUWVyJ5GEp3MCACwwybmBHA71TuPBms3MHiZFsrlbma5t3trua4ika4iVUEyR7mcR79j8MoUhlBGMgfi2Z4PD1MdWl7VRvJ3vbfms+t+re2y67npwbSXy/I9D0vQrDRpr2XT0mV76c3FwZLiSXc54yN7HbxgYGBwPQVau7qCxs5ru8lWGCBDJJIx4VQMk15LrPgXVZvDcVjpej3smyG4ltjeyWfm2kxKFFVUIhjUlWwUUsM8FMmtTXvCWparBr8MOihjqNlMfMumhJaY7fLVWVsn7ufnB25G18ZFcUsFRnKMqldO712vZNLv229AUn2PSwwK7hyMZrK0TxDB4gsY7zT7W6EDzSws00YjaNo2ZTuUncMlSAMZ9QKydf0m5m8O6Tb2OjRzWVtMhu9GQxqJYAjL5YBIjO0lW2k7TtxmuY0Tw1r+my2Ec+gTRxxyalzaajHsijnctGCCww2TjKq2Bg55IGNHCUJ0ZSc1zX01WyUvPd2Xlr1K5nZHqdFebR+G9QhsYoLrw0uoaTBcuH0thbq9wvlqqylN/kkhgxxlc7t20MMGvZeDdbj1LUVNpOkjaMIbC+nullit7gNJtCguWUqrou8KPuMc85J9Ro2bdZfh3/xfP8AK+thSb6f1c762121u/Ed9oscc63NjDFNKzxFUZZN23aT977pyRx2znONOvILjwZr1xJqL6b4dXR7K6tbNJrWO5gMs5ildpVCkPEd4cnLnDYG4fMdt/R/Bc1n4j04yaNqk+mw6fOgOoXVswhlaVZI18uNtibSrY2IQMpzx8u1XAYZLmjWW22jfw3f2ravRLUXO77dj1LRdFsYbm8uBHI807BneWZ5D1J2gsTtUZOFGAMnA5rX+wW3/PP/AMeNcf8ADTSrvSLfULa4sfskCvGsDOIxJLgHczCMlTk5O7Ck5JKg9e4r9LyPLcFUy+nKrCNR6+84pt+87a67LTc4qlSXO7aFf7Bbf88//HjR9gtv+ef/AI8asUV7P9k5d/z4h/4DH/Iz9pPuV/sFt/zz/wDHjR9gtv8Ann/48asUUf2Tl3/PiH/gMf8AIPaT7kMdpBE4dEww6HJqaiiuuhh6OHjyUYKK3skl+RLbe4UUUVuI828WaVc6xLr9rYhWuFntJ40dtocxssm3PbO3Gfes7xJba34m0HUzHoN9ZTDTpra3t3u4VmllkKEMGjlKqqlBnLAnkY9etjj1GTxVrP8AZiWLYaHf9rDH+DjGPx/Sr32fxH/zx0T/AL5kr47MMhxOJxssTTnFapq6d1pFPZrflOqnXUEl2PKE8OaqLqTZ4RuBpjS2s11p8s9ti+2wvHICPNKswZkb5yA3l8nOM39V8L3l0TBB4fYxvZJFpczXMZfRpVLfMSXyOqnMZY/Lt6AGvSPs/iP/AJ46J/3zJR9n8R/88dE/75krkfDmOclL2kdP8X/yW/8Aw22glVglax5K/hbU/wDhIJriTwvfXIPiD7ULl7uBibUwhJB8024KzDOzoVwCOMVmJ4Q1yW3eC58H37RJpt/awxPeWzRI0k/mW+1PP2rsXjIAwQMZwMe2/Z/Ef/PHRP8AvmSj7P4j/wCeOif98yVtHIsfFL95DS38/RNfzeY/bRve39Xv/XkeUQ+HtcW+uivhicWM9vZPd2stxbkXzxhxMjYkO5jvTl+G8sgnGCX3PhK7W500nwxdXOmq14/9mrdQ+XaxyRgJCUaUITu3H5cqu7AOBXqn2fxH/wA8dE/75ko+z+I/+eOif98yVn/q9jr3VSH3S7W/m3t13+WglVgraDPh/De2vw+0W21a2ltr23tEhmjlkV2DKNpO5WYHOM9e/ODxXRVhqvihFwo0ZQOwEtL/AMVT/wBQf/yLX2eHpyp0YQluklptouhzadDborE/4qn/AKg//kWj/iqf+oP/AORa3A26KxP+Kp/6g/8A5Fo/4qn/AKg//kWgDborE/4qn/qD/wDkWj/iqf8AqD/+RaAOb+JVrfah4f1yw0rT5r+5u7aCJI4ZY4yMmX5izsoA47HPtXPeI/CNzdeF7G30yLUngN4t1fWM9zFc3EimMrs3XBkjcq204cleODwK7gjXP7VuNx0ky+TF5vmhwg+aTbt9T1zUv/E9/wCoB/4/Xx2b5dUxGLVSFaEba2d+1tdbdNOvmdFOaitjx7UvBerrHqEFroGr6graXBFZTXd/bM8U6SMwb/WqEZVKjKAY2nGerWr3wtqt7canYr4Tkj0u81BbhBJJbOqZttjOIzKULeYNxLK3XcAW6er/APE9/wCoB/4/R/xPf+oB/wCP1wf2ZX/5/wBP/wAm8v73l+ZaqJO9n/SseSv4Z8WXenm2bTrq2l/sOwtZZjcW7ec8MhaaIZZuWViAWUqec8dex8JaHHo1jZwPpd8SskrwyX32QvZBgMqBDhUVuyxgj1x0rqf+J7/1AP8Ax+j/AInv/UA/8frnr5LVrQcHiKaW+l+1u41USto9P+GON8U6bquqaxK2m6XMs9jDFcWF88sQiedGLeXjdvAZWKElccn2zz+reGPEdxqGsQWVhdKl1ZWiPerLbhbl45nlmUBmJG8SFRvTb1BG3r6l/wAT3/qAf+P0f8T3/qAf+P0UclqUUoxr09O9+jT7+W22r0G613ezPI5PBN5DJaRp4c1jULD7DeRvbXl1ZgRvJt8tPKR1iUAhyNoONy88YXTPhzWb+K3Go6HI161tbrZ6g88RfSpEUB8kOTywLZj3bt2GwBXpP/E9/wCoB/4/R/xPf+oB/wCP1rLKa8rXxFPT173/AJv6WjI512f9W/yPKn8HXclx9ol8M30k48RG4Er30TMbQkE5JmyUJUfIfQccVLF4c1Kz8Vm+tfCVwoj10TQTxzWyrHafZhCQo83IUkA7QOgHGQBXqH/E9/6gH/j9H/E9/wCoB/4/R/ZNdpp4ins1vLZ/9vD543vZ/wBX/wA/yPHB4a1XTdP1VrrRzYjVLe1i+zpLBsluVuGLKR5mZQykE+Y2XGQzL2vaF4euNMvtK/srw1cwz219cy34jNvbQxGWIhf3aTuMDcuMF2VQfUA+nXllqWo2j2uoW3hq6t5Bh4Z42dGHuDwaLOx1LTrRLXT7Xw1a28YwkMEbIij2UcCtJZXUnTaeIp3e+9vh5f5r7f536A6l3szlfhL4e1PQtc1KS90o6db3llbt5amLas6lxJ9x2Yk5U72LM3ds8D1SudV9fQ5RtBU+oMgp/wBo8R/89tE/76kr6XLpQw1HkrVYuV+j07dWzCSu7pG/RWB9o8R/89tE/wC+pKPtHiP/AJ7aJ/31JXo/W8P/AM/F96J5X2N+isD7R4j/AOe2if8AfUlH2jxH/wA9tE/76ko+t4f/AJ+L70HK+xv0VgfaPEf/AD20T/vqSj7R4j/57aJ/31JR9bw//Pxfeg5X2N+isD7R4j/57aJ/31JR9o8R/wDPbRP++pKPreH/AOfi+9Byvsb9FYH2jxH/AM9tE/76ko+0eI/+e2if99SUfW8P/wA/F96DlfY36KwPtHiP/nton/fUlH2jxH/z20T/AL6ko+t4f/n4vvQcr7G/RWB9o8R/89tE/wC+pKPtHiP/AJ7aJ/31JR9bw/8Az8X3oOV9jforA+0eI/8Anton/fUlQy6prVu4Se+8PRMxACvM4JJzgcnvg/kaaxWHe0196FyvsdLWfr3/ACL1/wD9e7/+gms63u/EN3EktpcaFPHIodHieRgynoQR1HvSX6a9Jp1yupS6ZDaNEwlkiSRmVcckAnmtozjNXi7iOioooqgMzRoYn09i0aMTcT8lR/z1er/2eH/njH/3yKp6J/yDT/18T/8Ao560K53haEndwV/RD5n3I/s8P/PGP/vkUfZ4f+eMf/fIqSil9Uw//Ptfch8z7kf2eH/njH/3yKPs8P8Azxj/AO+RUlFH1TD/APPtfcg5n3I/s8P/ADxj/wC+RR9nh/54x/8AfIqSij6ph/8An2vuQcz7kf2eH/njH/3yKPs8P/PGP/vkVJRR9Uw//Ptfcg5n3GpGkediKueuBinUUVvGEYR5YqyJ3CiiiqAKKKKACiiigAooooA5zT7pLbxVrm8MdzQ4wP8AYNa/9pw/3ZPyH+Nec+OLOa7n1j7Hf3en3S3dkkNxazvGULuqElVIDjDH5WyPasiHxKE8Refrr3cGqaLp85v7GG7kWGVlaMRyrFuCMrh2IJHBOCcrx8Hm2b5hQxlSlh5K0enLd/DF99m3a/R/I6oU4cilI9d/tOH+7J+Q/wAaP7Th/uyfkP8AGvMdV8Ya9bXUGnLpNnb6iby1R1N8zxNDKzAFX8rOcxspBXjqM1Y8X6vNovijw/OLqURTefD9j8zZFPKUHlhjjj5iBk8DOcV40eIM5coxbjdptaJ7K/R9ehbpU07en4s9G/tOH+7J+Q/xo/tOH+7J+Q/xrzSfxzqtlqV1ZX3h2NHsTaG5kj1AOhS4kKBo/kBbBHRgnf0G63J4vvWuFax0iKeymuZbK3na82M1xGXGHTYdqFkYbgWPT5aT4gzxa+7/AOS9r9+2pXsaZ6B/acP92T8h/jSpqMTyKgV8sQBkD/GvL7T4g3t7NDbwaRa/aLixhuYY3vnGXeRY3iY+TwULckZOMZAzxo+HfGt1q2u2ME2imzguLu4tRI90ruksDcgooxg4bkN1HTvW9LPM8dWKny2ur/D/AJ9rkulSSv8A1qelUUUV+nnEFFFFABRRRQAUUUUAed/FIOvhjX54J7uCe3tYJYntLl4HDAy/xIwyOehOKwzrY8I6aLhNK1wXWoXS2sFhqV9NeMSsZcvlDOygjOdm77oyBzjtPE+h2HiKS+0/VklktZI7cvHFcSQ7uZeCUYEj2zioL3QNO1HS4LC9jllhtyrRP9okEsbKMBhKG3hsfxbsnJyea/LuKMTRjjvZVU2tG/Syt17rt6M7aMW43OTm+JV3HbXMo8MXUX2OyivZ0u5vIfy2dkIVSu7cCrYDBc47ZGbN749vLOHUEOjwG8srwWxia+IV1MPnBgRGXZtpxsVGOe+AWrQvPh94dv5J3uoLx2uIFt5j/adyPMjU5CtiTnnJJPJJJPU0v/CA+Hvt0l4be7a4kkEryNqNwSWCbM8yf3TtI6EYBzivmfbZZ/z7f9W/v+v4G6U7/wBdv8zmj45az1W51t2vLizu9HsLi10/JYRyzyOgChFJ5O3JAZuuAeBXW+HtdvtdsoriXSXsAJJI51ufNjYEY2tGskSs6nPVgmPQ1Xi+H/huJWVbKZka0SzKPezuoiQ5RQC5AKkZDDkHJB5Natno1pYLALdrs+RuKmW8mkLbgAd5Zjv4AxuzjtissTWwU4fu4vm7vslbo+/X/hgSndX/AK0OV8RT3WhePLTW4726/s3y44NQtWndoVWRiizBCdqlWCZIA4LE1ky+KZtO8Yazrd7LeXNqljZ/2dYRyyCP99NJGpMa53FtqtnazAHABxg9xd+F9Kv766ur2Gad7y3NrPG91KYni/u+Xu2D6gZ5J71XufBGg3eoXV5c2s0kt1CsMoN5NsKLyoCb9q7TyCACCSRgnNa0sZhVFRqpvRJ2S2unbf1V97WVhyi23byMK18b63f6zpcEegtbJNFdvcQXDSQyOYtmPLEsSEg7xgsEzznGOben+NdQ1fTtOl07RIftWp2zXdtbXF9s/dJtDFmEbYOXXAAOc8la2D4T0hltw8VxI9sHEU0l5M0oDgBsyF9zfdXGScFVIwQKiTwVocWk2WmxW9xHb2GfspS9nWSIHqolD79p6bd2McYxUSrYBpWptff/AHv72u8fueoJSsYB+JVxJa6ldWnhyd4NNsIr6bzbqNHZHV8hQMglTGRyRkBiP4Q1fUfFGtaVr02qyWjS2y6Ib19ON6AkSCQZYEJzJt7cjIwGAOa6WTwN4fk+3A2kyJf2yWlxHHeTIjQpwqBVcBQBkfKB1b1ObN58LtG1AYu47mQGzFk3/EzuhuhBzsOH59yeT3Jr0sDQoYuT+rUJSSteyvo0v7/dPaxnNtKzdv6X/BMpPGsh8Y/2K2nKYnEvlTxXHmOWjRWKsoTauQTgF93HKisW3+I9zq1lfSf2JHJZQRwF5bHVSZEaWTb5b4RfLdBy6hiRkAA5zXXj4a6faBptLTyr1BI8Es93PKqSOm0sVL8543f3jyeeay9L+GE82nGx18PHabFjNtb6/e3CSbSpVsvsMeCD8q8cjngV308jmo831aWnL676tLn6qy8n2IdTT4h1h4ye78bPoEthHGhSZobiO58wt5TKrBgF2qTvyAHYj+IKeKi1Txtdadqeqwrope10hYJLq4kulVmikzl40Abdjb0Yrnn2ztx/DbTLaZrizjeG5xNsk+23B2GXHmEDeMZIBOMc88Hmsuz+G11J4uvL7WRb3Nl5FtHbt9vnMkjRA8zR7Qr5LZG4vgjPU8ZRyGq5OX1eVlFaPq7rb3u3np2HKqraMZH4yne5gk/srfp15JNBZzxXG6WSSMOSrR7QFDeW20hj2yBms6bxtq89zoiafp1mWur54LmH7Yd4CwNLtw0YKtx0cKcgDgNuHXxeANMhvLi5jtlD3BcuhnkMYZwQ7LGTtRmyclQCcnJ5pjfD/T0USR2yzTxTm6iae7mYmXYVGXJJ27Tt28qBxjtURyWsn/ustvx1/ven3dB+0X8xy1t8Q7mXT7a9n0RLeG+s5bm033yjLRkApISoVOCCCC3fjOASw+IF9qUtna2ugA3lzcXNuS12UgR4VzyzRiTDAjny+/er3hj4UxWfhdLLxFbW8t40RhlaC+nkRV37sxlgvlEkKTsC8gHJxmti3+G2k2uqw6jBFMt1DK8yMdQuCu9wAzFS20kgDOQc1vVyOUJTisLJ2vbt1t9vbb7vOxLqXStI5HQ/G/iK5WBL/R9PdryW+S3eLUHHzQO4CMDDwPlxuBJ747UR/E26lszcp4dcRRWtjdSlrxQSlycDYAp3FW4+bbnB6cZ7BvhzpDBB9lC+XcSXK7LmVcPJnf0P3W3HKfdOTxWevwd8MxwywwWMkEMqRo8UGo3MSFUOUG1XA4JJ+pJ6mj+x3KTcsJJei89ft/y6eoe0/vf19w/SdYn1y11e2nhOn3VjcPaO0EwlwfLV1dWZRzhxwV4IPUdeY8KeMtSj8I2h1S0E8y6Ot9HdTXyqbg7treYWACckHOW4PQEYrurDwLZaYdRNn5ytqTb7pnvp3LtjbuBZjtOMDK4PA9BjNi+Enh+GFIUt5/Kjt/syI2p3TBI924KAX4wwBBHIIGMYFYwyaulKMsPKzcWtOy1+11fm9PMp1FbfX9L/AORzDfFOT7LEkWgzXGotLcI9rbieUBYSoZlKwFzneuNyKOeWHGbn/Cwrp7l1j8OzJFFfwWUn2m4WOUNMisjBMH++uQSCAehIxXSH4a6RwVhljkEzTiaO/uElDsAGIkDBgGwMjODjJBqKT4WaJLdS3DQ3AkmuI7l9mp3KqZE4RtofAwAMcY4HoK1/sV/9Ak/6f+JdBe0dn7y/rYx7Txrf6jAIbDRoZNTja4E9s99tjUQS+WxWTy8sSfugqvuRVGX4mTtpOp6nY+HZ5rPTrWG6cyXSRvIkiFwVXnp3yQcZwCcA9PH8LdEiXEcEyt50k/mDUbnfuk5cb9+7axAJXO0nkinz/DLRriLUYpLdxFqUaR3UaX06I6IMKoVWAUADGFxxx0qVkslL/dZtennr9vtt+N903UV9JaHH3XiXXNI8Xanc3Fqbi2TTra4ayN6NlujTOhZT5fLlQGKnjIIDYxnXk8byw+LZdHbSxJGEmMUsFx5kjvEgcqUCbVJBOAX3ccqM1r33wv0bUppZbxLmR5rdLaUjVLpd8aHKqcOM4POepJJPU5ZdfDSyEM8umoIr5hK0Mk11PIiySJsZipbB3D73qeTk803k1Wpbmw0r2ttZXskn8XR36aruxe01vddP+CclB8VJpbaaf+ybWaMyRQWrWN7LdCWWRWbYwjgLKVVTuChiDjg9a2E1LWdfs9M1FdHWzso3M11DdtMlyjoxHyRGHLjAJXOwnKnA6G1pPw5nexeDXk2RFVAt01u7vArKQVkSSXa0TDkDZjr1PGOqs9ANhaJbW7ZRBgGWZ5HPuXbLMfckmpxOS4iD/cYWV797q1v8T1vr1/QUaifxSM3wNFfW1s8F/aiADdJF+93Eh237SP4Su7b1I44Nbuvf8i9f/wDXu/8A6CafZ2clvMXcqQVxwaZr3/IvX/8A17v/AOgmvveHaFehgeWvDlk23b1Oaq05aGhRRRX0JkZ+if8AINP/AF8T/wDo560K5jS/FWjW9kY5rza3nStjynPDSMR29CKuf8JjoX/P9/5Bf/4mgDborE/4THQv+f7/AMgv/wDE0f8ACY6F/wA/3/kF/wD4mgDborE/4THQv+f7/wAgv/8AE0f8JjoX/P8Af+QX/wDiaANuisT/AITHQv8An+/8gv8A/E0f8JjoX/P9/wCQX/8AiaANuisT/hMdC/5/v/IL/wDxNH/CY6F/z/f+QX/+JoA26KxP+Ex0L/n+/wDIL/8AxNH/AAmOhf8AP9/5Bf8A+JoA26KxP+Ex0L/n+/8AIL//ABNH/CY6F/z/AH/kF/8A4mgDborE/wCEx0L/AJ/v/IL/APxNH/CY6F/z/f8AkF//AImgDborE/4THQv+f7/yC/8A8TR/wmOhf8/3/kF//iaANuisT/hMdC/5/v8AyC//AMTR/wAJjoX/AD/f+QX/APiaAMO+8N23ibXtZtb7zvKjmt5QIbqWA7gpKndGwPBGcZ6gHqBWndeELO+naa8tbeeR7ZrR2kyd8LEEofUZHf39TVLTfEmlW/iDV7mW62w3Bi8pvLc7tqkHjHH41rf8JjoX/P8Af+QX/wDia8HF5DhMZWdeq5XfaTS2S/JI1jWlFWRlJ8O9KSxFoYGkjEscu+W7mkk3Icp+8Zi2Bzhc4wSMYJqTWPAWn6/cQTarEZnt45I4wt1LGoV12sCqkA5HHINaP/CY6F/z/f8AkF//AImj/hMdC/5/v/IL/wDxNc/+rOB5ubmnfvzPrv8AeP20jnZfhPoc7TtMl67XAjErNrF4SwjO5BnzOik5HpWlb+BNPtdVOowQAXBYyc3ErIHIwZBGTtDkZBcDccnJ5rQ/4THQv+f7/wAgv/8AE0f8JjoX/P8Af+QX/wDiacuG8HJWlKb/AO33/XQPbS8jNt/h/pVrdQXEFlCk1vcS3UT+Y52yS/fb3z6dBgYAwKg074aaPpmp2t7bJcrLa3L3UedTuXAkc/O21nIO7nIIwcn1NbP/AAmOhf8AP9/5Bf8A+Jo/4THQv+f7/wAgv/8AE1dPh3CU5KUZTv8A4n/XV/ewdaTVmbdFYn/CY6F/z/f+QX/+Jo/4THQv+f7/AMgv/wDE19EYm3RWJ/wmOhf8/wB/5Bf/AOJo/wCEx0L/AJ/v/IL/APxNAG3RWJ/wmOhf8/3/AJBf/wCJo/4THQv+f7/yC/8A8TQBt0Vif8JjoX/P9/5Bf/4mj/hMdC/5/v8AyC//AMTQBznxH0aw17SNVsdUiR4ZFtAGYDMbGSRQyk9G54PvXAa9eXGu+D7TSdXBeTSNTs7XVA4Gy4k+0xooI6FWQ+YR/tJXourXnhXX7q5i1kWt5ZskJRLqzMyl1MmflZeo3Dn3qO+i8EapAINTSwvIg4kEdxpvmKGC7Q2Cp52gDPpxXxOcYDHVsaqlKm5RTTTvFWeidrtb/LWz6HVTnFQs33Oau/Ed3ceIrjQCtqdHniurZGtUkieFoowSPN3jJ5IIVAFwPmJ4rL8N+K9ei07QNK0XSVu7e00qxlvHkaNSUkQZYM0ylQoBPCPkjHy9a7V7LwFK0jSW+mu0md5bS8lvl28/Lz8vy/TilS18CRm0McOnIbHP2QrpmPs+Tk7Pl+XnnjFeEsjxyp8n1a+27ja+uuk1rZ2/Hct1It/F3/T/ACNT7M1xZT2+q/Z7uOUurIINqNGc4VlZmz8vBPQ+g6V434f0/VPDXgmHxho2m6LZpYabMSsMrhtQy3BmAQAFACRyxJONyivWhc+FFs5rRZ7cW05czQiybZIXJL7l24O4k5z1zzVZbbwKmkPpSRaeunO25rMaZiFjkHJTbtJyAenassJkmbYeMoOjdSaurxtZXvpzdb/07Fyq031Ma/1/UtL1K9+3ppC3EOmCeC78uTOXl2iNgMsQDtHH3j2XoM/TvGviTUL6201k0u1uJZryBrm4icANAFI/ciQ4yGGR5hI59K6eSz8BSyGSW3013aD7MWbS8kxYx5edv3cDG3pWRqXh7wlf65p1yl1pUenWok8+wfRS4uWcKNxOQARsXGVPT8taXD2LatPD62et4720subv029CPax3v/Vilp3jDVNTFzdQaXp8N62l2c0MgO9n82R1YHJTcoKsVQMN2RyC1R6n491uCC+lsE0t47LS5tQLSJLucxSlGjKEqUPykZy2D6gc9U1v4Ge8lu3i09rmaMRSzHTcu6DHyltuSPlHB9B6VBLpPw7nCiaw0mQLEIVD6SDiMHIQfJ90Ht0oWQ4vn5nhdNNLwfRafF/XYp1YPr2/Qk8Pazf3+rarY6kLUm08mSJrdWX5JU3BTknJGCNwxn0Feg15ydK8AA7reLT7Z90bF4NMCM3lkFBnZnjAxjkY4xXV/wDCY6F/z/f+QX/+Jr6XhvLK+BlWlVhy83LZadE77N9Wc9WfMkr3NuisT/hMdC/5/v8AyC//AMTR/wAJjoX/AD/f+QX/APia+uMDborE/wCEx0L/AJ/v/IL/APxNH/CY6F/z/f8AkF//AImgDborE/4THQv+f7/yC/8A8TR/wmOhf8/3/kF//iaANuisT/hMdC/5/v8AyC//AMTR/wAJjoX/AD/f+QX/APiaANuisT/hMdC/5/v/ACC//wATR/wmOhf8/wB/5Bf/AOJoA26KxP8AhMdC/wCf7/yC/wD8TR/wmOhf8/3/AJBf/wCJoA26KxP+Ex0L/n+/8gv/APE0f8JjoX/P9/5Bf/4mgDborE/4THQv+f7/AMgv/wDE0f8ACY6F/wA/3/kF/wD4mgDborE/4THQv+f7/wAgv/8AE0f8JjoX/P8Af+QX/wDiaANuisT/AITHQv8An+/8gv8A/E0f8JjoX/P9/wCQX/8AiaANus/Xv+Rev/8Ar3f/ANBNVP8AhMdC/wCf7/yC/wD8TVPVvFWjXWjXkEF5ukkhZUXynGSR7igDp6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==" alt="" width="563" height="739" vspace="0" hspace="0" border="0" style="width:563px;height:739px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RD+RXhpZgAATU0AKgAAAAgABAE7AAIAAAARAAAISodpAAQAAAABAAAIXJydAAEAAAAiAAAQ1OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE1vaGFtbWVkIE1haG1vdWQAAAAFkAMAAgAAABQAABCqkAQAAgAAABQAABC+kpEAAgAAAAM3MwAAkpIAAgAAAAM3MwAA6hwABwAACAwAAAieAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMzowNjoxOSAxNjo0MjoyMgAyMDIzOjA2OjE5IDE2OjQyOjIyAAAATQBvAGgAYQBtAG0AZQBkACAATQBhAGgAbQBvAHUAZAAAAP/hCyNodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIzLTA2LTE5VDE2OjQyOjIyLjcyNzwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5Nb2hhbW1lZCBNYWhtb3VkPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAHYCMwMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APo8yIOrL+dHmJ/fX86y7KCJfEWpMEGZIoWYnnJzIP5AVqeWn9xfyoAPMT++v50eYn99fzo8tP7i/lR5af3F/KgA8xP76/nR5if31/Ojy0/uL+VHlp/cX8qADzE/vr+dHmJ/fX86PLT+4v5UeWn9xfyoAPMT++v50eYn99fzo8tP7i/lR5af3F/KgA8xP76/nR5if31/Ojy0/uL+VHlp/cX8qADzE/vr+dHmJ/fX86PLT+4v5UeWn9xfyoAPMT++v50eYn99fzo8tP7i/lR5af3F/KgA8xP76/nR5if31/Ojy0/uL+VHlp/cX8qADzE/vr+dHmJ/fX86PLT+4v5UeWn9xfyoAPMT++v50eYn99fzrA1i3hn8V6LDNDHJEwn3I6gqfk9K1P7F0r/oGWf/AIDr/hQBb8xP76/nR5if31/Oqn9i6V/0DLP/AMB1/wAKP7F0r/oGWf8A4Dr/AIUAW/MT++v50eYn99fzqp/Yulf9Ayz/APAdf8KP7F0r/oGWf/gOv+FAFvzE/vr+dHmJ/fX86qf2LpX/AEDLP/wHX/Cj+xdK/wCgZZ/+A6/4UAW/MT++v50eYn99fzqp/Yulf9Ayz/8AAdf8KP7F0r/oGWf/AIDr/hQBb8xP76/nR5if31/Oqn9i6V/0DLP/AMB1/wAKP7F0r/oGWf8A4Dr/AIUAW/MT++v50eYn99fzqp/Yulf9Ayz/APAdf8KP7F0r/oGWf/gOv+FAFvzE/vr+dHmJ/fX86qf2LpX/AEDLP/wHX/Cj+xdK/wCgZZ/+A6/4UAW/MT++v50eYn99fzrD1TTNOgubEpp9ooMr7h5KgMBE5546ZAP4VzFt4s0i9UXFn4XafTWcRpqSWUXkyHdt+UbvMK5/j2bcc5xXlY7NcPgZKNa+vZf1r2RpGnKSuj0PzE/vr+dHmJ/fX865XU7nS9K0u5v7nSLR4raNpXWGzDuQBk4Uck0+xk03UNPt7yHSbJY7iJZUD2yggMARn35ryf8AWzLeXnvK22xfsJ3sdP5if31/OjzE/vr+dczdSaVZW7T3en6dFEpALNbr1JwB+JIFTeRY/wDQK0//AMB1qf8AW7LLXvL7g+rzOg8xP76/nR5if31/Ouf8ix/6BWn/APgMtZ2h6ro/iCwe7sdItkjSeSAieyEbBkYq3ynkcg9eapcWZa4uScrLy7h9Xmdj5if31/OjzE/vr+dc/wCRY/8AQK0//wAB1o8ix/6BWn/+A61P+t+V95fcP6vM6DzE/vr+dHmJ/fX86oxaPpbwo50yzyygnFuv+FP/ALF0r/oGWf8A4Dr/AIV9VTmqkFOOz1OfYt+Yn99fzo8xP76/nVT+xdK/6Bln/wCA6/4Uf2LpX/QMs/8AwHX/AAqwLfmJ/fX86PMT++v51U/sXSv+gZZ/+A6/4Uf2LpX/AEDLP/wHX/CgC35if31/OjzE/vr+dVP7F0r/AKBln/4Dr/hR/Yulf9Ayz/8AAdf8KALfmJ/fX86PMT++v51U/sXSv+gZZ/8AgOv+FH9i6V/0DLP/AMB1/wAKALfmJ/fX86PMT++v51U/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KALfmJ/fX86PMT++v51U/sXSv+gZZ/+A6/4Uf2LpX/AEDLP/wHX/CgC35if31/OjzE/vr+dVP7F0r/AKBln/4Dr/hR/Yulf9Ayz/8AAdf8KALfmJ/fX86PMT++v51U/sXSv+gZZ/8AgOv+FH9i6V/0DLP/AMB1/wAKALfmJ/fX86PMT++v51U/sXSv+gZZ/wDgOv8AhR/Yulf9Ayz/APAdf8KALfmJ/fX86PMT++v51U/sXSv+gZZ/+A6/4Uf2LpX/AEDLP/wHX/CgC35if31/OjzE/vr+dVP7F0r/AKBln/4Dr/hR/Yulf9Ayz/8AAdf8KALoIIyDke1FZ+iYGlhVVUVZplVUUKABKwHA+lFADbT/AJD99/1wh/8AQpa0qw45L/8A4SLUBa20DARRDM0xXcMyHIwp7kjn096ueZrH/PrY/wDgS/8A8boA0KKz/M1j/n1sf/Al/wD43R5msf8APrY/+BL/APxugDQorP8AM1j/AJ9bH/wJf/43R5msf8+tj/4Ev/8AG6ANCis/zNY/59bH/wACX/8AjdHmax/z62P/AIEv/wDG6ANCis/zNY/59bH/AMCX/wDjdHmax/z62P8A4Ev/APG6ANCis/zNY/59bH/wJf8A+N0eZrH/AD62P/gS/wD8boA0KKz/ADNY/wCfWx/8CX/+N0eZrH/PrY/+BL//ABugDQorP8zWP+fWx/8AAl//AI3R5msf8+tj/wCBL/8AxugDQorP8zWP+fWx/wDAl/8A43R5msf8+tj/AOBL/wDxugDQorP8zWP+fWx/8CX/APjdHmax/wA+tj/4Ev8A/G6AKWp/8jjof+7P/wCgVu1zGovf/wDCTaMXhthcfv8AYgmYoRsHVtuR37Vr+ZrH/PrY/wDgS/8A8boA0KKz/M1j/n1sf/Al/wD43R5msf8APrY/+BL/APxugDQorP8AM1j/AJ9bH/wJf/43R5msf8+tj/4Ev/8AG6ANCis/zNY/59bH/wACX/8AjdHmax/z62P/AIEv/wDG6ANCis/zNY/59bH/AMCX/wDjdHmax/z62P8A4Ev/APG6ANCis/zNY/59bH/wJf8A+N0eZrH/AD62P/gS/wD8boA0KKz/ADNY/wCfWx/8CX/+N0eZrH/PrY/+BL//ABugDQorP8zWP+fWx/8AAl//AI3R5msf8+tj/wCBL/8AxugCt4hgFylrAzFRK0qFh1GYJBXlg0PxJF4N03wmun38MunyQxJq2n6isELwo4BLbZFlBMYI27WG4jnjI9Qvm1FrrT/Nt7TzPtDbFE7FW/dSZydnHHsaseXqX/QP07/v+3/xuvnM3yqvjqkJ0pRSj3T376Nd+uhtTqKK1PHpPDGuQeJtS1K20CQfaLa/tn8maEm537fIYu8m9sgH75AXoFA5IfDGuz6xod8dBe2n08WS/aBJAzhFQrKpYuSME52pgMOSWPA9h8vUv+gfp3/f9v8A43R5epf9A/Tv+/7f/G68j/V7HW/iQ2ttLb7zSVWEunf8bf5HkEngu4u/B0tjdeFVOqo1sbu4kmhddSaOZWZxl+WZQ/MgU/NtzitL/hG759e82XRNl1Hd+fHq0E0a4tcf8eo+YOOMoFwE/iyDXpvl6l/0D9O/7/t/8bo8vUv+gfp3/f8Ab/43UPhzHu/72Ot/5utvPbTbb8B+2ja1jxvTPBV0sHhQX3hi6LwXVx/afnXcUgMTLIF8z96fNGZBx8xADDHODHb+GdfS4aSx8O3WnX811qX/ABMDPb/uop9xiztlLbQSpIA4KkgevtHl6l/0D9O/7/t/8bo8vUv+gfp3/f8Ab/43WjyDHttupB3v0l1bf83978EJVYpWt2/A8ivvCGp3ek339kaK+hwzi3+06bHLbk3jI5MrKDuiyykDLj58YYCqep+B9UOk2Vppuj3kotIzNaS3ktoZ7aTzlcxgKRHEMA48sHj5dyjivafL1L/oH6d/3/b/AON0eXqX/QP07/v+3/xulDh/MINWqQ0d9pdrd7vTuJ1INWsy/akmzhJBUmNeD24qWs8Pq4AAtLEAdALl/wD43R5msf8APrY/+BL/APxuvtaMHTpRg+iSOd6s0KKz/M1j/n1sf/Al/wD43R5msf8APrY/+BL/APxutRGhRWf5msf8+tj/AOBL/wDxujzNY/59bH/wJf8A+N0AaFFZ/max/wA+tj/4Ev8A/G6PM1j/AJ9bH/wJf/43QBoUVn+ZrH/PrY/+BL//ABujzNY/59bH/wACX/8AjdAGhRWf5msf8+tj/wCBL/8AxujzNY/59bH/AMCX/wDjdAGhRWf5msf8+tj/AOBL/wDxujzNY/59bH/wJf8A+N0AaFFZ/max/wA+tj/4Ev8A/G6PM1j/AJ9bH/wJf/43QBoUVn+ZrH/PrY/+BL//ABujzNY/59bH/wACX/8AjdAGhRWf5msf8+tj/wCBL/8AxujzNY/59bH/AMCX/wDjdAGhRWf5msf8+tj/AOBL/wDxujzNY/59bH/wJf8A+N0AaFFZ/max/wA+tj/4Ev8A/G6PM1j/AJ9bH/wJf/43QAaJ/wAg0/8AXxP/AOjnop+kqiWGI5PMHnSknbjBMjEj8DkfhRQBFaf8h++/64Q/+hS1pVmWTq3iDUArAlYYQwB6HdIcH8CPzrToAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5zX7ZL3xJpNtI8qJNFcIzQytG6gx4yrqQVPuCCK5rRLVrzQo/Cd3qerNqWn6o0d1c/2lOs7xofMDmTfuKvGyDGcAt7V0+szxW/ivRZbiVIo1WfLuwUD5MdTUkSeGIfEFxrkU9gupXMC28twLgZeNSSFxnHU9cZ6egoWjv8A15A9jkJfi9LHZ6ne23hTUrqws4ZZYblFkRJBG+1t7yRrGM8kbHkyFPQ8Vt3Xi/W7DUJbW/0PT4WktTPp/wDxNHJuX3qgib9xhG+dc4LdRjdyQl14Z8D3ltfW01wgtr9i09vHq8scRJOWKosgVCT12gZyc5yanuE0281rTDc3Olmx0hhNaSvfebO0nlsnzbhwAGzu3MWPXGOWrWVwfkXdZ16+0+WwsNP02G81W9jeRYJLsxRKIwpf95sJPLAD5ec84GazrrxtdwTSyR6Jvs7KeG21BjdqJoJZFQgKgUq4XzFyd474BxV/WYfDOvpANSvoC9u/mQywag0EsTYwSskbqwyODg81Wk0nwdJqS3zT2wnUJkLqDKkhT7jOgfa7LxhmBIwMGl/X9f18+gGNZ/ErVL9bYweGFjN5FeNAs+ogFXtpNrrJtRgoPYqW54xj5qj/AOFrXEtu91a+G5WtYbewuZHlvEVmjujgbFAOSp4wxXODyOM3IPBngO28ryLuRPJWZY8a/c/J5ufMx++6tnJPXPPWoY/APw8itpLeOeQRSJFGyf8ACQXWCkRzGv8AruinoOgqlbr/AFv/AMAH5F+Dxve3Mk9hDpEH9sx6hJYpbtfEQsUiEpcy+XkDYw42E7uOnNZk/wAUrtIbpoPDUhNjZSXd15t6iBfKmMUqJgMWIKtjIUHA6ZrR/wCEY8Ef6UftXz3VyLuSU6zN5izAbd6P5u6M7flyhGRgHgYpl74S8B6gZPtEygSWv2R1h1iaJXi3bipVJQDliST1JJznNLS6/rp/mH9fj/kdqrblDDuM0tZttqWj2lrFbw6nbGOJAimS7EjYAwMszEsfckk1L/bWlf8AQTs//Ahf8aHvoJXtqXaKpf21pX/QTs//AAIX/Gj+2tK/6Cdn/wCBC/40hl2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AM1D/AJCWlf8AXw//AKJeuFj8V3C/Fy2zdagdLvjLpqwyWcyWqSIAySLKyiNmZllU7WJxtHY11eq6hpd3PYxNqMBiMriRoroIVUxOM7lIK9eoIOcVQudB8HXfh+z0We93WNjKstuo1mZXRlJKnzBJvOCeMk44x0FC0lcHtb+v6uUPEXjzUrLQ/Ecljp1vBeaZBLJCtzcMrsqkKJDGY+h5YbSykAZYE4FLQ/FGuad4l1WDV4TeW8mr29s7m93CyMtuj7Ix5a70DEjJCnBB5Oa35NF8GzC7E89vMt5A9vKsuou6+W5y4UF8JuOCSuCSASeBVJfB/gRbh5lu3DvcpdsRr1wA0yDCvjzsZA4/AelNWX9ea/QHs7eZmR/F+abT7rULbwpqU9ksay21wqSRxyKZAnzPLGiA/MCAjSZGeeK1Y/Gc1zrVnp2o6NNBOusSWLSW9/mJGW385WbAUuGRvulcAg5PAJfP4X8D3Fnc2klwotblw728esTJGpDbvkVZQI/m5IQDPeol8IeBU1Jb/wC2Stcrc/a9z6/cspl27d5UzbSdvy8j7vHTihW6/wBbf8EOr/roy14R8cSeJdZv9OuNOjtHtYY7iN4brz1kjdnUZbYq7hs52F154Y4NddXL6LpXhDw9c+fpFzBDJ5C2wL6i8gESsWVMO5GAWOPQHAwOK2/7a0r/AKCdn/4EL/jQ7dAe7LtFUv7a0r/oJ2f/AIEL/jR/bWlf9BOz/wDAhf8AGkBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQBdoql/bWlf9BOz/wDAhf8AGj+2tK/6Cdn/AOBC/wCNAF2iqX9taV/0E7P/AMCF/wAaP7a0r/oJ2f8A4EL/AI0AXaKpf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjQAzRP8AkGn/AK+J/wD0c9FJoTrJpW+NgytPOVZTkEea/NFAENt5FprmqzyMsSGGKSV3bAGDIMknpwBVjS9d0jW4fN0XVbLUY+fntLhJRx15Un1H51w/xBimbULSeSCS50q2v7ObVIo0L5gDTYJUcsquUYj0Ge1ZuueNbyXWtU1DwPdaFq1rbaWjfabOMySRbpVUq8quy/KN0mDGSAOh7pP+vlcH/X32PWaK8Zj8b6zFJpltqfjvQ4ba8W8Zb2zmhuHZEjBQmVo44ywbIIWIDgA85osviB4k1m+0NrLW9Gs4prG1n/0q5WNb9mH+kBEELmRlIK7UkQqeoIqrf19/+Qr/ANfd/mezVEt1btdParPGbhFDvCHG9VPQkdQDg8+1ePxeNdYu/A1pqK+MEe9vb+5tI5LSG2jhzEZSg3Or7CwCHkSEjaFGSWrV+H2vWWtePZLz7RZNqV/4a0+4ukhZQzyZkLEgc5AZPoCvtTUW2/L/ACb/AEH0/rul+p6XNdW9s0S3E8cTTPsjDuFLt/dGep9qW3uYLuATWs0c8TEgPGwZTg4PI9wRXj/ijxAlx4y02TUtS8i703XzFHp5s1f7LD5Um24JC+ZtbgltwTAxgbSa0NK8eXl7p3hy+k8QW1yt0qRTx2flbp5mmKnCMPmAVTwjhlAJIYVMdVf+tglo/wCu7R6pUVzcwWdtJcXk0cEES7pJZXCqg9STwBXkWrePNZtdDv8AUrHxHAt7FaXD32m3VvERpMiD92MDaw3EBB5jNuLBl4GDW+IWtSX3g+/03Utd86C60MX1mRbQuupzNuyifIeEwjDYd43BixAppX/r+uxSWuv9bf5ntQIZQVIIIyCO9LXjp8beI316+8rWtK0iztImKWWpvslMHk7lnFuYVc/MQSTKFABBUEZq7ZeL9TXw74a1e78SrcrqVtFJPHCturPM4VdkaFPnAIkJVXD7gcZHyh8t/wAPxv8A5Gd9Nf6/q56rRXnvxW8T6h4fsoF0fVW0+7Nrc3MaeXFtnMSg7C0it6k7FXc395QCa56L4lztr07TeL9NMMGs29rHZReSqywywgsGJJbKsSNwI5Q59BK1/rzsW1ZXf9WPXmu7dbxLRp4hcyIZEhLjeyggFgvUgZHPuKlrx/wnrSaz8U9E1O5vXu9RutHuoryFbNR/Z8oeJvs7MiZULh+JCTk5z84FewVTVkn3/wA2hPdoKKKKkAooooAwNXdYvFuiySMERUuGZicAAJ1qOx8ZwagsVxBpWp/2dcSRx22otHH5M+9goYDfvC8/eZQD2JyMweLNPGr6rY6c0jRC7tbuAyL1XdEVyPzpvhp/ENno9loV5optpbKBIH1HzomtpFRQNyKH8zJx0ZVA9TjkW7+X63/QH0/rtb9TrKK8X1fwNrl14XvIbXw5cQ6t/Z72t5cW19FEdXnLJslLCQFgMMxMmCASoDA0+58LavHqF7d6d4Hvoj/bFle2oS5tFZEUL9oK/v8A5WfawJyC24Z74dl/Xr/TBnstFeI6Z4K1SJbFb7wPfShYdSju/Pu7WUzJLIXgRy05MmPRsgMc+prSi8K+Ib7Q7K31jw9LNf8A9lW9tZ3st1Cz6Tcxgq8hO8kBjtbdHuYgYYCnb+vv/wAvxA9coryXRfDWsad4tsr4+FtQDprl1NJfyXlvIwtZIigyTMXK7irbMcbemQBXrVLomLq0FFFFIYUUUUAFFFFABRRRQBmavI0N1p8kcLzsk0jLFGVDORDJ8o3EDJ9yB71l+HfGj+IzbyQ+GdZtLS4eRFu7n7MY1ZCwIYJMzjlSMlcZxzyK1NXkaK60+SOF53SaRlijKhnIhk+UbiBk+5A964nwr4V1Gx8D6nLNpOoW+tzRXca2N7qheKTzHLrs2SssQOQCUKHOc9jS7hvZHodxeW9o0K3MqxtPIIogeruQTgfgCfwp0ErzKxkgkgKuygSFSWAOAw2k8HqM8+oHSvHdL+Huo281s03hiJrW21yK/htJVtVEcZtdjhVRiq7ZcEgEk43ZY1BfaBqdz4fsdCu/D1y9yb7UJlsb17a9Z7d3JWQo1yoLKJFAcyblYHhgc1TVlp/W3/BHZf18/wDJfee20V4ovgWaO1nHhTwnE1rcQ6ZLbNK9vbhLi2mbzDJsJw5U/fQMCM8ngHovAng7U9H8WXWp6zHqIvnMyzXIltPst2rvuU/IondlGAPN+7yAccU7K9rk9LnpNFFFSMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKWkyvNYbpDuImlUHHYSMB+gFFM0T/AJBp/wCvif8A9HPRQBDp7SnxHqglUKojhEZH8S5fk/juH4VY1nWtO8P6ZJqGs3aWlrGQrSPnqTgAAckknGBXIeNftb3DW9kupf6RLBHJJp7zKYh+/wAM/k/vNm7aPlK84ywXNcVqf/CTap4JS11nT/Et1ftpFsLSO3jlVZJwxE/njhd3Cn97wRyvOaFr94PRHuXWo3uES5jgIk3yKzKRExUAYzlgMA88AkZ5xnBrx5bzWZNeZ7mTxkA3iIoFNpdBEsmgAZf3aeXtEnAYZIxuVuSxrWmt+IPsiQ+Z4yjMem6lCM6TdMVkE261bc8JLOY+MsT05wx5Ol/62v8A8D1Gld2/re36fce1XFwltD5kgkZdwXEcTSHJIA4UE455PYcngU6SRIYmkmdY40GWdjgKPUmvFf7X1qzUJbv4zYsNKmffpl7LvcOftS5aI7V2bSVXaCRxnkHR8S2eq6lp/iKx8nXrtHVrkOv2qLA89MRqmcMdgOBEegO5Qzc042f9dLEp3jc9bprSIjqjOoZ87VJ5bHXA715QG1PyPFbE+Lp47e6gjsI2+0xMluyxhyhCZkCnfkrvfC5BBbcaWl2GsrfaReayPEbNYpqtuLiJLpnQeYpgbYxYuNm4jfv3YAO5gBU9L/1tcvlPYredLq2jniEipIu4CWNo2H1VgCD7EVJXkNvda/f+GtNGpL4njuzo8QspLeK4ik/tBdwk+0KAOCdmDKPLIyaNNvdct/FaSahN4quJF8QtGd1ldfZvsrW+D8qxiMxiXoxHGM55JN8vvOP9b2/ryJen9eV/+B6nr1QQ3kM6qVLIWZkVZY2jZipIOFYAkcdehHIyDmuT8SSahb+MbGa3/tWaBhFF5NqkwjQbyXk3LmM4AGRIoOBhGyxB4y1t/EN8uh6lBFr8+pW1pqkEUt9HcQZnLgwNKhCrtK85K7TgDqABHS47e9Y9morhfhpBq8dteyarqd/d+YE/0e+0+5tzbygHfta4ldnByPuHYMfL1xWTayayNDvJlHiU64pRdTgkE3ksgmHmNbFhs3eWGCiE9CMjdg02rO39f8N5krVXPUKpaxrOn+H9Jn1PWbqO0srdd0s0nRecDpySSQMDk15bcnU4tY0xIbrxiPDst7NiMQXbTeQbbnzH2GdcSnC72DckjgAjN1Z/EOteATZahY+J7iWXQPJtEjguI2kvBvWUXAwM/LsI8z5W5xlsUWLik3qe0x39vIX+ZkCMqbpI2RWLAFdpYANnIHGeeOvFSQzpP5mwSDy3KNvjZMkemQMjnqMj3ryCRNT1rzl1C18TtFaeIbSeOKSG4gaOAxKGVDHtVlWQMMqWA+8Tg7joQ32pT2rxasPFMulLql2txLDbXUN1sJBtyojVZDF1H7sY+7njNFv6/wDAf8yNdP67/wCX4nqdFeJ3lx4ntZr5dQuPFs01vp9rJZrbWlwyGYTNkEwx7Xby/L3gkglmHbA7nQZ79vHF15i6pNa3CSTB7mOeGOEblCJtfMZOA2NhVgPvrk5ot+o3p+H4mlrIlbxXoot3RJNs+GdCwHyegI/nWp5Wq/8AP5Z/+Ajf/HKx/EUC3XiDS4HaVFkhuVLQytG4zH/CykMp9wQa5vRLI6h8HvDj3mpas1xNJaSS3A1W4SaRpJVVwZA4YghmG3OB2AwKFr+H4jtpc7zytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8cri4vie8Vu13qGgy2lhH9tjLm7WSYPa53KUAxghTg7zyPTmth/EutwpBbXGgW0ep3kpSzh/tLMEihC5ZpBHuXAGCNh5xjI5pdLi2dmbnlar/wA/ln/4CN/8co8rVf8An8s//ARv/jlcVc/E+7RHFr4bd5YdPub2bzr1Y0U28vlyxghWJIOcHaAePUkSXHxLura5aCTw7I8jTWKx+XeIQI7olUZ8gbWBUgqu7qOcZw1Fv+vO35g9NzsfK1X/AJ/LP/wEb/45R5Wq/wDP5Z/+Ajf/AByuPg+JU0TwtrGipZ25uby0nlivPN2S26O7FRsXchWNuTtOeNuOafqPxC1DR7K4l1Hw2TILeO6to7W+WQSxM6plmZV2MpZcgbhzwTzSB6bnW+Vqv/P5Z/8AgI3/AMco8rVf+fyz/wDARv8A45VPw7rlxrJ1KK9sVsrnTrw2siJP5qt8iOrBtq9VcZGODnr1rZoApeVqv/P5Z/8AgI3/AMco8rVf+fyz/wDARv8A45V2igCl5Wq/8/ln/wCAjf8AxyjytV/5/LP/AMBG/wDjlXaKAKXlar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOVdooAxL6PUhqGm77u1LGdtpFqwAPlP1/ec8Z9KveVqv8Az+Wf/gI3/wAcqtrs72zWU8aeY8Tyuqf3iIJDivPmu9Qt/hVZ+PItYvp9akggunjN05tpTI65txBnywPm2Ahd+cck5yLX8Px/4YD0rytV/wCfyz/8BG/+OVQ1Tw6uuRxprVvo2opE2+NbvTPNCN6jc5wfeuZi+LEb3V+76Df/ANmWgnC3qQzbWeJipVmaNYhuYEKRI3uFrNHjbVvDviLX21u2muLqeWzhstNiuJLmKJnjkYhTHCXxhCTiNmyO4waPMV+h6KsGpooVLuyVVGABZsAB/wB/Kd5Wq/8AP5Z/+Ajf/HK4af4p30VhcXB8JXcBtNNbUZ0vZjbnYkhRwqsm8ngldypkY6Z4vXfj++to9QjOi24u7S4hjjjk1DCSJJGZFJIjLb8AjYiOc9CRkgeiu/61sNauy/rS51flar/z+Wf/AICN/wDHKPK1X/n8s/8AwEb/AOOVD4b1pPEfhjTtZihaBb63ScRMclNwzjPfFadNpp2YblLytV/5/LP/AMBG/wDjlHlar/z+Wf8A4CN/8cq7RSApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooApeVqv/P5Z/wDgI3/xyjytV/5/LP8A8BG/+OVdooAo6MgTTQBKJT5spZlQqNxkbIwSehyPwopuif8AINP/AF8T/wDo56KAGWTq3iDUArAlYYQwB6HdIcH8CPzrTrMskVfEGoFVALQwliB1O6QZP4AflWnQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBz2tTRW/ivRZbiRIo1Wfc7sFA+THU1Vs9G8HWGoC8tbmFWVzJHC2pu0ETnqyQlzGh68qoPJ9TVjXnuI/EukvZRRzXCx3BjjlkMas3l8AsFYqPfB+lZHhj4h3ms6ho9tqui29iNatZLm0a1vzclRHjcJFMSbOvBG4HpkULfT+v6sHQdF4P8BRSIwn3hJJZRHLrU8iFpf9ZlGlKsGycggg5PrVkeH/AAZ/ZkdgbsNFDIskLtrExmgIBA8uUyb0ABIwrAYJHc1uW/iXQrsXBtda06cWsginMd2jeU5OArYPynPGDzTofEOi3N7DZ2+r2Et1cR+bDBHcozyJ/eVQckcdRxQHW5zl74W8DX8ivcTopW1azAh1eaIGFzudSEkAO48sTy3cmq8vgjwBNcJPLdSNIghAP9v3P/LH/Vcedg7TyPck9Sa7yigOljiIvCPgSGaGVbks0Fy92nma3O481xh2IaUhtwyCDkEEjHJzI3hfwM+kzaa06G1m2bl/teXcqqdyoreZuRAeQikKPSuzooDzOc0W08MaBPezaZqCiS+kEtw0+qST73Axu/eO2DgAcY4AHYVrf21pX/QTs/8AwIX/ABq7RQBS/trSv+gnZ/8AgQv+NH9taV/0E7P/AMCF/wAau0UAUv7a0r/oJ2f/AIEL/jR/bWlf9BOz/wDAhf8AGrtFAFL+2tK/6Cdn/wCBC/40f21pX/QTs/8AwIX/ABq7RQBiX2r6a+oaay6hasqTsWImUhR5TjJ545IFZ0WheCodRF5HJahll89IDqDG3STOfMWAv5avnncFBzzmtrVTIt5pxgVXkEz7FdtoJ8mTAJwcD3wfpXI6L8TZrmawbxFpljpVpf8A2kR3MWp+cIjAW8zzQ0cexcKSGyR64zQtwexrHRvBhmvnaW1ZL8P9pt2v2MDlxhm8kv5YY5OWCgnJ55qnH4R+H8Uc4RbQyzhBJdNqLtcHZ9wiYv5gI7EMCMCt8eLfDha2UeINLLXaCS3H22PMyE7Qyc/MM8ZHelPivw6HKHX9LDC2+1kfbI8+RjPm9fuY53dKA3OevfCXgXUWka9u3laW1+xyk67cAyQ5yVYiX5snqTknuTSjwn4FF99sN0Wud0bea2uTsQY1KKeZf7pKn1BIOcmt0+KtHuLWd9L1jSbuaK3FwFN+gTYfuuzLuKoT/Fg/jVtdb0ptYOkjU7I6mE8w2QuFMwX+9szux74p6gVNJl8PaHpVvpumXtpDaWybIozd79i+mWYnH41c/trSv+gnZ/8AgQv+NWLm6t7OHzbueOCPIXfK4UZPAGTVG18SaHezQRWWtafcSXG/yUiukcy7Dh9oB52nrjp3pbgTf21pX/QTs/8AwIX/ABo/trSv+gnZ/wDgQv8AjWNrHjnTbPw7d6rokttros5khnjsruNvKLMF+YgnGM5I5PtWsmv6RNf3Vhb6rYy31om+e2W5QyQj1dQcqORyRQHUf/bWlf8AQTs//Ahf8aP7a0r/AKCdn/4EL/jUdnrdjO1vby31gL6aBZzbQ3ayZUj7y9CydcNgZqXTtX03WIpJdJ1C1vo4nMcj2s6yBGHVSVJwfagBP7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAFL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAFL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAFL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBS/trSv+gnZ/wDgQv8AjR/bWlf9BOz/APAhf8au0UAUv7a0r/oJ2f8A4EL/AI0f21pX/QTs/wDwIX/GrtFAFL+2tK/6Cdn/AOBC/wCNH9taV/0E7P8A8CF/xq7RQBnaE6yaVvjYMrTzlWU5BHmvzRT9Hdn08l2LHz5hknPAlYAflRQBHaf8h++/64Q/+hS1pVmf2ffpqE9zBfW6ecAu1rUthQWI53jn5jzT/s+rf9BC1/8AANv/AI5QBoUVn/Z9W/6CFr/4Bt/8co+z6t/0ELX/AMA2/wDjlAGhRWf9n1b/AKCFr/4Bt/8AHKPs+rf9BC1/8A2/+OUAaFFZ/wBn1b/oIWv/AIBt/wDHKPs+rf8AQQtf/ANv/jlAGhRWf9n1b/oIWv8A4Bt/8co+z6t/0ELX/wAA2/8AjlAGhRWf9n1b/oIWv/gG3/xyj7Pq3/QQtf8AwDb/AOOUAaFFZ/2fVv8AoIWv/gG3/wAco+z6t/0ELX/wDb/45QBoUVn/AGfVv+gha/8AgG3/AMco+z6t/wBBC1/8A2/+OUAaFFZ/2fVv+gha/wDgG3/xyj7Pq3/QQtf/AADb/wCOUAaFFZ/2fVv+gha/+Abf/HKPs+rf9BC1/wDANv8A45QBma+bhfEmkmyjiluBFceUk0hjRm8vgFgrED3AP0rmPCXgXXfB+n2c2l2Ohx6g8Zt9ThS5kWG5AJKzhxDnzBkggrhhjLcCuwn0fULjUbW9fUbcS2u/Zi0ODuGDn56tfZ9W/wCgha/+Abf/ABygOljyu6+F3ia4hYz22g3crpZKyTXcixIbed5CY1EBVAytt2qAF3N97v048BXH/Cfz6zcRx3drPdx3qO+qXMRtZEjVMC3X91JwvDMQRuIIIGK637Pq3/QQtf8AwDb/AOOUfZ9W/wCgha/+Abf/AByndr+vT/JDl725oUVn/Z9W/wCgha/+Abf/AByj7Pq3/QQtf/ANv/jlIRoUVn/Z9W/6CFr/AOAbf/HKPs+rf9BC1/8AANv/AI5QBoUVn/Z9W/6CFr/4Bt/8co+z6t/0ELX/AMA2/wDjlAGhRWf9n1b/AKCFr/4Bt/8AHKPs+rf9BC1/8A2/+OUAaFFZ/wBn1b/oIWv/AIBt/wDHKPs+rf8AQQtf/ANv/jlAGhRWf9n1b/oIWv8A4Bt/8co+z6t/0ELX/wAA2/8AjlADdVMgvNOMCq8gmfYrttUnyZMAkA4Hvg/Suc8D+FYPCOhXN1r+m6HY6jvmkutQtCG8yJnL5klaNDxnBzkYUHPYdBNp+pzTQSPqFtugcumLQ9SpXn956Mal+z6t/wBBC1/8A2/+OUAedv4MvNc0WB9NGm6pb2urwS6a96zRrHZQyFwEYI+4klkDDAKbTyOukfAV9b+ML7V0t7XUN9y99ZyXWrXUQhmMezYbdQYiMZG/rg/dOOey+z6t/wBBC1/8A2/+OUfZ9W/6CFr/AOAbf/HKd+39bf5IPX+t/wDOx53L4A8TR+G9Y0K2tNBnstQijlhFxdyA21xkFguID+6U5KDquB0Bwug3hLxGfGlt4gmXTQlrdvc+TDdSKGV7XyipVYcMwYD523MV6bcba7T7Pq3/AEELX/wDb/45R9n1b/oIWv8A4Bt/8co5n0FZM57xjomqeL/BVnBDpunC/wDtNtdNDfTMI4ijh2Ct5RbJAK8qpwxzjpWA3grxWdRN1FZaBEza9Jqh/wBNlb5GgMO0jyBuPzFuw7d816B9n1b/AKCFr/4Bt/8AHKPs+rf9BC1/8A2/+OUu9v62/wAkVd6f13X6s83i+HniqHRtXgX+ynudRtLGDa19KI0aB2LEAQ4RSpGFVQB0x3Np/AfiKbWrm/vINGuVkt7+3+zG5dYZFuGVkygh2jBUhjhi33iT0HffZ9W/6CFr/wCAbf8Axyj7Pq3/AEELX/wDb/45Tl7zbf8AV9BL3djhYPAXiCXSrWxuJbGw3WItbye1upJc7bcwqyxvGBu5zvBQgAKQ3WtzwL4Tm8NpcSXtrFFdyxxwvNHqtze+esYIU/v/APV9T8i5Az1Nb32fVv8AoIWv/gG3/wAco+z6t/0ELX/wDb/45T5m233EkklHsaFFZ/2fVv8AoIWv/gG3/wAco+z6t/0ELX/wDb/45UjNCis/7Pq3/QQtf/ANv/jlH2fVv+gha/8AgG3/AMcoA0KKz/s+rf8AQQtf/ANv/jlH2fVv+gha/wDgG3/xygDQorP+z6t/0ELX/wAA2/8AjlH2fVv+gha/+Abf/HKANCis/wCz6t/0ELX/AMA2/wDjlH2fVv8AoIWv/gG3/wAcoA0KKz/s+rf9BC1/8A2/+OUfZ9W/6CFr/wCAbf8AxygDQorP+z6t/wBBC1/8A2/+OUfZ9W/6CFr/AOAbf/HKANCis/7Pq3/QQtf/AADb/wCOUfZ9W/6CFr/4Bt/8coA0KKz/ALPq3/QQtf8AwDb/AOOUfZ9W/wCgha/+Abf/ABygDQorP+z6t/0ELX/wDb/45R9n1b/oIWv/AIBt/wDHKANCis/7Pq3/AEELX/wDb/45R9n1b/oIWv8A4Bt/8coANE/5Bp/6+J//AEc9FT6fatZWYhkkErb3dmVdoJZy3TJ9fWigCzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==" alt="" width="563" height="118" vspace="0" hspace="0" border="0" style="width:563px;height:118px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Number of patients: citalopram / placebo = 1346 / 545<br />1) Cases of suicidal ideation and suicidal behaviours have been reported during citalopram therapy or early after<br />treatment discontinuation (see section 4.4).<br />2) This event has been reported for the therapeutic class of SSRIs/SNRIs (see sections 4.4 and 4.6).<br />Cases of QT-prolongation and ventricular arrhythmia including torsade de pointes have been reported during<br />the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing<br />QT prolongation or other cardiac diseases (see sections 4.3, 4.4, 4.5, 4.9 and 5.1).<br />Class effects<br />Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone<br />fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.<br />Withdrawal symptoms seen on discontinuation of SSRI treatment.<br />Discontinuation of citalopram (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness,<br />sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams),<br />agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations,<br />emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally<br />these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or<br />prolonged. It is therefore advised that when citalopram treatment is no longer required, gradual discontinuation<br />by dose tapering should be carried out (see section 4.2 and section 4.4).<br />Reporting of suspected adverse reactions<br />The National Pharmacovigilance Center (NPC):<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>Comprehensive clinical data on citalopram overdose are limited and many cases involve concomitant overdoses of other drugs/alcohol. Fatal cases of citalopram overdose have been reported with citalopram alone; however, the majority of fatal cases have involved overdose with concomitant medications.</p><p>Fatal dose is not known. Patients have survived ingestion of more than 2 g citalopram.</p><p>The effects may be potentiated by alcohol taken at the same time.</p><p>Potential interaction with TCAs, MAOIs and other SSRIs.</p><p><u>Symptoms</u></p><p>The following symptoms have been seen in reported overdose of citalopram: convulsion, tachycardia, somnolence, QT prolongation, coma, vomiting, tremor, hypotension, cardiac arrest, nausea, serotonin syndrome, agitation, bradycardia, dizziness, bundle branch block, QRS prolongation, hypertension, mydriasis, torsade de pointes, stupor, sweating, cyanosis, hyperventilation, hyperpyrexia, and atrial and ventricular arrhythmia.</p><p>ECG changes including nodal rhythm, prolonged QT intervals and wide QRS complexes may occur. Fatalities have been reported.</p><p>Prolonged bradycardia with severe hypotension and syncope has also been reported.</p><p>Rarely, features of the &quot;serotonin syndrome&quot; may occur in severe poisoning. This includes alteration of mental status, neuromuscular hyperactivity and autonomic instability. There may be hyperpyrexia and elevation of serum creatine kinase. Rhabdomyolysis is rare.</p><p><u>Treatment</u></p><p>There is no known specific antidote to citalopram.</p><p>Treatment should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of ECG and vital signs until stable. ECG monitoring is advisable in case of overdose in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.</p><p>Consider oral activated charcoal in adults and children who have ingested more than 5 mg/kg body weight within 1 hour. Activated charcoal given &frac12; hour after ingestion of citalopram has been shown to reduce absorption by 50%.</p><p>Osmotically working laxative (such as sodium sulphate) and stomach evacuation should be considered.</p><p>If consciousness is impaired the patient should be intubated.</p><p>Control convulsions with intravenous diazepam if they are frequent or prolonged</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Pharmacotherapeutic group: antidepressants, selective serotonin reuptake inhibitors</u></p><p><u>ATC-code: N 06 AB 04</u></p><p><u>Mechanism of action</u></p><p>Biochemical and behavioural studies have shown that citalopram is a potent inhibitor of the serotonin (5-HT)-uptake. Tolerance to the inhibition of 5-HT-uptake is not induced by long-term treatment with citalopram.</p><p>Citalopram is a very Selective Serotonin Reuptake Inhibitor (SSRI), with no, or minimal, effect on noradrenaline (NA), dopamine (DA) and gamma aminobutyric acid (GABA) uptake.</p><p>In contrast to many tricyclic antidepressants and some of the newer SSRIs, citalopram has no or very low affinity for a series of receptors including 5-HT&nbsp;<sub>1A,&nbsp;</sub>5-HT<sub>2</sub>, DA D<sub>1</sub>&nbsp;and D<sub>2</sub>&nbsp;receptors, &alpha;<sub>1</sub>-, &alpha;<sub>2</sub>-, &beta;-adrenoceptors, histamine H<sub>1</sub>, muscarine cholinergic, benzodiazepine, and opioid receptors. A series of functional&nbsp;<em>in vitro</em>&nbsp;tests in isolated organs as well as functional&nbsp;<em>in vivo&nbsp;</em>tests have confirmed the lack of receptor affinity.</p><p>This absence of effects on receptors could explain why citalopram produces fewer of the traditional side effects such as dry mouth, bladder and gut disturbance, blurred vision, sedation, cardiotoxicity and orthostatic hypotension.</p><p>The main metabolites of citalopram are all SSRIs although their potency and selectivity ratios are lower than those of citalopram. However, the selectivity ratios of the metabolites are higher than those of many of the newer SSRIs. The metabolites do not contribute to the overall antidepressant effect.</p><p>Pharmacodynamic effects</p><p>Suppression of rapid eye movement (REM) sleep is considered a predictor of antidepressant activity. Like tricyclic antidepressants, other SSRIs and MAO inhibitors, citalopram suppresses REM-sleep and increases deep slow-wave sleep.</p><p>Although citalopram does not bind to opioid receptors it potentiates the anti-nociceptive effect of commonly used opioid analgesics. There was potentiation of d-amphetamine-induced hyperactivity following administration of citalopram.</p><p>In humans citalopram does not impair cognitive (intellectual function) and psychomotor performance and has no or minimal sedative properties, either alone or in combination with alcohol.</p><p>Citalopram did not reduce saliva flow in a single dose study in human volunteers and in none of the studies in healthy volunteers did citalopram have significant influence on cardiovascular parameters. Citalopram has no effect on the serum levels of prolactin and growth hormone.</p><p>In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 7.5 (90%CI 5.9-9.1) msec at the 20 mg/day dose and 16.7 (90%CI 15.0-18.4) msec at the 60 mg day/dose (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Absorption is almost complete and independent of food intake (T&nbsp;<sub>max</sub>average/mean 3.8 hours). Oral bioavailability is about 80%.</p><p><em>Distribution</em></p><p>The apparent volume of distribution (V<sub>d</sub>)<sub>&beta;&nbsp;</sub>is about 12.3 L/kg. The plasma protein binding is below 80% for citalopram and its main metabolites.</p><p><em>Biotransformation</em></p><p>Citalopram is metabolized to the active demethylcitalopram, didemethylcitalopram, citalopram-N-oxide and an inactive deaminated propionic acid derivative. All the active metabolites are also SSRIs, although weaker than the parent compound. Unchanged citalopram is the predominant compound in plasma.</p><p><em>Elimination</em></p><p>The elimination half-life (T<sub>&frac12;&beta;</sub>) is about 1.5 days and the systemic citalopram plasma clearance (Cl<sub>s</sub>) is about 0.33 L/min, and oral plasma clearance (Cl<sub>&nbsp;oral</sub>) is about 0.41 L/min.</p><p>Citalopram is excreted mainly via the liver (85%) and the remainder (15%) via the kidneys. About 12% of the daily dose is excreted in urine as unchanged citalopram. Hepatic (residual) clearance is about 0.35 L/min and renal clearance about 0.068 L/min.</p><p>The kinetics are linear. Steady state plasma levels are achieved in 1-2 weeks. Average concentrations of 250 nmol/L (100-500 nmol/L) are achieved at a daily dose of 40 mg. There is no clear relationship between citalopram plasma levels and therapeutic response or side effects.</p><p><em>Elderly patients&nbsp;</em>(&ge; 65 years)</p><p>Longer half-lives and decreased clearance values due to a reduced rate of metabolism have been demonstrated in elderly patients.</p><p><em>Reduced hepatic function</em></p><p>Citalopram is eliminated more slowly in patients with reduced hepatic function. The half-life of citalopram is about twice as long and steady state citalopram concentrations at a given dose will be about twice as high as in patients with normal liver function.</p><p><em>Reduced renal function</em></p><p>Citalopram is eliminated more slowly in patients with mild to moderate reduction of renal function, without any major impact on the pharmacokinetics of citalopram. At present no information is available for treatment of patients with severely reduced renal function (creatinine clearance &lt;20 mL/min).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute toxicity</u></p><p>Citalopram has low acute toxicity.</p><p><u>Chronic toxicity</u></p><p>In chronic toxicity studies there were no findings of concern for the therapeutic use of citalopram.</p><p><u>Reproduction studies</u></p><p>Based on data from reproduction toxicity studies (segment I, II and III) there is no reason to have special concern for the use of citalopram in women of child-bearing potential.</p><p>Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in the implantation number and abnormal sperm at exposure well in excess of human exposure.</p><p><u>Mutagenic and carcinogenic potential</u></p><p>Citalopram has no mutagenic or carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose (200 mesh)</p><p>Maize Starch</p><p>Microcrystalline Cellulose PH101</p><p>Povidone (K30)</p><p>Crospovidone</p><p>Magnesium Stearate</p><p>Coating material (Opadry II White OY-L-28900).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack: Packs contain (30) film coated tablets Transparent PVC/PVDC &ndash; Aluminium foil blister of 15 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>